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Abstract 
Adverse drug reactions (ADRs) in children are common but their predictors are not fully 
characterised. It is known that both increasing age and number of concomitant medicines 
increase ADR risk in children, and there is also some evidence that off-label and unlicensed 
medicine use may contribute.  The purpose of the thesis was to characterise ADRs in 
children, focusing on known risk factors, which have not been adequately evaluated in the 
literature. 
The contribution of off-label and unlicensed prescribing to ADR risk in children was 
assessed in two large prospective studies.  In the first study, which evaluated ADR-related 
hospital admissions, off-label or unlicensed medicines were more likely to be implicated in 
an ADR than authorised medicines (relative risk 1.67, 95% CI 1.38, 2.02, p < 0.001). In a 
multivariate analysis, patients admitted under the care of oncology were more likely to 
have experienced an ADR (odds ratio (OR) 25.70, 95% CI 14.56, 45.38, p < 0.001). The 
following risk factors were also associated with increased ADR risk: increasing age (OR 1.04, 
95% CI 1.00, 1.08, p = 0.045), number of authorised medicines (OR 1.25, 95% CI 1.16, 1.35, 
p < 0.001) and number of off-label or unlicensed medicines (OR 1.23, 95% CI 1.10, 1.36, p < 
0.001). In a sub-group analysis which excluded oncology patients, age and number of 
authorised medicines predicted ADR risk (OR 1.05, 95% CI 1.01, 1.09, p = 0.023 and OR 1.33, 
95% CI 1.23, 1.44, p < 0.001 respectively) but the number of off-label and unlicensed 
medicines did not (OR 1.04, 95% CI 0.89, 1.12, p = 0.627). The second prospective study 
examined ADRs occurring in paediatric inpatients.  Again, off-label or unlicensed medicines 
were more likely to be implicated in an ADR than authorised medicines (OR 2.25, 95% CI 
1.95, 2.59, p < 0.001). Medicines licensed in children but given to a child below the 
minimum age or weight recommended had the greatest risk of being implicated in an ADR. 
Multivariate analysis showed that increasing age (HR 1.04, 95% CI 1.02, 1.05, p < 0.001) and 
receipt of a general anaesthetic (HR 5.30, 95% CI 4.42, 6.35, p < 0.001) were positive 
predictors of ADR risk. Both the number of authorised (HR 1.22, 95% CI 1.17, 1.26, p < 
0.001) and the number of off-label or unlicensed (HR 1.27, 95% CI 1.20, 1.34, p < 0.001) 
medicines were predictors of ADR risk. 
ADR detection in the above studies was based on intensive surveillance.  One possible 
method of detecting ADRs may be through the ICD-10 clinical coding system but this has 
not been investigated for paediatrics.  Only 31.5% of the 241 ADRs evaluated from the 
prospective admissions study were coded correctly using at least one ICD-10 code. The 
clinical coding system could contribute to pharmacovigilance if deficiencies in how ADRs are 
recorded in the case notes and the clinical coding system can be addressed.  
An important ADR detected in the admissions study was the occurrence of haemorrhage 
post-tonsillectomy which has been attributed to the use of dexamethasone.  In order to 
analyse this further, a systematic review and meta-analysis of dexamethasone and non-
steroidal anti-inflammatory drug (NSAID) use in paediatric tonsillectomy was undertaken. 
Although there were a large number of randomised controlled trials and observational 
studies in this area, analysis of all of these led to the conclusion that there was insufficient 
evidence to rule out an increased risk of haemorrhage with dexamethasone use whether in 
combination with NSAID or not (Peto odds ratio for dexamethasone versus another 
intervention 1.41, 95% CI 0.89, 2.25, p = 0.15). Further, well powered, well designed studies 
are needed in this area.  
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An important ADR detected in the in-patient study was post-operative nausea and 
vomiting.  More detailed analysis was therefore undertaken to identify the risk factors for 
post-operative vomiting (POV), with a view to developing a risk score. The following were 
all identified as predictors of POV risk: age (OR 1.06, 95% CI 1.03, 1.10, p<0.001), duration 
of anaesthesia (OR 1.00, 95% CI 1.00, 1.01, p <0.001) and the use of intra-operative 
analgesics (OR 2.22, 95% CI 1.58, 3.12, p < 0.001). However, it was not possible to develop a 
robust model to predict the risk of POV because of the heterogeneity of the patient groups, 
the types of surgery, and the different clinical practices between different anaesthetists in 
terms of anti-emetic (choice, timing and doses). 
The use of off-label and unlicensed medicines in children is common but necessary and 
these medicines are frequently associated with ADRs. The rational prescribing of medicines 
is an important measure in the reduction of ADR risk and a solid evidence-base is a pre-
requisite. The aim should be that the minimum number of medicines is used safely and 
effectively, at the lowest dose possible, for the minimum duration necessary. 
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1 Introduction 
1.1 Background 
When making decisions about prescribing medicines, clinicians are required to consider 
both the potential benefits and the potential risks of the treatments available. Potential 
risks relate to the likelihood of the patient developing an adverse drug reaction (ADR). The 
risk of an ADR may be intrinsic to the medicine or it may be related to the susceptibility of 
the patient to the adverse effects of the medicine (Aronson and Ferner, 2003).  
 
Clinicians are guided by the available evidence. Information about medicine use in children 
and its potential risks is of varying quality; this may be particularly true for off-label and 
unlicensed medicines. Where there is a lack of good quality information, this is a result of 
how the development of medicines has traditionally focussed on the adult population with 
few clinical trial data being generated in children (Choonara and Dunne, 1998). When 
prescribing for children, evidence about ADR risk may be derived from various sources: 
extrapolation of adult data, consideration of any clinical trial data which does exist, other 
studies of the medicine in use, or the experience of clinicians. Epidemiological studies 
which present data on ADR risk factors in children also provide insight. In practice, this 
information is collated into an accessible format such as, in the UK, the British National 
Formulary for Children. This reference is evidence-based and is regularly updated as new 
evidence emerges. Updates are the responsibility of a team of writers who assess that the 
new data are relevant and reliable. Draft amendments are made and then reviewed by 
expert advisers. Subsequently, the amendments are discussed and ratified by the Paediatric 
Formulary Committee (PFC). The PFC includes a neonatologist, paediatricians, paediatric 
pharmacists, doctors appointed by the BMJ Group, a GP and representatives from the 
Medicines and Healthcare products Regulatory Agency (MHRA) and the Department of 
Health for England (Paediatric Formulary Committee, 2009/2010).  
In 2007, The National Institute of Health Research (NIHR) awarded a grant to the University 
of Liverpool and Alder Hey Children’s Hospital in Liverpool to fund a series of studies into 
ADRs in children – the Adverse Drug Reactions in Children (ADRIC) programme. The work 
included two large observational studies; the first investigated the prevalence of ADRs 
detected at the point of admission and the second investigated the prevalence of ADRs in 
inpatients. A series of qualitative studies described the experiences of children who had 
experienced an ADR and their families.  
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Both observational studies of ADR prevalence were undertaken by a multidisciplinary study 
team made up of a paediatrician, a paediatric nurse and at least one clinical pharmacist. 
Having joined the ADRIC programme in March 2008, the author of this thesis (JRB) was a 
full time member of the study team for the duration of both observational studies and 
contributed to design, planning and data collection. Subsequently JRB contributed to the 
clinical evaluation of suspected ADRs, inclusive of the development of a novel causality 
assessment tool (Gallagher et al., 2011). Finally, in co-operation with experts in statistical 
analysis, JRB assisted in the analysis and interpretation of the study findings.  The aims of 
these studies were to quantify the burden of ADRs in a paediatric population and to 
characterise those ADRs. The author’s unique contribution to this work was to describe, in 
detail, the medicines involved inclusive of whether they were off-label or unlicensed. 
Having done this, JRB undertook and investigation ofthe relationship between the use of 
such medicines and ADR risk.   
This chapter will discuss how ADRs are defined and detected, their prevalence in children, 
risk factors, mechanisms and characterisation. It will go on to define off-label and 
unlicensed medicine use, explain why it is necessary in paediatric practice and describe its 
prevalence. Finally, it will review previous studies which have examined off-label and 
unlicensed medicines use as an ADR risk factor. 
1.2 Adverse drug reactions in children 
1.2.1 Definition of adverse drug reaction 
A clear definition of adverse drug reaction is needed so that data on ADRs can be 
consistently reported and reliably interpreted. A definition commonly used in the existing 
pharmacovigilance literature is the World Health Organisation (WHO) definition (1972): 
‘A response to a drug that is noxious and unintended and occurs at doses normally used in 
man for the prophylaxis, diagnosis or therapy of disease, or for modification of physiological 
function’.  
Edwards and Aronson (2000) proposed a definition which has also been widely used:  
‘An appreciably harmful or unpleasant reaction, resulting from an intervention related to 
the use of a medicinal product, which predicts hazard from future administration and 
warrants prevention or specific treatment, or alteration of the dosage regimen, or 
withdrawal of the product.’ 
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Although both of these commonly used definitions do not include responses or reactions 
which result from drug errors or deliberate or accidental poisoning, some studies have 
included ADRs alongside drug errors under the term ‘adverse drug events’ (Bates et al., 
1999). The definition utilised in European Parliament Directive on the Community code 
relating to medicinal products for human use corresponds to the WHO definition (World 
Health Organisation, 1972)  but also includes noxious and unintended effects resulting from 
medication errors and uses outside the terms of the marketing authorisation, including the 
misuse and abuse of the medicinal product (The European Parliament and the Council of 
the European Union, 2010).  
1.2.2 Detection of adverse drug reactions 
Although the adverse reaction profile of a medicine may be predictable from its known 
pharmacology, much of the information about ADRs is derived from ADR reports for 
medicines in use. ADRs may be detected during the development of the medicine when its 
effects, both beneficial and adverse are intensively monitored. Any ADRs detected during 
the development process will, in the UK, appear in the summary of product characteristics 
(SmPC) when the medicine is granted a marketing authorisation (MA). Once a medicine is in 
use in clinical practice, the detection of ADRs is undertaken by clinicians and patients in co-
operation with the MA holder and their regulator. ADRs detected may be those which 
appear in the SmPC or may be previously unrecognised reactions. The reason why 
additional ADRs are likely to be detected once the medicine is in clinical use is that a greater 
number of patients, including those originally excluded from the drug development 
process, will be exposed to the medicine; these include patients with multiple co-
morbidities and those who are taking other medicines (including non-prescription and 
alternative therapies) which have the potential to interact with the new medicine, 
previously unrecognised food-drug interactions may also emerge. Children are one patient 
group which, until recently, has frequently been excluded from the drug development 
process. Clinicians may observe previously unrecognised ADRs or patterns of ADR 
occurrence and disseminate their observations by publishing a case report or case series. 
Clinicians, patients and carers may also report ADRs using a voluntary, spontaneous 
reporting system which in the UK is known as the Yellow Card Scheme and is administered 
by the Medicines and Healthcare products Regulatory Agency (MHRA, 2012). An advantage 
of this system is that it has the potential to pick up ADR signals from across the UK; 
submitted reports are monitored and previously unrecognised reactions have been 
highlighted in this way. When an important new ADR is identified, the regulator will issue 
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advice which may include amendments to, or the withdrawal of the medicine’s MA. 
However, the spontaneous reporting system is hindered by under-reporting. A systematic 
review of 37 studies of under-reporting estimated its incidence to be between 6 and 100% 
(Figure 1.1) (Hazell and Shakir, 2006).   
Figure 1.1 Distribution of under-reporting rates across 37 studies (taken from Hazell, 
Shakir 2006) 
 
 
 
 
 
 
 
 
Another method for the detection of ADRs is intensive surveillance which can be 
undertaken by manufacturers, clinicians and/or researchers. Examples include post-
marketing studies and epidemiological work such as cohort and case-control studies.  
There is considerable interest in linking existing prescription data to patient medical records 
in order to conduct large pharmacovigilance studies. The benefit of this approach is that it 
links together large amounts routinely collected data making it far more cost-effective than, 
for example, a prospective cohort study. This approach assumes the suitability of routinely 
collected data for research, however it must be remembered that this is not the primary 
purpose for which they are collected. There are concerns about sharing confidential patient 
information for research and undoubtedly it needs to be done with attention to the 
security of the data. Therefore, work is underway in the UK to explore this strategy, 
inclusive of whether such an approach to pharmacovigilance in children is acceptable to 
stakeholders, inclusive of patients, their families and healthcare professionals (Hopf et al., 
2012). 
This text box is where the unabridged 
thesis included the following third party 
copyrighted material: 
Hazell, L. and Shakir, S. A. W. (2006) 
'Under-reporting of adverse drug 
reactions : a systematic review', Drug Saf., 
29 (5), pp.385-96. Figure 1. 
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Since July 2012, MA holders in the European Union have been required to have a risk 
management plan (RMP) for new medicinal products (European Medicines Agency, 2012). 
This document details important identified risks, important potential risks, important 
missing information (patients or conditions where a product has not been used and where 
there is no clinical experience), efficacy, how safety is being monitored and measures being 
taken to minimise risk. This requirement for new medicinal products to have a RMP is an 
attempt to address the deficit of safety information that is available at the time that a 
medicine is authorised.  
Systematic reviews, which may include a meta-analysis of the adverse effects of medicines, 
can be used to synthesise data from a number of small clinical studies in order to increase 
the precision of the results (Loke et al., 2007).   
The trade-off between the benefits and harms of a drug intervention is of utmost 
importance in clinical decision making. 
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1.2.3 Incidence of adverse drug reactions in children 
A meta-analysis published in 2001 included 17 studies and described the incidence of ADRs 
in children as follows: 4.37% to 16.78% in hospitalised children, 0.59% to 4.1% in children 
being admitted to hospital and 0.7% to 2.7% in outpatients (Impicciatore et al., 2001). A 
more recent meta-analysis included fewer studies (eight) and found the incidence to be 
1.5% to 19.9% in hospitalised children, 0.6% to 6% in children being admitted to hospital 
and 0.7 to 11% in outpatients (Clavenna and Bonati, 2009). Finally, a systematic review 
published in 2012 included 102 studies but not all had reported ADR incidence (Smyth et 
al., 2012). There were 31 studies of hospital admissions and for those which reported 
results for single admissions (n=11), the ADR incidence ranged from 0.4% to 10.3% (Figure 
1.2). Of the inpatient studies included, 32 provided an estimate of ADR incidence. Amongst 
the studies which reported it for single admissions (n=11), the incidence ranged from 0.6% 
to 16.8% (Figure 1.3). 16 outpatient studies reported an ADR incidence which ranged from 
0.3% to 11.0%. These reviews established that ADRs in children are a significant problem 
but their aim was to estimate incidence rather than to explore in any detail the factors 
which contribute to ADR risk in children. 
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Figure 1.2  Adverse drug reaction incidence in admissions studies (taken from Smyth et al. 
2012) 
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Figure 1.3 Adverse drug reaction incidence in inpatient studies (taken from Smyth et al. 
2012) 
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1.2.4 Risk factors for adverse drug reactions in children  
Several ADR risk factors in children have been identified in previous studies. These have 
also described the types of drug or drug classes most frequently implicated in ADRs.  
In a study of paediatric inpatients in the UK (Whyte and Greenan, 1977), an ADR was 
defined as any undesired or unintended response to the patients’ own current medication 
(excluding accidental poisoning). Of 595 patients who received at least one medicine in 
hospital, 39 (6.6%) experienced at least one ADR. An evaluation of ADR risk factors 
determined that ADRs were more common in serious disease, 64.7% of ADRs occurred in 
children being treated for malignant disease. The number of medicines administered was a 
predictor of ADR risk, with patients who received more than four medicines at greater risk 
than those who received fewer than four. The types of medicine which most frequently 
caused ADRs were anti-neoplastic agents and antimicrobials. No association of ADR risk 
with either age or gender was demonstrated.  
A study of drug-related admissions undertaken on a paediatric ward in Israel reported an 
ADR incidence of 3.2% amongst 906 admissions (Yosselson-Superstine and Weiss, 1982). 
ADRs were more common amongst females and children aged between 6 and 10 years old 
and the most frequently implicated drugs were anti-neoplastic agents, corticosteroids, 
anticonvulsants and antimicrobials.  
A large US study prospectively monitored 3026 neonatal intensive care unit (NICU) 
admissions, 725 oncology admissions and 6546 general and specialty paediatric admissions 
(Mitchell et al., 1988). A small proportion of NICU admissions were ADR related (0.2%) and 
the ADRs recorded were not consistently associated with a particular drug or drug class. In 
contrast, 22% of oncology ward admissions were due to an ADR with the most common 
cause being anti-neoplastic drugs. Finally, 2.0% of general and specialty paediatric 
admissions were due to an ADR and the likelihood increased from birth until 5 years after 
which it did not increase significantly. In the latter group, anticonvulsants, antimicrobials 
and aspirin were the most frequently implicated drugs.  
A study of 219 paediatric inpatients in Chile reported an ADR incidence of 13.7% (Gonzalez-
Martin, Caroca and Paris, 1998). The most commonly implicated medicines were 
antineoplastic agents, anticonvulsants, antimicrobials and salbutamol. ADR risk factors 
were length of stay and number of medicines.  
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A UK study of 1046 inpatients reported that the number of medicines was a predictor of 
ADR risk and the drugs commonly implicated in ADRs were antimicrobials, opioids and 
diuretics (Turner et al., 1999). This study aimed to determine the impact of off-label and 
unlicensed medicine use and it, along with other studies of this particular risk factor, is 
described in more detail in section 1.4.1 below. 
The ADR incidence in a Brazilian study of 265 paediatric inpatients was 12.5% (dos Santos 
and Coelho, 2006). The most frequently implicated drug classes were antimicrobials, 
systemic hormones and central nervous system drugs including analgesics. ADR risk factors 
were decreasing age, increased length of stay and number of drugs. 
In a study of 1253 paediatric inpatients across five countries (Rashed et al., 2012), the WHO 
(1979) definition of ADR was adopted and ADR incidence of 16.7% was reported (The 
ADVISE Study). Five categories of high risk drugs were defined: analgesics, antiepileptics, 
antibacterials and antimycotics for systemic use, corticosteroids for systemic use and 
immunosuppressant agents. The administration of three of more high risk drugs was a 
predictor of ADR risk. All other drugs were defined as low risk and the administration of five 
or more of these predicted ADR risk, increasing age was also a risk factor. 
A large prospective study of 8345 paediatric admissions was undertaken as part of the 
ADRIC programme. It reported an ADR incidence of 2.9% and the most frequently 
implicated medicine types were antineoplastic agents, corticosteroids, non-steroidal anti-
inflammatory drugs, vaccines and immunosuppressants (Gallagher R.M. et al., 2012). Risk 
factors identified in this study were increasing age, number of medicines and being an 
oncology patient. A prospective study of 6,601 paediatric inpatients was also undertaken 
within the ADRIC programme and the ADR incidence was 17.7% (Thiesen et al., 2013). The 
most frequently implicated medicine types were opioid analgesics and anaesthetic agents.  
The ADR predictors were increasing age, number of medicines, receipt of a general 
anaesthetic and being an oncology patient. 
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1.2.5 Adverse drug reaction mechanisms 
1.2.5.1 Classification of adverse drug reactions 
The definition of ADR may be supplemented by a description of ADR type. A simple 
categorisation is type A or type B, the former being dose-related and predictable from the 
known pharmacology of the medicine and the latter being non-dose-related and 
unpredictable. This categorisation has been extended further to include type C (dose and 
time related) and type D (delayed reactions) (Edwards and Aronson, 2000).   
A ‘three dimensional’ classification has also been proposed which takes into account not 
only the properties of the medicine implicated in the ADR but also the characteristics of the 
reaction and of the individual who experienced the reaction i.e. Dose relatedness, Timing 
and Susceptibility (DoTS classification). The proposers of this classification describe how, 
although dose-relatedness is traditionally thought of in the context of non-immunological 
reactions, it is actually relevant to all reactions inclusive of immunological reactions. ADRs 
can be classified as either those that occur at supratherapeutic doses (toxic effects), at 
standard therapeutic doses (collateral effects) or at subtherapeutic doses in susceptible 
patients (hypersusceptibility reactions). The concept of timing takes into consideration 
when the reaction becomes apparent in relation to when the dose was given and a reaction 
can be classified as either rapid, first dose, early, intermediate, late or delayed. 
Susceptibility specifically relates to the patient and is made up of the interactions 
between genetic variation, age, sex, physiological variation, exogenous factors, and 
disease (Aronson and Ferner, 2003).  
1.2.5.2 Overview of adverse drug reaction mechanisms 
As described by the simple Type A/Type B classification, the mechanism of an ADR may be 
either related or unrelated to its known pharmacology.  
Examples of ADRs which result from an extension of the intended therapeutic effect of a 
drug are hypoglycaemia secondary to insulin and haemorrhage secondary to anticoagulant. 
Both of these reactions have potentially serious consequences but both would be expected 
to respond to dose reduction.  
Acute renal insufficiency secondary to non-steroidal anti-inflammatory drug (NSAID) use in 
patients with cardiac or hepatic disease is an example of an ADR which results from the 
known pharmacology of the drug but is distinct from its intended therapeutic effect. The 
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therapeutic uses of NSAIDs are in the management of fever, pain and inflammation. These 
effects are achieved via the inhibition of the cyclo-oxygenase enzyme and consequently the 
synthesis of prostaglandins. Within the renal vasculature, prostaglandins act to maintain 
adequate perfusion. An inhibition of prostaglandin synthesis results in decreased renal 
blood flow and a consequent reduction in the glomerular filtration rate. Patients with pre-
existing compromised renal function are more susceptible to this ADR (Murray and Brater, 
1993).  
Paracetamol-associated hepatotoxicity usually results from the administration of a dose 
above the therapeutic range for example in accidental or deliberate overdose, the 
mechanism by which it occurs illustrates some of the covalent and non-covalent 
interactions which facilitate drug toxicity. Paracetamol undergoes hepatic metabolism; at 
normal therapeutic doses it is deactivated via glucuronidation and sulphation and the 
resultant metabolites are excreted in the urine. At toxic doses, these metabolic routes 
become saturated and paracetamol undergoes bioactivation catalysed by cytochrome P450 
isoforms CYP2E1 and CYP3A4. It is converted to the reactive metabolite (n-acetyl-p-
benzoquinone imine - NAPQI). NAPQI is ordinarily inactivated by hepatic glutathione but in 
the case of paracetamol overdose, this becomes rapidly depleted. Glutathione plays a role 
in protecting cells from oxidative stress and so its depletion contributes to hepatotoxicity. 
The reactive metabolite NAPQI contributes to oxidative reactions and the covalent 
modification of proteins (inclusive of glutathione) within the hepatocytes (Rang and Dale, 
2012, Park et al., 2005).  
Hypersensitivity reactions are not related to the principle pharmacology of the drug. These 
types of reaction are often caused by a chemically reactive metabolite rather than the drug 
molecule itself and are thought to have an immunological mechanism, mediated either by 
B- or T-cell activation (although there are interactions between these pathways). An 
example of B-cell mediated hypersensitivity reaction is anaphylaxis secondary to beta-
lactam antibiotics. The drug or its active metabolite acts as antigen leading to the formation 
of specific IgE antibodies. When bound to the surface of mast cells and basophils, these 
antibodies cause the release of vasoactive mediators (e.g. histamine, bradykinin and 
platelet-activating factor) and these produce the clinical manifestations of facial and tongue 
oedema together with vascular collapse (Rieder, 2009). Other immune-mediated reactions 
include hepatotoxicity, toxic epidermal necrolysis and nephritis.  These are mediated by T 
cells rather than immunoglobulins.  There is evidence that an individual’s propensity to 
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developing a drug hypersensitivity reaction is genetically determined although there may 
also be other important contributors (environmental factors) which interact with the 
genome to increase susceptibility (Pirmohamed, 2006). 
To complement the DoTS classification, Ferner and Aronson (2010a) proposed a 
mechanistic adverse drug effect classification system (EIDOS) which takes into account 
various factors.  These can be illustrated using non-steroidal anti-inflammatory drug 
(NSAID) induced renal impairment as an exemplar:  
 the extrinsic chemical species (E) that initiates the effect, e.g. the non-steroidal 
anti-inflammatory drug (NSAID) 
 the intrinsic chemical species (I) that it affects, e.g. the inhibition of cyclo-
oxygenase and a reduction in prostaglandin synthesis 
 the distribution (D) of these species in the body, e.g. renal prostaglandins  
 the (physiological or pathological) outcome (O), e.g. reduced renal blood flow 
 and the sequela (S), which is the adverse effect e.g. renal impairment 
1.2.5.3 Developmental pharmacology and adverse drug reactions in children 
The paediatric population is diverse, ranging from pre-term neonates through to 
adolescents; this diversity brings with it challenges for those who develop and use 
medicines in children. These challenges include the production of appropriate formulations 
and the determination of appropriate dosing regimens. It is not always possible to translate 
what is known about medicine use in adults into recommendations for medicine use in 
children. As a child grows and develops, changes affecting drug pharmacokinetics (PK) and 
pharmacodynamics (PD) determine not only the likelihood of drug efficacy but also the 
likelihood of toxicity. Both the direction and the magnitude of these changes will differ 
depending on the drug involved as exemplified for the dose-response relationship in Figure 
1.4. 
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Figure 1.4 The sigmoid Emax model of exposure-response and hypothetical examples of 
developmental changes in this relationship (taken from Mulla 2010) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Developmental changes in children affect drug disposition; examples of this include 
differences in gastric pH and gastric emptying, differences in body composition, increased 
or decreased expression of circulating plasma proteins and drug targets, increased or 
decreased expression of the enzymes involved in drug metabolism and differences in 
glomerular filtration rate (GFR).  These differences are governed by developmental 
variations in gene expression (Kearns et al., 2003, Hines, 2008, Becker and Leeder, 2010, 
Mulla, 2010). The potential toxicity of excipients used to formulate drugs is also significant 
in children (Choonara and Rieder, 2002). 
 
The effect of changes in gastric pH on drug absorption are illustrated by a study of serum 
penicillin levels in premature and term neonates, older infants and children (Huang and 
High, 1953). At 30 minutes, 2, 4 and 6 hours after the oral administration of penicillin, 
premature and term neonates had significantly higher serum levels of the drug than older 
This text box is where the unabridged 
thesis included the following third party 
copyrighted material: 
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infants and children. The gastric pH gradually declines after birth and hence the rate of 
penicillin degradation in the stomach increases, leading to a reduction in drug absorption.   
 
The higher body water to fat ratio in infants may affect the apparent volume of distribution 
and hence the serum concentration of some drugs. For example, the apparent volume of 
distribution of the hydrophilic drug linezolid is higher in young infants and this must be 
taken into account in the extrapolation of adult linezolid doses and dose intervals to 
children in this age group (Kearns et al., 2000). 
 
Developmental changes in the expression and activity of enzymes responsible for drug 
metabolism influence the rate of drug clearance. For example, metabolism of the 
phospodiesterase-5 inhibitor sildenafil is catalysed by the cytochrome P450 enzymes 
CYP3A4 and CYP2C9 and potentially by the foetal isoform of CYP3A, CYP3A7. In vitro data 
demonstrated that CYP3A4 and CYP2C9 activity levels are low at birth but increase rapidly 
to adult levels by one month of age whereas CYP3A7 activity is greatest in the first week of 
life but subsequently declines. These developmental changes in enzyme expression and 
activity are the proposed mechanism by which sildenafil clearance is significantly correlated 
with postnatal age, observed in term neonates in the first 1-2 weeks of life (Mukherjee et 
al., 2009). 
 
The GFR in a term neonate increases rapidly in the first week of life and reaches that of a 
healthy adult by the age of one year. After the first year of life, GFR continues to rise 
reaching a peak at around three years old and gradually declining towards adulthood. 
These changes have implications for the clearance of drugs excreted by the kidneys. The 
milligram per kilogram dose of digoxin in young children is three times that required in 
adults. This can be partly explained by an increased rate of renal clearance but it is also 
thought that age-related changes in the secretory function of P-glycoprotein in the renal 
tubules may contribute (Chen et al., 2006). 
 
In children, an understanding of developmental changes in drug disposition informs 
appropriate dosing to avoid toxicity but also contributes to an appreciation of why their 
susceptibility to ADRs might vary. Sodium valproate-associated hepatotoxicity, inclusive of 
fatal cases, is more common in children. In young children, the hepatic clearance of valproic 
acid is increased. It is hypothesised that alongside this there is increased production of a 
hepatotoxic metabolite catalysed by CYP2C9 and CYP2A6. Conversely, children have a 
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decreased susceptibility to paracetamol overdose-induced hepatotoxicity which is thought 
to reflect differences in hepatic metabolism, for example an increased rate of sulphation 
and/or an increased rate of glutathione synthesis (Johnson, 2003).  
1.2.6 Evaluation of adverse drug reactions 
In the same way that the definition of ADR varies between authors, disparities exist in the 
way ADRs, once defined and detected, are evaluated. Three key aspects which are 
commonly considered are causality, severity and preventability (also called avoidability).  
1.2.6.1 Causality assessment methods 
The assessment of ADR causality is a process which aims to determine the likelihood that an 
ADR has occurred. To evaluate causality, there are six key questions about a suspected ADR 
which need to be considered: 
1. Does it have a temporal relationship with the administration of the medicine?  
2. Could there be another explanation for it? (e.g. underlying disease)  
3. Did it resolve when the medicine was withdrawn? (dechallenge)  
4. Has it happened before in the same patient when they received the same 
medicine?  
5. If the medicine was administered again, did it recur? (rechallenge)  
6. Is there any objective evidence for its occurrence?   
The causality assessment should also take into account whether the suspected reaction has 
previously been recognised.  
A recent systematic review of the available methods for causality assessment 
acknowledged that there is currently no ‘gold standard’ method; all the algorithms 
available have shortcomings and these relate in particular to the knowledge and experience 
of the person using the algorithm and the type of ADR being evaluated (Agbabiaka, Savović 
and Ernst, 2008). The review identified three types of method:  
1. Global introspection  
2. Probabilistic or Bayesian techniques  
3. Algorithms or standardised assessments  
The third of these was the most commonly used method. The authors of the review 
commented that those methods which relied on expert judgement did not guarantee a 
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consistent approach and better inter-rater reliability was found in studies which used 
algorithms composed of questions of a factual nature.  
Karch & Lasagna (1977) developed a methodology for assessing the causality of ADRs which 
comprises a series of three decision tables. The first table facilitates the identification of 
potential drug-related events – the investigator must consider the temporal relationship 
between drug administration and the event, and whether the event was secondary to one 
of the following circumstances: accidental poisoning, a suicide attempt or non-compliance. 
Only when the investigator has established a temporal relationship and determined that 
the event was not secondary to any of the circumstances listed, can they move on to the 
second decision table which assesses the link between the agent and the event by asking 
questions about concurrent disease, dechallenge and rechallenge. Having completed this 
assessment, a causality outcome can be assigned: definite, probable, possible, conditional 
or unrelated. Finally, if a drug-related event is classified as definite, probable, possible or 
conditional, the case is examined using the criteria in a third table which considers its 
cause, for example due to recreational drug use, poor prescribing or prescribing error.  
Kramer et al. (1979) developed an algorithm for the assessment of ADRs which consists of 
what they term ‘six axes of decision strategy’. These axes are used to assess the suspected 
ADR and are as follows: 
1. Previous general experience of the drug  
2. Alternative etiologic candidates 
3. Timing of events 
4. Drug levels and evidence of overdose  
5. Dechallenge 
6. Rechallenge  
As the assessor moves through these axes, they accumulate points depending on which 
path is taken and they are also directed to a subsequent axis to examine the case further. 
At the end of the process the score accumulated can be used to describe the probability, 
based on the weight of evidence, that the event represents an ADR.  
A widely used algorithm for the assessment of ADR causality is the Naranjo tool (Naranjo et 
al., 1981) which uses a scoring system to categorise ADRs as definite, probable, possible or 
doubtful. ADR cases are scored according to a series of questions (Table 1.1) which can be 
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answered yes, no or don’t know; each answer carries a score and the total of these scores 
determines which category the ADR will fall into:  
> 9 = definite ADR  
5-8 = probable ADR  
1-4 = possible ADR  
0 = doubtful ADR 
Table 1.1 The Naranjo tool for the assessment of ADR causality (Naranjo et al. 1981) 
Question 
No. 
Question Yes No Don’t 
know 
1 Are there previous conclusive reports of this reaction? +1 0 0 
 
2 Did the adverse event appear after the suspected drug 
was administered? 
 
+2 -1 0 
3 Did the ADR improve when the drug was discontinued 
or after a specific antagonist? 
 
+1 0 0 
4 Did the ADR reappear after the drug was restarted? 
 
+2 -1 0 
5 Are there alternative causes that could have caused 
the reaction on their own? 
 
-1 +2 0 
6 Did the reaction reappear after placebo was 
administered? 
 
-1 +1 0 
7 Were blood levels of the drug in a range known to be 
toxic? 
 
+1 0 0 
8 Was reaction more severe when dose was increased or 
less severe when dose was decreased? 
 
+1 0 0 
9 Did the patient have a similar reaction to the same or 
similar drugs in a previous exposure? 
 
+1 0 0 
10 Was the ADR confirmed by objective evidence? +1 0 0 
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Using the concepts of temporal relationship, dechallenge, rechallenge and relationship to 
disease, Jones (1982) formulated a causality algorithm, which is in the form of a flow 
diagram – the causal relationship between  the drug administered and the event under 
investigation can be assigned a category of remote, possible or probable.  
One group (Koh and Shu, 2005) developed an algorithm on the basis of the information 
contained in routine ADR reports and combined and modified their questions using 
Kramer’s work as a ‘gold standard’ (Kramer et al., 1979). Their algorithm takes the form of a 
list of nine weighted questions to which the user can answer yes, no or don’t know to 
produce a score which allows the reaction to be categorised as definite, probable, possible 
or unlikely – they conducted a comparative study of various algorithms, including their 
own, with Kramer’s algorithm and found that theirs had the highest congruency with 
Kramer in terms of the causality outcome for each of 450 cases, 98.44% (95% CI 96.82, 
99.37) compared with Naranjo which was the next best with 94.67% (95% CI 92.17, 96.55) 
congruency.  
In the process of assessing causality using the Naranjo tool for the ADRs identified in the 
ADRIC admissions study, Gallagher et al. (2011) identified several weaknesses in the tool 
which they felt could be improved upon. The team developed and validated the Liverpool 
Causality Assessment Tool (LCAT) using the Naranjo score as their comparator (Gallagher et 
al., 2011). This tool takes the form of a flow diagram (Figure 1.5); the user is able to 
categorise ADRs as unlikely, possible, probable or definite depending on how they answer 
the questions in the flow diagram. This tool was subsequently used to assess the causality 
of all the ADRs identified in both of the ADRIC observational studies of ADR incidence and 
characteristics.  
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Figure 1.5 The Liverpool ADR causality assessment tool (taken from Gallagher et al. 2011) 
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1.2.6.2 Severity assessment methods 
The severity of an ADR relates to the effect it has on an individual. This is distinct from the 
seriousness of an ADR which is a measure of the extent to which it causes harm. The 
relevance of severity assessment is that it describes the clinical impact of ADRs and enables 
researchers and clinicians to identify priorities for study and intervention. Severity 
classification systems have tended to employ terminology such as mild, moderate or severe 
but this makes the process of severity assessment subjective.  
In the context of an existing hospital based ADR reporting system, Hartwig, Siegel & 
Schneider (1992) used a scale which comprised seven levels to assess the severity of 
reported ADRs. The focus of the scale was the impact of the ADR on the patient in terms of 
additional treatment, permanent harm, and admission to hospital or prolonged stay. The 
severity levels range from level 1: an ADR occurred but required no change in treatment 
with the suspected drug, to level 7: the adverse reaction either directly or indirectly led to 
the death of the patient (Table 1.2).  
Table 1.2 ADR Severity Assessment (Hartwig, Siegel and Schneider, 1992) 
Level Description 
1 ADR occurred but required no change in treatment with the suspected drug 
 
2 ADR required that treatment with the suspected drug be held, discontinued, or 
otherwise changed. No antidote or other treatment required, No increase in 
length of stay 
 
3 ADR required that treatment with suspected drug be held, discontinued, or 
otherwise changed AND/OR an antidote or other treatment was required. No 
increase in length of stay 
 
4 Any level 3 ADR which increases length of stay by at least 1 day OR the ADR was 
the reason for admission 
 
5 Any level 4 ADR which requires intensive medical care 
 
6 The adverse reaction caused permanent harm to the patient 
 
7 The adverse reaction either directly or indirectly led to the death of the patient 
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Aronson and Ferner (2005) proposed a classification which minimises subjectivity because it 
asks specific questions about the ADR; it focuses on what needs to be done to manage the 
ADR. Firstly it asks whether any change in the patient’s treatment was required as a result 
of the ADR and secondly it asks whether the treatment was effective; they term this the 
‘treatability’ of the reaction (Table 1.3). 
Table 1.3 Proposed classification of ADR severity (Aronson and Ferner, 2005) 
Grade Change in dosage regimen of the 
offending drug 
Treatability of the reaction 
1 
No change in dosage regimen 
required 
A. No treatment required 
B. Relieved or partly relieved by 
treatment 
C. Not relieved by treatment 
 
2 
Altered dosage regimen required or 
desirable 
A. No other treatment required 
B. Relieved or partly relieved by 
treatment 
C. Not relieved by treatment 
 
3 Withdrawal required or desirable 
A. No other treatment required 
B. Relieved or partly relieved by 
treatment 
C. Not relieved by treatment 
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1.2.6.3 Preventability assessment methods 
In order to be able to target interventions aimed at preventing ADRs, it is vital to identify 
which ADRs are preventable. There is currently no universally accepted standard for the 
assessment of ADR preventability. Ferner and Aronson (2010) conducted a systematic 
review of the preventability of drug related harms in which they examined methods 
proposed to determine the preventability of ADRs. They identified seven proposed 
methods:  
1. analysis without explicit criteria  
2. consensus 
3. preventability linked to error  
4. preventability linked to standards of care  
5. preventability related to medication  
6. preventability linked to information technology  
7. the use of explicit lists 
They acknowledged that some authors use a combination of these approaches. They 
described the limitations of each method. In terms of consensus, it is possible for experts to 
agree but still be wrong. When considering preventability related to standards of care, if 
those standards are poorly defined it is difficult to determine preventability. In the final 
method, the investigator compiles an explicit list of potentially inappropriate medicines and 
then determines whether they were implicated in any adverse events. This approach 
considers only the medicine rather than the circumstances and the patient themselves and 
may result in an underestimate of how many ADRs are preventable.  
There are some methods described which appear to be suitable for preventability 
assessment but their remit could be interpreted as being inclusive of errors which are not 
consistently included in the definition of the ADR. One of these is the assessment of 
preventability linked to error; an example given is the widely used Hallas scale, which 
describes definitely avoidable ADRs as those in which ‘the drug event was due to a drug 
treatment procedure inconsistent with present-day knowledge of good medical practice or 
was clearly unrealistic, taking the known circumstances into account’ (Hallas et al., 1990). 
This may in some circumstances be considered a prescribing error depending on the details 
of the case.  
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Another of these methods is preventability related to medication which is exemplified by 
two commonly used tools, the Hartwig scale (Hartwig, Siegel and Schneider, 1992) and a 
tool devised by Schumock and Thornton (1992)(1992). Both tools describe the development 
of a drug allergy in a patient with documented drug allergy as a preventable ADR whereas 
some may consider this to be a drug error.  
The systematic review conducted by Ferner and Aronson (2010) was followed up with a 
proposed new method for the assessment of ADR preventability (Aronson and Ferner, 
2010). The proposed method takes into consideration both the mechanism of the ADR and 
its clinical manifestation and draws on both the DoTS and EIDOS classifications. It 
emphasises that in order to determine ADR preventability, we need to use the knowledge 
we have about how the implicated medicine acts and interacts as well as any information 
we have about the susceptibility of individual patients or populations (Figure 1.6). For 
example, it is known that patients develop a tolerance to carbamazepine-induced dizziness; 
therefore dizziness associated with the introduction of carbamazepine may be prevented 
by commencing the patient on a low dose which can be slowly titrated upwards.  
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Figure 1.6 Flowchart: how preventive strategies can be determined by considering the PKPD mechanisms of the adverse effect and the susceptibility of 
the patient, the time-course and the dose-responsiveness of the reaction (Aronson and Ferner, 2010) 
 
This text box is where the unabridged 
thesis included the following third party 
copyrighted material: 
Aronson, J. K. and Ferner, R. E. (2010) 
'Preventability of drug-related harms - 
part II: proposed criteria, based on 
frameworks that classify adverse drug 
reactions', Drug Saf., 33 (11), pp.995-
1002. Figure 2. 
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A recently published systematic review of ADRs in children highlighted that, amongst the 
120 studies included, only 21 performed a preventability assessment on the ADRs they had 
identified and only 13 of these presented preventability data (Smyth et al., 2012). The 
reasons why preventability has not been widely reported in paediatric ADR studies may 
include perceived problems with applying the tool criteria in the context of paediatric 
practice; for example, in cases which involve the management of a rare disease for which 
there is unlikely to be a well-defined standard of care.  
In cases where off-label or unlicensed medicines are implicated, questions about the 
appropriateness of dose, route and frequency may be difficult to answer. Indeed, although 
it did not focus on children, a study of the preventability of spontaneously reported ADRs 
focussed on the use of medicines outside the terms of the SmPC as a key factor in the 
process of preventability assessment. For any given ADR, if the suspected medicine was not 
prescribed in accordance with the SmPC and the non-conformity of the prescription to the 
SmPC was a known and validated ADR risk factor, the ADR was deemed to be either partly 
or entirely avoidable. The most frequently identified reasons for entirely avoidable ADRs 
were: not taking into account a history of allergy (could be considered an error), not taking 
into account altered renal function and not respecting the recommended dose (Jonville-
Béra et al., 2009). 
1.3 Off-label and unlicensed medicine use 
1.3.1 The regulation of medicines 
After a new medicine has been developed and before it can be marketed, it must receive 
approval from the regulatory authority of the country in which it is to be marketed. In the 
UK this regulatory body is the Medicines and Healthcare Devices Regulatory Authority 
(MHRA) and in the USA it is the Food and Drug Administration (FDA). Some medicine types 
in the UK are licensed by the European Medicines Agency (EMA) via the centralised 
procedure. This is a requirement for certain medicine types; high tech' biotechnology 
treatments such as gene therapies, medicines to treat HIV/AIDS, cancer, diabetes, and 
neurodegenerative diseases and orphan drugs (medicines developed for rare diseases, 
occurring in fewer than five in 10,000 people) (The European Parliament and the Council of 
the European Union, 2004).   
Pharmaceutical manufacturers are required to submit specified information to the relevant 
regulatory body; this information is derived from data obtained during the development of 
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the medicine and/or in the post-marketing period. It includes the precise indication and 
dosage of the product, instructions for administration, contraindications, interactions and 
possible adverse effects. If, after rigorous evaluation of the data and information 
submitted, the medicine is authorised it will be issued, in the UK or Europe with a 
Marketing Authorisation (MA) or, in the USA with an FDA approval (known as the ‘label’). 
One of the conditions of an approval is that the medicine is only marketed for use under 
the terms outlined in the MA; these terms reflect the content of the original information 
submitted by the manufacturer. This does not preclude the use of the medicine outside the 
terms of the MA by individual clinicians (Choonara and Dunne, 1998).   
In both Europe and the USA there is additional legislation pertaining to the development 
and approval of medicines for children namely the Regulation on Medicines for Paediatric 
Use (The European Parliament and the Council of the European Union, 2006) and the Best 
Pharmaceuticals for Children Act (Anon, 2007a) and the Pediatric Research Equity Act 
(Anon, 2007b).  
1.3.2 Definitions of off-label and unlicensed medicine use 
Broadly, the term ‘off-label medicine use’ is used to describe the use of a medicine outside 
the terms of its MA. The term ‘label’ in the USA is synonymous with MA. Other terms for 
off-label medicine use are ‘off-licence’ (Michael Tettenborn, 2003), ‘incorrect’ (Jonville-
Bera, Bera and Autret-Leca, 2005) and ‘not appropriate’ (Carvalho et al., 2003). 
The detailed definitions of off-label use proposed by Turner and Choonara (1997) have 
been widely used in subsequent studies of off-label prescribing albeit not always in their 
entirety and sometimes with modifications (Table 1.4). The use of a medicine may be 
defined as off-label if it matches at least one of the definitions. The detail of the definition 
varies between authors and is influenced by personal opinion, what information is available 
to them about the use of the medicine and also the setting of their study.  
In the case of surveys of prescription data, there is often no information recorded about 
indication so this aspect of off-label use cannot be examined (McIntyre et al., 2000, 
Bücheler et al., 2002, Schirm, Tobi and De Jong-van den Berg, 2002, Ekins-Daukes et al., 
2004, Neubert et al., 2004). This means that the prevalence of off-label use may be 
underestimated. The use of linked datasets would provide an advantage in such studies by 
linking the prescription data to the medical record, through the indication for the 
prescription could be determined. Some authors add detail, for example by defining off-
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label doses as only those 20% smaller or greater than that recommended (Chalumeau et al., 
2000). This approach takes into account the rounding up or rounding down of doses which 
may occur in practice to permit ease of preparation and administration. Another example is 
the inclusion of drug-drug interactions as a type of off-label use; a criticism of this is that 
the prescription of two interacting medicines is not always absolutely contra-indicated and 
so such a prescription would not necessarily contravene the terms of the MA (Jonville-Bera, 
Bera and Autret-Leca, 2005).  
Table 1.4 Definitions of off-label medicine use (Turner and Choonara, 1997) 
 
1. Medicine administered at a greater dose than recommended in the MA. 
2. Medicine administered for an indication not described in the MA. 
3. Medicine administered at a greater frequency than recommended in the MA. 
4. Medicine administered to children outside the age range specified in the MA. 
5. Medicine administered via a route not described in the MA. 
6. Medicine administered when a contra-indication is described in the MA. 
 
 
An unlicensed medicine is one which does not have a MA in the country in which it is being 
used. The term was coined at a time when MAs were referred to as product licences and a 
medicine which had received approval was referred to as being ‘licensed’.  
The definitions of unlicensed medicine outlined by Turner and Choonara (1997) have been 
adopted by most subsequent studies (Table 1.5). A medicine may have a MA in one country 
but it is still an unlicensed medicine if used in other countries even when used within the 
terms of that MA. Some studies define unlicensed medicines as those which are a 
modification of medicines which hold a MA, for example, the crushing of tablets to make an 
extemporaneous suspension in a pharmacy (Gavrilov et al., 2000, Bajcetic et al., 2005). 
Modification of medicines in this way has also been defined by some as off-label (Pandolfini 
et al., 2002).  Further discrepancies arise when authors include some of the uses commonly 
classified as off-label in their definition of unlicensed medicines, for example the use of a 
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contraindicated medicine or the use of a medicine with no dosing guidelines for children ('t 
Jong et al., 2002b).  
Table 1.5 Definitions of unlicensed medicines (Turner and Choonara, 1997) 
 
1. Modification to licensed medicines (e.g. extemporaneous pharmacy  
preparations) 
2. Licensed medicines in a modified formulation manufactured under a specials 
manufacturing licencei (e.g. a liquid form for ease of administration) 
3. New medicines available under a specials manufacturing licence (NB this assures 
the quality of the manufacturing process but not the safety or efficacy of the 
product)  
4. Use of chemicals as medicines 
5. Medicines used before a licence has been granted 
6. Imported medicines (licensed in another country) 
 
 
In view of these difficulties, the Task-force in Europe for Drug Development for the Young 
(TEDDY) Network of Excellence conducted a Delphi round survey. Their intention was to 
reach a consensus on the definitions of both unlicensed and off-label medicine use in 
children (Neubert et al., 2008).  
There was disagreement about some aspects of the definition amongst the 34 respondents 
in the first round of the survey which persisted amongst the 23 respondents in the second 
round. For example, the use of authorised drugs in an unapproved formulation prepared 
under good manufacturing practice (GMP) conditions e.g. by a pharmacist – was regarded 
as unlicensed by 42% of respondents while another 42% thought it was off-label. Similarly 
there was disagreement about use of authorised drugs in an unapproved formulation not 
prepared under GMP conditions e.g. by a parent – 50% thought it was unlicensed, 25% 
thought it was off-label and the remainder thought it was neither. The use of an authorised 
                                                          
i
 In the UK these are medicines made to satisfy an individual patient’s needs by a commercial or hospital MHRA 
licensed manufacturing unit  (MHRA, 2013) 
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drug in a condition labelled as ‘contraindicated’ was thought to be off-label by 21% of 
respondents, unlicensed by 33% and neither by 46%.  
Definitions of off-label and unlicensed use were agreed in the third round of the survey (20 
respondents). Off-label use was defined as:  
‘all uses of a marketed drug not detailed in the SPC including therapeutic indication, use in 
age-subsets, appropriate strength (dosage), pharmaceutical form and route of 
administration’ 
 Unlicensed use was defined as:  
‘all uses of a drug which has never received a European Marketing Authorisation as 
medicinal for human use in either adults or children’ 
1.3.3 Reasons for, and prevalence of, off-label and unlicensed medicine use in children 
Typically children have been excluded from the drug development process. There have 
been ethical concerns raised about testing new medicines on children. Investment in 
paediatric studies may also not give a good financial return because the number of patients 
for whom the product can be marketed is likely to be small. The result is that, although 
medicines which are authorised for use in children exist, there are many medicines which 
are not authorised for use in children and these have to be used off-label.  
Medicines to treat rare conditions may not be available at all and may have to be imported 
or made to satisfy an individual patient’s needs by a commercial or hospital MHRA licensed 
manufacturing unit or by a health care professional, for example a pharmacist. The 
available dosage forms of authorised medicines may not be appropriate for children to take 
so they may need to be altered before administration. This is done by pharmacists 
(extemporaneous preparation or compounding) and at the point of administration by a 
health-care professional, carer or patient (manipulation). These processes may or may not 
be supported by industry-generated data, pharmacopoeia information or peer-reviewed 
guidelines and some may also be outlined in the SmPC for the authorised medicine (Ernest 
et al., 2012).  
Out of necessity, clinicians prescribing for children commonly prescribe off-label and 
unlicensed medicines which have not been rigorously tested in children. The proportion of 
paediatric prescriptions which are off-label or unlicensed in the community setting is 11-
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40% and in hospital it is 22-87% (Kimland and Odlind, 2012).  For many off-label and 
unlicensed medicines used routinely in paediatrics, there is good information available 
about how they should be used which is derived from clinical experience and clinical 
studies. However for others, information is sparse and the data have not been subjected to 
regulatory scrutiny. Where the latter is true, children are being exposed to medicines for 
which the prescriber cannot make a detailed benefit-risk evaluation. In an attempt to 
address this problem, all new medicines under development in Europe now must have a 
paediatric investigation plan (PIP) and all applications submitted for a MA must contain the 
results of any studies included in that plan.  The pharmaceutical industry is now also 
offered incentives to develop medicines for use in children and to investigate and develop 
older off-patent medicines for paediatric use (The European Parliament and the Council of 
the European Union, 2006).  
1.4 Off-label and unlicensed medicine use and adverse drug reactions in children – an 
overview of the existing literature 
 
1.4.1 Search strategy and study selection 
 
A Medline search of titles and abstracts from 1950 to December 2009 was performed using 
the search terms unlicensed/ off-label/ license/ licensed/ licensing/ label/ labelled/ 
labelling/ approved/ approval/ unapproved/ prescription/ prescribed/ prescribing/ 
prescribe/ prescriber(s)/ incorrect AND adverse effects/ adverse drug reaction reporting 
systems / drug therapy / pharmaceutical preparations AND child/ child, preschool. An 
EMBASE search of titles and abstracts from 1980 to December 2009 was also performed 
using the search terms unlicensed and off-label use AND child AND adverse drug reaction/ 
drug surveillance program. The limits Human and English Language were applied to both 
searches.  
 
The method used to select papers for inclusion is summarised in Appendix 1. The titles 
were screened for reference to off-label and unlicensed medicine use or adverse drug 
reactions. Papers relating to specific treatments, conditions or reactions were excluded as 
well as those relating to prescribing and medication errors. Editorials, notes and letters 
were also excluded. The remaining abstracts (or papers when no abstract was available) 
were read and excluded if they made no reference to ADRs in the context of off-label or 
unlicensed medicine use. 
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The search was originally undertaken in December 2009 and 12 studies were identified. 
One additional study was identified by reviewing the reference lists of the original 12 and 
another was highlighted in a national update (Appendix 1). The search was updated in 2013 
during the preparation of this thesis, three additional studies were idenitified (Posthummus 
et al., 2012, Bissuel et al., 2013, Ballard et al., 2013). 
1.4.2 Prospective studies 
A prospective study of 5 months duration employed active patient follow up to monitor for 
adverse drug reactions in a community setting (Kramer et al., 1985).  No definition of ADR 
was provided. The percentage of patients who received off-label medicines was not 
recorded. The ADR incidence was 11.1% in the study population. This study considered only 
a single aspect of off-label medicine use: the receipt of a total daily dose above that 
recommended by the manufacturer. There was an increased relative risk of probable or 
definite ADRs in patients receiving medicines which were off-label for this reason (7% 
compared to 4.3%; relative risk 1.63; 95% CI 1.23, 2.16; p<0.001). The interpretation of 
these findings and their comparison with those of others is hindered by a lack of data on 
the prevalence of off-label medicine use and the inclusion of only one type of off-label use. 
Furthermore, since no definition of ADR was provided there is a possibility that reactions  
which were a result of medication errors were included. 
 
A prospective study carried out in the UK over 28 months (Gill et al., 1995) included all 
patients on a regional paediatric intensive care unit (PICU). No definitions of ADR or 
unlicensed medicine were provided. A medicine was described as off-label if it was 
prescribed at a different dose, for a different indication or for a child outside the age range 
specified in the MA. ADRs were detected by means of spontaneous reports from health 
professionals and daily chart review by a research pharmacist. There were 909 patients 
admitted to the PICU during the study and ten of these were admitted because of an ADR. 
76 ADRs were detected in 63 inpatients (7%), 25 (33%) of the medicines implicated in the 
76 ADRs were off label and one was unlicensed. In a subsequent study on the same PICU 
over a four month period 136 of the 166 patients admitted (70%) received at least one off-
label or unlicensed medicine during their stay (Turner et al., 1996). This demonstrates that 
although an association between ADR risk and off-label and unlicensed medicine use is 
implied by the initial study, it is important to take into account the prevalence of such use. 
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Turner et al. (1999) conducted a prospective study in a children’s hospital in the UK over 13 
weeks. It included the following specialities: medicine, surgery, neonatal surgery, cardiac 
PICU and general PICU. They did not record an ADR definition and their definitions of off-
label use and unlicensed medicines are shown in Tables 1.4 and 1.5. The primary reference 
source for details of the product licence (MA) was the Association of the British 
Pharmaceutical Industry’s (ABPI) data sheet compendium (1995-1996), while secondary 
reference sources were the package insert and the British National Formulary (BNF) 1996 
Edition.  ADRs were detected by means of spontaneous reports from health professionals 
and daily chart review by a research pharmacist. 936 of 1046 admissions reviewed received 
medicines during their hospital stay. The total number of prescriptions was 4455, of which 
1574 (35%) were off-label or unlicensed. 507 (48%) of these admissions received at least 
one unlicensed or off-label medicine and 116 (11%) of 1046 admissions experienced an 
ADR. 112 (3.9%) of 2881 authorised prescriptions were associated with an ADR and 95 (6%) 
of the 1574 off-label or unlicensed prescriptions were associated with an ADR. The number 
of medicines administered was significantly associated with the risk of an ADR but off-label 
or unlicensed medicine use did not impact ADR risk. There was a trend towards an 
increased risk of severe ADRs with off-label and unlicensed medicine use, 19 medicines 
were implicated in severe ADRs and of these, 14 were off-label or unlicensed. Again, the 
absence of an ADR definition in this study impacts of the interpretation of the results. The 
results must also be interpreted in the context of the specialties included. For example, due 
to differences in the clinical stability of the patients and the types of medicines being used, 
on PICU we might expect different ADR types and frequencies than on a general medical 
ward. Furthermore, because of differences in the the level of monitoring required there will 
be differences in how ADRs are detected and evaluated. For example, electrolyte 
disturbances may be easier to detect and subsequently monitor on PICU where they are 
monitored hourly than on a general medical or surgical ward where monitoring is more 
infrequent.  
 
A prospective pharmacovigilance study was undertaken in France over five months (Horen, 
Montastruc and Lapeyre-Mestre, 2002). The setting was community paediatric practice and 
patients <16 years old were included, no ADR definition was provided and the study did not 
consider unlicensed medicine use. Off-label medicine use was defined by one of seven 
categories which matched those described by Turner and Choonara (Turner and Choonara, 
1997) with the omission of ‘medicine administered at a greater frequency; the amendment 
of ‘medicine administered at a greater dose to ‘medicine administered at a different dose’ 
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and the addition of ‘medicine used in inadvisable co-prescription’. The source used for 
details of the MA was Dictionnaire Vidal 2000 (the French medicine formulary). All ADRs 
were identified by one of 39 participating paediatricians; they recorded the following 
information on the first patient seen during a medical visit or consultation until they had 40 
records: demographic details, age, weight, diagnosis and medicines prescribed (including 
dose and indication). The record was retained for seven days in order to describe any 
developing ADRs. 1419 patients were included and of these 20 (1.4%) experienced an ADR, 
18.9% of the total prescriptions were off-label and 42% of patients received at least one off-
label medicine. The incidence of ADRs in the population receiving at least one off-label 
medicine was 2%. In a multivariate analysis, the risk of ADR was significantly associated 
with exposure to off-label medicines (RR 3.44 95% CI 1.26, 9.38). In terms of the 
subcategories of off-label medicines use, medicines prescribed for an indication different to 
that recommended had the most significant impact on ADR risk (RR 4.42 95% CI 1.60, 
12.25). The mean number of medicines was 3.6 (standard deviation 1.5) in patients 
receiving off-label medicines and 2.6 (standard deviation 1.2) in patients not receiving off-
label medicines. This study did not include all patients within the community paediatric 
practice but relied on the participating clinicians to recruit the first patient seen, it is 
unclear whether this approach had the potential to introduce bias. It is also unclear 
whether data on ADRs were actively collected, for example by telephoning the patient or 
their family, or whether they were passively collected by waiting for the patient to return to 
the clinic with a problem. The latter approach would be likely to underestimate ADR 
incidence.  
Impicciatore et al. (2002) undertook a prospective study in Italy over 9 months. The setting 
was a paediatric ward and the WHO definition of ADR was used (World Health Organisation, 
1972), unlicensed medicine use was not considered in this study. Prescriptions were 
assigned off-label status as described by Turner and Choonara (1997) with the omission of 
‘medicine administered when a contra-indication is described’ and ‘medicine administered 
at a greater frequency than recommended’ and the amendment of ‘medicine administered 
at a greater dose’ to ‘medicine administered at a different dosage or frequency’. All eligible 
patients were monitored and demographic information, weight, reason for admission, 
length of stay and prescription information was recorded. The prescription information 
recorded was dose, route, indication, duration and changes. Of 1619 patients, 41 (2.53%) 
experienced an ADR, 29 ADRs were attributed to medicines administered in the hospital 
(1.8%) and 12 ADRs were attributed to medicines administered before admission (0.74%). 
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In 16 (39%) of the 41 patients experiencing an ADR, it was caused by a medicine which was 
being used off-label. This was made up of 11 (38%) of the 29 patients who experienced an 
ADR due to medicines administered in the hospital and 5 (42%) of the 12 patients who 
experienced an ADR due to medicines administered before admission. The authors 
commented that there was an association between off-label medicine use and the 
occurrence of ADRs but that the small study size limited an evaluation of its significance.  
Neubert et al. (2004) conducted a prospective study in Germany over eight months in 2001. 
The setting was a ten-bed paediatric ward, patients <18 years were included and the WHO 
definition (World Health Organisation, 1972) of ADR was used. To retrospectively assign off-
label or unlicensed status to the use of a medicine, the system described by Turner and 
Choonara (1997) was used. Some details of the off-label definition were expanded - if use in 
children was not mentioned, the minimum age for use was assumed to be 18 years, if use in 
children was mentioned but without a specified age range, the minimum age was assumed 
to be 0 years. If the medicine was being used in a child of an authorised age via an 
authorised route and the dose did not exceed the maximum recommended (for any 
indication) then the use was considered not to be off-label. The primary reference source 
for details of the MA was Fachinfo (2001) and the secondary source was Rote List 2001 
(equivalent of the BNF). ADRs were identified by a weekly review of patient charts; this was 
conducted by a team comprised of a clinical pharmacologist, a pharmacist and a 
paediatrician. 178 patients were reviewed and 156 of these had received at least one 
medicine, the total number of prescriptions was 740, of these three (0.4%) were unlicensed 
medicines and 195 (26.3%) were off-label, 25 (3.4%) could not be classified. 31(17.4%) of 
the 178 admissions experienced an ADR and 92 (51.7%) patients received at least one off-
label or unlicensed medicine. Of the 517 licensed prescriptions, 29 (5.6%) were associated 
with an ADR and of the 198 off-label or unlicensed prescriptions, 12 (6.1%) were associated 
with an ADR. The risk of ADR increased with number of medicines prescribed but there was 
no significant relationship between off-label or unlicensed medicine use and the risk of an 
ADR. Patients receiving at least one off-label or unlicensed medicine experienced at least 
one ADR more frequently (26 out of 92 patients, 28.3%) than those receiving only licensed 
medicines (5 out of 64 patients, 7.8%). In this study, the retrospective approach to 
classification meant that the indication for use could not be assessed and it was not always 
clear from the patient record precisely which formulation had been administered. If a 
classification could not be made because information was incomplete, the prescription was 
excluded from further analysis. The exclusion of ‘different indication’ as a type of off-label 
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use will have resulted in an underestimate of off-label medicine use. If some of these off-
label medicine courses contributed to ADRs, the study may have demonstrated a 
relationship between off-label use and ADR risk. 
A Brazilian study carried out over 5 months was undertaken in a 36 bed paediatric ward, no 
definition of ADR was given (Santos et al., 2008). Unlicensed medicines were those:  
 contraindicated for use in children  
 extemporaneous preparations that were manufactured (home label medicines) or 
modified by the hospital or nurse 
 drugs for which safety and efficacy in the paediatric population were not 
established  
Off-label medicines were those for which the prescription showed a discrepancy with the 
licence information for:  
 age (or weight)  
 dose (or frequency)  
 route of administration  
 formulation 
ADRs were detected on a daily ward visit by a clinical pharmacist who reviewed medical 
records and attended clinical rounds. 272 patients were reviewed, 265 had received at least 
one medicine and 47 ADRs were detected in 33 children. 5.5% of prescriptions were 
unlicensed, 39.6% were off-label. 82.6% of children had received at least one unlicensed or 
off-label drug. The ADR incidence was 12.5% in whole study population and 16.3% in 
patients exposed to at least one off-label drug. The definitions of off-label and unlicensed 
medicines used in this study were different to those used in the majority of others. 
Medicines contra-indicated for use in children and those for which safety and efficacy in 
children were not established were defined as unlicensed rather than off-label. In 
agreement with previous studies, extemporaneous preparations were defined as 
unlicensed however, unlike in other studies, modifications by nursing staff were also 
included. These discrepancies in defining off-label and unlicensed medicines complicate the 
interpretation of the results of this study. This is one of only two non-European studies 
included in this review of the literature and therefore the results must also be interpreted 
in the context of differences in the patterns of disease and medicine use. For example, 
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there were a high number of prescriptions for anthelmintics, this was not seen in other 
studies. 
A prospective study of admissions related to ADRs was carried out in a paediatric hospital in 
The Netherlands over a period of 18 weeks (Posthumus et al., 2012). ADR was defined as 
‘an unintended noxious response to a drug’ and the medicines implicated in an ADR were 
categorised as ‘licensed’, ‘unlicensed’ or ‘off-label used’. ‘Licensed’ medicines were 
registered for children at the Dutch Medicine Evaluation Board, and ‘unlicensed’ medicines 
were not, ‘off-label used medication’ referred to medicines used outside the terms of the 
product licence. 47 of 683 (6.9%) patients were admitted due to an ADR and eight ADRs 
involved an unlicensed medication, eight involved medicines used off-label and 16 involved 
a combination of unlicensed, off-label and licensed medications. In contrast to the majority 
of other studies, this study included medication errors which resulted in an adverse drug 
reaction in the definition of ADR. Two ADRs which resulted from a medication error were 
identified. Exposure to cancer chemotherapy had a significant impact on the results of this 
study. 68.1% of admissions who had been exposed to cancer chemotherapy were admitted 
due to an ADR, compared to 2.4% of non-oncology admissions. ADRs detected in the 
oncology sub-group were more likely to be attributed to an off-label or unlicensed medicine 
(84.6%) than those in the non-oncology sub-group (33.3%) but this finding must be 
interpreted with caution due to the small size of the study. Since the medicines not 
involved in an ADR were not categorised, it was not possible to compare ADR risk for off-
label or unlicensed medicines and licensed medicines. 
A study of off-label and unlicensed prescribing and related ADRs in France included patients 
aged 0-16 years who consulted their general practitioner (GP), it was undertaken over a 
period of 5 months (Bissuel et al., 2013). No definition of ADR was provided. Off-label 
prescribing was defined as prescribing outside the specifications of the SmPC and 
unlicensed medicines were those without a valid MA. Amongst 1960 patients who received 
at least one prescription, 37.6% were exposed to at least one off-label medicine and 6.7% 
to at least one unlicensed drug. The most common type of off-label use was for an 
unapproved indication. There were 23 ADRs reported; the ADR incidence in the entire 
population was not significantly different to that in the subpopulation of patients exposed 
to at least one off-label prescription (1.0% vs. 1.5%). It is unclear whether active 
surveillance for ADRs was undertaken in this study, or whether ADRs were only identified if 
patients re-presented. The study relied on the GP, rather than an independent observer, to 
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detect and record the ADR. If no definition of ADR was provided to the GPs involved in the 
study, it is possible that they may have overlooked some ADRs or included drug-related 
problems which were not ADRs. Furthermore, it is possible that they may have been less 
willing to report an ADR to an off-label or unlicensed medicine because of concerns about 
their liability for the event. 
1.4.3 Retrospective studies 
A retrospective study of off-label prescribing for paediatric inpatients (< 12 years old) in 
Australia examined the medical records and prescription charts of 300 patients admitted 
over approximately 3 months (Ballard et al., 2013). Prescriptions were classified as off-label, 
registered (i.e. licensed) or unregistered (i.e. unlicensed) using eMIMS as a reference for 
the Australian Product Information (PI). A medicine could be classified as off-label for one 
or more of the following reasons: dose/frequency, age/weight, indication or route. 32% of 
prescriptions were off-label; the most common category was dose or frequency greater 
than that sanctioned by the PI. Five ADRs were identified (incidence 1.7%) of which two 
involved off-label medicines. The retrospective design of this study relied on the accurate 
recording of both prescription details and suspected ADRs. Although the proportion of off-
label prescriptions was similar to that reported in other inpatient studies, the ADR 
incidence reported was lower, which may reflect poor record-keeping. 
1.4.4 Studies of spontaneous ADR reports 
Studies of spontaneous ADR reports seek to characterise those ADRs and consider trends in 
ADR reporting. They are unable to estimate ADR incidence because not every ADR is 
reported. Guidance varies between countries but, in general, spontaneous reporting 
schemes request that only serious or unexpected ADRs be reported. Furthermore, they 
cannot estimate the likelihood of an ADR for a particular medicine because, in addition to 
incomplete reporting, data on medicine consumption in the general population is not 
always available. In the context of this review of the literature, their value is limited since 
they cannot compare the rate of ADRs with authorised medicines to that with off-label or 
unlicensed medicines. 
 
Ufer, Kimland and Bergman (2004) reviewed a national database of spontaneous ADR 
reports in Sweden during the year 2000. The system relies on the legal obligation of 
healthcare professions to report ADRs to new medicines and ADRs which are serious, 
uncommon or unexpected.  The WHO definition of ADR was used (World Health 
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Organisation, 1972) and they selected reports involving individuals < 16 years old and 
excluded ADR reports concerning over the counter preparations, vaccines given at vaccine 
centres, medicines administered during pregnancy and affecting the newborn and 
medicines administered in hospital.  The primary reference sources for details of the MA 
were the Swedish Physician’s Desk Reference (2000) and Pharmacy Prepared Drugs (2000), 
the secondary source was product information provided by the medicines regulatory 
authority (Swedish MPA) or the manufacturer. To assign off-label or unlicensed status to 
the use of a medicine, the authors used a similar system to Turner and Choonara (1997) 
with some amendments:  
 ‘Medicine administered when a contra-indication is described’ was omitted  
 If no information about paediatric use was found, the use was classified as off-label  
 If paediatric use was mentioned but no age was specified, the use was not classified 
as off-label  
 If the dose was weight or surface area based, this was estimated according to age. 
 ‘Medicine administered at a greater dose than recommended’ was defined as a 
dose exceeding that recommended by greater than 20%  
The study included 112 reports and these contained 158 ADRs; of these 42.4% were related 
to off-label medicine use. Of the ADRs reports classified as serious, 51% were related to off-
label medicine use and 38.5% of non-serious ADRs were related to off-label medicine use. 
Schirm et al. (2004) reviewed a national database of spontaneous ADR reports in the 
Netherlands from 1995-2001 and aimed to compare these reports with the use of 
medicines in the general paediatric population. The reports were spontaneous and more 
likely to concern reactions to new medicines or those considered serious or unexpected. All 
ADR reports from GPs or pharmacists for children aged 0-16 years were included; reports 
concerning vaccines were excluded. The use of medicines in the general population was 
obtained from a regional community pharmacy database. For each medicine, the following 
details were obtained – demographic data for recipient, route, licensed / unlicensed / off-
label, frequency of use in the population, years on the market (>/<10 years) and target 
organ class. Off-label medicine use was defined as follows: the medicine was not authorised 
for use in children or if the child was below the minimum age specified. The dose, 
frequency, route and indication were not considered. Unlicensed medicines were defined 
as those without a MA; in this study this would only include pharmacy preparations. It was 
determined that, in the general paediatric population, 23% of medicines were off-label and 
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14.6% of medicines were unlicensed and in 773 paediatric ADR reports 24% of medicines 
suspected of causing an ADR were off-label and 1.9% were unlicensed. As well as evaluating 
data on off-label and unlicensed medicine use in a sample of the national paediatric 
population represented in spontaneous ADR reports, this study evaluated paediatric 
medicine use in a regional population. The retrospective approach to medicine 
categorisation meant that several aspects of off-label use could not be assessed. Therefore 
the rate of off-label prescribing may have been underestimated. Since the spontaneous 
reports were more likely to concern reactions to new medicines or those considered 
serious or unexpected, the sample did not reflect the full range of ADRs in the population 
and may have over- or under-estimated the relative involvement of off-label and 
unlicensed medicines. 
Spontaneous paediatric ADR reports were reviewed in one region of the UK over three 
years (1998 - 2000) (Clarkson et al., 2004). The principle aim of the study was to evaluate a 
regional paediatric ADR monitoring scheme and reports were received from 20 selected 
hospitals. To assign off-label or unlicensed status to the use of a medicine, the system 
described by Turner and Choonara (1997) was used. The SmPC for a medicine was used as 
the reference source when assigning off-label status to medicines and the manufacturer of 
the medicine was contacted if further clarification was required. Over the period of the 
study, 456 ADR reports were received and 242 of these were used for the analysis. 84 (35%) 
involved a medicine that was either used off-label or was unlicensed. The reports were 
classified in several ways including those considered to be medically significant i.e. fatal, 
potentially life threatening or disabling. 45 (27%) of the 165 reports considered to be 
medically significant involved a medicine that was either used off-label or unlicensed. There 
were ten fatalities associated with a suspected ADR, four were associated with an off-label 
medicine and two were associated with an unlicensed medicine, this association was not 
statistically significant.  
Jonville – Bera, Bera and Autret-Leca (2005) reviewed all ADR reports (adult and paediatric) 
sent to a French regional pharmacovigilance centre over a period of five months. The 
reports were submitted by physicians under a legal obligation to report serious or 
unexpected ADRs. The information obtained for each report included ADR details and also 
precise information about the medicine, in particular its indication. A medicine was defined 
as being used incorrectly (off-label) if it was not being used according to the specifications 
in the SmPC. The defined categories of incorrect medicine use were:  
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 administered at a different dose than recommended  
 administered for an indication not described  
 administered when a contra-indication was described  
 used for an improper duration 
 involved in a drug-drug interaction  
Incorrectly used medicines were more often causally linked to ADRs than correctly used 
medicines. 182 reports were reviewed: there were 169 ‘incorrectly’ used medicines and 
127 (75%) of these were implicated in an ADR, 281 (59%) of 473 ‘correctly’ used medicines 
were implicated in an ADR.  
A study of paediatric ADR-related queries to a drug information centre over a period of 10 
years was carried out in Sweden (Kimland et al., 2007). Unlicensed medicines were defined 
as those not in the Swedish catalogue of medical products (FASS). Off-label medicines were 
those which fulfilled at least one of the following criteria: 
 explicitly not recommended in children 
 administered for an indication not described  
 administered to children outside the age range specified 
 no information about the mode of paediatric use 
 no paediatric safety or efficacy studies 
The prevalence of off-label and unlicensed medicine use in the general population was not 
described. The study found that of 91 ADR-related queries, 27% involved off-label 
medicines and 17% involved unlicensed medicines. Jonville-Bera et al. (2009) undertook a 
retrospective evaluation of spontaneous ADR reports (for adults and children) received at a 
French pharmacovigilance centre over a period of 1 year. The study did not consider 
unlicensed medicine use and they defined off-label use as the use of the medicine outside 
at least one of the recommendations in the summary of product characteristics, with 
specific attention to;  
 duration of treatment 
 dose adaptation 
 precautions for use  
 monitoring of treatment 
 absolute contraindications  
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 indication 
 route 
32% of 360 ADR reports were associated with off-label medicine use. 
A retrospective study of ADR reports for children 0-17 years which were submitted in 
Denmark over a ten year period (1998 to 2007) included 4388 reports (Aagaard and 
Hansen, 2011). The reporting of ADRs in Denmark has been obligatory for doctors and 
dentists since 1972 and has also been possible for patients since 2003. The authors used 
the WHO definition of ADR (World Health Organisation, 1972) and the SmPC as their source 
for details of each MA, off-label medicine use was defined as the use of a medicine in a 
child below the recommended age group listed in the SmPC. There was also a focus in the 
study on the seriousness of the ADR and a serious ADR was defined as one that was either 
fatal or life threatening, required hospitalisation or prolonged hospitalisation, resulted in 
significant disability or incapacity or another medically important condition. 17% of the 
reports involved an off-label medicine with two thirds of these involving children between 
11 and 17 years old. Of the ADRs reported which did not involve off-label medicines, 35% 
were classified as serious whereas of those that did involve off-label medicines, 60% were 
classified as serious. 
1.5 Summary 
In summary, adverse drug reactions are a significant problem in children but their 
predictors are not fully established. One risk factor that has been proposed is the use of off-
label and unlicensed medicines. In previous studies of the link between off-label and 
unlicensed medicine and ADR risk there have been discrepancies between how authors 
have defined ADR, off-label medicine use and unlicensed medicine; this makes the 
interpretation of their results far from straightforward. However, there seems to be some 
indication that off-label and unlicensed medicine use is an ADR risk factor and this warrants 
further detailed investigation. 
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1.6 Aim of thesis 
1.6.1 Aim 
The aim of this thesis was to assess, within the ADRIC programme, the 
characteristics of adverse drug reactions (ADRs) in children in a large children’s 
hospital. The thesis focusses on the contribution of off-label and unlicensed 
medicines to ADR risk.  
1.6.2 Objectives 
 Determine the contribution of off-label and unlicensed medicine use to ADR risk 
when the ADR has led to or contributed to hospital admission. 
 Determine the contribution of off-label and unlicensed prescribing to ADR risk 
when the ADR has occurred during hospital admission. 
 Describe in detail off-label and unlicensed medicine use, determine whether some 
types of off-label or unlicensed medicines are more likely to be implicated in ADRs 
than others. 
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2 ADRs detected at the point of admission to a children’s hospital – 
contribution of off-label and unlicensed medicine use to ADR risk  
2.1 Introduction 
A recent meta-analysis, which included eight studies, reported the incidence of ADRs in 
children being admitted to hospital as being between 0.6% and 6% (Clavenna and Bonati, 
2009). A recent systematic review included 31 studies of paediatric hospital admissions and 
reported an ADR incidence of between 0.4% and 10.3% (Smyth et al., 2012). A better 
understanding of the risk factors which predispose children to ADRs will contribute to 
strategies for their prevention and management. 
There are no large paediatric studies which have looked at ADRs leading to hospital 
admission and then gone on to consider the influence of off-label and unlicensed medicine 
use. One small pilot study included ADRs to medicines administered before admission and 
recorded whether the medicines implicated were off-label (Impicciatore et al., 2002). Of 
the 41 ADRs detected in 41 of 1619 patients, 12 were attributed to medicines administered 
before admission and 29 were due to medicines administered in hospital. In 16 of the 41 
patients experiencing an ADR, an off-label medicine was implicated; five of these were 
patients who experienced an ADR due to medicines administered before admission. A 
second admissions study included 683 patients, of whom 47 were admitted due to an ADR. 
Of 47 ADRs, 20 involved an off-label or unlicensed medicine (Posthumus et al., 2012). 
Neither study was large enough to prove or disprove a relationship between off-label and 
unlicensed medicine use and ADR risk. 
This present study aims to describe the contribution of off-label and unlicensed medicine 
use to the risk of ADRs detected at the point of admission to a children’s hospital.  
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2.2 Methods 
2.2.1 Setting & participants  
A twelve month prospective cohort study of unplanned admissions to a paediatric tertiary 
referral centre in the UK was carried out from 1st July 2008 to 30th June 2009. The study 
included children between the ages of 0 and 16 years 11 months. A sample size calculation 
for this cohort study was not undertaken, since the aim of the study was to determine the 
incidence of ADRs in unplanned admissions. Unplanned admissions were defined as those 
via the accident and emergency department (AED) and emergency transfers from other 
hospitals. Also included in this definition were unplanned admissions direct to wards, for 
example, acutely unwell patients under the care of the oncology unit.  Patients who were 
electively admitted were excluded. The study also excluded patients who presented with 
deliberate or accidental overdose and those in whom the misuse of medicines (prescription 
or illicit) had occurred. This study was part of a larger study which used routinely collected 
clinical data in an anonymised format. The Chair of Liverpool Paediatric Research Ethics 
Committee (REC) informed us that this study did not require individual patient consent or 
review by an Ethics Committee. The planned analysis required routinely collected patient 
data and was therefore classified as an audit (Appendix 13). 
2.2.2 Data collection 
Patients were identified on a daily basis by use of a file download of new admissions from 
the hospital electronic patient record system (Meditech®). The file contained the details 
required for the patient to be identified and located within the hospital, that is, name and 
ward and also some of the details that were required for analysis:  age, sex and admitting 
specialty. Each eligible patient was reviewed by one member of a multidisciplinary team 
which consisted of a trainee paediatrician, a paediatric nurse and a pharmacist (JRB). JRB 
reviewed 2969 of 8345 unplanned admissions (Gallagher, 2013). The aim of the review was 
to collect the minimum dataset (Table 2.1) and to determine whether any of the signs or 
symptoms recorded at the time of admission could be attributable to medicines 
administered in the preceding two weeks. The data were obtained from one or more of the 
following sources at the team’s discretion: hospital electronic medical records system 
(Meditech®), patient casenotes, clinical team, the patient themselves or their parents.  If an 
ADR was suspected, the case was taken through further evaluation by the study team. A 
case report was compiled by one member of the team. The case report described in detail 
the suspected ADR inclusive of the results of any investigations and any action taken by the 
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clinical team and its outcome. Each ADR case report was then used to assess the following: 
causality using the Liverpool Causality Assessment Tool (LCAT), (Gallagher et al., 2011) 
severity using the Hartwig scale (Hartwig, Siegel and Schneider, 1992) and avoidability using 
the system described by Hallas et al (1990). JRB identified and evaluated 96 of 240 ADRs 
(Gallagher, 2013). 
Table 2.1 Minimum dataset collected for all eligible patients 
 
 Age  
 Sex  
 Weight 
 Admitting speciality 
 Underlying diagnoses 
 Presenting complaint, signs and symptoms. 
 Details of all medicines administered in the 2 weeks before admission, including 
over the counter medicines, herbal medicines and prescribed medicines 
 
 
2.2.3 Classification of Medicines 
The details of any medicine taken at any time during the two weeks before admission were 
recorded by the study team, specifically:  drug name, route, dose, frequency, duration, 
indication (if this required clarification) and whether it was a prescription or non-
prescription medicine. The definition of a prescription medicine included those 
administered under a patient group direction. A medicine course was defined as the 
administration of one type of medicine at least once in the preceding two weeks; this 
encompassed regular medicines e.g. daily anti-epileptic treatment, short courses e.g. a five 
day course of antibiotics and intermittent doses e.g. paracetamol for fever given as 
required. 
The data on prescription medicine use were scrutinised by one member of the study team 
(JRB) in order to define each medicine course as either authorised, off-label, unlicensed or 
unknown. Non-prescription medicine courses were not classified because the focus of the 
study was on off-label and unlicensed prescribing. The use off-label and unlicensed non-
 47 
 
prescription medicines by parents and patients involves a different range of medicines and 
happens for different reasons.  
Authorised use was defined as the use of a medicine with a UK marketing authorisation 
(MA), within the terms of that MA. The terms of the MA were found in the Summary of 
Product Characteristics (SmPC) available online from the Electronic Medicines Compendium 
(eMC) (DataPharm Communications Ltd., 2010). The version of the SmPC which was the 
most up to date during the study was referred to. The ‘date of revision of the text’ at the 
end of the electronic SmPC indicated when the information was last updated, if the 
document had been updated since the date that the medicine was administered, the 
contemporaneous SmPC was consulted.  
If no SmPC was available, the British National Formulary for Children (BNF-C) (Paediatric 
Formulary Committee, 2008/2009) was consulted for details of the product MA. If neither 
reference source provided adequate clarity of information, the manufacturer of the 
medicine was contacted.  
Off-label use was defined as the use of a medicine with a UK MA, outside the terms of that 
MA. A medicine was defined as off-label in this study if its use fitted one of the definitions 
in Table 2.2, adapted from Turner and Choonara (1997). The specific type of off-label use 
was not prospectively recorded. Since the primary purpose of the SmPC is not to inform the 
classification of medicines in this study, it was necessary to develop and apply some rules 
for the classification of licensed medicines in various scenarios by reference to the SmPC 
(Table 2.3). Where there was ambiguity in the classification process, rules for specific 
medicines and groups of medicines were developed and applied (Table 2.4).  
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Table 2.2 Definitions of off-label use 
 
1. Medicine administered at a greater dose than recommended in the MA, doses less 
than those recommended will be considered to be authorised 
2. Medicine administered for an indication not described in the MA 
3. Medicine administered at a greater frequency than recommended in the MA 
4. Medicine administered to children outside the age range specified in the MA 
5. Medicine administered via a route not described in the MA 
6. Medicine administered when a contra-indication is described in the MA 
7. Medicine administered in combination with another medicine when the 
combination is contraindicated in the MA 
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Table 2.3 Rules for the classification of licensed medicines by reference to the SmPC 
  
Scenario Rule 
 
SmPC states ‘not suitable for children’ or makes no 
reference to use in children  
 
Apply the age range 0-18 years and 
classify as off-label 
 
SmPC does not provide neonatal (0-27 days) doses 
 
Classify use in a neonate as off-label 
 
Medicine administered off-label for only part of 
the treatment course  
 
Classify as off label 
 
Exact concentrations of inhaled anaesthetic 
administered not recorded  
 
Assume that the dosage 
recommendations in the SmPC have 
been complied with 
 
Intravenous medicines prepared on a ward or in 
the Central Intravenous Additive Service (CIVAS)  
 
Assume that the preparation 
recommendations in the SmPC have 
been complied with 
 
Dosage form likely to have been manipulated 
before administration 
 
Do not  take in to consideration as 
will not have been recorded 
consistently 
 
Weight or surface area not recorded but is 
required to check that doses are authorised 
 
Use the age-related values found in 
the appendix ‘approximate 
conversions and units’ of the BNF-C 
(Paediatric Formulary Committee, 
2008/2009) 
 
Neonates born pre-term 
 
Although it is certainly not the case, 
assume that all neonates were born 
at term because gestational age was 
not recorded in this study 
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Table 2.4 rules for the classification of specific medicines and groups of medicines 
  
Medicine or medicine group Rule 
 
Aspirin oral  
 
Assume use is authorised unless being 
used as an analgesic. SmPC states not 
to be administered to children unless 
specifically indicated, main use at this 
centre is in cardiac cases i.e. 
specifically indicated 
 
Beclomethasone inhaled  
 
Assume Clenil® brand has been 
prescribed (this formulation is 
licensed in children 2-12 years) 
 
Codeine oral 
 
If dose is 15mg, 30mg, 45mg or 60mg 
might have had tablet or liquid, 
tablets not licensed in children but 
liquid is so allocate unknown. If any 
other dose assume liquid used. 
 
Cytotoxic drugs (medicines in BNF-C section 8.1) 
 
If BNF-C states ‘consult local 
treatment protocol’ assume use is 
authorised provided that the relevant 
indication is mentioned in the SmPC, 
if BNF-C states ‘not licensed in 
children’ classify use as off-label 
 
Diclofenac oral  
 
Dosage forms >25mg not licensed in 
children. If dose = 25mg and dose 1-
2mg/kg, assume used 25mg tablet i.e.  
course is authorised. If dose >25mg 
we do not know if they used 2 x 25mg 
or 50mg (50mg dispersible are 
available in our centre) therefore 
allocate unknown. 
 
Ibuprofen oral  
 
Use BNF-C 2008/09 (Paediatric 
Formulary Committee, 2008/2009) 
dose rangesii  and categorise all use in 
children under 3 months as off-label 
                                                          
ii Child 3–6 months 50 mg 3 times daily; max. 30 mg/kg daily in 3–4 divided doses 
Child 6 months–1 year 50 mg 3–4 times daily; max. 30 mg/kg daily in 3–4 divided doses 
Child 1–4 years 100 mg 3 times daily; max. 30 mg/kg daily in 3–4 divided doses 
Child 4–7 years 150 mg 3 times daily; max. 30 mg/kg daily in 3–4 divided doses 
Child 7–10 years 200 mg 3 times daily; max. 30 mg/kg (max. 2.4 g) daily in 3–4 divided doses 
Child 10–12 years 300 mg 3 times daily; max. 30 mg/kg (max. 2.4 g) daily in 3–4 divided doses 
Child 12–18 years initially 300–400 mg 3–4 times daily; increased if necessary to max. 600 mg 4 times daily; 
maintenance dose of 200–400 mg 3 times daily may be adequate 
 
 
 51 
 
 
Low birth weight infant supplements  
 
Multivitamins Dalivit® and Abidec®– if 
dose not recorded assume 
authorised. 
Sodium feredetate and folic acid to be 
categorised as off-label - they are 
indicated for the treatment of 
deficiency rather than prevention 
 
Omeprazole oral  
 
If treatment time exceeds 2-4 weeks 
or indication is anything other than 
gastro-oesophageal reflux disease 
(GOR), categorise as off-label 
 
Paracetamol oral  
 
Use BNF-C 2008/09 (Paediatric 
Formulary Committee, 2008/2009) 
dose rangesiii and refer to the SmPC 
for details of lower age limit i.e. 
categorised use in children under 2 
months old as off-label and all use 
except for post-immunisation pyrexia 
in children under 3 months old as off-
label 
 
Paracetamol infusion 
 
Assume licensed product has been 
administered. Although some doses 
are packed down by CIVAS it will not 
be clear from the prescription 
whether this is the case. 
 
                                                                                                                                                                    
 
iii Child 1–3 months 30–60 mg every 8 hours as necessary   
Child 3–12 months 60-120 mg every 4–6 hours (max. 4 doses in 24 hours) 
Child 1–6 years 120-250 mg every 4–6 hours (max. 4 doses in 24 hours) 
Child 6–12 years 250–500 mg every 4–6 hours (max. 4 doses in 24 hours) 
Child 12–18 years 500 mg 4–6 hours (max. 4 doses in 24 hours) 
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Unlicensed medicines were defined as those without a UK MA and could be one of the 
types listed in Table 2.5, as per Turner and Choonara (1997). A reference list of unlicensed 
medicines in use at Alder Hey was obtained from the pharmacy procurement department 
to assist in the identification of which products had been used. The specific type of 
unlicensed medicine was not prospectively recorded.  
An ‘unknown’ category was reserved for medicine courses for which inadequate detail was 
available to decide whether use was authorised, off-label or unlicensed. 
Table 2.5 Definitions of unlicensed medicines 
 
1. Modification to licensed medicines (e.g. extemporaneous pharmacy  
preparations) 
2. Licensed medicines in a modified formulation manufactured under a specials 
manufacturing licence (e.g. a liquid form for ease of administration) 
3. New medicines available under a specials manufacturing licence (NB this gives 
some assurance of the quality of the manufacturing process but not to the standard 
of a licensed medicine, the safety and efficacy of the product will not have been 
assessed)  
4. Use of chemicals as medicines 
5. Medicines used before a licence has been granted 
6. Imported medicines (licensed in another country) 
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2.2.4 Data analysis  
Advice on the approach to analysis was obtained from the ADRIC programme statistics 
team and broadly reflects the approach taken in the cohort study, of which this work is a 
part. The analysis was carried out by JRB. 
2.2.4.1 All first admissions – patient risk factors 
Some participants had more than one unplanned admission during the study, in order to 
avoid including the same patients (and potentially the same medicine courses) repeatedly 
in the analysis, risk factors were analysed for first admissions only. Using data obtained for 
each participant who had received at least one prescription medicine course, univariate 
analysis was performed to compare differences in ADR risk factors for patients with ADRs 
and those without  (age, gender, number of prescription medicines, whether they were 
oncology patients and off-label/unlicensed prescription medicine use).  Categorical 
outcomes were compared between groups using the chi-square statistic. For normally 
distributed data, the Student t-test was used to compare groups while for non-normally 
distributed data, the Mann-Whitney U test was used.  
A logistic regression model was used to assess the influence of independent variables (risk 
factors) on the likelihood of an ADR occurring. Differences were considered significant at 
the 5% level (p < 0.05), and where appropriate, all results were presented with 95% 
confidence intervals.  
Post-hoc, two separate logistic regression models were used to explore two of the 
significant risk factors identified in the initial logistic regression model; number of 
medicines and being an oncology patient. 
A second logistic regression model was used to assess the influence of the independent 
variable ‘number of medicines’ by splitting it into three variables as follows: number of 
authorised prescription medicines, number of off-label or unlicensed prescription 
medicines, number of unknown prescription medicines. Consideration was given to splitting 
this variable further by separating off-label and unlicensed medicines. Since this was a post-
hoc analysis, it was known that only around 960 out of 16 551 medicines (6%) were 
unlicensed and that only 51 of 481 medicines (10.6%) implicated in an ADR were 
unlicensed, therefore the variable was not split further.  
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A third logistic regression model was used to assess the influence, in non-oncology patients 
only, of the variables age, gender, number of authorised prescription medicines, number of 
off-label or unlicensed prescription medicines and number of unknown prescription 
medicines. 
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2.2.4.2 All admissions – medicine courses 
The proportions of all prescription medicine courses which were authorised, off-label or 
unlicensed were calculated for prescription medicine courses administered to all 
participants on every admission. 
To determine the likelihood of medicine courses in each of these categories being 
implicated in an ADR, the relative risk (with 95% confidence intervals) for off-label and 
unlicensed medicine courses being implicated in an ADR was calculated for prescription 
medicine courses administered to all participants on every admission. A p-value of <0.05 
was considered to be significant. 
The clinical details of ADRs involving off-label and unlicensed medicine courses were 
described for non-oncology and oncology ADRs. 
Post-hoc, the proportion of authorised, off-label or unlicensed prescription medicine 
courses was calculated for the medicines administered to two patient sub-populations: 
non-oncology patients and oncology patients. The relative risk (with 95% confidence 
intervals) for off-label and unlicensed medicine courses being implicated in an ADR was 
calculated for medicine courses both non-oncology and oncology patients. 
Additional post-hoc analysis was undertaken on the descriptive data relating to ADR cases. 
The difference in proportions (with 95% confidence intervals) for causality, avoidability and 
severity of ADR cases was compared for two ADR case subgroups: ADRs not involving off-
label or unlicensed medicines, ADRs involving at least one off-label or unlicensed medicine. 
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2.3 Results  
2.3.1 Description of medicine courses 
The study examined 19975 medicine courses from 6020 separate unplanned admissions of 
patients who had received at least one medicine course in the two weeks prior to their 
admission (Figure 2.1). An assessment of the medication histories of all admissions revealed 
that prescription medicines accounted for 88.9% (17758/19975) of the medicine courses 
investigated while the remaining 11.1% (2217/19975) were non-prescription.  A total of 
8.3% (1655/19975) of the medicine courses were administered to patients admitted under 
the care of oncology but only three (0.2%) of these were non-prescription.  Two out of the 
2217 non-prescription medicines were implicated in one ADR each. 
2.3.2 Analysis of patient characteristics (first admissions only) 
2.3.2.1 Univariate analysis 
A univariate analysis was carried out using the prescription medicine data of patients on 
their first admission only (3869 patients); those who had received non-prescription 
medicines only were excluded. The analysis compared each variable in the group who had 
experienced at least one ADR with those who had not for: all patients, patients who had 
been exposed to at least one off-label or unlicensed (OLUL) prescription medicine and 
patients who had received only authorised prescription medicines.   
The results of the univariate analysis are summarised in Table 2.6. There was no significant 
difference in the proportion of each gender in any of the subpopulations. The median age 
and median number of prescription medicines was greater in patients who had experienced 
at least one ADR. However, within the population of patients exposed to authorised 
prescription medicines only, there was no significant difference in the median age of the 
patients who had experienced an ADR and those who had not (p=0.968).  Oncology patients 
and patients exposed to off-label and/or unlicensed medicines were significantly more 
likely to experience an ADR. 
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Figure 2.1 Medicine courses categorised 
Total medicine 
courses in 6020 
admissions   
(n=19 975) 
Non-prescription 
medicine courses  
(n=2217) 
Non-oncology 
(n=2214) 
2 implicated in ADR 
Oncology  
(n=3) 
Prescription 
medicine courses 
(n=17 758) 
Non-oncology  
(n= 16 106) 
Not classified 
(n=1183) 
10 implicated in 
ADR 
Classified (n = 14 923) 
198 (1.3%)  implicated in ADR 
 
Authorised (n=10 579, 70.9%) 
139 (1.3%) implicated in ADR 
Off-label (n=3522, 23.6%) 
42 (1.2%) implicated in ADR 
Unlicensed (n=822, 5.5%) 
17 (2.1%) implicated in ADR 
Oncology  
(n=1652) 
Not classified 
(n=24) 
0 implicated in ADR 
Classified (n = 1628) 
283 (17.4%) implicated in ADR 
 
Authorised (n=932, 57.2%) 
139 (14.9%) implicated in ADR 
Off-label (n=558, 34.3%) 
110 (19.7%) implicated in ADR 
Unlicensed (n=138, 8.5%) 
34 (24.6%) implicated in ADR 
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Table 2.6 Univariate analyses of ADRs for all first admissions by gender, age, and number 
of prescription medicines taken (3869 patients) 
     
Gender All No ADR ADR p-value
iv
 
All boys 2247 2172 (96.7%) 75 (3.3%) 
0.271 
All girls 1622 1557 (96.0%) 65 (4.0%) 
OLUL exposed boys 869 812 (93.4%) 57 (6.6%) 
0.920 
OLUL exposed girls 627 585 (93.3%) 42 (6.7%) 
Authorised only boys 1321 1303 (98.6%) 18 (1.4%) 
0.063 
Approved only girls 953 930 (97.6%) 23 (2.4%) 
     
Age (years, months) 
[median; Q1, Q3] 
All No ADR ADR p-value
v
 
All 
[3y 1m; 8m, 9y] 
(n=3869) 
[3y; 8m, 9y] 
(n=3729) 
[6y; 2y 4m, 11y] 
(n=140) 
<0.001 
OLUL exposed 
[2y 5m; 3m, 8y] 
(n=1595) 
[2y 1m; 3m, 7y] 
(n=1496) 
[7y; 3y 7m, 12y] 
(n=99) 
<0.001 
Authorised only 
exposed 
[3y 8m; 1y, 10y] 
(n=2274) 
[3y 8m; 1y, 10y] 
(n=2233) 
[3y 9m; 5m, 8y 6m] 
(n=41) 
0.968 
     
Number of 
prescription medicines 
[median; Q1, Q3] 
All No ADR ADR p-value
v
 
All 
[2; 1, 4] 
(n=3869) 
[2; 1, 3] 
(n=3729) 
[6; 3, 9] 
(n=140) 
<0.001 
OLUL exposed 
[3; 2, 6] 
(n=1595) 
[3; 2, 6] 
(n=1496) 
[8; 5, 11] 
(n=99) 
<0.001 
Authorised only 
exposed 
[2; 1, 2] 
(n=2274) 
[2; 1, 2] 
(n=2233) 
[2; 1, 3] 
(n=41) 
0.003 
     
Specialty All No ADR ADR p-valueiv 
Oncology 73 32 (43.8%) 41 (56.2%) 
<0.001 
Non-oncology 3796 3697 (97.4%) 99 (2.6%) 
     
OLUL exposure All No ADR ADR p-value
iv
 
OLUL exposed 1595 1496 (93.8%) 99 (6.2%) 
<0.001 
Authorised only 
exposed 
2274 2233 (98.2%) 41 (1.8%) 
                                                          
iv
 Chi-square test 
v
 Mann-Whitney U test 
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2.3.2.2 Multivariate Logistic Regression 
Logistic regression analysis indicated that patients admitted into the care of the oncology 
specialty were more likely to have experienced an ADR, (odds ratio (OR) 25.07, 95% CI 
14.53, 43.26, p<0.001) as were patients who had been exposed to a greater number of 
prescription medicines (OR 1.20, 95% CI 1.15, 1.26, p<0.001). In addition, increasing age 
was associated with an increased risk of ADR; (OR 1.05, 95% CI 1.01, 1.09, p=0.017). 
Although the results did not reach statistical significance, there was trend towards an 
increased ADR risk with exposure to an off-label or unlicensed medicine; (OR 1.43, 95% CI 
0.91, 2.27, p=0.124) and there was a trend towards males being less likely to experience an 
ADR than females (OR 0.73, 95% CI 0.50, 1.07, p=0.106) (Table 2.7).  
Table 2.7 Multivariate logistic regression analysis for all first admissions (3869 patients) 
 
     
Variable 
Odds Ratio 
(OR) 
Standard 
error of OR 
95% CI for OR p-value 
Gender (male) 0.73 0.196 0.50, 1.07 0.106 
Specialty (oncology) 25.07 0.278 14.53, 43.26 <0.001 
No. of prescription medicines 1.20 0.024 1.15, 1.26 <0.001 
OL/UL Exposure 1.43 0.234 0.91, 2.27 0.124 
Age in years 1.05 0.019 1.01, 1.09 0.017 
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We dissected the variable ‘number of medicines’ to determine the relative influences of the 
number of authorised, and the number of off-label and unlicensed medicines (Table 2.8). 
Each additional authorised medicine administered in the two weeks before admission 
increased the risk of an ADR by 25% and each additional off-label or unlicensed medicine 
increased the risk by 23%; both variables were significant predictors. 
Table 2.8 Multivariate logistic regression analysis for all first admissions, number of 
authorised and number of off-label and unlicensed prescription medicines (3869 patients) 
 
     
Variable Odds Ratio (OR) Standard 
error of 
OR 
95% CI for 
OR 
p-value 
Gender (male) 0.74 0.196 0.51, 1.09 0.130 
Specialty (oncology) 25.70 0.290 14.56, 45.38 <0.001 
No. of authorised medicines 1.25 0.037 1.16, 1.35 <0.001 
No. of off-label/unlicensed 
medicines 
1.23 0.054 1.10, 1.36 <0.001 
No. of unknown medicines 0.84 0.175 0.59, 1.18 0.303 
Age in years 1.04 0.019 1.00, 1.08 0.045 
     
 61 
 
Since the influence of a patient being admitted under the care of the oncology specialty 
was so significant, multivariate analysis was repeated after excluding oncology patients (to 
leave 3796 patients). Each additional authorised prescription medicine increased ADR risk 
by 33% (p<0.001). The number of off-label/unlicensed prescription medicines was not a 
significant predictor of ADR risk (p=0.627) Older patients were more likely to experience an 
ADR (OR 1.05, 95% CI 1.01-1.09 p=0.023). There was still a trend towards males being less 
likely to experience an ADR, (OR 0.71, 95% CI 0.47, 1.08, p=0.107) (Table 2.9). 
Table 2.9 Multivariate logistic regression analysis for all non-oncology first admissions 
(3796 patients) 
 
     
Variable Odds Ratio 
(OR) 
Standard 
error of OR 
95% CI for OR p-value 
Gender (male) 0.71 0.211 0.47, 1.08 0.107 
No. of authorised medicines 1.33 0.040 1.23, 1.44 <0.001 
No. of off-label/unlicensed medicines 1.04 0.079 0.89, 1.12 0.627 
No. of unknown medicines 0.79 0.202 0.53, 1.17 0.233 
Age in years 1.05 0.020 1.01, 1.09 0.023 
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2.3.3 Analysis of medicine courses (all admissions) 
Considering the 17758 prescription medicine courses, 1207 (6.8%) of these could not be 
categorised because insufficient information about the patient or the medicine had been 
recorded, for example no patient weight or no medicine frequency (Figure 2.1). Considering 
the 16551 medicine courses which could be categorised, off-label or unlicensed medicines 
were more likely to be implicated in an ADR than authorised medicines (relative risk (RR) 
1.67, 95% CI 1.38, 2.02, p<0.001).    
14923 of 16106 medicine courses administered to non-oncology patients could be 
categorised (Figure 2.1). Of these, 70.9% were authorised, 23.6% off-label and 5.5% 
unlicensed. Off-label or unlicensed medicines were not more likely to be implicated in an 
ADR than authorised medicines, (RR 1.03, 95% CI 0.72, 1.48, p=0.830). 
In comparison, among the 1652 medicine courses administered to oncology patients, 1628 
could be classified and 57.2% were authorised, 34.3% off-label and 8.5% unlicensed (Figure 
2.1).  Off-label or unlicensed medicines were more likely to be implicated in an ADR than 
authorised medicines, (RR 1.39, 95% CI 1.12, 1.71, p=0.02). 
2.3.4 Description of ADRs in which off-label and unlicensed medicines were implicated 
2.3.4.1 All ADRs in which off-label and unlicensed medicines were implicated 
Of 247 ADRs, 45 (18.3%) were attributed to off-label or unlicensed medicines alone, 96 
(38.9%) to authorised medicines alone and 98 (39.7%) to a combination of off-label or 
unlicensed and authorised medicines. The remainder involved at least one medicine which 
could not be categorised. Table 2.10 summarises the characteristics of these 247 ADRs in 
terms of severity, avoidability and causality and the number of medicines involved in each. 
2.3.4.2 Non-oncology ADRs in which off-label and unlicensed medicines were implicated 
48 of 127 non-oncology ADRs involved at least one off-label or unlicensed medicine (see 
Appendix 2 for details). Of these, 37 involved two or more medicines. In the nine cases 
where three medicines were implicated, at least one of these was always an authorised 
medicine. In the 29 cases where two medicines were implicated, 23 involved at least one 
authorised medicine as well, three involved off-label only, two involved off-label and 
unlicensed and one involved only unlicensed.  
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The following list provides reasons for the off-label and unlicensed categorisation of 
medicines implicated in non-oncology ADRs (Appendix 2). 
 Acetazolamide oral – for intra-cranial hypertension, not authorised for this 
indication via this route.  
 Anakinra injection –administered to a child, not authorised for use in children.  
 Contraceptive Mercilon® oral - to regulate menstruation in a patient with polycystic 
ovary disease, not authorised for this indication. 
 Dexamethasone injection - for the prevention of post-operative vomiting and/or 
post-tonsillectomy pain, not authorised for use in children for this indication.  
 Diclofenac by mouth – for post-operative pain in children, not authorised for use in 
children for this indication.  
 Dihydrocodeine by mouth - recipient three years old, preparation not authorised 
for use in children under four years old.  
 Fentanyl infusion - patient-controlled analgesia infusion, not authorised for this 
indication   
 Ibuprofen by mouth - dose not authorised (see Table 2.4).  
 Infliximab infusion - to facilitate fistula healing in a two year old without Crohn’s 
disease, not authorised for children under six years old or for this indication.  
 Methotrexate by mouth – recipient nine years old with juvenile idiopathic arthritis 
(JIA), not authorised for this indication. 
 Methotrexate infusion – for juvenile idiopathic arthritis (JIA), not authorised for this 
indication.  
 Mycophenolate by mouth - for systemic lupus erythematosus (SLE) and for 
prevention of hepatic transplant rejection in a thirteen year old, not authorised for 
these indications.   
 Ondansetron injection – for vomiting not induced by anaesthetic (PONV) or 
chemotherapy (CINV), not authorised for this indication.  
 Oxybutynin by mouth – recipient two years old, not authorised for children under 5 
years old.  
 Propranolol oral –for the management of haemangioma, not authorised for this 
indication.  
 Tacrolimus by mouth - to prevent rejection of lung transplant, not authorised for 
this indication.  
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2.3.4.3 Oncology ADRs in which off-label and unlicensed medicines were implicated 
93 of 120 oncology ADRs involved at least one off-label or unlicensed medicine (see 
Appendix 3 for details). Of these, seven involved only one medicine; four were due to an 
off-label medicine and three were due to an unlicensed medicine. 28 ADRs did not involve 
any authorised medicines. The remaining 58 ADRs involved between two and six medicines 
made up of a combination of authorised, off-label and unlicensed medicines.  
The following list provides reasons for the off-label and unlicensed categorisation of 
medicines implicated in oncology ADRs (Appendix 3). 
 Carboplatin infusion - administered to a child, not authorised for use in children. 
 Cyclophosphamide infusion - administered to a child, not authorised for use in 
children. 
 Doxorubicin – administered to a child, not authorised for use in children.  
 Etoposide infusion – administered to a child, not authorised for use in children. 
 Ifosfamide infusion – for primitive neuroectodermal embriogenic tumour, not 
authorised for this indication. 
 Imatinib tablets – for relapsed neuroblastoma, not authorised for this indication. 
 Ondansetron oral - frequency not authorised.  
 Prednisolone – for haemangioma, not authorised for this indication (NB this patient 
was under the care of oncology for treatment of a steroid unresponsive 
haemangioma).
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Table 2.10 Characteristics of ADRs which involved at least on off-label or unlicensed medicines 
ADR type 
Severityvi                                      
count of ADRs (%) 
Avoidability                                                  
count of ADRs (%) 
Causality                                        
count of ADRs (%) 
Total number of 
medicines 
implicated count of 
ADRs (%) 
Number of OLUL 
medicines  
implicated          
count of ADRs (%) 
1 2 3 4 5 Unavoidable 
Possibly 
avoidable 
Definitely 
avoidable 
Possible Probable Definite 1 2 >3 1 2 >3 
Non-
oncology 
(n = 48) 
1 
(2.1) 
1 
(2.1) 
41 
(85.4) 
5 
(10.4) 
0 
40           
(83.3) 
7         
(14.6) 
1         (2.1) 
33  
(68.8) 
12      
(25.0) 
3      
(6.3) 
11 
(22.9) 
29 
(60.4) 
8 
(16.7) 
36 
(75) 
12 
(25.0) 
0 
Oncology 
(n = 93) 
4 
(4.3) 
0 
88 
(94.6) 
0 
1 
(1.1) 
88           
(94.6) 
5         
(5.4) 
0 
6      
(6.5) 
20   
(21.5) 
67 
(72.0) 
7 
(7.5) 
41 
(44.1) 
45 
(48.4) 
42 
(45.2) 
44 
(47.3) 
7 
(7.5) 
                                                          
vi Modified Hartwig scale (Hartwig, Siegel and Schneider, 1992) 
Severity level Description 
1 Required no change in treatment 
2 Drug dosing or frequency changed 
3 Required treatment, or drug administration discontinued 
4 Result in patient transfer to higher level of care 
5 Caused permanent harm to patient or significant haemodynamic instability 
6 Directly or indirectly resulted in patient death 
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2.3.5 Causality, avoidability and severity of ADRs  
In terms of causality, ADRs in which at least one off-label or unlicensed medicine was 
implicated were more likely to be classified as definite or probable (difference in 
proportions 12%, 95% CI 0.4%, 25%, p = 0.047, Table 2.11). ADRs involving off-label or 
unlicensed medicines were more likely to be classified as unavoidable than ADRs involving 
only authorised medicines (difference in proportions 30%, 95% CI 20%, 40%, p < 0.001, 
Table 2.11). Finally, there was no difference in the severity of ADRs involving only 
authorised medicines when compared to ADRs involving at least one off-label or unlicensed 
medicine (difference in proportions 6%, 95% CI -0.5%, 12%, p = 0.066, Table 2.11).   
In a comparison of oncology and non-oncology ADRs, oncology ADRs were more likely to 
involve at least one off-label or unlicensed medicine (difference in proportions 40%, 95% CI 
32%, 48%, p < 0.01, Table 2.12). Oncology ADRs were also more likely to have been definite 
or probable (difference in proportions 50%, 95% CI 40%, 60%, p<0.001, Table 2.12). In 
addition, oncology ADRs were more likely to have been unavoidable (difference in 
proportions 29%, 95% CI 24%, 34%, p<0.001, Table 2.12). Oncology ADRs were less likely to 
have been severe (Hartwig score 4 or 5) than non- oncology (difference in proportions 3%, 
95% CI 1%, 13%, p = 0.032, Table 2.12). 
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Table 2.10 Comparison of causality, avoidability and severity assessments for ADRs 
involving off-label and unlicensed medicines and those which did not 
     
Assessment Score 
ADRs not involving 
off-label or 
unlicensed 
medicines (n=106) 
Count for ADRs 
involving at least 
one off-label or 
unlicensed medicine 
(n=141) 
p-
valuevii 
Causality 
Definite & Probable 64 102 
0.047 
Possible 42 39 
     
Avoidability 
Definitely & possibly 
avoidable 
41 13 
<0.001 
Unavoidable 65 128 
     
Severity 
1,2,3 95 135 
0.066 
4,5 11 6 
     
 
                                                          
vii difference in proportions 
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Table 2.11 Comparison of causality, avoidability and severity assessments of non-
oncology and oncology ADRs 
 
Assessment 
 
 
Score 
 
 
Non-oncology 
ADRs (n=127) 
 
 
Oncology ADRs 
(n=120) 
 
 
p-valuevii 
 
Causality 
 
Definite & 
Probable 
 
55 
 
111 
<0.001 
 
Possible 
 
72 
 
9 
     
 
Avoidability 
 
Definitely & 
possibly avoidable 
 
46 
 
8 
<0.001 
 
Unavoidable 
 
81 
 
112 
     
 
Severity 
 
 
1,2,3 
 
114 
 
116  
0.032  
4,5 
 
13 
 
4 
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2.4 Discussion 
This is the first large scale study of the contribution of off-label and unlicensed prescribing 
to the risk of ADR-related hospital admissions. In this study exposure to off-label and/or 
unlicensed medicines, in the two weeks before admission, was not a significant predictor of 
ADR risk. However both the number of authorised and the number of off-label or 
unlicensed medicines administered in the two weeks before admission were significant 
predictors of ADR risk. This increased risk associated with off-label and unlicensed medicine 
use was also seen in the analysis of medicine courses; off-label and unlicensed medicines 
were more likely to be implicated in an ADR than authorised medicines. Given that 
oncology drugs were a major risk factor in causing ADRs in this study, further analyses 
showed that, when oncology patients were excluded, the number of off-label or unlicensed 
medicines was not a significant predictor of ADR risk and the risk of an unlicensed or off-
label medicine being implicated in an ADR was not significantly greater than that for an 
authorised medicine. This shows that the data from our whole population was strongly 
influenced by the characteristics of the oncology sub-population with its high rate of off-
label and unlicensed medicine use and by the therapeutic regimens for which we would 
anticipate toxicity.  
The results described here cannot be compared easily with those of similar studies since 
this is the first large admissions study of this type. Furthermore, the statistical methods 
employed by previous authors have varied. Although 17.7% of our ADRs were due to 
medicines prescribed in community settings, 82.3% (205/247) of ADRs involved prescription 
medicines originating from hospital and so we will also compare our findings to previous 
hospital-based studies. Compared here are the findings of seven prospective studies: one 
study of admissions, four studies of inpatients and two community-based studies.  
In a prospective study of ADRs causing admission (Posthumus et al., 2012), the off-label or 
unlicensed status of the medicines implicated in ADRs was reported. 683 acutely admitted 
patients were separated into two groups, ADRs were reported for those exposed to cancer 
chemotherapy and those not exposed. The overall ADR rate was 6.9%, compared to our 
2.2%. The definitions of off-label and unlicensed medicine use were the same as in this 
study. Amongst 47 patients exposed to cancer chemotherapy there were 32 ADRs of which 
84% involved off-label or unlicensed drugs. Of 636 patients not exposed to cancer 
chemotherapy, 15 were admitted due to an ADR. 33% of these ADRs were due to off-label 
or unlicensed drugs. Medicines not involved in ADRs were not classified so no change in 
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ADR risk associated with off-label or unlicensed medicine use could be calculated. The 
results of this study, like ours, are indicative of the influence of oncology treatment on 
studies of off-label and unlicensed medicine use and ADRs - a greater proportion of 
oncology ADRs involved off-label and unlicensed medicines. 
There have been three previous prospective inpatient studies of off-label and unlicensed 
medicine use and ADRs, all of which reported a higher ADR incidence than this study. In 
agreement with our findings, Turner et al. (1999) reported that off-label and unlicensed 
medicines were more likely to be implicated in an ADR than authorised medicines (RR 1.46, 
95% CI 1.11, 1.93). Multivariate analysis demonstrated a non-significant relationship 
between off-label and unlicensed drug use and ADR risk, (RR 1.74, 95% CI 0.89, 3.41, 
p=0.106). The incidence of ADRs in their study was 116/1046 (11%) and the proportion of 
off-label and unlicensed prescriptions was similar to that in our study 1574/4455 (35%). 
However, they did not include oncology patients. In contrast with our findings, Neubert et 
al. (2004) reported no significant difference in the number of off-label or unlicensed 
medicines implicated in ADRs compared to the number of medicines not defined as off-
label or unlicensed (RR 1.08. 95% CI 0.50, 2.35). Patients receiving at least one off-label or 
unlicensed medicine experienced an ADR significantly more frequently than those receiving 
only medicines not defined as off-label or unlicensed, (RR 3.62, 95% CI 2.23, 5.85). Their 
finding that exposure to off-label and/or unlicensed medicines increased ADR risk reflects 
the higher proportion of patients exposed (59% compared to our 40%) and a higher ADR 
incidence (12.5%). Theirs was a much smaller study (156 patients) and oncology patients 
were not included. A Brazilian hospital-based study demonstrated that exposure to at least 
one off-label medicine was associated with an increased ADR risk (RR 2.44, 95% CI 2.12, 
2.89) which reflects a higher incidence of off-label and unlicensed medicine use (45.1% of 
prescriptions) and a higher ADR incidence (19.9%), amongst 265 non-oncology patients 
(Santos et al., 2008). A fourth hospital-based study included ADRs to medicines 
administered before admission as well as those to medicines administered in hospital. It 
included 1619 patients of whom 12 were admitted due to an ADR. No significant 
association between ADR risk and off-label medicine use was reported (Impicciatore et al., 
2002).  
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In a prospective community-based study, Horen et al. (2002) reported that ADR risk was 
related to off-label drug use (RR 3.44, 95% CI 1.26, 9.38). In comparison to this study, they 
recorded a lower proportion of off-label prescriptions (18.9%) as well as a lower ADR 
incidence (1.41%). In a second community-based study, Kramer et al. (1985) examined only 
one aspect of off-label use; the administration of a total daily dose greater than that 
recommended by the manufacturer whether prescribed or secondary to parental 
overtreatment (NB the latter could be considered an error rather than off-label use). They 
found that medicines used in this way were more likely to be implicated in an ADR (RR 1.63, 
95% CI 1.23, 2.16, p<0.001). They did not describe the proportion of patients who had 
received off-label or unlicensed medicines or the incidence of ADRs.  
Multivariate analysis showed that exposure to off-label or unlicensed medicines was not a 
significant predictor for the development of an ADR which is in accordance with one 
previous inpatient study (Turner et al., 1999) but contradicts two others (Neubert et al., 
2004, Santos et al., 2008). This method of analysis treats exposure to off-label or unlicensed 
medicines as a characteristic of the patient and fails to take into the account whether those 
medicines directly contributed to the ADRs. It may be that the predictor variable ‘off-label 
and/or unlicensed medicine exposure’ is actually telling us something else about our 
patients. Previous studies have shown that children who receive these types of medicines 
may be more likely to be neonates or infants, to consult their general practitioner more 
often, to receive more prescriptions, to have more specialist referrals or to be cared for by 
certain specialties e.g. dermatology, cardiology or ophthalmology (Schirm, Tobi and de 
Jong-van den Berg, 2003, 't Jong et al., 2003, 't Jong et al., 2002a). We conducted an 
alternative multivariate analysis in which the number of authorised medicines and the 
number of off-label or unlicensed medicines were predictor variables. Both were significant 
predictors of ADR risk and the odds ratios were similar (1.25 and 1.23 respectively) which 
suggests that the number of medicines is a more important predictor  than whether they 
are authorised or not.  
From the analysis of medicine courses, off-label and unlicensed medicines were more likely 
to be implicated in ADRs than authorised medicines. Before discussing this finding further, 
it is important to highlight that 87.2% of ADRs which involved at least one off-label or 
unlicensed also involved at least one other medicine (Appendices 2 & 3). Our calculation of 
relative risk for individual medicines does not describe the relative contribution of 
individual medicines to each ADR. In some cases the off-label or unlicensed medicine may 
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not have caused the ADR in the absence of the authorised medicine. Oncology ADRs made 
up 48.6% of all ADRs but they were significantly more likely to involve at least one off-label 
or unlicensed medicine than non-oncology ADRs. Hence, oncology ADRs made a substantial 
contribution to the likelihood of off-label and unlicensed medicines being implicated in an 
ADR.  
ADRs involving off-label and/or unlicensed medicines were more likely to have been 
classified as unavoidable and their causality was more likely to have been probable or 
definite (Table 2.12). This can be explained by the fact that oncology ADRs were more likely 
to involve off-label or unlicensed medicines and were also more likely to be unavoidable 
and probable or definite (Table 2.13). The majority of oncology ADRs resulted from the 
unwanted effects of medicines used to treat malignant disease, because of the severity of 
the disease and the limited treatment options available, many of these reactions were 
unavoidable. Oncology ADRs were frequently classified as probable or definite because we 
had confidence in many cases that there was no other likely cause for the signs and/or 
symptoms. These ADRs are, in general, well characterised and predictable. Since the same 
medicine was administered intermittently over a period of weeks or months, in accordance 
with the treatment protocol for these patients, there was a positive re-challenge in many 
cases and therefore an increased likelihood that the ADR would be classified as ‘definite’. 
The prospective design of the cohort study had limitations. The recording of a medication 
history for each participant was recorded at the point of admission by the admitting 
clinician and clarified soon after admission by the study team. It relied on parents and/or 
patients recalling and communicating accurately all medicines administered in the 
preceding two weeks. Clearly there was scope for errors and omissions in this process. The 
detection of suspected ADRs by the study team relied on two things: a) signs and symptoms 
associated with the ADR being recorded by the clinical team looking after the patient; and 
b) the study team suspecting a link between signs and symptoms recorded and the 
medicines administered before admission. Where signs and symptoms were not recorded 
or the study team missed the link, the ADR will not have been highlighted or evaluated. The 
result of these limitations would be an underestimate of ADR incidence, an inaccurate 
estimate of medicine use and of the contribution of off-label and unlicensed medicines to 
ADR risk. The classification of medicine courses as authorised, off-label or unlicensed was 
done retrospectively using information about recent medicine use which had been 
collected prospectively. A consequence of this approach was that assumptions had to be 
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made in the classification process (Tables 2.3 & 2.4) and 6.8% of medicine courses could not 
be classified. It seems unlikely that classification of medicine courses at the time of data 
collection would have overcome these problems because the requisite details of a medicine 
used up to two weeks previously may still not have been available. An assumption which 
may have led to an overestimate of off-label and unlicensed medicine use was the necessity 
to categorise a course as off-label even if only part of that course had been off-label. 
Assumptions which may have led to an underestimate of off-label and unlicensed medicine 
use included the expectation that inhaled anaesthetic use was authorised and that CIVAs 
doses were prepared in accordance with manufacturers’ instructions. The assumption that 
all neonates were born at term prevented the exploration of off-label medicine use in pre-
term infants and may have led to an underestimate of off-label use. Assumptions about 
intravenous paracetamol, inhaled beclomethasone and cytotoxic drugs may have all led to 
an underestimate of off-label and unlicensed medicine use. Employing standard rather than 
actual weight and surface area for some children may have under- or overestimated off-
label medicine use.  
Our results must be considered in the context of the diversity of off-label and unlicensed 
medicines and the complexity of the ADRs detected. Different off-label and unlicensed 
medicines have different propensities to cause ADRs.  There are various categories of off-
label and unlicensed medicine use (Tables 2.2 & 2.5) some of which may carry a greater risk 
of being implicated in an ADR than others. For example, Horen et al. (2002) found that 
there was a significant increase in ADR risk when medicines were used for a different 
indication than recommended. We must also consider that the same medicine may be 
classified as off-label or authorised, even in the same patient, depending on the context of 
its use. The pharmacological and pharmacokinetic profiles of off-label and unlicensed 
medicines are diverse.  A key consideration is whether off-label and unlicensed medicines 
would be any less likely to be implicated in an ADR if their use was authorised. Finally, in 
this study, ADRs rarely resulted from the unwanted effects of a single medicine 
administered to a mildly unwell child. They were more often a result of the administration 
of multiple medicines to a child unwell enough to require admission to hospital. In these 
complex cases there was potential for both drug-drug and drug-disease interactions which 
could not be investigated in the analyses conducted here. 
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2.5 Conclusion 
There is some indication that the use of off-label and unlicensed medicines may contribute 
to ADR risk in children admitted to hospital but this needs to be investigated in more detail. 
This finding is influenced by the inclusion of oncology ADRs in this study. Off-label and 
unlicensed medicines should not be treated as a homogenous group but should be 
considered according to their individual characteristics both in terms of their propensity to 
contribute to ADRs and the reasons that they are classified as off-label or unlicensed. A 
more detailed examination of the characteristics of medicines implicated in ADRs, inclusive 
of a comparison with those not implicated in ADRs, could inform an understanding of why 
off-label and unlicensed medicines may be more likely to be implicated in ADRs.  
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3 ADRs detected in paediatric inpatients – contribution of off-label and 
unlicensed medicine use to ADR risk  
3.1 Introduction 
Adverse drug reactions in paediatric inpatients have an incidence ranging from 0.6% to 
16.8% (Smyth et al., 2012). The wide variation in incidence can be explained by a number of 
factors. Although all the studies included children who were inpatients, there was variation 
in the study settings, for example some were undertaken on paediatric intensive care units 
whereas other were undertaken on general paediatric wards or surgical wards. In these 
various settings there would be variation in the extent and severity of the underlying 
disease for individual patients as well and in the types of medicine being used, both of 
these factors would be expected to have an impact on ADR rate.  The approach to ADR 
detection varied between studies with some employing multiple approaches in 
combination, for example case record review, screening of laboratory results and 
prescription charts, spontaneous reports and ward round attendance. Clearly, some of 
these approaches are more thorough and systematic than others, this would affect how 
many ADRs were detected. An understanding of the risk factors for ADRs in this population 
will inform the development of measures to reduce the burden of ADRs.  
Off-label and unlicensed medicine use in children is a potential risk factor for ADRs. In 
paediatric hospital settings, between 18 and 65% of prescriptions are off-label while 1 to 
48% of prescriptions are for unlicensed medicines (Kimland and Odlind, 2012). Three 
previous studies have investigated the contribution of off-label and unlicensed medicine 
use to ADR risk in paediatric inpatients. Turner et al. (1999) found that the proportion of 
unlicensed and off-label medicines administered to paediatric inpatients was significantly 
associated with ADR risk. Another  inpatient study identified that patients who received at 
least one off-label or unlicensed medicine were more likely to experience an ADR than 
those who did not (Neubert et al., 2004) while a third study identified that off-label drug 
use was significantly associated with ADR risk in paediatric inpatients (Santos et al., 2008).  
These previous studies did not report any attempt to find reasons for their findings, for 
example by scrutiny of the types of off-label medicine use or the drug types implicated in 
ADRS. With the knowledge that off-label and unlicensed medicines are a diverse group of 
medicines, this study extends the methodology described in the previous chapter. We 
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hypothesise that some types of off-label or unlicensed medicine use may carry a greater 
risk than others. 
This study aims to describe the contribution of the different types of off-label and 
unlicensed medicine use to the risk of ADRs in paediatric inpatients. 
3.2 Methods 
3.2.1 Setting & participants  
This was a nested case-control study within a twelve month prospective cohort study of 
6601 admissions in a paediatric tertiary referral centre in the UK (Thiesen et al., 2013). The 
cohort study was carried out between 1st October 2009 and 30th September 2010 and 
included all patients aged 0-16 years who were inpatients for longer than 48 hours. Patients 
were not observed in theatre, recovery, the department of radiology, paediatric intensive 
care unit (PICU), the hospital’s transitional care unit (for patients on long term ventilation) 
or the psychiatry unit. Patients with missing prescription details for their entire stay were 
excluded. Patients with part of their prescription details missing were assessed on a case-
by-case basis and a decision was made on whether to include or exclude them. Some 
patients had multiple admissions over the study period. The cases for the nested case 
control study were defined as children on their first admission who had experienced at 
least one probable or definite ADR (n=694). Cases were matched 1:1 to controls defined as 
children on their first admission who had not experienced any possible, probable or definite 
ADRs, but may have had a suspected ADR assessed as unlikely. Matching was by closest 
date and time of admission, see Appendix 4 for details. A nested-case control design was 
chosen because the resources were not available to allow us to include all patients from the 
cohort study. This approach was preferable because it exploited ADR data from all first 
admissions that experienced at least one probable or definite ADR. The use of a random 
sample would have resulted in the loss of potentially valuable data from ADR cases not 
included. This study was part of a larger study which used routinely collected clinical data in 
an anonymised format. The Chair of Liverpool Paediatric REC informed us that this study did 
not require individual patient consent or review by an Ethics Committee (Appendix 13). 
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3.2.2 Data collection 
Patients were identified on a daily basis by the use of a twice-daily download from the 
hospital electronic medical records system (MEDITECH). This file contained details of all 
admissions whose stay had reached 48 hours since the previous download. The file 
contained the details required for the patient to be identified and located within the 
hospital: name and ward, and also details that were required for the final analysis: age, sex 
and admitting specialty. Each eligible patient was identified by this process and 
subsequently reviewed every 48 to 72 hours until they were discharged. Reviews were 
undertaken by one member of a multidisciplinary team which comprised a paediatrician, a 
paediatric nurse and at least one pharmacist (JRB was one of the pharmacists on the team 
for the duration of the study). The aim of the initial review was to record the patient’s 
medical and surgical history, reason for admission and medicines administered since 
admission as well as to identify any suspected ADRs which had occurred since admission. 
Subsequent reviews aimed to record medicines administered and to identify any ADRs 
suspected since the last review. Details of medicines administered were recorded for each 
day of the patient’s stay: drug name, dose, frequency, and indication (if this was thought to 
require clarification). The data required were obtained from one or more of the following 
sources at the study team’s discretion: hospital electronic medical records system 
(MEDITECH), patient’s case notes or bedside charts, the clinical team, the patient 
themselves or their carer.  If an ADR was suspected, these cases were taken through further 
evaluation by the study team. A case report was compiled by one member of the study 
team; this described in detail the suspected ADR inclusive of the results of any 
investigations, any action taken by the clinical team and its outcome. Each suspected ADR 
report was then subjected to the following assessments: causality using the Liverpool 
Causality Assessment Tool (LCAT) (Gallagher et al., 2011) and severity using the Hartwig 
scale (Hartwig, Siegel and Schneider, 1992). JRB prepared the case report for, and evaluated 
984 of 2933 ADR cases, JRB also contributed to the causality assessment of case reports 
prepared by other members of the team. 
3.2.3 Classification of Medicines 
For each of the 1388 cases and controls, JRB updated the record of medicines administered 
was updated to include a detailed off-label or unlicensed category for each medicine on 
each day it was administered. There were 28 possible off-label categories and five 
unlicensed medicine categories (Tables 3.1 & 3.2).  
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Table 3.1 Off-label categories 
  
Category Definition 
1 Authorised - medicine used within the terms of its MA 
2 Contraindication exists 
3 Dose greater than recommended 
4 Dose greater than recommended and contraindication exists 
5 Not licensed in child of this age (or child below minimum weight stated) 
 
6 Not licensed in child of this age and contraindication exists 
7 Not licensed by this route 
8 Not licensed by this route and contraindication exists 
9 Not licensed by this route or in a child of this age 
10 Not licensed by this route or in a child of this age and contraindication exists 
11 Not licensed for this indication 
12 Not licensed for this indication and contraindication exists 
13 Not licensed for this indication or at this dose 
14 Not licensed for this indication or at this dose and contraindication exists 
 
15 Not licensed for this indication or at this age 
16 Not licensed for this indication or at this age and a contraindication exists 
 
17 Not licensed for this indication or by this route 
18 Not licensed for this indication or by this route and a contraindication exists 
 
19 Not licensed for this indication or by this route or at this age 
20 Not licensed for this indication or by this route or at this age and a 
contraindication exists 
 
21 Not licensed f r use in children 
22 Not licensed for use in children and, a contraindication exists 
23 Not licensed for use in children or in adults by this route 
24 Not licensed for use in children or in adults by this route and a contraindication 
exists 
 
25 Not licensed for use in children or in adults for this indication 
26 Not licensed for use in children or in adults for this indication and a 
contraindication exists 
 
27 Not licensed f r use in children or in adults for this indication or in adults by this 
route 
 
28 Not licensed for use in children or in adults for this indication or in adults by this 
route and a contraindication exists. 
 
29 Category cannot be assigned 
30 Theatre medicine 
 
  
 
Table 3.2 Unlicensed categories 
  
Category Definition 
31 Prepared extemporaneously 
32 Manufactured under a specials manufacturing licence 
33 Chemical 
34 Import 
35 Awaiting a MA (e.g. previous trial medicine) 
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3.2.3.1 Off-label categories 
Off-label use was defined as the use of a medicine outside the terms of its UK marketing 
authorisation (MA).  
The categories for off-label use (Categories 2-28, Table 3.1) were allocated for each 
medicine according to the reason(s) why their use was deemed off-label when compared to 
the terms of the MA for that medicine. The terms of the MA were found in the Summary of 
Product Characteristics (SmPC) available online from the Electronic Medicines Compendium 
(DataPharm Communications Ltd., 2010). The version of the SmPC which was the most up 
to date during the study was referred to. The ‘date of revision of the text’ at the end of the 
electronic SmPC indicated when the information was last updated, if the document had 
been updated since the date that the medicine was administered, a paper version of the 
contemporaneous SmPC was used. If no SmPC was available, the British National Formulary 
for children (BNF-C) (Paediatric Formulary Committee, 2009/2010) was consulted for details 
of the product MA. If neither reference source provided adequate clarity of information, 
the manufacturer of the medicine was contacted.  
Off-label categories were assigned by using ‘decision trees’ which required the user to 
consider each aspect of medicine use as they followed the diagram in order that the 
resultant category would describe in detail the type of off-label use (Appendix 5).  Category 
29 ‘category cannot be assigned’ was used if insufficient information was available to 
allocate a category. Category 30 ‘theatre medicine’ was introduced because the prospective 
cohort study did not record theatre medicines for controls and only recorded them for 
cases where they were implicated, for example in post-operative vomiting). Therefore any 
theatre medicines which were recorded were highlighted and subsequently excluded. As in 
the admissions study reported in Chapter 2, rules for the classification of medicines were 
established. The rules for specific scenarios were those in Table 2.3 (previous chapter) and 
the additional rules outlined here (Table 3.3). Similarly, the rules for specific medicines and 
groups of medicines were those outlined in Table 2.4 (previous chapter) and the additional 
rules outlined here (Table 3.4).  
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Table 3.3 Additional rules for the classification of licensed medicines by reference to the 
SmPC 
  
Scenario Rule 
 
SmPC states ‘should be administered to children 
only if the potential benefits outweigh the risks’ 
 
Classify as off-label 
 
Paracetamol dose has been rounded up or down 
e.g. paracetamol infusion 15mg/kg in a 16.5kg 
child = 247.5mg rounded up to 250mg 
 
Classify as authorised if difference 
between calculated and prescribed 
doses less than or equal to 10% 
(Johnson et al., 2011) 
 
Medicine administered at greater frequency or for 
a longer period than the maximum recommended 
 
Consider frequency and duration to 
be part of the ‘dose’ recommendation 
therefore this would be off-label 
 
Dose less than that recommended 
 
Classify as authorised 
 
Prescription record indicates that medicine was 
administered via a nasogastric tube (NGT) 
 
Ignore this during classification 
process, prescription records seem to 
be unreliable, that is the route is 
often not amended to oral when the 
NGT is removed 
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Table 3.4 Additional rules for the classification of specific medicines and groups of 
medicines 
  
Medicine or medicine 
group 
Rule 
 
Ciprofloxacin + 
Metronidazole to treat 
an exacerbation of 
Crohn’s disease 
 
Classify as authorised. Although not an explicit indication, the 
principle is to use these agents to treat any bacterial contribution to 
the exacerbation. 
 
Fentanyl injection 
 
Use for post-operative analgesia by continuous infusion in an NCA 
or PCA should be classified as off-label. It is licensed for use in 
children >2 years for anaesthesia / intraoperative analgesia. 
 
Flucloxacillin 
 
Classify dose as off-label if it is above the relevant age- and 
indication-specific range recommended by the BNF-C. The SmPC 
information on dose is unclear. 
 
Heparin 
 
No preparations in the eMC are indicated for any indication apart 
from the treatment of thrombotic episodes. Therefore assume that 
a preparation licensed for use in children has been used but if it is 
for prophylaxis, consider it to be off-label. 
 
Gentamicin 
 
Follow these recommendations for authorised use: premature 
infants or neonates up to 2 weeks 3mg/kg 12 hourly and children 2 
weeks to 12 years 2mg/kg 8 hourly. Daily paediatric dosing was 
added to the SmPC in November 2010 after the end of the study. 
 
 
Ketamine  
 
 
Use for post-operative analgesia should be classified as off-label. It 
is licensed for use in children for anaesthesia. 
 
Magnesium sulphate 
injection 
 
Use in the treatment of acute exacerbations of asthma is off-label. 
For other indications the maximum single licensed dose is 2g. 
 
Metronidazole 
 
SmPC updated January 2011 to include dosing for children <8 weeks 
and >8 weeks but BNF-C for the period of the study stated: not 
licensed for use in neonates or children under one year, so classify 
as off-label in children under one year. 
 
Morphine injection 
 
One preparation (Minijet™) is licensed for IM, SC, IV injection and IV 
infusion in children. The SmPC for all other preparations state that 
use is not recommended in children and one (Hameln brand) 
specifies that it is not recommended in children <12years. During 
the period of the study, Martindale and Hameln brands were in use. 
Therefore, assume Hameln brand was used. If child is <12 years 
assign category ‘5’ (not licensed in a child of this age) if other 
aspects of use are authorised. If child is >12 years assign category 
‘1’(authorised) if other aspects of use are authorised 
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Medicine or medicine 
group 
Rule 
  
 
Ondansetron 
intravenous for PONVviii 
 
In children >2 years old, any doses which are in addition to a single 
intra-operative dose + a single post-operative dose are off-label. 
Amended prescribing recommendations were added to SmPC in 
December 2010 after the end of the study. 
 
 
Ondansetron 
intravenous for CINVix 
 
In children >2 years old, any doses which are in addition to a single 
pre-chemotherapy dose + two post-chemotherapy doses are off-
label. Amended prescribing recommendations were added to SmPC 
in December 2010 after the end of the study. 
  
  
Oseltamivir 
 
Over the period of the study, Alder Hey was using oseltamivir 
capsules and both the licensed Tamiflu 60mg/mL and the 
unlicensed, Department of Health (DH) product, oseltamivir 
15mg/mL which is a manufactured special. Since this product was 
dispensed for individual patients rather than held as ward stock, 
refer to pharmacy records for the exact product dispensed for 
individual patients and categorise accordingly. 
 
Phenytoin doses  
(including intravenous 
loading)  
 
 
 
Classify dose as off-label if it is above the relevant age- and 
indication-specific range recommended by the BNF-C. The SmPC 
information on dose is unclear. 
 
 
 
 
 
 
 
                                                          
viii
 Post-operative nausea and vomiting 
ix
 Chemotherapy-induced nausea and vomiting 
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3.2.3.2 Unlicensed categories 
Unlicensed medicines were defined as those without a UK MA. 
A list of each of the unlicensed medicines recorded in the study was produced and with the 
assistance of a member of the hospital pharmacy staff responsible for the procurement of 
these products, this list was updated to indicate the type of unlicensed medicine in 
accordance with one of the five categories outlined (Appendix 6). 
3.2.4 Data analysis  
 
Advice on the approach to analysis was obtained from the ADRIC programme statistics 
team and broadly reflects the approach taken in the cohort study with the exception of the 
nested case-control design. The analysis of medicines courses was carried out by JRB. The 
datasets for the univariate and multivariate analyses within the case-control study were 
prepared by JRB, the analysis was carried out by the statistics team. 
 
The odds ratio with 95% confidence intervals (95% CI) for off-label and unlicensed 
medicines being implicated in a probable or definite ADR was calculated for all medicines 
administered in the nested case-control study. The odds ratios (with 95% CI) for each of the 
off-label and unlicensed categories being implicated in a probable or definite ADR were also 
calculated. It was recognised that some types of off-label and unlicensed medicine use are 
rarer than others, for example imported medicines are used infrequently. It was 
acknowledged that if there were too few medicine courses in a category or if no medicines 
within a category were implicated in an ADR, it would not be possible to determine the 
odds ratio for that category. 
A univariate analysis was undertaken; time to first ADR was compared between groups 
using a log-rank test and Kaplan-Meier curves were estimated. The following categorical 
variables were compared: gender, age category and oncology status. A Cox univariate 
regression analysis was undertaken to compare ADR risk in the group that had received a 
GA and those who had not (categorical time-varying variable). A multivariate Cox 
proportional hazards regression model was fit to the data to assess the influence that off 
label and unlicensed medicine use has on the hazard of an ADR occurring (discrete time-
varying). In addition to the number of off-label and unlicensed medicines administered 
during the admission, the following risk factors were included in the model: age, gender, 
having received a general anaesthetic (GA) during the admission, oncology patient status 
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and the number of authorised medicine courses administered during the admission. Due to 
their clinical importance, all risk factors remained in the final model. Results are given in 
terms of the hazard ratio (HR) together with the accompanying 95% CI and p-value. The 
analysis was carried out using the statistical software package R (version 2·13·2) using a 
significance level of 0·05 (5%) throughout.  
3.3 Results  
3.3.1 Participants & descriptive data 
In this study, there were 754 male and 634 female patients, 21.2% were < 1 year old, 24.6% 
were 1-4 years, 27.7% were 5-11 years and 26.6% were teenagers (> 12 years). The median 
age of patients was 5.96 years (inter-quartile range (IQR) 1.36-12.43 years). There were 43 
oncology patients (3.1% of all patients) and 873 patients (62.9% of all patients) received a 
general anaesthetic. The median daily number of medicines was 3 (IQR 1-5), the median 
daily number of authorised medicines was 2 (IQR 1-3) and the median daily number of off-
label and unlicensed medicines was 1 (IQR 0-2). 
3.3.2 Medicine courses 
10,699 medicine courses were administered to the 1388 patients included in this study. 
There were 723 probable and 62 definite ADRs which involved 694 patients. Of these ADRs, 
505 involved one medicine course, 172 involved two medicine courses, 77 involved three 
medicine courses and the remaining ADRs involved four or more medicine courses. Of the 
10, 699 medicine courses, 10, 145 could be categorised using one of the definitions listed in 
Tables 3.1 and 3.2. The reason that 554 (5.2%) of courses could not be categorised was that 
the prescription record did not provide the required information, for example missing dose 
information or insufficient detail about the exact preparation used. 301 (38%) of ADRs 
involved only off-label or unlicensed medicines, 290 (37%) of ADRS involved only authorised 
medicines, 160 (20.4%) involved a combination of off-label or unlicensed and authorised 
medicines and the remaining 34 (4.3%) involved at least one medicine for which the 
category was unknown. 
6990 (68.8%) of all medicine courses were authorised, 2407 (23.7%) were off-label and 758 
(7.5%) were unlicensed. 435 (6.2%) of all authorised medicine courses were implicated in at 
least one probable or definite ADR compared with 298 (12.4%) of off-label medicine 
courses and 113 (14.9%) of unlicensed medicine courses. The odds ratio (OR) of an 
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unlicensed or off-label medicine being implicated in an ADR when compared with an 
authorised medicine course was 2.25 (95% CI 1.95, 2.59, p<0.001).  
The three most common categories of off-label medicine use represented 85.2% of all off-
label medicine courses. In order of frequency they were: Category 11: not licensed for this 
indication, Category 3: dose greater than recommended and Category 5: not licensed in a 
child of this age, or child below minimum weight stated.  Category 11 was the most 
common off-label category (764 courses). 257 courses were ondansetron for indications 
other than post-operative or cytotoxic-induced nausea and vomiting (CINV or PONV). 136 
courses were fentanyl by intravenous infusion for post-operative analgesia. 105 courses 
were intravenous dexamethasone for the management of nausea and vomiting or oral 
dexamethasone for the management of nausea and vomiting other than CINV and 78 
courses were ketamine by intravenous infusion for post-operative analgesia. The second 
most common category was Category 3 (698 courses) of which 484 were paracetamol at a 
dose of 15-20mg/kg. This weight-based dosing frequently resulted in a greater dose being 
prescribed and administered than that recommended, by age band, in the BNF-C. We 
referred to the contemporaneous BNF-C age-related dose recommendations to categorise 
paracetamol courses (Paediatric Formulary Committee, 2009/2010). 79 Category 3 
medicine courses were nebulised or inhaled salbutamol at a greater frequency than 
recommended in the SmPC. Salbutamol nebules were administered every 20–30 minutes or 
as necessary and metered dose inhalers were used to deliver 100mcg every 15–30 seconds 
up to a maximum of 10 puffs, both in accordance with British Thoracic Society Guidelines as 
summarised in the BNF-C at that time (Paediatric Formulary Committee, 2009/2010). 69 of 
the Category 3 courses were intravenous gentamicin as a single daily dose. The third most 
common category was Category 5 (588 courses). 186 of these were morphine by 
continuous intravenous infusion, the SmPC for the morphine brand in use during the study 
stated that it was not suitable for use in children younger than 12 years old. 111 of the 
Category 5 courses were oral paracetamol; these were courses of oral paracetamol in 
children younger than 2 months.  
The most common category of unlicensed medicine use was Category 32: manufactured 
under a specials licence (577 courses) which represented 76% of all unlicensed medicine 
courses: 142 diclofenac 10mg dispersible tablet, 106 fentanyl + levobupivicaine epidural, 69 
spironolactone oral suspension and 58 midazolam oral or buccal solution (Table 3.5).  
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The proportion of medicine courses from each category which were implicated in at least 
one probable or definite ADR (PD ADR) was calculated and this was compared to the 6.2% 
of authorised medicine courses implicated (Table 3.5). Eighteen off-label and unlicensed 
categories were utilised (excluding ‘authorised’, ‘unknown’ and ‘theatre medicine’). There 
were seven categories in which none of the medicine courses were implicated in an ADR 
and one in which only one of courses was implicated, the largest of these categories 
contained 21 medicine courses. There were four categories which contained small numbers 
of medicine courses, the largest of these contained 61 medicine courses. In two of these 
categories the confidence interval for the odds ratio demonstrated non-significance and in 
the remaining two it was indicative of imprecision, a consequence of the small number of 
courses identified. Considering only the remaining six categories, medicines licensed for use 
in children but given at a dose greater than recommended (Category 3) had a lower risk of 
being implicated in an ADR than authorised medicines (2.7% implicated, OR 0.42, 95% CI 
0.26, 0.67). Medicines licensed in children but given to a child below the minimum age or 
weight had the greatest risk of being implicated in an ADR (19.0% implicated, OR 3.54, 95% 
CI 2.82, 4.44) followed by medicines not licensed for use in children at all (18.6% implicated, 
OR 3.44, 95% CI 2.41, 4.91). Medicines administered for a different indication were more 
likely to implicated in an ADR than authorised medicines (14.3% implicated, OR 2.50, 95% CI 
2.00, 3.13). Amongst unlicensed medicines, medicines manufactured under a specials 
licence were the most likely to implicated in an ADR (14.9% implicated, OR 2.64, 95% CI 
2.05, 3.38), followed by medicines prepared extemporaneously (14.7% implicated, OR 2.59, 
95% CI 1.61, 4.16). 
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Table 3.5 Number of medicine courses in each authorised, off-label or unlicensed category and number implicated in at least one PD ADR 
      
Category Definition 
Number of medicine 
courses 
% of courses 
implicated in at least 
one PD ADR 
Odds ratio of ADR vs. 
Authorised 
95% confidence 
interval 
      
1 Authorised 6980 6.2 1.00 - 
      
2 Contra-indication exists 1 0 - - 
      
3 
Dose greater than 
recommended 
698 2.7 0.42 0.26, 0.67 
      
5 
Not licensed in a child of this 
age (or child below minimum 
weight stated) 
588 19.0 3.54 2.82, 4.44 
      
6 
Not licensed in a child of this 
age and a contraindication exists 
1 0 - - 
      
7 Not licensed by this route 61 9.8 1.64 0.70, 3.83 
      
11 Not licensed for this indication 764 14.3 2.50 2.00, 3.13 
      
13 
Not licensed for this indication 
or at this dose 
8 0 - - 
      
15 
Not licensed for this indication 
or at this age 
35 25.7 5.21 2.43, 11.18 
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Category Definition 
Number of medicine 
courses 
% of courses 
implicated in at least 
one PD ADR 
Odds ratio of ADR vs. 
Authorised 
95% confidence 
interval 
      
17 
Not licensed for this indication 
or by this route 
21 0 - - 
      
19 
Not licensed for this indication 
or by this route or at this age 
2 0 - - 
      
21 Not licensed for use in children 215 18.6 3.44 2.41, 4.91 
      
22 
Not licensed for use in children 
and, a contraindication exists 
1 100.0 - - 
      
23 
Not licensed for use in children 
or, in adults by this route 
1 0 - - 
      
25 
Not licensed for use in children 
or, in adults for this indication 
11 18.2 3.34 0.72, 15.52 
      
31 Prepared extemporaneously 143 14.7 2.59 1.61, 4.16 
      
32 
Manufactured under a specials 
manufacturing licence 
577 14.9 2.64 2.05, 3.38 
      
33 Chemical 1 0 - - 
      
34 Import 37 16.2 2.91 1.21, 7.02 
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For medicine types with more than 100 courses administered, the proportion of medicine 
courses implicated in a probable or definite ADR is presented alongside the proportion of 
those courses which were categorised as off-label or unlicensed (Table 3.6). Fentanyl via 
any route excluding epidural administration had the greatest proportion of courses 
implicated in an ADR (48.0%) and 99.3% of courses were off-label. 44.3% of epidural 
fentanyl courses were implicated in an ADR with 100% of courses categorised as 
unlicensed. 39.6% of morphine courses were off-label or unlicensed. 28.5% of authorised 
morphine courses and 44.9% of off-label and unlicensed courses were implicated in at least 
one ADR.  
Table 3.7 shows the four most frequently implicated medicines and which off-label and 
unlicensed categories were assigned to them. These medicines were intravenous fentanyl, 
epidural levobupivicaine + fentanyl, morphine by any route and codeine by any route. The 
details of the ADRs in which these four medicines were implicated are as follows: 
Intravenous fentanyl: 48% of fentanyl courses (all off-label) were implicated in 136 ADRs, 
most commonly pruritus (49), constipation +/- abdominal pain (22) and vomiting (19). We 
examined the use of fentanyl leading to severe ADRs (Hartwig scale 4-6). There were only 
two severe ADRs secondary to fentanyl, both were severity level 4 (resulted in patient 
transfer to a higher level of care). One case was a respiratory arrest in a 9 year old; drugs 
received for general anaesthesia were also implicated in the ADR. The second case was 
respiratory depression in a 15 year old, intravenous ketamine infusion was also implicated. 
Both patients were receiving fentanyl at a rate of 1mcg/kg/hr.; the record of bolus doses 
was unreliable.  
Fentanyl + levobupivicaine epidural: 47 courses of fentanyl + levobupivicaine via the 
epidural route (all manufactured under a specials licence) were implicated in 106 ADRs, 
most commonly: pruritus (26), constipation +/- abdominal pain (20) and vomiting (19). 
There were no severe ADRs (Hartwig scale 4-6) secondary to fentanyl + levobupivicane via 
the epidural route. 
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Morphine via any route: Amongst the authorised morphine courses, 60.3% were 
administered to children aged 12 years or older. Almost all  of the off-label morphine 
courses were administered to children younger than 12 years (99%). 28.5% of authorised 
morphine courses were implicated in 142 ADRs, most commonly pruritus (42), constipation 
+/- abdominal pain (39) and vomiting (29). 44.9% of off-label morphine courses were 
implicated in 173 ADRs, and the most common ADR types were the same as those caused 
by authorised morphine courses: pruritus (78), vomiting (31) and constipation +/- 
abdominal pain (15). There were no severe ADRs (Hartwig scale 4-6) secondary to 
morphine.  
Codeine via any route: 13.2% of codeine courses were implicated in 101 ADRs (all 
implicated courses were oral). 49/483 (10.1%) of authorised courses were implicated in 67 
ADRs and 80.6% of these ADRs were constipation. 31.2% of codeine courses could not be 
categorised because the preparation used was not recorded on the prescription. 33/257 
(12.8%) of uncategorised courses were implicated in 34 ADRs and 73.5% of these were 
constipation. There were no severe ADRs (Hartwig scale 4-6) secondary to codeine. 
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Table 3.6 Medicines course frequency administered, implicated and off-label, unlicensed 
or unknown. Greatest proportion of courses implicated first (only medicines with > 100 
courses shown, n=7007) 
Medicine 
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Fentanyl 150 48.0 149 0 99.3 0   0 
Fentanyl & 
Levobupivicaine epidural 
106 44.3 0 106 0 100 0 
        
Morphine 500 35.0 197 1 39.4 0.2 0 
        
Codeine Phosphate 752 13.2 9 3 1.2 0.4 257 
        
Furosemide 123 9.8 13 0 11.8 0 0 
        
Cefotaxime 388 9.0 0 0 0 0 0 
        
Salbutamol 146 8.9 84 0 56.8 0 0 
        
Metronidazole 257 7.8 21 0 8.2 0 0 
        
Cefalexin 148 7.4 9 0 6.1 0 0 
        
Dexamethasone 166 6.6 107 0 64.5 0 7 
        
Ondansetron 550 5.8 290 0 52.7 0 48 
        
Cefuroxime 245 4.5 0 0 0 0 1 
        
Lactulose 272 2.2 13 0 4.8 0 0 
        
Diazepam 107 1.9 2 0 1.9 0 0 
        
Diclofenac 331 1.5 7 142 2.1 42.9 159 
        
Ranitidine 109 0.9 65 0 59.6 0 0 
        
Ibuprofen 545 0.7 26 0 4.8 0 0 
        
Chlorphenamine 339 0.3 1 0 0.3 0 1 
        
Paracetamol 1786 0.1 596 0 33.4 0 2 
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Table 3.7 Off-label and unlicensed category proportions for medicines with >10% of 
courses implicated 
   
Category Definition 
Count of medicine courses (count of courses implicated in 
an ADR) 
 
Fentanyl 
 
Fentanyl & 
Levobupivicaine 
Epidural 
Morphine 
 
Codeine 
 
1 
 
Authorised 
 
1 (0) - 302 (86) 483 (49) 
3 
 
Dose greater 
than 
recommended 
 
- - 2 (0) - 
5 
 
Not licensed in a 
child of this age 
(or child below 
the minimum 
weight stated) 
 
1 (0) - 189 (88) 9 (0) 
11 
 
Not licensed for 
this indication 
 
136 (66) - 6 (1) - 
15 
 
Not licensed for 
this indication or 
at this age 
 
12 (6) - - - 
29 
 
Category cannot 
be assigned 
 
- - - 257 (33) 
32 
 
Manufactured 
under a specials 
manufacturing 
licence 
 
- 106 (47) 1 (0) 3 (0) 
 Total 150 (72) 106 (47) 500 (175) 752 (99) 
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3.3.3 Univariate analysis 
Gender, age, oncology patient status and receipt of a general anaesthetic (GA) were the 
variables examined in the univariate analysis (Table 3.8 & Figures 3.1-3.3). There was no 
difference in the time to first ADR between males and females; children in the teenage 
category (>12 years) were at greatest risk of experiencing an ADR, with neonates at the 
lowest risk. Oncology patients were more likely to experience an ADR than non-oncology 
patients and patients who had received a GA were more likely to experience an ADR than 
those who had not. 
 
Table 3.8 Univariate analysis 
     
Variable ADR No ADR Kaplein-Meir 
Curve 
p-value 
Gender 
Male 382 372 
Figure 1 0.446x 
Female 312 322 
      
 
 
Age 
 
Infant: < 1 years 78 322 
Figure 2 <0.001xi 
Pre-school: 1 to 4 years 155 186 
School-aged: 5 to 11 years 231 153 
Teenage: >12 years 230 139 
      
Oncology 
status 
Oncology 38 5 
Figure 3 <0.001xi 
Non-oncology 656 689 
      
GA 
exposure 
GA 533 340 
- < 0.001xi 
No GA 161 354 
      
  
 
 
 
 
                                                          
x
 Log-rank test for significant difference between curves 
xi
 Cox univariate regression for significant difference between curves 
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Figure 3.1 Univariate analysis of gender 
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Figure 3.2 Univariate analysis by age categoryxii 
 
 
 
 
 
 
 
 
 
                                                          
xii
 Infant: < 1 years, Pre-school: 1 to 4 years, School-aged: 5 to 11 years, Teenage: >12 years 
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Figure 3.3 Univariate analysis by oncology patient statusxiii 
 
 
 
 
 
 
 
 
 
 
                                                          
xiii
 No = non-oncology patient, Yes = oncology patient 
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3.3.4 Multivariate analysis 
All patients (n=1388) were included in the multivariate analysis. All variables included in the 
univariate analysis were included in the model due to their clinical importance, the number 
of authorised, off-label or unlicensed and unknown medicines per day were also included. 
Age on admission and receipt of a GA each had a significant effect on ADR risk. The risk of 
an ADR increased with each year increase of age. Gender and oncology patient status did 
not have a significant effect on the hazard of an ADR. Each additional off-label and/or 
unlicensed medicine given per day significantly increased the risk of an ADR (HR 1.27, 95% 
CI 1.20, 1.34, p<0.001). Similarly, each unit increase in the number of authorised medicines 
in a single day also significantly increased the hazard of an ADR (HR 1.22, 95% CI 1.17, 1.26, 
p <0.001) (Table 3.9).   
 
Table 3.9 ADR risk factors assessed by multivariate analysis 
   
Predictor HR (95% CI) p-value 
Gender 
Female 1 
0.152 
Male 0.90 (0.77, 1.04) 
Age on admission (years) 
 
1.04 (1.02, 1.05) <0.001 
Received a GA 
No 1 
<0.001 
Yes 5.30 (4.42, 6.35) 
Oncology 
No 1 
0.655 
Yes 0.93 (0.66, 1.30) 
Number of authorised medicines 1.22 (1.17, 1.26) <0.001 
Number of OLUL medicines 1.27 ( 1.20, 1.34) <0.001 
Number of uncategorised medicines 1.14 (0.97, 1.34) 0.116 
   
 98 
 
3.4 Discussion 
This is the largest study of this kind undertaken. Off-label and unlicensed medicines were 
significantly more likely to be implicated in a probable or definite ADR than authorised 
medicines. In a survival analysis model, the number of off-label and/or unlicensed 
medicines administered was a significant predictor of ADR risk but so was the number of 
authorised medicines.  
One of the key limitations of the observational study design was that signs, symptoms or 
measurements indicative of an ADR which were not detected and recorded by the clinical 
team looking after the child could not be detected by the study team. A nested case-control 
design was appropriate to test our hypotheses in the context of the resources we had 
available and the detailed evaluation of each prescription that was required. Controls were 
matched to cases using the nearest date and time of admission in order to avoid using as 
matching criteria any of the variables we planned to examine. As this study takes much of 
its dataset from a larger prospective study, there is no reason to suppose that the quality of 
data available for our variables of interest was any different between cases and controls. 
The study may have had greater power to detect differences between patients who 
experienced an ADR and those who did not if cases had been matched to controls in a ratio 
of 1:2 or 1:3 rather than 1:1. This limitation is illustrated in this study by the fact that, in 
contrast to the main cohort study (Thiesen et al., 2013), we did not demonstrate a 
significant difference in ADR risk between oncology and non-oncology patients. Another 
limitation was the necessity for a minimum amount of information to be available for 
medicine categorisation, this led to 5.2% of medicine courses not being categorised and 
consequently being excluded from the risk analysis. This limitation could only have been 
overcome by requesting a change to prescribing practice i.e. recording of drug name and 
preparation on every prescription; this was not achievable. Further limitations result from 
the assumptions outlined in the methodology which pertain to the SmPC definitions of age, 
gestational age and the classification of cytotoxic medicines. 
In our study, 23.7% of medicine courses were off-label and 7.5% were unlicensed. The 
percentage of off-label prescriptions in observational studies of paediatric inpatient 
prescribing ranges from 18 to 60%, the percentage of unlicensed prescriptions in these 
studies ranges from 3.4 to 36% (Cuzzolin, Atzei and Fanos, 2006). Turner et al. (1999) 
conducted a similar study at Alder Hey which was published in 1999, they found that 35% 
of prescriptions were off-label or unlicensed. With the introduction of the paediatric 
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regulation in 2007 (The European Parliament and the Council of the European Union, 2006) 
it might be assumed that, 5 years on, the incidence of off-label and unlicensed prescribing 
would be less, our results show that this is not the case. The European Medicines Agency 
Paediatric Committee’s 5-year report to the European Commission indicated that by the 
end of 2011, 29 PIPs had been completed leading to new paediatric indications for 24 
medicines and to new pharmaceutical forms appropriate for children for 7 medicines. 
Between 2008 and 2012, 10 out of 113 new centrally authorised medicinal products 
received a paediatric indication (out of 113 new active substances in total). For one of these 
products, a Paediatric Use Marketing Authorisation (PUMA) was granted. For medicines 
already authorised centrally or nationally, 18 and 12 respectively, received a new paediatric 
indication (European Medicines Agency with its Paediatric Committee, 2012). 
In our study, based in a large paediatric tertiary referral centre, off-label and unlicensed 
medicines were significantly more likely to be implicated in an ADR than medicines used 
within the terms of their MA, OR 2.25 (95% CI 1.95, 2.59). This was a greater increase in risk 
than that reported in previous inpatient studies. In their study of paediatric outpatients, 
Horen et al. (2002) reported a similar risk for off-label medicines (RR 3.44 95% CI 1.26, 9.38) 
however the design and setting of this study were dissimilar to ours. The odds ratio 
reported here summarises the likelihood of individual medicines being implicated in an ADR 
but it does not reflect the complexity of the dataset. 20.4% of ADRs involved a combination 
of off-label and/or unlicensed and authorised medicines and some medicines were involved 
in multiple ADRs. The authors of two previous prospective inpatient studies have reported 
on the likelihood of off-label and unlicensed medicines being implicated in ADRs. Turner et 
al. (1999) found a smaller but still significant increase in ADR risk associated with off-label 
and unlicensed medicines (relative risk 1.46, 95% CI 1.11, 1.93). We used the same 
definitions of off-label and unlicensed medicine but included more than twice the number 
of medicine courses. Although carried out at the same centre as ours, their study was 
carried out on fewer wards and included some different ward types:  PICU, cardiac ICU, 
neonatal surgery, a medical ward and a surgical ward; their cohort of patients may have a 
different medicine use profile and/or susceptibility to ADRs. Neubert et al. (2004) reported 
a small non-significant increase in ADR risk with off-label and unlicensed medicine use 
(relative risk of 1.08, 95% CI 0.50, 2.35). Theirs was a smaller study based on a single 
paediatric isolation ward, this is reflected in the nature of the adverse drug reactions they 
observed and the medicines implicated in them. They used different definitions of off-label 
and unlicensed medicine use, they compared the official licence information with the 
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patient’s age, the dose of the medicine given and the route it was given by but indication 
was not considered. 
The three most common categories of off-label medicine use in our study were: Category 
11: not licensed for this indication, Category 3: dose greater than recommended and 
Category 5: not licensed in a child of this age, or child below minimum weight stated.  The 
most common category of unlicensed medicine use was Category 32: manufactured under 
a specials licence. Two previous inpatient studies have described in detail the categories of 
off-label and unlicensed medicine use. Santos et al. (2008) used different definitions to 
ours; unlicensed medicines were those contraindicated in children, extemporaneous 
products and medicines for which safety and efficacy have not been established in children. 
In their off-label assessment they considered age or weight, dose or frequency, route and 
formulation. They found that the most frequent off-label reason was dose/frequency 
different from that recommended in local pharmaceutical references followed by 
age/weight different from that recommended and that the most frequent type of 
unlicensed medicine was ‘safety and efficacy have not been established in children’. The 
categories used by Neubert et al. (2004) are outlined earlier in this discussion, they 
reported that the only type of unlicensed medicine use was modification to licensed 
medicines and the most common type of off-label use was use at an inappropriate age, 
they did not consider indication.  
To our knowledge, there are no previous inpatient studies which compare ADR risk for 
authorised and off-label and unlicensed medicine use categories. In a community-based 
study Horen et al. (2002) reported that a significant increase in ADR risk with medicines 
used for different indication, the risk was greater than that found in our study (RR 4.42 95% 
CI 1.60, 12.25). Jonville-Bera et al. (2005) studied medicines implicated in spontaneous ADR 
reports and found that the most common categories were indication not authorised and 
precautions for use not being respected. Our ability to consider the odds of each category 
being implicated in an ADR was limited by the low number of courses in some categories. 
Medicines given at a dose greater than recommended (Category 3) had a lower risk of 
being implicated in an ADR than authorised medicines; this can be explained by the fact 
that this category is dominated by paracetamol courses which were frequently off-label 
(but followed national peer-reviewed guidance (Anonymous 2012)), only one paracetamol 
course was implicated in an ADR. When the analysis was repeated without any paracetamol 
courses, the proportion of authorised medicines implicated in an ADR increased from 6.2% 
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to 7.5% and Category 3 medicines had a greater risk of being implicated in an ADR than 
authorised medicines, 8.9% courses were implicated (OR 1.20, 95% CI 0.74, 1.94).  
We examined, with reference to their off-label or unlicensed status, the use of the four 
medicine types for which more than 10% of courses were implicated in at least one ADR 
(Table 3.7). Notably, these medicines are all opioids mainly used in the management of 
post-operative pain. This is reflective of the case-mix within this study; 873 of 1388 (62.9%) 
patients received a general anaesthetic. We can assume that, within a tertiary care setting 
and with the inclusion of only those patients who had been in hospital for longer than 48 
hours, the majority of these general anaesthetics were given for major operative 
procedures following which opioids were required to provide adequate analgesia. 
Intravenous fentanyl:  99.3% of intravenous fentanyl courses were off-label because the 
commonly used infusion and bolus doses used for nurse- and patient-controlled post-
operative analgesia (NCA and PCA) are not found in the SmPC for this medicine. The use of 
fentanyl in this way is not mentioned in the BNF-C but is recommended at a rate of 0.5-
2.5mcg/kg/hr. in a UK peer-reviewed guideline. (Anonymous 2012, Monitto et al., 2000) 
Although the administration of fentanyl via NCA or PCA is off-label using our definition, 
there is an evidence base for its use. If this use was authorised there is no obvious reason 
why the frequency of the most common ADRs (pruritus, constipation and vomiting) would 
be diminished. There may be other characteristics of these patients which made them 
susceptible to these ADRs, for example underlying disease, but these have not been 
investigated here.  
Fentanyl + levobupivicaine epidural: All fentanyl + levobupivicaine epidural courses were 
unlicensed. Peer-reviewed guidelines (Anonymous 2012) recommend the use of fentanyl + 
levobupivicaine via the epidural route at a rate of 0.3-0.8mcg/kg/hr. to manage post-
operative pain, following certain procedures in children. Local guidelines in use during this 
study recommended a rate of 0.1-0.3mcg/kg/hr. If we assume that the epidural infusion we 
use delivers an accurate dose there is no reason to suppose that the use of a licensed 
infusion would result in fewer ADRs.  
Morphine via any route: 35% of morphine courses (via any route) were implicated in an 
ADR (Table 3.6).  The most common route was via NCA or PCA. A UK peer-reviewed, 
evidence-based guideline (Anonymous 2012) recommends: NCA background 0-
0.02mg/kg/hr. (0mg/kg/hr. if patient <5kg), 0.01 – 0.02 mg/kg bolus with a  20-30 minute 
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lock-out period, PCA background 0.004mg/kg/hr., 0.01-0.02mg/kg bolus with a 5-10 minute 
lock-out. Morphine NCA and PCA guidelines at Alder Hey correspond to this with the 
exception that the NCA guideline recommends a background infusion from birth (regardless 
of patient weight) and a 15 minute lock-out period. Authorised and off-label morphine 
courses were not uniformly distributed across the age groups in our study population. Only 
one off-label course was administered to a child 12-16 years old whereas amongst 316 
courses given to children under 12 years old, 196 (62.0%) were off-label. Our data indicate 
that off-label morphine courses are more likely to be implicated in an ADR. One possible 
interpretation of this is that children under 12 years old are more susceptible to ADRs. 
However, on closer inspection of the data, the proportion of morphine courses implicated 
in an ADR was similar in both age groups: 110/316 (34.8%) in children <12 years old and 
65/184 (35.3%) in children 12-16 years old. In children under 12 years old, 88/197 (44.7%) 
of off-label courses and 22/119 (18.5%) of authorised courses and were implicated in at 
least one ADR (Chi-square test for difference in proportions p<0.001). Amongst children 
under 12 years old, the mean age of those who received off-label morphine was less than  
the mean age of children who received authorised morphine; 4.9 years (SD 3.8) vs. 6.2 
years (SD 3.5), Student’s t-test for difference between means p = <0.001. Therefore, off-
label morphine was more likely to be implicated in an ADR and younger children were more 
likely to receive off-label morphine. Because of developmental differences in pharmaco - 
kinetics and – dynamics, younger children may be more likely to experience an ADR to 
morphine.  In terms of metabolism, glucuronidation of morphine occurs in the liver of 
neonates and infants but it is unclear whether the capacity of the liver is fully mature (Kart, 
Christrup and Rasmussen, 1997a). The half-life of morphine decreases and its elimination 
increases up to the age of two months; in children older than this these parameters are 
similar to those in adults (Kart, Christrup and Rasmussen, 1997a). The quantity and location 
of opioid receptors and their affinity for morphine may change with age and the immature 
blood-brain barrier in very young children may also influence the effects of morphine (Kart, 
Christrup and Rasmussen, 1997b). In a large-scale clinical study of morphine NCA use in 
children, neonates were significantly more likely than older children to experience serious 
adverse events (respiratory depression or over-sedation for which active resuscitation 
measures were taken and naloxone was administered) (Howard et al., 2010). Conversely, 
the risk of ‘non-serious’ cases of respiratory depression and sedation and post-operative 
nausea and vomiting increased with increasing age. The incidence of pruritus was similar 
across all ages (with the exception of neonates, amongst whom the incidence was low). 
Data on the incidence of constipation was not collected. As in the case of fentanyl, there 
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are likely to be other pre-disposing patient-related factors which we have not examined 
here. For example, morphine pharmacokinetic parameters may be affected by surgery or 
cardiac state (Kart, Christrup and Rasmussen, 1997a). The pharmacodynamics of morphine 
may also affected by the clinical state of the patient if severe illness alters the pattern of 
opioid receptor expression and affinity (Kart, Christrup and Rasmussen, 1997b). 
Codeine via any route: None of the nine off-label codeine courses were implicated in an 
ADR. If we assume that the majority of ‘unknown’ courses were authorised, authorised 
codeine courses were more likely to be implicated in an ADR than off-label courses. If we 
assume that the majority of ‘unknown’ courses were off-label, the proportion of authorised 
and off-label courses implicated in at least one ADR is similar. Therefore, we do not have 
any evidence that ADRs are more likely with off-label codeine use. Codeine was implicated 
alongside at least one other medicine in 81/101 ADRs, most commonly fentanyl or 
morphine in cases of constipation. This exemplifies how the involvement of multiple 
medicines in one ADR can limit our ability to evaluate the contribution of individual drugs, 
inclusive of their category. 
Multivariate analysis indicated that the number off-label and unlicensed medicines 
administered per day has a similar influence on ADR risk as the number of authorised 
medicines administered per day. Two previous inpatient studies have considered off-label 
and unlicensed medicine use as an ADR risk factor in multivariate analyses. Turner et al. 
(1999) used a binary variable; patient exposed to at least one off-label or unlicensed 
medicine or not, they did not demonstrate a significant contribution of off-label or 
unlicensed medicine exposure to ADR risk, RR 1.74, 95% CI 0.89, 3.41, p<0.06. Santos et al. 
(2008) found that off-label medicine use was significantly associated with ADR risk, RR 2.44, 
95% CI 2.12, 2.89, we have described above how their definitions of off-label and 
unlicensed medicine use were disparate from ours. Our method of analysis differs from that 
in these two previous studies and allows us to examine the influence of the number of off-
label medicines and compare this to the influence of the number of authorised medicines. 
Our findings indicate, in accordance with the results of previous studies, (Turner et al., 
1999, Neubert et al., 2004, Davies et al., 2009) that the overall number of medicines is a 
significant predictor of ADR risk. This may result from the increased risk of drug-drug 
interactions or may also be a reflection of the fact that patients on more medicines are 
more likely to be seriously unwell or have on-going complex medical needs.  
 104 
 
The risk of ADRs was greater with off-label and unlicensed medicines but we have no 
evidence that if these medicines were used in accordance with a MA they would be 
implicated in fewer ADRs. The terms of a MA are derived from the data submitted as part of 
the drug regulatory process and may subsequently be updated with data obtained from 
post-marketing evaluation. If a MA does not cover some or all use in children it is because, 
in that specific circumstance, there is evidence that the medicine is not efficacious and/or 
not safe or because there is a lack of evidence that the medicine is efficacious and/or safe. 
Therefore, when the use of a medicine is categorised as ‘off-label’ this does not provide a 
consistent indication of the risk associated with that use. Unlicensed medicines need to be 
used in clinical practice because a suitable authorised medicine does not exist or has not 
been granted a MA in the UK, the reasons for this are generally commercial or practical and 
therefore there is no consistent link to the safety of the product.  
Off-label medicines given to individuals below the minimum age recommended were the 
most likely to be implicated in ADRs. For many off-label and unlicensed medicines there is a 
lack of pharmacokinetic data in children, however off-label prescribing does not 
consistently equate to off-evidence prescribing, indeed some off-label use is supported by 
evidence derived from clinical experience or studies (Epstein and Huang, 2012). For some 
unlicensed medicines there may be a lack of formulation data, which contributes further to 
the evidence deficit.  
It is unequivocal that children should be treated in accordance with the best available 
evidence. Clinicians incorporate relevant evidence, knowledge and experience into their 
decision-making regardless of whether this information has been incorporated into the 
medicine’s MA. Information comes from a variety of sources: relevant paediatric studies, 
extrapolation from adult or less relevant paediatric studies, it is derivative of an 
understanding of the drug’s pharmacology and the patient’s underlying illness or clinical 
experience. The relevance and reliability of these sources of information will vary and the 
application of this information will be tailored to individual patients. In terms of adverse 
effects, caution is required when extrapolating data from adult and less relevant paediatric 
studies. The pharmacokinetic and pharmacodynamic behaviour of a drug may change as a 
child develops, with the greatest period of development occurring in the first two to three 
years of life (Kearns et al., 2003, Mulla, 2010). Furthermore, in children, consideration must 
be given to adverse effects relating to growth and development and to the potential for 
adverse effects associated with long term use. Knowledge of the pharmacology and 
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published safety data relating to the authorised formulations of a drug enable clinicians to 
predict some adverse effects but it may not always be appropriate to extrapolate these 
data to the use of the drug in an unlicensed formulation. Studies to improve the relevance 
and reliability of information about medicine use in children are needed. Effective 
strategies to disseminate and translate this information into clinical practice will help 
clinicians to optimise the use of medicines in children in terms of both efficacy and safety 
3.5 Conclusion 
 
While good quality data on the safe use of some off-label and unlicensed medicines in 
children may not be available, it is too simplistic to say that this translates directly into an 
increased risk of ADRs. Using detailed off-label and unlicensed categories, we have 
described which types of off-label and unlicensed use contributed to ADR risk and we have 
attempted to discuss the reasons for this. However, our off-label or unlicensed categories 
do not reveal anything about the pharmacological properties of the medicines. 
Furthermore, our analysis did not consider any variation in the susceptibility of the patients 
to ADRs, in terms of physiological development or underlying disease. Both the 
pharmacological properties of the medicine and the susceptibility of the individual patient 
influence the likelihood of ADR occurence. In order to target interventions aimed at 
reducing the risk of ADRs in children, the contribution of individual off-label and unlicensed 
medicines to this risk must be considered in the context of the evidence available and its 
appropriate application. 
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4 ICD-10 Coding of ADRs 
4.1 Introduction 
National Health Service (NHS) hospitals in the UK use a system of coding alongside the 
length of hospital stay to determine the chargeable cost of care for each patient. The 
coding systems used are the International Classification of Disease (ICD-10) codes for signs 
and symptoms and the Office of Population Census and Surveys (OPCS) codes for 
interventions and procedures. The process of coding is by case note review, undertaken by 
trained coders. It relies on diagnoses, procedures and other events being written down by 
the clinical team caring for the patient.  Accurate coding is essential to obtain payment for 
the treatments and procedures undertaken in a hospital. The data are also submitted to 
become part of the national hospital episode statistics (HES) which record, for the NHS in 
England, each episode of admitted patient care. The data are used for research and 
planning in the NHS.  
There are specific ICD-10 codes which relate to either adverse drug events (ADEs) or 
adverse drug reactions (ADRs) (Tables 4.1 & 4.2) which have been used in surveillance 
methods in studies of ADEs and ADRs. Some studies have used clinical codes to identify 
their cases and then examined the casenote record to ascertain that the coding is accurate 
(Schlienger et al., 1998, Backstrom, Mjorndal and Dahlqvist, 2004, Hougland et al., 2006, 
Hodgkinson, Dirnbauer and Larmour, 2009). Other studies, in a variety of settings, have 
used clinical codes as a method of estimating the prevalence of ADRs or ADEs without 
validation of those codes (Waller et al., 2005, Patel et al., 2007, Al-Malaq, Al-Aqeel and Al-
Sultan, 2008, Shamliyan, 2010, Bourgeois et al., 2009, Carrasco-Garrido et al., 2010, Kane-
Gill, Van and Handler, 2010, Wu et al., 2010, Stausberg and Hasford, 2011). There are some 
studies which identified ADR cases by searching for the relevant ICD code and compared 
these with spontaneously reported cases. They found that not all ADRs were identified by 
both methods and concluded that neither method in isolation was reliable for ADR 
surveillance. In general, they comment that spontaneous reports and hospital 
administrative data could be used in conjunction to increase the, currently suboptimal, 
detection of ADRs overall. (Cox et al., 2001, Lugardon et al., 2006, Batz et al., 2011, Mahe et 
al., 2013, Verriere et al., 2013). None of the approaches described above allowed an 
examination of whether coding provided a good estimate of ADE or ADR prevalence. Three 
studies in the adult population have identified ADRs or ADEs either by retrospective case 
note review or by prospective monitoring, and then reviewed the ICD codes for these cases; 
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these studies showed that, in the majority of cases, ADRs and ADEs had not been coded 
properly (Juntti-Patinen et al., 2006, Brvar et al., 2009, Hohl et al., 2012).  
When undertaking research which uses data derived from administrative healthcare 
databases it is essential to first consider the reliability of those data. A systematic review of 
studies which compared discharge codes with the medical record for hospitals in the UK 
found a median coding accuracy rate of 91% for diagnostic codes and of 69.5% for 
operation or procedure codes in England and Wales and of 82% for diagnostic codes and 
98% for operation or procedure codes in Scotland (Campbell et al., 2001). This finding 
implies good accuracy of the coding system but many of the studies that were included 
looked only at specific diagnoses. Thus the review findings may not actually tell us about 
the overall accuracy of the system, particularly in the context of pharmacovigilance. Many 
studies that have used administrative data to provide an estimate of ADR or ADE incidence 
did not validate their selected codes; they assumed accuracy of the coding system (Waller 
et al., 2005, Patel et al., 2007, Al-Malaq, Al-Aqeel and Al-Sultan, 2008, Shamliyan, 2010, 
Carrasco-Garrido et al., 2010, Kane-Gill, Van and Handler, 2010, Wu et al., 2010, Stausberg 
and Hasford, 2011). A UK study of ‘drug-induced disorders’ as a cause of hospital admission 
used HES data to estimate their prevalence but acknowledged that, in comparison to 
published prospective studies; their methodology underestimated the ADR prevalence 
(Waller et al., 2005). Other studies of ADR or ADE incidence have validated their findings by 
going back to the case note record for ADR cases identified by ICD. This method can identify 
false positives but does not allow the investigators to estimate how many ADRs have been 
missed by using ICD codes to identify ADR cases (Schlienger et al., 1998, Backstrom, 
Mjorndal and Dahlqvist, 2004, Hougland et al., 2006, Hodgkinson, Dirnbauer and Larmour, 
2009). It is acknowledged that the accuracy of clinical coding is variable which limits its 
usefulness in the context of clinical studies because its focus is on reimbursement and legal 
documentation rather than on clinical care. In addition, it provides limited temporal and 
causal information and may be subject to ‘code creep’, that is, a bias towards higher paying 
codes (Bates et al., 2003). 
Spontaneous ADR reporting systems have limitations as described in Chapter 1 of this 
thesis. Furthermore, extensive resources are required to conduct intensive surveillance for 
ADRs in, for example, prospective cohort studies like those described in Chapters 2 and 3 of 
this thesis. Therefore, it would be of great benefit if we could rely on hospital 
administrative data, which is collected routinely and easy to access, for the identification of 
ADRs. However, this requires ADRs to be coded accurately. The aim of the present study 
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was to determine whether ADRs in a paediatric population identified prospectively through 
intensive surveillance were coded appropriately using ICD-10. 
 
Table 4.1 ICD-10 codes which may apply to adverse drug events or adverse drug 
reactions. Y40-Y59 external cause codes (adverse effects in in therapeutic use)xiv  
  
Code  Description 
Y40 Systemic antibiotics 
Y41 Other systemic anti-infectives/antiparasitics 
Y42 Hormones (including synthetic, antagonists) 
Y43 Primarily systemic agents 
Y44 Agents primarily affecting blood constituents 
Y45 Analgesics/antipyretics/anti-inflammatories 
Y46 Antiepileptics/antiParkinsonism drugs 
Y47 Sedatives, hypnotics, antianxiety drugs 
Y48 Anaesthetics, therapeutic gases 
Y49 Psychotropic drugs 
Y50 CNS stimulants 
Y51 Drugs affecting autonomic nervous system 
Y52 Agents primarily affecting cardiovascular   system 
Y53 Agents primarily affecting gastrointestinal system 
Y54 Agents affecting water/mineral balance/uric acid 
Y55 Agents affecting muscle/respiratory system 
Y56 Topical agents affecting skin, ENT, dental 
Y57 Other and unspecified medicaments 
Y58 Bacterial vaccines 
Y59 Other vaccines/biologicals 
  
 
 
 
 
                                                          
xiv
 Waller et al. 2005 
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Table 4.2 ICD-10 codes which may apply to adverse drug events or adverse drug reactions 
– codes including the word ‘drug induced’xiv  
  
Code Description 
D61.1 Drug-induced aplastic anaemia 
D59.0/2 Drug-induced haemolytic anaemia 
E03.2 Hypothyroidism due to medicaments 
E27.3 Drug-induced adrenocortical failure 
F11 Mental disorders due to opioids 
F13 Mental disorders due to sedatives/hypnotics 
F19 Mental disorders due to multiple psychoactive drugs 
G21.0 Malignant neuroleptic syndrome 
G21.1 Drug-induced Parkinsonism 
G24.0 Drug-induced dystonia 
G25.0/4/6 Drug-induced extrapyramidal syndrome/chorea/tics 
G72.0 Drug-induced myopathy 
H91.0 Ototoxic hearing loss 
I42.7 Drug-induced cardiomyopathy 
J70.2/3/4 Drug-induced interstitial lung disorders 
K71 Drug-induced liver disease 
L56.0/1 Drug-induced phototoxicity 
M10.2 Drug-induced gout 
M32.0 Drug-induced systemic lupus erythematous 
M34.2 Drug-induced systemic sclerosis 
N14.0/1/2 Drug-induced nephropathy 
T88.3 Malignant hyperthermia due to anaesthesia 
T88.6 Drug-induced anaphylaxis 
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4.2 Methods 
4.2.1 Detection of ADRs 
The method by which the 241 ADRs included in this study were detected and evaluated is 
described in chapter 2. The study described in this chapter was undertaken by JRB. 
For each ADR, the following information was obtained from the dataset to meet the specific 
objectives of the present study: patient identification, suspected drug(s), a description of 
the ADR (usually a symptom), ADR type (A or B), severity and causality assessment.  
4.2.2 Matching ADRs detected to ICD-10 codes for each admission 
The electronic admission abstract recorded in Alder Hey NHS Foundation Trust’s electronic 
medical records system (MEDITECH) displays the ICD-10 codes for that admission. 
Therefore, the electronic admission abstract for each patient with at least one ADR was 
examined and a record was made of whether the ADR had been coded using ICD-10 and if 
so, which code(s) had been used, these will be referred to here as ICD-10 ADR codes. A 
record was also made of whether the ADR signs and symptoms had been coded using ICD-
10 with no acknowledgment of their drug cause. Again the codes used were recorded and 
will be referred to here as ICD-10 sign and symptom codes. 
4.2.3 Comparison of ADR type, severity and causality 
A Chi-square test for difference in proportions was used to determine whether there were 
any differences in the characteristics of coded and uncoded ADRs. The null hypotheses 
were as follows: 
1. Type A and Type B reactions were equally likely to be coded using ICD-10. 
2. ADRs of severity 1, 2, 3 and 4, 5 were equally likely to be coded using ICD-10.  
3. Possible ADRs were equally likely to be coded as probable and definite ADRs using 
ICD-10. 
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4.3 Results 
4.3.1 Description of ADRs coded using ICD-10 
Of the 241 ADRs evaluated in this study, 76 (31.5%) were coded correctly using at least one 
ICD-10 code (Table 4.3). One reaction was incorrectly coded, a skin reaction to topical 
dimeticone, was coded as Y53.1 Other antacids and anti-gastric-secretion drugs, the 
suspected drug had been incorrectly identified during the coding process. Two reactions 
had two codes as follows:  
1. pancytopenia coded as  
a) Z51.2 other chemotherapy 
b) Y43.3 other antineoplastic drugs  
2. post-immunisation irritability coded as  
a) T88.1 Other complications following immunization 
b) Y59.9 Vaccine or biological substance, unspecified 
There were 126 non-oncology ADRs and 115 reactions that involved a patient under the 
care of the oncologists in this study.  
Of the 126 non-oncology ADRs, 6 (4.8%) were coded (see figure 4.1).  
Of the 115 oncology reactions, 70 (61%) were coded correctly and without exception, the 
code Y43.3 other antineoplastic drugs was used (see figure 4.2). 
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Table 4.3 ADRs coded using ICD-10 ordered by reaction frequency (n=76, two reactions 
had two codes) 
Description of reaction (s) ICD -10 Code Number of 
reactions 
 
ADRs secondary to chemotherapy: 
neutropenia, anaemia, thrombocytopenia, 
immunosuppression, deranged liver 
function tests, mouth ulcers, nausea, 
vomiting, diarrhoea, back pain, fever, 
deranged renal function  
 
Y43.3 Other antineoplastic 
drugs 
 
 
70 
   
Rash secondary to penicillin, Vomiting 
secondary to penicillin 
Y40.0 Penicillins 2 
   
Hyperglycaemia secondary to 
dexamethasone 
Y42.7 Androgens and anabolic 
congeners 
2 
   
Anaemia, immunosuppression, 
thrombocytopenia, neutropenia 
Z51.2 Other chemotherapy  1 
   
Hypoglycaemia secondary to insulin E16.0 Drug induced 
hypoglycaemia without coma 
1 
   
Irritability following pneumococcal and DTP 
vaccines 
T88.1 Other complications 
following immunization    
1 
   
Irritability following pneumococcal and DTP 
vaccines 
Y59.9 Vaccine or biological 
substance,  unspecified 
1 
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4.3.2 Description of ADR signs and symptoms coded using ICD-10 
The signs and symptoms of 212/241 (88%) ADRs were acknowledged by the ICD-10 code(s) 
for the relevant admission. These 212 ADRs cases were made up of 107 oncology cases of 
which 70 also had an ADR code and 104 non-oncology cases of which 4 also had an ADR 
code. There were 20/126 (15.9%) non-oncology ADRs and 8/115 (7.0%) oncology ADRs not 
acknowledged by either an ADR ICD-10 code or an ICD-10 code pertaining to the signs and 
symptoms of the ADR (Figures 4.1 and 4.2). 
Table 4.4 shows which ICD-10 codes were used to acknowledge the signs and symptoms of 
the 100 non-oncology ADRs which did not have an ADR specific code.  
Table 4.5 shows which ICD-10 codes were used to acknowledge the signs and symptoms of 
the 37 oncology ADRs which did not have an ADR-specific code. 
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Figure 4.1 Summary of results for non-oncology ADRs 
 
 
 
Figure 4.2 Summary of results for oncology ADRs 
 
Non-oncology ADRs 
n=126 
ICD-10 ADR code 
n=6 
Signs or symptoms 
of ADR coded n=4 
No ICD-10 ADR code 
n=120 
Signs or symptoms 
of ADR coded n=100 
Signs or symptoms 
of ADR not coded 
n=20 
Oncology ADRs 
n=115 
ICD-10 ADR code     
n = 70 
Signs or symptoms 
of ADR coded n=70 
No ICD-10 ADR code 
n=45 
Signs or symptoms 
of ADR coded n=37 
Signs or symptoms 
of ADR not coded 
n=8 
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Table 4.4 Non-oncology ADR only acknowledged by signs and symptoms coded using ICD-10, ordered by reaction frequency (n=100) 
   
Reaction ICD-10 code for signs and or symptoms Number of reactions 
 
Post-tonsillectomy bleed 
 
T81.0 Haemorrhage and haematoma complicating a procedure NEC  
K92.0 haematemesis  
H95.8 other post procedural disorders of ear and mastoid process 
 
27 
   
Immunosuppression 
 
 
 
 
 
 
 
 
 
 
 
Z94.8 Other transplanted organ and tissue status  
Z94.4 Liver transplant status  
B00.9 Herpes viral infection, unspecified  
A41.9 Septicaemia, unspecified  
Z94.2 Lung transplant status  
Z94.0 Kidney Transplant status  
R50.9 Fever, unspecified 
N39.0 Urinary tract infection, site not specified  
M72.58 Fasciitis nec, other head neck ribs skull trunk vertebral column  
L30.9 Dermatitis unspecified  
J02.9 Acute pharyngitis, unspecified  
B96.8 Other specific bacterial agents as cause of disease 
18 
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Reaction ICD-10 code for signs and or symptoms Number of reactions 
Immunosuppression (continued) B02.9 Zoster without complication 
B01.9 Varicella without complication 
A40.9 streptococcal septicaemia, unspecified 
   
   
Rash R23.3 Spontaneous ecchymoses  
R21.X Rash and other nonspecific skin eruption 
D69.0 Allergic purpura  
L03.1 Cellulitis of other parts of limb 
6 
   
Hypoglycaemia E16.2 Hypoglycaemia, unspecified 6 
   
Constipation R32.X Unspecified urinary incontinence  
R10.4 Other and unspecified abdominal pain  
K62.5 Haemorrhage of anus and rectum  
K59.0 Constipation 
4 
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Reaction ICD-10 code for signs and or symptoms Number of reactions 
Seizure R56.8 Other and unspecified convulsions  
R56.0 Febrile convulsions  
G41.9 Status epilepticus 
3 
   
Respiratory depression R09.2 Respiratory arrest  
R06.0 Dyspnoea  
E85.2 Non-invasive ventilation 
3 
   
Haematemesis K29.7 gastritis, unspecified  
K29.0 Acute haemorrhagic gastritis 
2 
   
Fever, seizure R56.0 Febrile convulsions 2 
   
Fever R50.9 Fever, unspecified 2 
   
Diarrhoea K52.9 Noninfective gastroenteritis and colitis, unspecified  
A08.4 Viral intestinal infection, unspecified 
2 
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Reaction ICD-10 code for signs and or symptoms Number of reactions 
   
Wheeze, increased work of breathing B34.9 Wheezing 1 
   
Vomiting, diarrhoea, difficulty in breathing K52.9 Noninfective gastroenteritis and colitis, unspecified 1 
   
Vomiting, abdominal pain R21.X Rash and other nonspecific skin eruption  
R11.X nausea and vomiting 
1 
   
Thrombocytopenia D69.3 Idiopathic thrombocytopenic purpura 1 
   
Seizure, respiratory depression R56.0 Febrile convulsions 1 
   
Renal dysfunction N28.9 Disorder of kidney and ureter, unspecified 1 
   
Rash, irritability, fever B34.9 viral infection, unspecified 1 
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Reaction ICD-10 code for signs and or symptoms Number of reactions 
   
Rash, fever, lethargy R50.9 Fever, unspecified 
R23.3 Spontaneous ecchymoses 
1 
   
Pyrexia, vomiting R50.9 Fever, unspecified, R11.X nausea and vomiting 1 
   
Pyrexia, irritability J06.9 Acute upper respiratory infection, unspecified 1 
   
Post-operative bleeding T81.0 Haemorrhage and haematoma complicating a procedure NEC 1 
   
Limb swelling L03.1 Cellulitis of other parts of limb 1 
   
Kawasaki disease M30.3 Mucocutaneous lymph node syndrome 1 
   
Irritability R68.1 nonspecific symptoms peculiar to infancy 1 
   
Intestinal obstruction J56.0 Paralytic ileus 1 
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Reaction ICD-10 code for signs and or symptoms Number of reactions 
   
Intermenstrual bleed N92.0 Excessive and frequent menstruation with regular cycle 1 
   
Impaired healing T81.3 Disruption of operation wound, not elsewhere classified 1 
   
Ileus K56.7 Ileus unspecified 1 
   
Hypertension I10.X Essential (primary) hypertension 1 
   
Hyperglycaemia E13.8 Other specified diabetes mellitus with unspecified comps 1 
   
Headache G93.2 Benign intracranial hypertension 1 
   
Diarrhoea, vomiting K21.9 gastro-oesophageal reflux disease without oesophagitis 
K90.4 malabsorption due to intolerance, not elsewhere classified 
1 
   
Cyanosis/pallor R23.0 Cyanosis 1 
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Reaction ICD-10 code for signs and or symptoms Number of reactions 
Apnoea J98.8 Other specified respiratory disorders 1 
   
Adrenal suppression E27.4 Other and unspecified adrenocortical insufficiency 1 
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Table 4.5 Oncology ADRs only acknowledged by signs and symptoms coded using ICD-10, ordered by reaction frequency (n=37) 
   
Reaction ICD-10 code for signs and or symptoms Number of reactions 
Immunosuppression R50.9 fever, unspecified  
Z94.2 Lung transplant status 
J22.X Unspecified acute lower respiratory infection  
K61.0 Anal abscess  
B08.1 Molluscum contagiosum  
J22.X Unspecified acute lower respiratory infection 
Z94.9 other transplanted organ and tissue status  
J06.9 Acute upper respiratory infection, unspecified 
 
5 
Constipation R10.4 Other and unspecified abdominal pain.  
R11.X Nausea and vomiting 
K59.0 Constipation 
 
3 
Neutropenia  X90.3 Neutropenia drugs band 1  
R50.9 Fever, unspecified  
D70.X Aranulocytosis 
3 
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Thrombocytopenia, neutropenia R50.9 Fever, unspecified  
R04.0 Epistaxis 
 
3 
Anaemia, thrombocytopenia, neutropenia R50.9 Fever, unspecified  
D70.X Agranulocytosis 
 
2 
Immunosuppression, deranged LFTs J22.X Unspecified acute lower respiratory infection 
 
2 
Neutropenia, immunosuppression A08.0 Rotaviral enteritis  
D70.X Agranulocytosis 
R50.9 fever, unspecified 
 
2 
Vomiting R11.X Nausea and vomiting 
 
2 
Abdominal pain R10.4 Other and unspecified abdominal pain 1 
Diarrhoea, immunosuppression B34.9 viral infection, unspecified  
R21.X rash and other nonspecific skin eruption 
R50.9 Fever, unspecified 
 
1 
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Haematuria, thrombocytopenia, anaemia R31.X Unspecified haematuria 
 
1 
Headache R51.X Headache 
 
1 
Headache, thrombocytopenia, neutropenia, 
anaemia, diarrhoea, vomiting 
D70.X Agranulocytosis 
R50.9 fever, unspecified 
 
1 
Immunosuppression, low lymphocyte count B02.9 Zoster without complication 
B01.9 varicella without complication 
 
1 
Immunosuppression, anaemia R30.0 Dysuria 1 
Leukencepalopathy R11.X Nausea and vomiting 
G81.9 Hemiplegia unspecified 
R29.8 Other specific signs involving nervous/musculoskeletal 
systems 
 
1 
Mucositis, neutropenia, anaemia, 
thrombocytopenia 
D70.X agranulocytosis 
R50.9 fever, unspecified 
K12.1 Other forms of stomatitis 
1 
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Neutropenia, gastritis K29.7 Gastritis, unspecified 
 
1 
Neutropenia, thrombocytopenia, anaemia, 
immunosuppression 
K13.7 Other and unspecified lesion of oral mucosa 
 
1 
Thrombocytopenia D69.6 Thrombocytopenia, unspecified 
 
1 
Thrombocytopenia, anaemia, deranged LFTs, 
vomiting, nausea, diarrhoea 
K52.9 Noninfective gastroenteritis and colitis, unspecified 
 
1 
Thrombocytopenia, immunosuppression, 
neutropenia 
D70.X Agranulocytosis 
R50.9 fever, unspecified 
 
1 
Vomiting, neutropenia, immunosuppression, 
diarrhoea, thrombocytopenia, deranged LFTs 
D70.X Agranulocytosis 
 
1 
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4.3.3 ADRs coded using ICD-10 – consideration of type, severity and causality 
Considering oncology and non-oncology reactions together, coded ADRs were not more 
likely to be type A than type B reactions, difference in proportions 3%, CI -3.0%, 8.9%, p = 
0.255. Coded ADRs were not more likely to be of severity 1,2 and 3 than those of severity 4 
and 5, difference in proportions 6%, CI -0.1%, 11.9%, p = 0.069. Coded ADRs were more 
likely to be definite and probable ADRs than possible ADRs, difference in proportions 47%, 
CI (32.3%, 59.7%) p < 0.001 (Table 4.6). 
 
Table 4.6 Comparison of type, severity and causality assessments for coded and uncoded 
ADRs 
     
Assessment Score 
ADRs coded 
(n = 76) 
ADRs not coded 
(n = 165) 
p –value 
(difference in 
proportions) 
     
Type 
A 74 155 
0.255 
B 2 10 
     
Severity 
1,2,3 74 150 
0.069 
4,5 2 15 
     
Causality 
Definite & Probable 75 87 
<0.001 
Possible 1 78 
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4.4 Discussion 
We have demonstrated that the majority of ADRs detected in prospective cohort study at a 
paediatric tertiary care centre would not have been identified if the study had relied on 
ICD-10 codes as a single means of detection. This is due to deficiencies in how ADRs were 
recorded in the case notes and in how they were recorded in the clinical coding system.  
We attempted to validate the use of ICD codes in the detection of ADRs by reviewing the 
ICD codes in the records of patients who have been identified as having had a suspected 
ADR in the course of a pharmacovigilance study. The results of our study demonstrate that 
ADRs are not consistently coded using ICD ADR codes, 4.8% non-oncology ADRs were 
coded. However, oncology ADRs were coded with much greater accuracy (61%). In a 
similar, albeit retrospective, study of the medical records of 530 adult patients in a 
Slovenian hospital, 30 ADRs leading to admission were identified of which 30 were 
documented by a physician but only 1 (3.3%) had an ICD-10 code which identified it as an 
ADR. This was a case of drug-induced liver disease secondary to an antifungal agent. Three 
of the 30 ADRs identified were secondary to antineoplastic agents (Brvar et al., 2009). A 
prospective study of drug-related problems leading to emergency department visits in 
Finland included 7113 visits of which 167 were classified as certainly or probably drug-
related, and of these, 102 were ADRs. Only 2% of the ADR-related visits were coded as 
‘drug-related’ using ICD but the authors do not report the details of these cases. Seven of 
the 102 ADR-related visits were oncology patients and were secondary to antineoplastic 
agents (Juntti-Patinen et al., 2006). A further prospective study of ADEs detected in the 
emergency department determined that 221 of 1574 (14%) of attendances were due to an 
ADE. However, only 15 of these 221 (6.8%) ADEs had an ICD-10 diagnostic code which 
indicated a causal relationship between the presentation and a medication (Hohl et al., 
2012).  
There are several reasons why ADRs identified in this prospective study may not have been 
correctly coded. The ADRs were identified based on a definition chosen for the specific 
purpose of studying ADRs prospectively. It is possible that the individuals involved in coding 
the events, that is clinicians and clinical coders, may not agree with, or be aware of this 
definition. For example, defining post-tonsillectomy haemorrhage as an ADR may meet 
with opposition because, at present, the contribution of dexamethasone and non-steroidal 
anti-inflammatory drugs to this event is not yet established (Geva and Brigger, 2011, Lewis 
et al., 2013). It is interesting to note that ADRs which were classified as definite or probable 
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in this study were more likely to have been coded using an appropriate ICD-10 ADR code. 
This suggests that whether or not an event is recorded and subsequently coded may rely on 
the ease of its detection and the assessment of its causality by the clinician. Finally (and 
crucially), if an ADR is not identified and recorded by the clinician it cannot be coded 
correctly. 
In this study, there was a far greater proportion of oncology ADRs than non-oncology ADRs 
coded using ICD-10 ADR codes. The two main reasons for this are – a) the oncology unit was 
using a structured admission proforma for unplanned admissions presenting with febrile 
neutropenia (one of our most common ADRs) and b) there were specifically trained coding 
staff assigned to the oncology unit who had the opportunity to become familiar with the 
diagnoses and complications inclusive of ADRs in oncology patients and how to code them. 
Other specialties have structured admission proformas but these are mainly for planned 
admissions (e.g. neurosurgery) and they are thus unlikely to be used in the context of an 
ADR-related admission. Other specialities also have specifically trained coding staff (e.g. 
cardiology) but ADR recording in the case notes is less likely to be consistent because a 
specific proforma does not exist.  A study of ADRs in a Canadian paediatric hospital which 
used ICD codes to estimate ADR incidence over a period of 21 years showed that the 
incidence increased throughout the study. They concluded that the reason for this apparent 
increase in incidence reflected the fact that the more complete coding of episodes of care 
had been prioritised in their hospital (Huet et al., 2011). This finding suggests that changes 
in organisational priorities can improve the recording of ADRs as part of hospital 
administrative data which in turn improves the utility of those data for pharmacovigilance. 
The ICD-10 sign and symptom codes for each reaction were recorded to facilitate an 
exploration of whether any of these codes were commonly being used for ADR cases and if 
so, could these provide an additional means of ADR detection. Considering the two most 
common ADRs which were not coded using ICD-10 ADR codes, tables 4.3 and 4.4 show that 
the codes used to describe immunosuppression were diverse and table 4.4 shows that post-
tonsillectomy haemorrhage is consistently recorded. However, this consistency must be 
balanced against the fact that the causes of post-tonsillectomy haemorrhage are multi-
factorial and cannot be attributed to peri-operative medicine use alone (Windfuhr, Chen 
and Remmert, 2005, Lowe et al., 2007) The diversity of codes used to describe 
immunosuppression limits their usefulness in the identification of ADRs. Therefore, the only 
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codes which would have been specific enough for the reliable detection of a proportion of 
the ADRs in our study were the ICD-10 ADR codes.  
4.5 Conclusion 
The use of ICD-10 codes to identify ADRs in a paediatric tertiary care centre is not currently 
a reliable method of pharmacovigilance due to deficiencies in how ADRs are recorded in the 
case notes and how they are recorded in the clinical coding system. This finding is 
consistent with similar studies carried out in adult centres. 
The use of ICD-10 codes to identify ADRs could be made more reliable if deficiencies in case 
note recording and coding systems for ADRs are addressed through changes to current 
practice, complemented by relevant training. Since the most useful codes available to us in 
this context relate either to ‘adverse effects in therapeutic use’ for specific medicine classes 
or are prefixed ‘drug induced’ they will not be specific to ADRs but will encompass ADRs.  
Training of clinicians should focus on the consolidation of existing knowledge in relation to 
the identification of suspected drug-related problems (inclusive of ADRs), assessment of 
causality and an improved awareness of the potential utility of the clinical coding system in 
the context of pharmacovigilance. It may be possible to provide, or revise existing, 
admission and discharge proformas with specific sections which ask for details of drug-
related problems identified by the clinician at the point of admission and during the 
hospital stay. Training of clinical coders should focus on the consolidation of existing 
knowledge of codes for ‘adverse effects in therapeutic use’ for specific medicine classes or 
those prefixed ‘drug induced’. Coders should understand the potential utility of these codes 
in the context of pharmacovigilance and they should be updated on the introduction of any 
existing or revised proformas which document drug-related problems at the points of 
admission and discharge. Any changes made should be monitored through audit which 
would focus on the frequency and accuracy of the use of codes for ‘adverse effects in 
therapeutic use’ for specific medicine classes or those prefixed ‘drug induced’. 
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5 Dexamethasone and post-tonsillectomy haemorrhage risk in children – a 
systematic review and meta-analysis 
5.1 Introduction 
Chapter 2 of this thesis describes a study of ADRs identified at the point of admission to 
hospital. 26 cases of post-tonsillectomy haemorrhage were identified and highlighted as 
ADRs to non-steroidal anti-inflammatory drugs (NSAIDs) and/or dexamethasone (Gallagher 
R.M. et al., 2012). The link between the use of NSAIDs and dexamethasone and post-
tonsillectomy haemorrhage risk in children warrants further investigation. If a link exists, it 
may be possible to avoid some post-tonsillectomy haemorrhages by rationalising the use of 
anti-emetics and analgesia. Since there are a large number of studies of the use of these 
medicines in children undergoing tonsillectomy, albeit that they focus on benefit rather 
than harm, a systematic review was designed to investigate the link between their use and 
the risk of haemorrhage. 
Children who undergo tonsillectomy or adenotonsillectomy are at risk of experiencing 
complications. These include post-operative nausea and vomiting (PONV) and post-
operative haemorrhage. In studies where intra-operative anti-emetics were not 
administered, post-tonsillectomy nausea and vomiting rates as high as 70% have been 
reported (Ferrari and Donlon, 1992). Post-tonsillectomy haemorrhage rates range from 0.1 
to 8.1% (Randall and Hoffer, 1998).  
The Association of Paediatric Anaesthetists of Great Britain and Ireland (APAGBI) guideline 
on the prevention of post-operative vomiting (POV) recommends the use of 
dexamethasone (0.15mg/kg in combination with ondansetron 0.05mg/kg) to minimise the 
risk of POV in children undergoing tonsillectomy (The Association of Paediatric 
Anaesthetists of Great Britain & Ireland, 2009). A Cochrane review of dexamethasone use in 
tonsillectomy supports this recommendation: children receiving a single intraoperative 
dose of dexamethasone at a dose between 0.15 and 1mg/kg were half as likely to vomit 
within 24 hours of their operation (Steward, Grisel and Meinzen-Derr, 2011).  
Although there is evidence of the efficacy of dexamethasone in the context of 
tonsillectomy, evidence of its safety is less well established. Czarnetzki et al. (2008) showed 
that post-operative haemorrhage rates were increased by 6.5 fold (95% CI 1.69, 16.3) with 
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intraoperative dexamethasone use in children undergoing tonsillectomy (a single dose of 
0.05, 0.15, or 0.5 mg/kg). Three  recent meta-analyses have also addressed this issue: (a) 
using 14 randomised controlled trials (RCTs) of adults and children who underwent 
tonsillectomy, no difference in bleeding rates were demonstrated between dexamethasone 
and comparator arms (RR 1.02 95% CI 0.65, 1.61, p=0.92) (Geva and Brigger, 2011); (b) 
using 12 paediatric studies that reported data on haemorrhage rates (Shargorodsky, 
Hartnick and Lee, 2012), again no significant difference in post-operative bleeding was 
identified in patients receiving single-dose dexamethasone versus placebo (OR 1.07 95% CI 
0.58, 1.98, p=0.82); and (c) using data from 29 RCTs of adult and paediatric tonsillectomy 
patients (Plante et al., 2012), a pooled effects estimate again revealed no significant 
difference in post-operative haemorrhage rate in patients who had received 
dexamethasone versus those who had not (OR 0.96 95% CI 0.66, 1.40, p=0.83).  
Although three previous systematic reviews have already been undertaken, including one 
which focussed on paediatric studies, this study was undertaken because there are 
limitations to the use of standard systematic review methodology in the evaluation of 
adverse event outcomes. This is particularly true of rare adverse events such as post-
tonsillectomy haemorrhage because haemorrhage rate data derived from small RCTs of 
dexamethasone may not be generalizable, particularly if adverse event reporting was sub-
optimal. It has been recommended that systematic reviews of rare adverse effects should 
include non-randomised studies (NRS) which may cover a broader population than RCTs 
and in which the adverse event may be the primary outcome (Loke, Golder and 
Vandenbroucke, 2011, Chou and Helfand, 2005). Furthermore, an assessment of adverse 
event monitoring and reporting can provide an indication of the reliability of the reported 
adverse event rate. It is possible that haemorrhage rate data for dexamethasone used in 
this context may be unpublished (publication bias) or that it may have been selectively 
unreported due to undesirable outcome results (outcome reporting bias)(Kirkham et al., 
2010).   
This chapter describes a systematic review which aimed to determine whether the use of 
dexamethasone with or without NSAIDs in paediatric tonsillectomy affects the rate of post-
tonsillectomy haemorrhage in children. In order to address some of the limitations of 
standard systematic review methodology in the evaluation of a rare adverse event 
outcome, this study considers both RCTs and NRS and furthermore assesses the 
methodological quality of haemorrhage rate recording and reporting. 
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5.2 Methods 
5.2.1 Search strategy 
The databases and tertiary sources used in this review are listed in Table 5.1. Searches were 
carried out in November 2011.  Search strategies were developed specifically for each 
database and tertiary source, they are presented in Appendices 7 (database search 
strategies) & 8 (restricted interface search strategies). The reference lists of previous 
systematic reviews, identified during the search, were also examined for additional 
references. Following the selection of studies via this process, forward and backward 
citation tracking was undertaken for each study if it was indexed in the Scopus database. 
Contact was made with experts to identify other potentially relevant published and 
unpublished studies. Although contact with the pharmaceutical industry to obtain adverse 
event data may be considered when investigating rare adverse events, we did not carry this 
out. The use of dexamethasone is not specifically licensed for use in paediatric 
tonsillectomy so it was thought unlikely that the manufacturers would hold relevant data 
on the use of their product in this narrow context. 
5.2.2 Study eligibility 
Randomised controlled trials (RCTs) and quasi-randomised controlled trials (q-RCTs) that 
considered dexamethasone (except by peri-tonsillar infiltration) or, dexamethasone in 
combination with NSAIDs, in the context of paediatric tonsillectomy or 
adenotonsillectomyxv in the immediate peri-operative period were included. For the 
purposes of this study, the immediate peri-operative period was defined as: within the 24 
hours before the procedure, during the procedure or in the 24 hours which followed the 
procedure.  This review considered only children up to the age of 18 years; studies that 
included both adults and children were also considered and, if possible, only the data for 
the children were used. If data for children and adults could not be separated, the study 
was excluded.  Studies were only considered for inclusion if they were published in English.       
                                                          
xv
 for the remainder of this chapter, the term tonsillectomy will be used to encompass both tonsillectomy and 
adenotonsillectomy  
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Table 5.1 Databases and tertiary sources searched 
Agency for Health & Research Quality http://www.ahrq.gov/ 
BioSciences Information Service of Biological Abstracts (BIOSIS) Citation Index via 
webofknowledge.com 
British Nursing Index (BNI) via www.library.nhs.uk 
British Library Direct http://direct.bl.uk/bld/Home.do 
Cumulative Index to Nursing and Allied Health Literature (CINAHL®)  via ebscohost.com 
Cochrane Library, The http://www.thecochranelibrary.com/view/0/index.html 
Current Controlled trials http://www.controlled-trials.com/ 
Clinical Trials http://clinicaltrials.gov 
Database of Abstracts of Reviews of Effectiveness (DARE)  http://www.crd.york.ac.uk/CMS2Web 
Excerpta Medica database (EMBASE™)  via www.library.nhs.uk 
Faculty of 1000 http://f1000.com/ 
Iowa Drug Information Service (IDIS) via http://www.uiowa.edu/idis 
Medical Literature Analysis and Retrieval System Online (MEDLINE®) via ovid.com 
Medscape http://www.medscape.com/ 
Science Citation Index via ebscohost.com 
Scirus http://www.scirus.com/ 
Scopus via ebscohost.com 
Toxicology Information Online (TOXLINE®) – US National Library of Medicine via proquest.com 
TRIP database http://www.tripdatabase.com/ 
UK Clinical Research Network Portfolio Database http://public.ukcrn.org.uk/search/ 
US Food & Drug Administration http://www.fda.gov/ 
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5.2.3 Types of outcome measure 
The main outcome of interest extracted from each study was haemorrhage rate. The 
definition of haemorrhage included any bleeding which required a change in post-operative 
management, for example re-operation, blood transfusion, prolonged hospital stay, re-
admission or contact with a healthcare provider, for example an accident and emergency 
department (AED) or a general practitioner. In some studies, where some participants may 
have experienced more than one haemorrhage, we recorded the number of haemorrhages 
rather than the number of patients who experienced a haemorrhage. This is because we 
considered recurrent bleeding to be a clinically important outcome in post-operative 
patients. 
5.2.4 Study selection 
5.2.4.1 Inspection of citations 
After duplicate citations were removed, all titles and abstracts were independently 
reviewed by two reviewers with reference to the inclusion/exclusion criteria (Appendix 9), 
and a decision was made about whether to retrieve the full report of the study.  The 
number of titles/abstracts identified, selected and rejected was recorded.   
5.2.4.2 Inspection of retrieved reports 
Once the full reports were retrieved, they were inspected for relevance to the review and 
the inclusion and exclusion criteria were applied.  Studies not meeting the pre-determined 
criteria were excluded.  If there was any disagreement about whether to include any of the 
studies, a third reviewer assessed them and, together with the other reviewers made a 
consensus decision about whether to include or exclude.  A record was made of the 
number of full reports retrieved and the number excluded.  
For quality assurance purposes, 5% of studies excluded at title and abstract stage were re-
reviewed by the original reviewers for inclusion and five studies excluded at the full article 
stage were re-reviewed by a third reviewer.  
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5.2.5 Data collection 
A formal data extraction form was designed, piloted on a small selection of studies and 
adjusted as necessary (Appendices 10 & 11). For each study, information regarding 
methods, participants, comparison groups, interventions and outcomes was tabulated. 
Where they were recorded or provided by the author, the following data were extracted 
for each randomised study: 
1. Study characteristics: number of participants, number of participants in  each 
 intervention group, year completed, setting, inclusion criteria, definition of 
 post-operative haemorrhage, and length of follow-up. 
2. Participant characteristics: age, sex, underlying disease, indication for surgery. 
3. Interventions: number of intervention groups, intervention details: peri- operative 
 medicines inclusive of dose, surgical technique.  
4. Outcomes reported: post-operative haemorrhage rate. 
5. Additional data relating to haemorrhage:  severity, timing (i.e. need for 
 intervention, primary or secondary). 
Where they were recorded or provided by the author, the following data were extracted 
for each non-randomised study: 
1. Study characteristics: number of participants, number of participants in  each 
 intervention group, year completed, setting, inclusion criteria, definition of 
 post-operative haemorrhage, and length of follow-up. 
2. Participant characteristics: age, sex, underlying disease, indication for surgery. 
3. Characteristics of surgery: surgical technique, peri-operative medicines  inclusive of 
 dose. 
4. Characteristics of peri-operative care: medicines 
5. Data relating to haemorrhage: number of haemorrhages, severity, timing 
 (i.e. need for intervention, primary or secondary), risk factors identified. 
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5.2.6 Quality assessment 
For RCTs which compared dexamethasone with another intervention and reported 
haemorrhage rate or for which haemorrhage rate data were obtained from the author(s), 
the methodological quality was assessed using the Cochrane Collaboration’s domain based 
evaluation tool for assessing risk of bias (Higgins and Green, 2009). The overall risk of bias 
was summarised for each study as follows: low risk of bias if low risk of bias for all key 
domains, unclear risk of bias if unclear risk of bias for one or more key domains and high 
risk if high risk of bias for one or more key domains. The methodological quality of 
haemorrhage rate recording and reporting was assessed for both randomised and non-
randomised studies using selected elements of the McMaster Quality Assessment Scale of 
Harms for primary studies (the McHarm Scale) http://hiru.mcmaster.ca/epc/mcharm.pdf. 
The elements used were selected based on an evaluation of their relevance to our research 
question and they aimed to evaluate: the quality and appropriateness of study design and 
reporting, the applicability of the study findings to the population and measures taken to 
reduce bias (Appendix 12) (Downs and Black, 1998). 
Both data collection and quality assessment of studies were undertaken by one reviewer, 
with three randomised and three non-randomised studies assessed by a second reviewer to 
check for consistency.  
5.2.7 Statistical analysis and synthesis 
Statistical analyses were performed using RevMan (version 5.1 software).  As haemorrhage 
rate data are dichotomous, the data were analysed by calculating the Peto odds ratio for 
each randomised study and for non-randomised studies odds ratios (OR) were calculated 
with corresponding 95% confidence intervals (CIs). For each study, we only included data 
for participants who were not excluded following randomisation and for whom follow-up 
was complete. 
5.2.7.1 Meta-analysis 
We aimed to conduct two meta-analyses. For randomised controlled trials, dexamethasone 
alone was compared with any other intervention used in paediatric tonsillectomy. For non-
randomised studies, dexamethasone alone was compared with any other intervention used 
in paediatric tonsillectomy. Publication bias for trials included in the meta-analysis was 
assessed by visual inspection of a funnel plot.  All study authors were contacted where 
possible for missing outcome data.      
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5.2.7.2 Heterogeneity and subgroups 
A chi-squared test for statistical heterogeneity was undertaken, and the I2 statistic was 
calculated.  Where the necessary data were available, the following subgroup analysis was 
also planned: 
 A comparison of primary and secondary haemorrhage rates  
 A comparison of studies in which some participants received NSAIDs in addition to 
dexamethasone with those in which no participants received NSAIDs 
5.2.7.3 Studies not suitable for inclusion in a meta-analysis 
Randomised controlled trials in which all patients received dexamethasone: 
 Report the haemorrhage rate for each arm of the trial 
Non-randomised studies in which all patients received dexamethasone: 
 Report the haemorrhage rate for each study 
5.3 Results 
5.3.1 Search results 
The database searches undertaken in November 2011 identified 3419 abstracts for 
screening after duplicate records were removed. After review of abstracts, 139 full text 
articles were reviewed.  Of these, 52 unique studies (37 RCTs and 15 NRS) fulfilled the 
inclusion criteria (Figure 5.1).     
Forward and backward citation tracking for all the eligible articles in the database search, 
plus the reference sections of 15 review articles identified in our database search, identified 
962 potentially relevant citations not identified in our initial searches. After review of 
abstracts, 880 articles were excluded, leaving 82 full articles to be reviewed.  Of these, ten 
additional articles (3 RCTs and 7 NRS) met the inclusion criteria (Figure 5.2). One article 
reported a RCT already identified in another article picked up by our database search. In 
total, 61 studies were included in this review (39 RCTs and 22 NRS). 
{{5769 El,Sabiee S.A. 2004/h;3617 Helmus,Christian 1979/h;6961 Macassey,E.A. 2007/h;6962 Rabbani, M.Z. 2010/h;3204 
Islam,M.R. 2011/h;6963 Scarlett, M. 2005/h;6957 Fujii,Yoshitaka 1996/h;6958 Cyranoski, D. 2012/h;7080 Borges,S. 
2007/h;7033 Kim,M. 2012/h;7081 Kim,M.W. 1998/h;6964 Collison,P.J. 2000/h}} 
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5.3.2 Included studies  
Of the 39 RCTs, 32 compared dexamethasone with another intervention (Catlin and Grimes, 
1991, Volk et al., 1993, Ohlms, Wilder and Weston, 1995, April et al., 1996, Splinter and 
Roberts, 1996, Tom et al., 1996, Splinter and Roberts, 1997, Pappas et al., 1998, Splinter et 
al., 1998, Vosdoganis and Baines, 1999, Holt et al., 2000, Nawasreh, Fraihat and Maaita, 
2000, Kyrou et al., 2001, Aouad et al., 2001, Giannoni, White and Enneking, 2002, Elhakim 
et al., 2003, Celiker et al., 2004, Hanasono et al., 2004, Samarkandi et al., 2004, Gunter et 
al., 2006, Malde, Sonawane and Jagtap, 2005, Kaan et al., 2006, Mohammad et al., 2006, Al-
Shehri, 2007, Fazel et al., 2007, Alajmi et al., 2008, Czarnetzki et al., 2008, Bhattacharya et 
al., 2009, Karaman et al., 2009, Khani et al., 2009, Mohamed, Ibraheem and Abdelraheem, 
2009, Gallagher T.Q. et al., 2012), of these, 17 studies involving 1973 participants did not 
report haemorrhage rate (Splinter and Roberts, 1996, Tom et al., 1996, Splinter and 
Roberts, 1997, Splinter et al., 1998, Vosdoganis and Baines, 1999, Kyrou et al., 2001, Aouad 
et al., 2001, Elhakim et al., 2003, Celiker et al., 2004, Samarkandi et al., 2004, Gunter et al., 
2006, Al-Shehri, 2007, Fazel et al., 2007, Bhattacharya et al., 2009, Karaman et al., 2009, 
Khani et al., 2009, Mohamed, Ibraheem and Abdelraheem, 2009). In the remaining seven 
randomised studies, all participants received dexamethasone (Splinter et al., 1999, Sukhani 
et al., 2002, O'Flaherty and Lin, 2003, Derkay et al., 2006, Kim et al., 2007, Erdem et al., 
2008, Rawlinson et al., 2011) and of these four did not report haemorrhage rate (588 
participants) (Splinter et al., 1999, Sukhani et al., 2002, Kim et al., 2007, Erdem et al., 2008). 
Nine of the 22 NRS compared dexamethasone with another intervention (Shikowitz and 
Jocono, 1996, Conley and Ellison, 1999, Lalakea, Marquez-Biggs and Messner, 1999, Werle 
et al., 2003, Edler et al., 2007, Liechti et al., 2007, Bennett and Emery, 2008, Shakeel et al., 
2010, Windfuhr et al., 2011). Of these, six studies involving 688 participants did not report 
haemorrhage rate (Shikowitz and Jocono, 1996, Lalakea, Marquez-Biggs and Messner, 
1999, Werle et al., 2003, Edler et al., 2007, Liechti et al., 2007, Bennett and Emery, 2008). In 
the remaining 13 (Gallagher R.M. et al., 2012, Thiesen et al., 2013, Postma and Folsom, 
2002, Stewart, Baines and Dalton, 2002, Betts et al., 2003, Bent et al., 2004, Ewah, Robb 
and Raw, 2006, Kalantar, Takehana and Shapiro, 2006, Brigger, Cunningham and Hartnick, 
2010, Rashid et al., 2010, Ahmed et al., 2011, Hanss et al., 2011, Robb and Ewah, 2011), all 
participants received dexamethasone and of these two did not report haemorrhage rate 
(258 participants) (Betts et al., 2003, Rashid et al., 2010). 
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5.3.2.1 Randomised studies which compared dexamethasone with another intervention & 
reported haemorrhage rate   
These 15 studies involving 1693 participants are summarised in Table 5.2 (Catlin and 
Grimes, 1991, Volk et al., 1993, Ohlms, Wilder and Weston, 1995, April et al., 1996, Pappas 
et al., 1998, Holt et al., 2000, Nawasreh, Fraihat and Maaita, 2000, Giannoni, White and 
Enneking, 2002, Hanasono et al., 2004, Malde, Sonawane and Jagtap, 2005, Kaan et al., 
2006, Mohammad et al., 2006, Alajmi et al., 2008, Czarnetzki et al., 2008, Gallagher T.Q. et 
al., 2012). They were all published between 1991 and 2012; the length of follow up ranged 
from 24 hours to 16 days and all of the studies compared dexamethasone with placebo. 
Seven of the studies used sharp dissection to remove the tonsils (Catlin and Grimes, 1991, 
Ohlms, Wilder and Weston, 1995, Holt et al., 2000, Malde, Sonawane and Jagtap, 2005, 
Kaan et al., 2006, Mohammad et al., 2006, Alajmi et al., 2008), three used more than one 
method, (Volk et al., 1993, Hanasono et al., 2004, Czarnetzki et al., 2008) while the 
remainder used electrodissection (April et al., 1996, Pappas et al., 1998, Nawasreh, Fraihat 
and Maaita, 2000, Giannoni, White and Enneking, 2002, Gallagher T.Q. et al., 2012). The 
dose of peri-operative dexamethasone ranged from 0.05mg/kg to 1mg/kg; in one study all 
patients received 10mg rather than a weight-based dose (Volk et al., 1993). At least some 
of the participants in four of the studies received NSAIDs (Giannoni, White and Enneking, 
2002, Mohammad et al., 2006, Alajmi et al., 2008, Czarnetzki et al., 2008). The primary 
outcome in the majority of studies was post-operative nausea and vomiting and/or post-
operative pain. Haemorrhage rate and severity was the primary outcome in one study 
(Gallagher T.Q. et al., 2012). Four studies pre-defined haemorrhage (April et al., 1996, 
Nawasreh, Fraihat and Maaita, 2000, Czarnetzki et al., 2008, Gallagher T.Q. et al., 2012) and 
seven reported additional information about the haemorrhages they detected (Table 5.3) 
(Catlin and Grimes, 1991, Volk et al., 1993, Ohlms, Wilder and Weston, 1995, April et al., 
1996, Hanasono et al., 2004, Czarnetzki et al., 2008, Gallagher T.Q. et al., 2012). The risk of 
bias assessment using the Cochrane risk of bias tool was completed for these studies (Table 
5.4): 12 had a high overall risk of bias (Catlin and Grimes, 1991, Volk et al., 1993, Pappas et 
al., 1998, Holt et al., 2000, Nawasreh, Fraihat and Maaita, 2000, Giannoni, White and 
Enneking, 2002, Hanasono et al., 2004, Malde, Sonawane and Jagtap, 2005, Mohammad et 
al., 2006, Alajmi et al., 2008, Czarnetzki et al., 2008, Gallagher T.Q. et al., 2012), and the 
remainder had an unclear overall risk of bias (Ohlms, Wilder and Weston, 1995, April et al., 
1996, Kaan et al., 2006). The results of the McHarm scale assessment were as follows: only 
one of these studies pre-defined haemorrhage (Gallagher T.Q. et al., 2012), four actively 
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collected data on haemorrhage rate (Hanasono et al., 2004, Alajmi et al., 2008, Czarnetzki 
et al., 2008, Gallagher T.Q. et al., 2012),  two passively collected data on haemorrhage rate 
(Pappas et al., 1998, Czarnetzki et al., 2008) and one used a standard check-list for 
haemorrhage rate data collection (Gallagher T.Q.et al., 2012). It was unclear whether there 
was a possibility of selective outcome reporting bias for five of these studies (April et al., 
1996, Pappas et al., 1998, Nawasreh, Fraihat and Maaita, 2000, Hanasono et al., 2004, Kaan 
et al., 2006). 
The overall haemorrhage rate for participants who received placebo ranged from 0% to 
8.6% and the overall haemorrhage rate for participants who received dexamethasone 
ranged from 0% to 15.6%.  The pooled estimate of haemorrhage rate for children who 
received dexamethasone was 6.2%. Of the 15 studies that reported data on haemorrhage 
rate, there was a non-significant increase in risk of haemorrhage for the dexamethasone 
intervention group (Peto odds ratio 1.41, 95% CI 0.89, 2.25, p = 0.15) (Figure 5.3).   
14 out of 15 studies reporting data on haemorrhage separated the data into primary and 
secondary haemorrhage rates. For primary haemorrhage, only seven events were observed 
in the dexamethasone group and three on placebo; the pooled estimate demonstrated a 
non-significant increase in haemorrhage rate (Peto odds ratio 1.42, 95% CI 0.38, 5.36, 
p=0.61; Figure 5.4).  For secondary haemorrhage, the pooled estimate again suggested that 
there was a non-significant increase in risk of haemorrhage for the dexamethasone 
intervention group (Peto odds ratio 1.42, 95% CI 0.86, 2.35, p = 0.17; Figure 5.4). In the four 
studies in which some patients also received NSAIDs, the pooled estimate indicated that 
there was a non-significant increase in risk of haemorrhage for the dexamethasone 
intervention group (Peto odds ratio 1.56, 95% CI 0.69, 3.51, p=0.28).  For the eight studies 
in which no patients received NSAIDs, again there was a non-significant increase in risk of 
haemorrhage in the dexamethasone group (Peto odds ratio 1.32, 95% CI 0.73, 2.37, p=0.36) 
(Figure 5.5). A funnel plot of the studies included in the meta-analysis shows no evidence of 
publication bias (Figure 5.6). 
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Table 5.2 Description of randomised studies which compared dexamethasone with another intervention and reported haemorrhage ratexvi 
Study 
 
No. of 
participants 
 
No. of 
participants 
in analysis 
 
Length 
of follow 
up 
 
Primary 
outcome(s) 
 
Interventions 
 
Participants 
per 
intervention 
group 
 
Dissection 
Technique 
 
 
Haemostasis 
Technique 
 
 
Dexamethasone 
Dose 
 
 
Peri-operative 
NSAID 
 Dex Other 
Catlin 1991 29 25 7 days 
Length of stay, 
intravenous 
fluid 
requirement, 
pain, nausea, 
emesis, fever, 
post-op 
analgesia, 
complications, 
appetite. 
Dexamethasone 
vs. Placebo 
10 15 
Adenoidectomy 
by curette, 
excision of 
tonsils by sharp 
and blunt 
dissection and 
snare 
Electrocautery 
8mg / square 
metre 
None 
Volk 1993 50 49 
7-10 
days 
Fever, mouth 
odour, oral 
intake, pain, 
activity, weight 
loss, trismus 
and analgesic 
usage 
Dexamethasone 
vs. Placebo 
25 24 
Combination of 
blunt and sharp 
dissection 
Suction 
cautery 
10mg None 
                                                          
xvi
 Key to abbreviations used in tables Dex = dexamethasone, NSAID = non-steroidal anti-inflammatory drug, POD = post-operative day, PONV = post-operative nausea and vomiting, PR = per 
rectum 
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Study 
 
No. of 
participants 
 
No. of 
participants 
in analysis 
 
Length 
of follow 
up 
 
Primary 
outcome(s) 
 
Interventions 
 
Participants 
per 
intervention 
group 
 
Dissection 
Technique 
 
 
Haemostasis 
Technique 
 
 
Dexamethasone 
Dose 
 
 
Peri-operative 
NSAID 
 Dex Other 
Ohlms 1995 69 69 7 days Pain scores 
Dexamethasone 
vs. Placebo 
34 35 
Sharp 
dissection - 
snare 
technique, 
adenoid 
removed using 
curettes if 
indicated 
Using packs, 
electro-
cautery if 
persistent 
bleeding 
0.5mg/kg (max 
12mg) 
None 
April 1996 80 80 24 hours 
Post-operative 
oral intake, 
pain, vomiting, 
temperature 
and 
complications 
Dexamethasone 
vs. Placebo 
41 39 
Electro-
dissection 
Suction 
cautery 
1mg/kg (max 
16mg) 
None 
Pappas 1998 130 128 
24hours  
from 
discharge 
Post-operative 
nausea and 
vomiting 
Dexamethasone 
vs. Placebo 
63 65 
Electro-
dissection 
Not reported 
1mg/kg (max 
25mg) 
None 
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Study 
 
No. of 
participants 
 
No. of 
participants 
in analysis 
 
Length 
of follow 
up 
 
Primary 
outcome(s) 
 
Interventions 
 
Participants 
per 
intervention 
group 
 
Dissection 
Technique 
 
 
Haemostasis 
Technique 
 
 
Dexamethasone 
Dose 
 
 
Peri-operative 
NSAID 
 Dex Other 
Nawasreh 2000 120 120 24 hours 
Temperature, 
vomiting, oral 
intake 
Dexamethasone 
vs. Placebo 
62 58 
Electrocautery 
dissection, 
enlarged 
adenoid 
removed by 
shaving + 
curette 
Not reported 
1mg/kg (max 
16mg) 
Not reported 
Holt 2000 132 125 6 days 
Post- operative 
nausea and 
vomiting 
Dexamethasone 
+ tropisetron 
vs.tropisetron 
66 59 
Sharp 
dissection 
Suture 
ligation 
0.5mg/kg (max 
8mg) 
None 
Giannoni 2002 50 50 10 days 
Post-operative 
pain assessment 
Dexamethasone 
vs. Placebo 
25 25 Electrocautery Not reported 
1mg/kg (max 
16mg) 
Single pre-
operative dose 
ibuprofen 
15mg/kg 
Hanasono 2004 222 222 3 days 
Oral intake, pain 
scores, vomiting 
Dexamethasone 
vs. Placebo 
106 113 
Electro-cautery 
OR sharp wire 
snare tran-
section 
Electrocautery  
OR  directed 
cautery 
1mg/kg None 
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Study 
 
No. of 
participants 
 
No. of 
participants 
in analysis 
 
Length 
of follow 
up 
 
Primary 
outcome(s) 
 
Interventions 
 
Participants 
per 
intervention 
group 
 
Dissection 
Technique 
 
 
Haemostasis 
Technique 
 
 
Dexamethasone 
Dose 
 
 
Peri-operative 
NSAID 
 Dex Other 
Malde 2005 90 78 7 days 
Post-operative 
pain and post-
operative 
nausea and 
vomiting 
Dexamethasone 
vs. Placebo 
39 39 
Sharp 
dissection 
snare 
technique 
Ligation using 
ties, packs or 
sutured 
0.15mg/kg None 
Kaan 2006 62 62 6 hours 
Early oral 
intake, pain and 
vomiting 
Dexamethasone 
vs. Placebo 
32 30 
Sharp 
dissection 
Suture 
ligation 
0.5mg/kg (max 
16mg) 
None 
Mohammad 
2006 
50 50 24 hours 
Vomiting, 
trismus, pain, 
fever, time to 
first  solid 
intake, primary 
haemorrhage 
Dexamethasone  
vs. Placebo 
25 25 
Sharp 
dissection 
snare 
technique 
Electro-
cautery OR 
ligation with 
silk 
1mg/kg (max. 
12mg) 
Diclofenac IV if 
required 
Czarnetzki 2008 215 207 10 days 
Prevention of 
post-operative 
nausea and 
vomiting at 24 
hours 
Dexamethasone 
vs. Placebo 
154 53 
Cold steel, 
electro-cautery 
Gauze 
compression, 
electrocautery 
 
0.05-0.5mg/kg 
 
Yes – some 
patients 
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Study 
 
No. of 
participants 
 
No. of 
participants 
in analysis 
 
Length 
of follow 
up 
 
Primary 
outcome(s) 
 
Interventions 
 
Participants 
per 
intervention 
group 
 
Dissection 
Technique 
 
 
Haemostasis 
Technique 
 
 
Dexamethasone 
Dose 
 
 
Peri-operative 
NSAID 
 Dex Other 
Alajmi 2008 80 80 16 days 
Post-op pain, 
nausea, 
vomiting and 
oedema 
Dexamethasone 
vs. Placebo 
42 38 
Sharp 
dissection 
Packs or 
sutures, 
electrocautery 
if persistent 
bleed 
1mg/kg 
Profinal 
(ibuprofen) 
5mg/kg PO if 
required 
Gallagher T.Q. 
2012 
314 305 14 days 
Rate and 
severity  of 
post-
tonsillectomy 
haemorrhage 
Dexamethasone 
vs. Placebo 
154 151 
Mono-polar 
electrocautery 
and a spatula-
tip 
Suction 
cautery 
 
0.5mg/kg (max 
20mg) 
None 
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Table 5.3 Details of haemorrhages in randomised studies which compared dexamethasone with another intervention 
Study 
Definition of 
haemorrhage 
Participants per 
intervention group 
Post-operative haemorrhage rate 
 
 
Severity of Haemorrhage 
 
Contact with 
author 
    Primary Secondary Total   
  Dex Other Dex Other Dex Other Dex Other Dex Other  
Catlin 1991 None 10 15 0 0 2 1 2 1 2x day 5, neither 
required 
treatment 
1x day 6, did not 
require treatment 
None 
Volk 1993 None 25 24 0 0 2 1 2 1 Minor – con-
trolled in the 
operating room 
Minor –  controlled in 
the operating room 
Author 
confirmed that 
these were 
delayed bleeds 
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Study 
Definition of 
haemorrhage 
Participants per 
intervention group 
Post-operative haemorrhage rate 
 
 
Severity of Haemorrhage 
 
Contact with 
author 
    Primary Secondary Total   
  Dex Other Dex Other Dex Other Dex Other Dex Other  
Ohlms 1995 None 34 35 0 0 3 0 3 0 Day 3 – 
cauterized in 
emergency 
department 
Day 10 – 
observed for 24 
hours 
Day 12 – 
cauterized in 
theatre 
- None 
April 1996 Primary  < 24 hours, 
Secondary 2-14 
days 
41 39 0 0 1 1 1 1 Treated with 
suction and 
silver nitrate but 
not admitted 
Day 7, admitted and 
required observation 
and intravenous fluids 
Author provided 
data on NSAID 
use 
Pappas 1998 None 63 65 0 0 0 0 0 0 - - Author provided 
data on bleeds 
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Study 
Definition of 
haemorrhage 
Participants per 
intervention group 
Post-operative haemorrhage rate 
 
 
Severity of Haemorrhage 
 
Contact with 
author 
    Primary Secondary Total   
  Dex Other Dex Other Dex Other Dex Other Dex Other  
Nawasreh 2000 Primary <24 hours. 
Secondary post-
operative day 2-14 
62 58 0 0 2 2 2 2 No details No details Author provided 
data on timing 
of bleeds 
Holt 2000 None 66 59 - - - - 1 2 No details No details Author could 
not provide 
data on timing 
of bleeds by 
intervention 
Giannoni 2002 None 25 25 0 0 1 1 1 1 No details No details None 
Hanasono 2004 None 106 113 0 0 1 1 1 1 Day 3 requiring 
re-admission 
Day 1 requiring re-
admission 
None 
Malde 2005 None 39 39 0 0 0 1 0 1 - Day 4 None 
Kaan 2006 None 32 30 0 0 0 0 0 0 - - Author provided 
data on bleeds 
Mohammad 2006 None 25 25 0 1 0 0 0 1 No details No details None 
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Study 
Definition of 
haemorrhage 
Participants per 
intervention group 
Post-operative haemorrhage rate 
 
 
Severity of Haemorrhage 
 
Contact with 
author 
    Primary Secondary Total   
  Dex Other Dex Other Dex Other Dex Other Dex Other  
Czarnetzki 2008 Category 1 - 3
xvii
 
 
154 53 5 0 19 2 24
xviii
 2 7x category 1
 
8x category 2
 
9x category 3 
1x category 1 
1x category 2 
None 
Alajmi 2008 None 42 38 0 0 0 3 0 3 - All readmitted None 
Gallagher T.Q. 
2012 
Severity levels I-III
xix
 
 
154 151 2 2 15 11 17 13 11x level I
 
3x level II 
3x level III 
7x level I 
5x level II 
1x level III 
None 
                                                          
xvii
 Category 1 - history of bleeding leading to readmission but without evidence of bleeding at re-admission. Category 2 - readmission due to bleeding with evidence if bleeding at medical 
examination but no need for reoperation. Category 3 - emergency reoperation due to bleeding. 
xviii
 count of bleeds, there were 22 patients affected by 26 bleeds 
xix
 Level I -  All children who reported to have any history of postoperative haemorrhage, whether or not there was clinical evidence. Level II - All children who required inpatient admission for 
post-operative haemorrhage regardless of the need for operative intervention. This level excludes children undergoing evaluation in the emergency department for reported postoperative 
haemorrhage who had no evidence of clot formation or haemorrhage and were deemed safe discharge. Level III - All children who required return to the operating department for control of 
postoperative bleeding. 
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Table 5.4 Risk of bias for randomised studies which compare dexamethasone to another intervention and reported haemorrhage rate 
St
u
d
y 
Su
m
m
ar
y 
as
se
ss
m
e
n
t 
o
f 
ri
sk
 o
f 
b
ia
s 
How was 
allocation 
sequence 
generated? 
How was allocation 
sequence 
concealed? 
What measures were 
taken to blind 
participants and 
personnel? 
What measures 
were taken to 
blind outcome 
assessors? 
Is the outcome data 
complete? Did the authors 
report exclusion and 
attrition and give reasons 
for these? 
Is there a possibility of 
selective outcome 
reporting? 
Are there any 
other potential 
sources of bias? 
C
at
lin
 1
9
9
1
 
H
ig
h
 
Unclear – ‘double –
blind 
randomisation 
system’ – no 
details given 
Unclear – see 
previous comment 
Unclear – see previous 
comment 
Unclear – not 
described 
High - 29 patients recruited 
but 4 lost to follow up, 
unclear which intervention 
group these 4 were in. 
High - reporting of pain 
and nausea and 
vomiting rates is 
incomplete 
Low - none 
 
V
o
lk
 1
9
9
3 
H
ig
h
 
Unclear - not 
described 
Unclear - not 
described 
Unclear – can’t tell if 
both study drugs looked 
the same 
Unclear - not 
described 
High -  had problems with 
compliance with the post-
operative questionnaire - 
so only got complete follow 
up for 19/25 
dexamethasone and 16/24 
placebo 
Low - all outcomes 
reported for the 
patients followed up 
Low - none 
 
O
h
lm
s 
1
9
9
5
 
U
n
cl
ea
r 
Unclear - not 
described 
Unclear -not 
described 
Low - medication 
prepared in pharmacy 
and administered in a 
double blind fashion 
Low - see 
previous 
comment 
Low - outcomes reported 
for all participants 
Low -all outcomes 
reported  for all 
patients 
Unclear - 
although 
haemorrhage 
rate reported, 
looks like only 
detected if 
patients 
presented. 
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St
u
d
y 
Su
m
m
ar
y 
as
se
ss
m
e
n
t 
o
f 
ri
sk
 o
f 
b
ia
s 
How was 
allocation 
sequence 
generated? 
How was allocation 
sequence 
concealed? 
What measures were 
taken to blind 
participants and 
personnel? 
What measures 
were taken to 
blind outcome 
assessors? 
Is the outcome data 
complete? Did the authors 
report exclusion and 
attrition and give reasons 
for these? 
Is there a possibility of 
selective outcome 
reporting? 
Are there any 
other potential 
sources of bias? 
A
p
ri
l 1
9
9
6
 
U
n
cl
ea
r 
Low - table of 
random numbers 
distributed in 
blocks of six 
according to 
diagnosis 
Low - patients 
weight and 
diagnosis list was 
sent to pharmacy 
and a syringe was 
prepared based on 
the random 
number 
Low - numbered 
otherwise unmarked 
syringe containing 
colourless 
dexamethasone or 
saline 
Low -parents 
undertook 
observations - 
they did not 
know which 
intervention 
the child had 
received 
Low - outcomes reported 
for all participants 
Unclear -reporting 
incomplete about pain 
medication 
requirements and pain 
rating 
Low - none 
 
P
ap
p
as
 1
9
9
8
 
H
ig
h
 
Low - computer 
generated table 
Unclear - not 
described 
Unclear -  states 
administered in a 
randomized double 
blind fashion - study 
drugs were prepared by 
pharmacy but don't 
know if they looked 
identical 
Unclear - not 
described 
Low - 2 had to be excluded 
– both were from the 
dexamethasone  group 
High - do not report 
compliance with 
analgesic regime at 
home 
Unclear – relied 
on all parents 
completing diary 
adequately and 
reporting 
accurately 
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St
u
d
y 
Su
m
m
ar
y 
as
se
ss
m
e
n
t 
o
f 
ri
sk
 o
f 
b
ia
s 
How was 
allocation 
sequence 
generated? 
How was allocation 
sequence 
concealed? 
What measures were 
taken to blind 
participants and 
personnel? 
What measures 
were taken to 
blind outcome 
assessors? 
Is the outcome data 
complete? Did the authors 
report exclusion and 
attrition and give reasons 
for these? 
Is there a possibility of 
selective outcome 
reporting? 
Are there any 
other potential 
sources of bias? 
N
aw
as
re
h
 2
0
0
0
 
H
ig
h
 Unclear -patients 
were divided into 
two groups 
High - first group 
received 
dexamethasone, 
second group 
received placebo 
High – see previous 
comment 
Unclear - not 
described 
Low - outcomes reported 
for all participants 
Unclear - reporting 
incomplete about pain 
medication 
requirements 
Unclear - follow 
up beyond 
discharge for 
adverse events 
seems to have 
only been if 
patients 
presented with a 
problem 
H
o
lt
 2
0
0
0
 
H
ig
h
 Low- random 
number generation 
tables 
Low- packed in 
pharmacy and 
numbered 
according to 
randomisation 
Low- two ampoules per 
study arm (saline 
instead of 
dexamethasone in one 
group) 
Low- 
anaesthetist 
took no part in 
outcome 
assessment, 
this was 
undertaken by 
nursing staff 
who did not 
know which 
patients had 
received which 
intervention 
Low- 132 enrolled - 7 
excluded: 3x received 
propofol, 4x tonsillectomy 
cancelled. 
High- followed up on 
day 6 - no report of 
haemorrhage rate 
despite this being 
reported for patients in 
the pre-discharge 
period 
High-5 patients 
could not be 
contacted so no 6 
day follow up 
data available for 
them - 3 x 
tropisetron, 2x 
tropisetron + dex 
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St
u
d
y 
Su
m
m
ar
y 
as
se
ss
m
e
n
t 
o
f 
ri
sk
 o
f 
b
ia
s 
How was 
allocation 
sequence 
generated? 
How was allocation 
sequence 
concealed? 
What measures were 
taken to blind 
participants and 
personnel? 
What measures 
were taken to 
blind outcome 
assessors? 
Is the outcome data 
complete? Did the authors 
report exclusion and 
attrition and give reasons 
for these? 
Is there a possibility of 
selective outcome 
reporting? 
Are there any 
other potential 
sources of bias? 
G
ia
n
n
o
n
i 2
0
0
2
 
H
ig
h
 Low - random 
number generator 
(Excel) 
Low -study drug 
was supplied as 
syringes of a liquid, 
identical in colour 
and volume but 
designated by a 
letter 
Low - see previous 
comment 
Low –all 
physicians, 
nurses, 
patients, 
parents and 
others caring 
for the subjects 
were blinded to 
the assignment 
until the 
conclusion of 
the study. 
High - 3 patients, all from 
the dex group had data 
collection on the day of 
surgery but did not 
complete the evaluation 
period - 1 required steroid 
injection for asthma 
exacerbation on Day 2 and 
2 could not be contacted 
after Day 2 so data for 
these 3 patients was 
excluded from analysis 
from day 1-10 
Low - all endpoints are 
reported on 
Low -none 
 
 156 
 
St
u
d
y 
Su
m
m
ar
y 
as
se
ss
m
e
n
t 
o
f 
ri
sk
 o
f 
b
ia
s 
How was 
allocation 
sequence 
generated? 
How was allocation 
sequence 
concealed? 
What measures were 
taken to blind 
participants and 
personnel? 
What measures 
were taken to 
blind outcome 
assessors? 
Is the outcome data 
complete? Did the authors 
report exclusion and 
attrition and give reasons 
for these? 
Is there a possibility of 
selective outcome 
reporting? 
Are there any 
other potential 
sources of bias? 
H
an
as
o
n
o
 2
0
0
4
 
H
ig
h
 Unclear - random 
number list - does 
not describe how it 
was generated 
Unclear  - study 
medication was 
supplied in a 
blinded manner and 
medication records 
were maintained in 
pharmacy until the 
end of the study 
Unclear – see previous 
comment 
Unclear – see 
previous 
comment 
High – outcome measures 
for pain, emesis and oral 
intake only reported for 
173 of 219 participants 
 
Low – all outcomes are 
reported on 
 
High - Only 
followed up for 3 
days so would not 
observe 
haemorrhage 
occurring after 
that. Patients 
were only asked 
about post-op 
problems leading 
to unplanned 
office or 
emergency 
department visit 
on POD 3, minor 
bleeds might not 
have been 
reported. 
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St
u
d
y 
Su
m
m
ar
y 
as
se
ss
m
e
n
t 
o
f 
ri
sk
 o
f 
b
ia
s 
How was 
allocation 
sequence 
generated? 
How was allocation 
sequence 
concealed? 
What measures were 
taken to blind 
participants and 
personnel? 
What measures 
were taken to 
blind outcome 
assessors? 
Is the outcome data 
complete? Did the authors 
report exclusion and 
attrition and give reasons 
for these? 
Is there a possibility of 
selective outcome 
reporting? 
Are there any 
other potential 
sources of bias? 
M
al
d
e 
2
0
0
5
 
H
ig
h
 Low - computer 
generated random 
number table 
Unclear - not 
described 
Unclear - not described 
Low – 
undertaken by 
second 
anaesthetist 
who was 
unaware which 
drug had been 
administered 
High- follow up details 
were not available for six 
patients of each group - 
does not specify from 
which point, assume means 
post-discharge follow-up 
Low - all outcomes 
reported on 
Low - none 
 
K
aa
n
 2
0
0
6
 
U
n
cl
ea
r 
Low - 
randomizer.org 
was used 
Unclear - not 
described 
Unclear - all procedures 
were performed in a 
double-blind fashion - 
no details of how 
Unclear - 
independent' 
observer - no 
details of how 
or whether they 
were blinded 
Low - outcomes reported 
for all participants 
Low – all outcomes are 
reported on 
 
Unclear - 
instructed to 
return if bleeding, 
2+ vomiting or 
inadequate oral 
intake - might 
have decided not 
to return so 
wouldn't have 
picked up these 
adverse events 
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St
u
d
y 
Su
m
m
ar
y 
as
se
ss
m
e
n
t 
o
f 
ri
sk
 o
f 
b
ia
s 
How was 
allocation 
sequence 
generated? 
How was allocation 
sequence 
concealed? 
What measures were 
taken to blind 
participants and 
personnel? 
What measures 
were taken to 
blind outcome 
assessors? 
Is the outcome data 
complete? Did the authors 
report exclusion and 
attrition and give reasons 
for these? 
Is there a possibility of 
selective outcome 
reporting? 
Are there any 
other potential 
sources of bias? 
M
o
h
am
m
ad
 2
0
0
6
 
H
ig
h
 
Unclear - not 
described 
Unclear - not 
described 
Unclear - not described 
Unclear - not 
described 
Unclear - method of scoring 
pain is not well described 
High - patients observed 
for 24 hours and 
discharged the day after 
surgery but study 
reports outcome data 
for secondary 
haemorrhage, oral 
intake at 36 & 72 hours, 
note the statement 
about contacting people 
by phone only if they 
had  the facility 
Low - none 
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St
u
d
y 
Su
m
m
ar
y 
as
se
ss
m
e
n
t 
o
f 
ri
sk
 o
f 
b
ia
s 
How was 
allocation 
sequence 
generated? 
How was allocation 
sequence 
concealed? 
What measures were 
taken to blind 
participants and 
personnel? 
What measures 
were taken to 
blind outcome 
assessors? 
Is the outcome data 
complete? Did the authors 
report exclusion and 
attrition and give reasons 
for these? 
Is there a possibility of 
selective outcome 
reporting? 
Are there any 
other potential 
sources of bias? 
C
za
rn
et
zk
i 2
0
0
8
 
H
ig
h
 
Unclear - 
randomization was 
done in blocks of 
40 children (10 per 
group) - study 
medications were 
produced and 
randomized 
Unclear - see 
previous comment 
Low - indistinguishable 
syringes 
Low -
anaesthetist did 
not know what 
had  been given 
so could not tell 
nurses / 
surgeons / 
parents what 
had been given 
Low - patients lost to follow 
up or excluded because did 
not meet inclusion criteria 
are described 
Low - all endpoints are 
reported on albeit with 
limited detail for some 
High - 
Questionnaire at 
home was not 
completed for 23 
children - so do 
not know if had 
NSAIDs, minor 
bleed or PONV 
that has not been 
recorded. There 
could be partial 
completion of 
some of the 
returned 
questionnaires. 
Early termination 
of this trial may 
have exaggerated 
harm. 
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St
u
d
y 
Su
m
m
ar
y 
as
se
ss
m
e
n
t 
o
f 
ri
sk
 o
f 
b
ia
s 
How was 
allocation 
sequence 
generated? 
How was allocation 
sequence 
concealed? 
What measures were 
taken to blind 
participants and 
personnel? 
What measures 
were taken to 
blind outcome 
assessors? 
Is the outcome data 
complete? Did the authors 
report exclusion and 
attrition and give reasons 
for these? 
Is there a possibility of 
selective outcome 
reporting? 
Are there any 
other potential 
sources of bias? 
A
la
jm
i 2
0
0
8
 
H
ig
h
 
Unclear - first two 
patients were 
given 
dexamethasone 
and the rest were 
given saline - in the 
next operating 
theatre this was 
reversed 
Unclear - not 
described 
Unclear -states that 
participants were 
blinded 
Unclear - some 
personnel knew 
who had which 
intervention, 
don't know who 
did 
observations 
Low - outcomes reported 
for all participants 
High - outcomes not 
reported for each 
follow-up visit, 
haemorrhage only 
reported in the context 
of readmission - authors 
state that no re-
admission signified no 
complication but do not 
report what was 
recorded at POD 7, POD 
10 & POD 16 follow ups 
Low -none 
 
G
al
la
gh
er
 T
.Q
. 2
0
1
2
 
H
ig
h
 
Low - random 
number generator 
Low - carried out by 
hospital pharmacy 
Low- identical 
packaging of dex and 
placebo 
Low - 
anaesthetist, 
surgeon, 
patients, 
guardians, data 
collectors were 
blinded 
Low - 9 excluded, 3 
received additional post-op 
steroid, 6 lost to follow up 
but clear which 
intervention groups these 9 
were in 
High – data on 
secondary outcomes 
not fully reported 
Unclear - strict 
instructions to 
return with 
bleeding - but 
might have gone 
elsewhere or not 
attended if only 
minor 
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Figure 5.3 Haemorrhage rates for randomised studies which compared dexamethasone 
with another interventionxx 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
xx
 The following reported zero haemorrhages in both intervention groups: Pappas (1998) dexamethasone (0/63) 
control (0/65), Kaan (2006) dexamethasone (0/32) control (0/30) 
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Figure 5.4 Sub-group analysis – Primary & Secondary Haemorrhage Ratesxxi 
 
 
 
          
 
 
 
 
 
 
                                                          
xxi
 Holt (2000) reported only overall haemorrhage rate. The following reported zero primary haemorrhages in 
both intervention groups: Volk (1993), Ohlms (1995), April (1996 , Pappas (1998), Nawasreh (2000), Giannoni 
(2002), Hanasono (2004), Malde (2005), Kaan (2006), Catlin (2006), Alajmi (2008). The following reported zero 
secondary haemorrhages in both intervention groups: Pappas (1998), Kaan (2006) 
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Figure 5.5 Sub-group analysis – Haemorrhage rates with NSAID usexxii 
 
 
 
 
 
 
 
 
 
 
 
                                                          
xxii
 The following reported zero haemorrhages in both intervention groups: Pappas (1998), Kaan (2006) 
For the following it was unclear whether NSAIDs had been administered: Nawasreh (2000) 
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Figure 5.6 Funnel Plot 
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5.3.2.2 Randomised studies in which all participants received dexamethasone and 
reported haemorrhage rate 
These three studies involved 249 participants and were published between 2003 and 2011 
(O'Flaherty and Lin, 2003, Derkay et al., 2006, Rawlinson et al., 2011).  Rawlinson et al. 
(2011) followed patients up for 14 days, Derkay et al. (2006) for four hours and O’Flaherty 
& Lin (2003) followed up patients for 24 hours. The primary outcome in all three studies 
was post-operative pain and/or post-operative nausea and vomiting. In Rawlinson’s study, 
study all patients received dexamethasone 0.4mg/kg and the electrocautery and 
microdebrider dissection techniques were compared; no patients received NSAIDs 
(Rawlinson et al., 2011). Derkay et al. (2006) administered dexamethasone 0.1mg/kg to all 
participants and tonsillectomy was undertaken by cold steel dissection. In their study which 
compared magnesium and ketamine use, O’Flaherty & Lin (2003) administered 0.2mg/kg 
dexamethasone to all participants, but did not report the tonsillectomy technique(s) used 
and their reporting of early post-operative haemorrhages was ambiguous (Table 5.5). Only 
one study pre-defined haemorrhage (Derkay et al., 2006). Another actively collected 
haemorrhage rate data as well as specifying the timing and frequency of haemorrhage rate 
data collection (O'Flaherty and Lin, 2003). The haemorrhage rates in two of these studies 
ranged from 0% to 2% (Derkay et al., 2006, Rawlinson et al., 2011). The rate was unclear in 
one of these studies (O'Flaherty and Lin, 2003). 
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Table 5.5 Randomised studies in which all participants received dexamethasone and in which haemorrhage rate was reported 
           
St
u
d
y No. of participants 
 
Length of 
follow up 
Primary 
outcome(s) 
Interventions 
 
Dissection 
Technique 
 
Haemostasis 
Technique 
 
Dex 
Dose 
 
Peri-operative 
NSAID 
 
Post-operative haemorrhage 
rate 
 
Contact 
with 
authors Primary 
 
Secondary 
 
Total 
 
             
O
’F
la
h
er
ty
 2
0
0
3
 
10 Ketamine/Placebo 
 
24 hours 
Post-
operative 
pain 
All had dex Not reported Not reported 
0.2 
mg/kg 
1 patient had 
ibuprofen 
Unclear 0 - 
None 
11 Magnesium/Placebo 
 
none Unclear 1 - 
9 Ketamine/Magnesium 
 
1 patient had 
ibuprofen 
Unclear 1 - 
7 Placebo/Placebo 
 
none Unclear 1 - 
             
D
er
ka
y 
2
0
0
6
 
150 
14 days 
 
Post-
operative 
pain 
All had dex 
 
Electrocautery 
Suction 
electrocautery 
 
0.4 
mg/kg 
(max 
20mg) 
 
Not reported 
 
Not 
reported 
Not 
reported 
3 None 
             
R
aw
lin
so
n
 2
0
1
1
 
32 
 
4 hours 
 
PONV  and 
pain 
All had dex + 
ondansetron 
 
Cold steel 
 
Bipolar 
diathermy 
 
0.1 
mg/kg 
 
Ibuprofen 
5mg/kg 
0 0 0 
None 
30 
 
Diclofenac 1-
2mg/kg IV 
0 0 0 
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5.3.2.3 Non-randomised studies which compared dexamethasone with another 
intervention and reported haemorrhage rate 
There were 2088 participants in these three studies published between 1999 and 
2011(Conley and Ellison, 1999, Shakeel et al., 2010, Windfuhr et al., 2011). They were all 
retrospective case note reviews and two of them retrieved two week follow up data 
(Conley and Ellison, 1999, Shakeel et al., 2010). In one of the studies, a single method of 
tonsil dissection was employed (Windfuhr et al., 2011), while in the other studies there 
were several methods recorded (Conley and Ellison, 1999, Shakeel et al., 2010). In the 
retrospective chart review conducted by Conley & Ellison (1999), patients who received 
dexamethasone were operated on using a standard surgical technique – cold-knife 
dissection and snare and haemostasis was achieved using tonsillar packs dipped in bismuth 
subgallate-phenylephrine hydrochloride mixture followed by suction electrocautery and a 
three minute observation period. However, patients who did not receive dexamethasone 
were operated on using either cold-knife dissection, snare and suction electrocautery or 
electrocautery dissection; tonsillar packs were not used in any of these patients. The 
dexamethasone doses administered in these three studies ranged from 0.04mg/kg to 
0.62mg/kg. The report of one study specifies that dexamethasone was administered or 
withheld according to the anaesthetist’s preference (Windfuhr et al., 2011). NSAIDs were 
administered to some of the participants in one study (Table 5.6) (Shakeel et al., 2010). The 
primary outcome was haemorrhage rate for all of these studies. Two of these studies pre-
defined haemorrhage and all reported their haemorrhages in detail, providing information 
on the need for and types of re-intervention (Table 5.7) (Conley and Ellison, 1999, Windfuhr 
et al., 2011). All of these studies pre-defined haemorrhage but none actively collected data 
on haemorrhage rate. None of these studies used a standard checklist for haemorrhage 
rate data collection and for all of them it was unclear whether there was a possibility of 
selective outcome reporting bias. The haemorrhage rates for participants who did and did 
not receive dexamethasone ranged from 1.1% to 8.3% and 3.8% to 9.7%, respectively 
(Figure 5.7).  
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Figure 5.7 Haemorrhage rates in non-randomised studies 
 
5.3.2.4 Non-randomised studies in which all participants received dexamethasone & 
reported haemorrhage rate 
These 11 studies included 6200 participants, and were published between 2002 and 2011 
(Gallagher R.M. et al., 2012, Thiesen et al., 2013, Postma and Folsom, 2002, Stewart, Baines 
and Dalton, 2002, Bent et al., 2004, Ewah, Robb and Raw, 2006, Kalantar, Takehana and 
Shapiro, 2006, Brigger, Cunningham and Hartnick, 2010, Ahmed et al., 2011, Hanss et al., 
2011, Robb and Ewah, 2011). They comprise five retrospective chart reviews (Postma and 
Folsom, 2002, Bent et al., 2004, Kalantar, Takehana and Shapiro, 2006, Brigger, 
Cunningham and Hartnick, 2010, Hanss et al., 2011), three prospective observational 
studies (Gallagher R.M. et al., 2012, Thiesen et al., 2013, Ewah, Robb and Raw, 2006), two 
audits (Stewart, Baines and Dalton, 2002, Robb and Ewah, 2011)  and a retrospective 
analysis of data from an RCT (Ahmed et al., 2011). The period of follow-up in these studies 
ranged from six hours to 30 days and seven reported the technique used to remove the 
tonsils (Postma and Folsom, 2002, Stewart, Baines and Dalton, 2002, Bent et al., 2004, 
Ewah, Robb and Raw, 2006, Brigger, Cunningham and Hartnick, 2010, Hanss et al., 2011, 
Robb and Ewah, 2011). The primary outcome was haemorrhage rate in two of these studies 
(Brigger, Cunningham and Hartnick, 2010, Ahmed et al., 2011), while most of the remaining 
studies examined post-operative pain and vomiting. Dexamethasone doses ranged from 
0.06mg/kg to 1.5mg/kg and NSAID use was reported in four of the studies (Gallagher R.M. 
et al., 2012, Thiesen et al., 2013, Ewah, Robb and Raw, 2006, Robb and Ewah, 2011). Two of 
the studies pre-defined haemorrhage (Postma and Folsom, 2002, Brigger, Cunningham and 
Hartnick, 2010), one undertook passive haemorrhage rate data collection (Brigger, 
Cunningham and Hartnick, 2010), the timing and frequency of haemorrhage rate data 
collection was specified by two authors (Stewart, Baines and Dalton, 2002, Hanss et al., 
2011)  and there was a possibility of selective outcome reporting in two studies (Thiesen et 
al., 2013, Kalantar, Takehana and Shapiro, 2006). The haemorrhage rate in these 11 studies 
ranged from 0.4% to 5.7%.  
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Table 5.6 Description of non-randomised studies which compared dexamethasone with another intervention and reported haemorrhage rate 
Study 
 
No. of 
participants 
 
Design 
Primary 
outcome(s) 
 
Interventions 
 
Participants per 
intervention group 
 
Dissection 
Technique 
 
 
Haemostasis 
Technique 
 
 
Dex Dose 
 
 
Peri-operative 
NSAID 
 
Dex Other 
           
Conley 
1999 
1286 
Retrospective 
casenote 
review 
Incidence of 
post-
tonsillectomy 
haemorrhage 
Group 1 
Dexamethasone, 
Group 2 no 
dexamethasone 
705 581 
Cold -knife 
dissection + 
snare or 
electro-cautery 
dissection 
Group 1 - tonsillar 
packs dipped in 
bismuth 
subgallate +/- 
electro-cautery 
Group 2 - suction 
electro-cautery 
0.5mg/kg 
(max 10mg) 
None 
           
Shakeel 
2010 
530 
Retrospective 
casenote 
review 
Incidence of 
secondary 
post-
tonsillectomy 
bleeding 
Dexamethasone 
OR no 
dexamethasone 
253 277 
Cold steel, 
bipolar 
diathermy, 
harmonic 
scalpel, 
coblation, 
monopolar 
diathermy 
Not reported 
Various – 
recorded as 
<0.1mg/kg and 
>0.1mg/kg 
Post-operative 
ibuprofen 
           
Windfuhr 
2011 
272 
Retrospective 
casenote 
review 
Rates of 
post-
operative 
nausea, 
vomiting and 
bleeding 
Dexamethasone 
OR no 
dexamethasone 
121 151 
Cold - 
dissection with 
scissors, 
raspatory, 
removing the 
inferior pole 
with a snare 
Suture ligation 
and bipolar 
cautery where 
required 
0.04-
0.62mg/kg 
None 
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Table 5.7 Details of haemorrhages reported in non-randomised studies which compared dexamethasone with another intervention 
       
Study  
Definition of 
haemorrhage 
 
No. of 
participants 
 
Participants per 
intervention 
group 
Post-operative haemorrhage rate 
 Severity of haemorrhage 
 
Contact with 
authors 
Primary 
 
Secondary 
 
Total 
 
Dex Other Dex Other Dex Other Dex Other Dex Other 
              
Conley 
1999 
Category 1-
5
xxiii
 
 
1286 705 581 0 6 8 16 8 24 2x delayed major 
5x delayed minor 
1x delayed minor 
that occurred at 
home 
5x major primary 
1x minor primary 
11x major delayed 
5x minor delayed 
2x occurred at home 
Author provided 
data on NSAIDs 
              
Shakeel 
2010 
None 530 253 277 0 0 9 28 9 28 6x evidence on 
examination 
1x required re-
operation 
9x evidence on re-
examination 
5x required re-
operation 
Author provided 
data on 
dexamethasone 
dose, NSAID 
administration 
and timing and 
severity of bleeds. 
              
Windfuhr 
2011 
Primary <24 
hours, 
Secondary >24 
hours 
272 121 151 3 4 8 9 11
xxiv
 13
xxv
 3x day of surgery 
1 x days 2, 5, 7 
2x day 32x day 8 
1x day 10 
7 required surgical 
intervention 
4x day of surgery 
3x day 1 
1 x days 3,5,6,7,9,12 
10 required surgical 
intervention 
None 
                                                          
xxiii
 1.no bleeding 2. immediate major (<24 hours requiring re-operation) 3. immediate minor (<24 hours requiring admission) 4. delayed major (>24 hours requiring re-operation) 5. delayed 
minor (>24 hours, not requiring admission) 
xxiv
 Count of bleeds, 9 participants experienced 1 haemorrhage, 1 participant experienced 2 secondary haemorrhages 
xxv
 Count of bleeds, 11 participants experienced 1 haemorrhage, 1 participant experienced 2 secondary haemorrhages 
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5.4 Discussion 
5.4.1 Summary of findings 
Data from the 15 RCTs included in our meta-analysis and the three NRS in which 
dexamethasone was compared with another intervention, indicate that the overall risk of 
post-tonsillectomy haemorrhage in children is not significantly increased by the peri-
operative use of dexamethasone.  
5.4.2 Limitations of included studies 
The overall risk of bias was high or unclear for all of the included RCTs. Amongst both the 
randomised and non-randomised studies there was clinical heterogeneity. Some of the 
elements of study design that have an impact on haemorrhage risk are: dissection 
technique, haemostasis technique (Lowe et al., 2007), patient age, gender and the 
indication for surgery (Windfuhr, Chen and Remmert, 2005, Brigger, Cunningham and 
Hartnick, 2010)  and the peri-operative use of NSAIDs (Lewis et al., 2013). Our evaluation of 
haemorrhage rate data collection and reporting indicates that this was inadequately 
reported in the majority of studies. Many studies did not follow up patients beyond the 
point at which primary outcomes would be measured. Studies which relied on re-admission 
as a method of haemorrhage detection may have missed minor self-limiting bleeds or 
bleeds attended to at other healthcare facilities. Studies which used patient and parent 
questionnaires to detect bleeding episodes may have missed haemorrhages due to 
questionnaires being incomplete or unreturned.  Very few studies described active 
surveillance for adverse outcomes, for example a telephone call or face-to-face contact 
whereby participants were specifically asked about any haemorrhages experienced.  
5.4.3 Comparison with results of previous studies  
In our meta-analysis of 15 RCTs, the pooled estimate risk ratio for haemorrhage in patients 
who received dexamethasone was 1.41 (95% CI 0.89, 2.25, p=0.15; I2= 13%). The 
interpretation of this finding conforms to that of three previous meta-analyses of 
randomised studies although the difference in the summary statistic reflects differences in 
study identification and inclusion. Geva et al. (2011) calculated a relative risk of 
haemorrhage of 1.02 (95% CI 0.65-1.61, p=0.92) for adult and paediatric patients in their 
meta-analysis who received dexamethasone. The haemorrhage rate amongst those who 
received dexamethasone was 5.9%. Their analysis included 14 studies, nine of which were 
also included in this analysis; of the five that were not included in this analysis, three 
 172 
 
included adult participants only, one was in Hebrew and for one we were not able to obtain 
sufficient detail from the author about the participants who experienced a haemorrhage. A 
meta-analysis of studies involving only children calculated an odds ratio of haemorrhage for 
children who had received dexamethasone compared with those who did not (OR=1.07; 
95%CI 0.58, 1.98, p=0.82) (Shargorodsky, Hartnick and Lee, 2012). Their analysis included 
12 studies of which 10 were the same as those in this review. The two studies we did not 
include were those where haemorrhage rate data could not be obtained from the authors. 
The haemorrhage rate for children who received dexamethasone in this study was 6.2%. 
Finally, the most recent meta-analysis calculated an odds ratio of 0.96 (95% CI 0.66, 1.40, I2 
= 0%) (Plante et al., 2012). This review included 29 studies of systemic steroid use in 
tonsillectomy and haemorrhage rate in adults and children.  The haemorrhage rate for 
patients who received systemic steroids was 4.6%. We included 13 of these 29 plus an 
additional study they did not identify (Pappas et al., 1998) and another where the results 
were published more recently (Gallagher T.Q. et al., 2012). Of the 16 studies, we did not 
include: five were not in English, six involved adults only, for three data on haemorrhage 
rate could not be obtained, one reported combined data on adults and children and in one 
the intervention was prednisolone rather than dexamethasone. 
5.4.4 Data not included in previous reviews 
This study included two RCTs not included by previous systematic reviews. One of these 
studies was identified in both the EMBASE and MEDLINE.  Although it did not report 
haemorrhage rate, we obtained the necessary data from the author (Pappas et al., 1998). 
The results of the second randomised study by Gallagher T.Q. et al. (2012) were published 
after the previous reviews. This was the only randomised study included here which had 
the rate and severity of post-tonsillectomy haemorrhage as its primary outcome measure. 
The study was a non-inferiority study (1-sided test). Non-inferiority was tested for 
haemorrhage events in each of three groups (level I-III, see footnote to Table 5.3 for 
definitions) rather than grouping all haemorrhage events together. The hypothesis was that 
dexamethasone would not increase haemorrhage rate by more than 5% (rather than that 
there would be no difference between the two groups). Non-inferiority was not shown for 
level I bleeding events but it was demonstrated for both level II and level II bleeding events. 
Unsurprisingly, the assessments of risk of bias and methodological quality show that the 
risk of bias for this study is generally low and overall the methodology for haemorrhage 
rate detection and reporting was the most robust. Consequently, the haemorrhage rate in 
this study (9.6%) is at the upper end of the range for the randomised studies included in 
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this review. The overall relative risk of haemorrhage with dexamethasone administration 
was calculated in this study and a non-significant increase in risk was found: 1.32 (95% CI 
0.58-3.07, p = 0.5653). The categorisation of haemorrhages by severity level was one 
strength of this study; this was undertaken by only six of the randomised studies included in 
the meta-analysis. When haemorrhages are categorised in such a way the results become 
useful to clinicians and policy-makers. In T.Q. Gallagher’s study, although there were a total 
of 30 haemorrhages, 18 did not require any change in post-operative care and only four 
required re-operation.  
The evaluation of haemorrhage rate data from NRS was not conducted in previous reviews.  
Evaluation of three studies provided conflicting results. The data for two of these studies 
indicated that patients in the control group were more likely to experience a haemorrhage 
than patients who received dexamethasone (Conley and Ellison, 1999, Shakeel et al., 2010). 
In one of these studies, there were too many differences in the way the two intervention 
groups were managed to draw any meaningful conclusions about the effects of 
dexamethasone administration on haemorrhage risk (Conley and Ellison, 1999). In a third 
study, there was no difference between the intervention groups but dexamethasone had 
been administered according to anaesthetist preference (no further details available), and 
it is therefore possible that patients with an increased risk of haemorrhage were not 
administered dexamethasone (Windfuhr et al., 2011). All three studies were retrospective 
chart reviews using hospital records. Although they report haemorrhage rates which 
correspond to those quoted in the literature (Randall and Hoffer, 1998), there is some 
evidence that retrospective chart review underestimates haemorrhage rate (Doshi et al., 
2008). 
5.5 Conclusion  
This study did not find any evidence that dexamethasone significantly increases the risk of 
post-tonsillectomy haemorrhage.  However the degree of imprecision of the odds ratio in 
the pooled estimate (upper bounds of the 95% CI was 2.25) prevents us from ruling out a 
clinically relevant doubling in risk. There were insufficient data to determine any additional 
impact of NSAID use, an issue which needs further investigation given the recent moves 
away from use of codeine in children after tonsillectomy. In the studies included here, 
inadequacies in haemorrhage rate detection and reporting were identified. Further large 
studies (both randomised and observational) are needed to provide evidence about the 
safety of dexamethasone ± NSAIDs in paediatric tonsillectomy. These need to have 
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haemorrhage rate as their primary outcome with pre-defined levels of severity. Robust 
methodologies need to be developed with strategies to prospectively and actively capture 
data on haemorrhage outcomes for all participants over an adequate follow up period. The 
findings of four ongoing trials will provide additional data on outcomes for the use of 
dexamethasone (Centre Hospitalier Universitaire Vaudois, University of Turku) and 
ibuprofen (Massachusetts Eye and Ear Infirmary, Cumberland Pharmaceuticals) in 
paediatric tonsillectomy. 
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6 Development of a risk score for post-operative vomiting in children 
6.1 Introduction 
In chapter 3 of this thesis, the impact of off-label and unlicensed prescribing on ADR risk in 
inpatients was explored in a case-control study nested within a prospective cohort. 
Medicines administered in theatre were not included in the analyses because, in the 
prospective cohort study, they had only been recorded if they had been implicated in an 
ADR. In the multivariate analysis, exposure to GA was a significant predictor of ADR risk (HR 
5.30, 95% CI 4.42, 6.35 p<0.001). In the prospective cohort study, nausea and/or vomiting 
following GA was the most common reaction type (Thiesen et al., 2013). In view of the 
significant impact of GA on ADR risk and of PONV on the ADR rate, a more detailed 
assessment of these cases was undertaken.  
Post-operative nausea and vomiting (PONV) are significant causes of morbidity in paediatric 
surgical patients. Post-operative vomiting (POV) rather than PONV rates tend to be 
reported in paediatric studies because very young children may not be able to report 
nausea. The overall incidence of POV in children is 9-42%, although severe or intractable 
POV is far less common (Rose and Watcha, 1999, Kovac, 2007). The reported incidence of 
POV in some surgery types is higher, for example up to 80% in strabismus surgery, 70% in 
tonsillectomy and 66% following craniotomy (Kovac, 2007). 
It is important that we are able to predict the likelihood of POV. Prediction provides us with 
opportunity for prevention either by the administration of prophylactic anti-emetics or the 
modification of other aspects of peri-operative care.  
The POst-operative VOmiting in Children (POVOC) score was developed as a simplified 
model to assess POV risk in children undergoing surgery, since pre-existing tools had been 
developed for use in adults and had limited application in children (Eberhart et al., 2004). 
Its development utilised data from 1401 children aged 0-14 years. Individuals who had 
received intra-operative anti-emetics were excluded (n=88), as were those who were lost to 
follow up, or had incomplete records (n=56). Data from the remaining 1257 children were 
analysed, 657 cases to develop the score and 600 to validate it. The final score contained 
the following four risk factors:  
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1. strabismus surgery 
2. age > 3 years 
3. duration of surgery >30 minutes; and  
4. history of POV in the child or history of PONV in the father, mother or siblings 
The UK national guideline (The Association of Paediatric Anaesthetists of Great Britain & 
Ireland, 2009) on the prevention of POV places risk factors for POV into three categories:  
1. patient-related e.g. age > 3years, history of POV 
2. surgery-related e.g. duration of the procedure and type of surgery; and 
3. anaesthetic-related e.g. technique, anaesthetic agents 
They specify that there is an increased risk with adenotonsillectomy and strabismus surgery 
and that volatile anaesthetic, opioids and anticholinesterase agents may increase the risk of 
POV.  
The aim of the study described in this chapter was to explore in more detail the POV cases 
detected in the prospective cohort study and to use a case-control design to develop a risk 
score for POV in children. The additional data in this study were collected and analysed by 
JRB, with advice from the ADRIC statistics team. 
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6.2 Methods 
6.2.1 Study design 
In order to identify risk factors for POV, it was necessary to compare the characteristics of 
patients from the prospective cohort study who experienced POV with those who did not. 
POV was defined as that which started within 24hrs after a general anaesthetic. The 
analysis in chapter 3 included only probable and definite ADRs because these were deemed 
to have a low probability of the underlying disease being responsible for the reaction. 
Possible ADRs were included in this study of POV risk factors because we wanted to explore 
more than just drug-related risk factors. Due to resource constraints, it was not possible to 
include all patients who did not experience POV as controls. Therefore, a nested case-
control design was chosen; all possible, probable and definite POV cases were included and 
they were matched 1:1 to controls who had not experienced POV. This study used data 
derived from a larger study which used routinely collected clinical data in an anonymised 
format, the Chair of Liverpool Paediatric LREC informed us that this study did not require 
individual patient consent or review by an Ethics Committee. 
6.2.2 Identification of cases 
Cases were patients from the prospective cohort study who experienced POV which, 
following causality assessment using the LCAT (Gallagher et al., 2011) was deemed to be 
possible, probable or definite.  The inclusion and exclusion criteria for the prospective 
cohort study are described in chapter 3 of the thesis. POV was defined in the prospective 
cohort study protocol as that which started within 24hrs after general anaesthetic and 
when the patient was back on the ward, it was recorded in the study database as 
‘procedural vomiting’. 
There were 367 possible, probable or definite cases of POV in the prospective cohort study. 
We included only the first episode of POV in each individual. After subsequent episodes of 
POV in the same individual were excluded, 356 cases remained in this study.  
6.2.3 Identification of controls 
Controls were first admissions who met the inclusion criteria for the prospective cohort 
study and who underwent a surgical procedure within the time frame of the study but did 
not go directly to PICU after theatre and were not suspected of experiencing POV. The 
 178 
 
procedure for identifying potential controls is shown in Figure 6.1. Controls were selected 
at random from the list of patient numbers, ordered lowest to highest.  
If a patient who a) experienced POV which started in theatre recovery or b) was not 
identified in the prospective cohort, was identified amongst the controls, they were 
included as a case and a new control was selected.  
6.2.4 Selection of predictors  
The selection of candidate predictors for inclusion was based on the risk factors proposed 
in UK (The Association of Paediatric Anaesthetists of Great Britain & Ireland, 2009) and US 
(Gan et al., 2003) guidelines and was discussed with clinical experts. The data available in 
patient records were examined and the practicalities and relative merits of collecting each 
item in terms of predictive value were discussed with a clinical expert. The following 
predictors were identified: specialty, age, gender, history of POV, pre-operative state, 
procedure type, duration of anaesthesia, pre-medication, induction agent, maintenance 
agent, intra-operative analgesia, intra-operative anti-emetics, other intra-operative 
medicines, intra-operative fluids, post-operative opioids, post-operative epidural, post-
operative non-steroidal anti-inflammatory drugs (NSAIDs), other post-operative medicines 
and intra- or post-operative hypotension. The following items were also included: patient 
identifier, patient weight and details of the POV episode (Table 6.1). 
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426 theatre 
episodes with POV 
detected in 
prospective cohort 
1429 duplicate 
admission 
identifiers removed 
352 not first 
admissions removed 
446 admissions not eligible:  
 not in cohort study (93)  
 went to PICU after theatre (316) 
 excluded from cohort (31) 
 in cohort but theatre date after 
cohort study end (30th Sept 2010) 
Theatre episode list supplied by hospital information 
department for all inpatients >48 hours, during the 
period of the prospective cohort study 
 
4747 theatre episodes listed by patient identifier and 
admission identifier 
 
NB if a patient had more than one procedure on the 
same visit to theatre; it was recorded as multiple 
theatre episodes 
4321 theatre episodes, no POV detected 
2892 admissions with at least one 
theatre episode, no POV detected 
2540 first admissions with at least one 
theatre episode, no POV detected  
2094 eligible first admissions from which to 
select controls 
Figure 6.1 Procedure for identifying controls 
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6.2.5 Data collection  
Data for each case and each control were obtained from the prospective cohort study 
database if it was available, with additional data obtained from the patients’ electronic 
theatre record and case notes. Table 6.1 indicates which data were collected, and from 
which sources, for both cases and controls. Definitions of intra-operative and post-
operative hypotension (Table 6.2, (Haque and Zaritsky, 2007)) were recommended by a 
clinical expert to inform a pragmatic approach for data collection, since there is no 
consensus definition of intra-operative hypotension in children (Nafiu et al., 2009). 
6.2.6 Refinement of predictors  
After data collection but before analysis was undertaken, the list of predictors was 
reassessed and amended. This was undertaken in conjunction with a clinical expert taking 
into account the clinical questions we might seek to address such as the differences in the 
likelihood of POV with different anti-emetic agents.  It also took into account the 
observations about data availability and quality made during data collection and the need 
to simplify predictors to facilitate analysis (Table 6.3). This process resulted in the inclusion 
of 28 predictors in the exploratory analysis (Table 6.8). 
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Table 6.1 Dataset items and sources 
    
Item Details recorded Source for cases Source for controls 
Unit Number (patient identifier) - Study database List of controls 
Specialty  Hospital record abbreviation e.g. NEUS Electronic theatre record Electronic theatre record 
ADRID (POV case identifier) - Study database Not applicable 
Weight (kg) - Study database Study database 
POV Duration (days) - Study database Casenotes 
Total vomits recorded - Study database/ casenotes Casenotes 
Post-operative anti-emetics Name, dose, frequency, duration Study database/ casenotes Study database/ casenotes 
Age on admission  - Study database Study database 
Gender  - Study database Study database 
Previous GA? Yes or No Study database/casenotes/electronic record Casenotes/electronic record 
History of POV  Yes or No, year of previous GA (if any) Study database/casenotes/electronic record Casenotes/electronic record 
Pre-operative state co-operative/upset/other Casenotes Casenotes 
Procedure Name of procedure Electronic record Electronic record 
Duration of anaesthesia  Minutes between anaesthesia started and into 
recovery 
Electronic record Electronic record 
Details of Premedication Name, dose Study database/casenotes Study database/casenotes 
Induction anaesthesia  Name, dose if intravenous Study database/casenotes Casenotes 
Maintenance anaesthesia  Name, dose if intravenous Study database/casenotes Casenotes 
Intra-operative analgesia Name, dose Study database/casenotes Casenotes 
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Item Details recorded Source for cases Source for controls 
Intra-operative fluids  Type, rate Casenotes Casenotes 
Intra-operative anti-emetics Name, dose Study database/casenotes Casenotes 
Other intra-operative medicines Name, dose Study database/casenotes Casenotes 
Post-operative opioids  Name, dose, frequency, duration Study database/casenotes Study database/casenotes 
Post-operative epidural  Name, dose, frequency, duration Study database/casenotes Study database/casenotes 
Post-operative NSAIDs  Name, dose, frequency, duration Study database/casenotes Study database/casenotes 
Other post-operative medicines Name, dose, frequency, duration Study database/casenotes Study database/casenotes 
Intra-operative hypotension 
xxvi
 Yes or no, details if yes Casenotes Casenotes 
Post-operative hypotension 
xxvii
 Yes or no, details if yes Casenotes Casenotes 
 
Table 6.2 Pediatric Advanced Life Support (PALS) definition of hypotension (Haque and Zaritsky, 2007) 
Age group Definition of hypotension (mmHg) 
0 days–1 wk. <60 
1 week–1 mo. <60 
1 mo.–1 yr. <70 
>1–5 yrs. 70  +  2 x yrs. 
6–12 yrs. 
 
70 + 2 x yrs. (up to 10 yrs.) 
<90 (>10 yrs.) 
13–18 yrs. <90 
                                                          
xxvi defined by us as four consecutive systolic BP readings (over 15 minutes) below the lower limits by age defined in the Pediatric Advanced Life Support (PALS) guidelines (Haque and Zaritsky, 2007), table 6.2   
xxvii
 defined by us as any systolic reading below the lower limits by age defined in the PALS guidelines (Haque and Zaritsky, 2007) in the first 24 hours post-op, see table 6.2 
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Table 6.3 Refinement of predictors before analysis 
Item Details recorded Refinement Data Type 
Specialty  Hospital record abbreviation e.g. 
NEUS 
24 abbreviations combined to 8xxviii: 
1. ANAES 
2. BURN PLAS 
3. CAD CARD CSUR 
4. CRANIO NEUS OSUR 
5. ENT EYE 
6. HAEM HO ONC 
7. PAES NEO PAED GASTRO RENAL RESP  
    UROP NEPH 
8. ORTH SPIN 
Categorical 
                                                          
xxviii Key to specialty groups: 1. ANAES = anaesthetics, 2. BURN = burns PLAS =plastic surgery, 3. CAD, CARD = cardiology CSUR = cardiac surgery, 4. CRANIO = craniofacial surgery, NEUS = 
neurosurgery, OSUR = oral surgery, 5. ENT = ear, nose and throat, EYE = ophthalmology, 6. HAEM = haematology, HO = haematology/oncology, ONC = oncology, 7. PAES = paediatric surgery, 
NEO = neonatal, PAED = general paediatrics, GASTRO = gastroenterology, RENAL = nephrology, RESP = respiratory medicine, UROP = paediatric urology, NEPH = nephrology, 8. ORTH = 
orthopaedics, SPIN = spinal surgery. 
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Item Details recorded Refinement Data Type 
    
Age on admission  - Age in years Continuous 
    
Gender  - Male/Female Categorical 
    
Previous GA? Yes or No 
- 
Only record if previous GA (Yes/No) 
Categorical  
Categorical 
  
History of POV  Yes or No, year of previous GA (if 
any) 
    
Pre-operative state co-operative/upset/other Excluded due to inconsistent reporting - 
    
Procedure Name of procedure Excluded due to large number of different procedures recorded - 
    
Duration of anaesthesia  Minutes between anaesthesia 
started and into recovery 
Time in minutes Continuous 
    
Details of Premedication Name, dose Indicate whether exposed or not (Yes/No) 
Drugs in this category: Midazolam/Ketamine 
Categorical 
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Item Details recorded Refinement Data Type 
    
Induction anaesthesia  Name, dose if intravenous Indicate which agent type (inhaled/intravenous/both) 
Drugs in this category: Sevoflurane, desflurane, nitrous oxide, 
isoflurane, propofol, thiopental 
Categorical 
Maintenance anaesthesia  Name, dose if intravenous Indicate which agent type (inhaled/intravenous/both) 
Drugs in this category: Sevoflurane, desflurane, nitrous oxide, 
isoflurane, propofol, thiopental 
Categorical 
    
Intra-operative analgesia Name, dose Indicate whether exposed or not (Yes/No)  
Drugs in this category: Morphine, fentanyl, ketamine, remifentanil, 
clonidine 
Categorical 
    
Intra-operative fluids  Type, rate Indicate rate mL/kg/hr. Continuous 
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Item Details recorded Refinement Data Type 
Intra-operative anti-emetics Name, dose Indicate whether exposed or not (Yes/No) and to which drug(s), 
each drug becomes a separate predictor: 
Ondansetron (Yes/No) 
Dexamethasone (Yes/No) 
Droperidol (Yes/No) 
Cyclizine (Yes/No) 
Categorical 
    
Other intra-operative 
medicines 
Name, dose Indicate whether exposed or not (Yes/No) and to which drug(s), 
each drug becomes a separate predictor: 
Reversal (Yes/No) 
Tranexamic acid (Yes/No) 
Categorical 
    
Post-operative opioids  Name, dose, frequency, duration Indicate whether exposed or not (Yes/No) and to which drug(s), 
each drug becomes a separate predictor: 
Morphine infusion (Yes/No) 
Fentanyl infusion (Yes/No) 
Enteral opioids (Yes/No) 
Categorical 
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Item Details recorded Refinement Data Type 
Post-operative epidural  Name, dose, frequency, duration Indicate whether exposed or not (Yes/No) and to which drug(s), 
each drug becomes a separate predictor: 
Fentanyl + Levobupivicaine Epidural (Yes/No) 
Clonidine + Levobupivicaine Epidural (Yes/No) 
Levobupivicaine Epidural (Yes/No) 
Categorical 
    
Post-operative NSAIDs  Name, dose, frequency, duration Indicate whether exposed or not (Yes/No)  
Drugs in this category: diclofenac, ibuprofen 
Categorical 
    
Other post-operative 
medicines 
Name, dose, frequency, duration Indicate whether exposed or not (Yes/No) and to which drug(s), 
each drug becomes a separate predictor: 
Clonidine (Yes/No) 
Ketamine (Yes/No) 
Categorical 
    
Intra-operative 
hypotensionxxvi 
Yes or no, details if yes Yes/No Categorical 
    
Post-operative hypotension 
xxvii 
Yes or no, details if yes Yes/No Categorical 
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6.2.7 Data Analysis 
A univariate analysis was performed to compare differences in POV risk factors for cases 
and controls. Categorical outcomes were compared between groups using the chi-square 
statistic. For continuous variables, the median and interquartile ranges were reported for 
each group and, since the distribution was found to be non-parametric for all continuous 
variables, these were compared using the Mann-Whitney U test. Differences were 
considered significant at the 5% level (p < 0.05). Checks were made for correlations 
between the continuous outcome variables using the Spearman’s ρ test for non-parametric 
data. A correlation was considered significant at the 5% level (p < 0.05), with significant 
correlations of magnitude >0.8 being highlighted. 
A logistic regression model was used to assess the influence of independent variables (risk 
factors) on the likelihood of POV. Both forward and backward selection procedures were 
undertaken. The final models from each process were compared and selection of variables 
for inclusion in the final model was undertaken. Differences were considered significant at 
the 5% level (p < 0.05) and, where appropriate, all results were presented with 95% 
confidence intervals. To evaluate competing models, the Nagelkerke R Square statistic was 
used to assess the proportion of variation in the outcome variable explained by the model. 
The final model was assessed for goodness-of-fit using the Hosmer-Lemeshow statistic. In 
this case, a p-value of >0.1 suggests that the model is a good fit to the data. Outliers were 
identified by plotting the standardised and normalised residuals against patient ID. 
Influential observations were identified by plotting Cook’s distance, Leverage and Delta of 
Beta against patient ID. A classification table, a classification plot and receiver operating 
characteristic (ROC) curve were produced to evaluate how well the model discriminated 
between outcomes. The following rules for interpreting the area under the ROC curve 
(AUC) were applied (Hosmer and Lemeshow, 2000):  
 0.5    discrimination no better than chance  
 0.7 ≤ AUC < 0.8  acceptable discrimination 
 0.8 ≤ AUC < 0.9  excellent discrimination 
 AUC ≥ 0.9  outstanding discrimination 
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The aim was to include, in the final risk score, those variables with the greatest predictive 
value considered in the context of the practical clinical application of the tool. The final 
score was evaluated by assessing its distribution amongst patients who experienced POV 
against those who did not.  
A post-hoc analysis was undertaken as part of the evaluation of the risk score. The median 
score and inter-quartile range (IQR) was reported for each of each of four groups:  
1. Administered antiemetic and experienced POV (antiemetic + POV)  
2. Administered antiemetic and did not experience POV (antiemetic + no POV) 
3. Not administered antiemetic and experienced POV (no antiemetic + POV)  
4. Not administered antiemetic and did not experience POV (no antiemetic + no POV)  
 
The difference between the median scores was tested using a Kruskal-Wallis test and the 
difference between the median scores of pairs of these groups was tested using a Mann-
Whitney U test.  
A second post-hoc analysis was undertaken to explore intra-operative anti-emetic use in 
the study population. The median ondansetron and dexamethasone doses (and IQR) were 
reported for both of the groups:  
1. Administered antiemetic and experienced POV (antiemetic + POV)  
2. Administered antiemetic and did not experience POV (antiemetic + no POV) 
The difference between median doses was tested using a Mann-Whitney U test. 
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6.3 Results 
6.3.1 Patients included in the analysis 
During case note review of the 356 randomly selected controls, 29 were identified as 
suspected POV cases. Therefore these controls became cases and an additional 29 controls 
were randomly selected. 
The 29 additional cases had not been identified in the prospective cohort study for the 
following reasons:  
 overlooked (21 cases)  
 started in theatre (4 cases) 
 identified but case notes not available for full assessment of case during the study 
(3 cases)  
 recorded as ‘vomiting’ rather than procedural vomiting (1 case)  
Subsequently the causality of these cases was assessed independently by a research nurse, 
a research pharmacist and a paediatric anaesthetist using the LCAT (Gallagher et al., 2011). 
If there was disagreement about causality, the cases were referred to a pharmacologist 
whose assessment was taken as definitive. One case was classified as unlikely, 14 cases 
were classified as possible and 14 as probable. Therefore the final number of cases was 384 
and the final number of controls was 385. 
Data were retrieved for 374 of 384 cases (97.4%) and 349 of 385 controls (90.6%). The 
reasons for missing data were as follows:  
 case notes not found (6 cases, 26 controls)  
 anaesthetic chart not filed (4 cases, 7 controls)  
 notes scanned into electronic storage but anaesthetic charts missing (3 controls) 
All patients for whom data were retrieved were included in the analysis. 
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6.3.2 Univariate analysis 
The results of this analysis are summarised in Tables 6.4, 6.5 and 6.6. There were no 
significant correlations of magnitude >0.8 found between the continuous outcome 
variables age, duration of anaesthetic and rate of intra-operative fluids. 
Patient-related variables are summarised in Table 6.4. Gender did not predict POV risk, but 
increasing age and a positive history of POV did. The median age of patients who 
experienced POV was significantly greater than that of those who did not (p < 0.001). 
Patients with a positive history of POV were significantly more likely to experience POV 
than those without (p = 0.006). Intra-operative hypotension increased the likelihood of POV 
(p < 0.001). Post-operative hypotension did not significantly increase the likelihood of POV.  
However, it is important to note that a record of post-operative blood pressure 
measurements was found for less than half of the participants. 
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Table 6.4 Results of univariate analysis, patient-related variables 
      
Categorical Variable All No POV 
n (%) 
POV 
n (%) 
Difference 
(95%CI) 
p-
value
xxix 
      
Gender (n=723)  n=349 n=374   
Male 403 204 (58.5%) 199 (53.2%) -5.2% 
(-12.5%, 2.0%) 
0.156 
Female 320 145 (41.5%) 175 (46.8%) 
      
History of POV (n=278)  n=89 n=189   
Yes 77 15 (16.9%) 62 (32.8%) 16% 
(5.7%, 26.2%) 
0.006 
No 201 74 (83.1%) 127 (67.2%) 
      
Intra-operative hypotension 
(n=701) 
 n=328 n=373   
Yes 269 102 (31.1%) 167 (44.8%) 13.7% 
(6.6%, 20.8%) 
<0.001 
No 432 226 (68.9%) 206 (55.2%) 
      
Post-operative hypotension 
(n=324) 
 n=113 n=211   
Yes 32 9 (8.0%) 23 (10.9%) 2.9% 
(-3.6%, 9.5%) 
0.399 
No 292 104 (92.0%) 188 (89.1%) 
     
     
Continuous Variable n No POV 
(median, IQR) 
POV 
(median, IQR) 
p-valuexxx 
     
Age (years) 723 4.0 
(1.0 – 11.0) 
8.0 
(3.0 – 13.0) 
<0.001 
 
     
 
  
                                                          
xxix
 Chi-square statistic 
xxx
 Mann-Whitney U test 
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Table 6.5 shows that surgery-related variables and membership of some specialty groups 
had a significant impact on POV risk (p < 0.001). The greatest differences were seen in the 
craniofacial surgery category 4 (more patients experienced POV than did not) and the 
general surgery category 7 (fewer patients experienced POV than did not). Some of the 
specialty groups contained very few patients. Duration of anaesthetic was a significant 
predictor of POV risk, the median duration significantly longer in patients who experienced 
POV (p < 0.001). The rate of intraoperative fluid infusion did not have a significant impact 
on POV risk. 
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Table 6.5 Results of univariate analysis, surgery-related variables 
      
Categorical Variable All No POV n (%) POV n (%) Difference (95%CI) p-valuexxxi 
      
Specialty Group  
 (n = 723) 
 n=349 n=374  
<0.001 
Anaesthetics 4 4 (1.1%) 0 1.1% (0.0%, 2.3%) 
Burns, plastic surgery 48 26 (7.4%) 22 (5.9%) 1.6% (-2.1%, 5.2%) 
Cardiology, cardiac surgery 22 10 (2.9%) 12 (3.2%) -0.3% (-2.8%, 2.2%) 
Craniofacial, neuro- and oral surgery 159 50 (14.3%) 109 (29.1%) -14.8% (-20.7%, -8.9%) 
Ear, nose and throat, opthalmology 42 23 (6.6%) 19 (5.1%) 1.5% (-1.9%, 4.9%) 
Haematology/oncology 12 9 (2.6%) 3 (0.8%) 1.8% (-0.1%, 3.7%) 
Paediatric and neonatal surgery,  paediatrics, gastroenterology, 
nephrology, respiratory medicine, urology, nephrology, 
259 152 (43.6%) 107 (28.6%) 14.9% (8.0%, 21.9%) 
Orthopaedics and spinal surgery 177 75 (21.5%) 102 (27.3%) -5.8% (-12.0%, 0.5%) 
     
Continuous Variable n No POV (median, IQR) POV (median, IQR) p-valuexxxii 
     
Duration of anaesthesia (minutes) 723 95 (55.0 – 163.5) 140 (95.0 – 226.3) <0.001 
     
Intraoperative fluid rate (mL/kg/hour) 723 6.0 (0.0 – 10.0) 6.0 (2.0 – 9.0) 0.349 
 
                                                          
xxxi
 Chi-square statistic 
xxxii
 Mann-Whitney U test 
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Finally, drug related risk variables are summarised in Table 6.6. Use of the following drugs 
was associated with increased POV risk:  
1. Pre-operative drugs 
a. Pre-medication (midazolam or ketamine)  
2. Intra-operative drugs 
a. Combination of intravenous and inhaled agents for induction  
b. Analgesia  
c. Tranexamic acid  
d. Anti-emetic  
e. Ondansetron 
f. Dexamethasone 
3. Post-operative drugs 
a. Morphine infusion 
b. Fentanyl infusion  
c. Ketamine infusion  
d. Fentanyl + levobupivicaine epidural 
e. Levobupivicaine epidural  
f. Enteral opioid  
g. NSAID  
The drugs most strongly associated with POV risk (p < 0.001) were intra-operative anti-
emetics, intra-operative analgesia, post-operative morphine and fentanyl, oral opioids and 
NSAIDs. 
Intra-operative anti-emetics were analysed together in a single category and also separately 
as ondansetron, dexamethasone, cyclizine and droperidol. Some patients received more 
than one anti-emetic and in the majority of patients that was ondansetron and/or 
dexamethasone.  
Intra-operative analgesia was defined as one or more of: morphine, fentanyl, remifentanil, 
ketamine or clonidine. Table 6.7 provides additional detail about how frequently each of 
these analgesic agents was administered. The most frequently used intra-operative 
analgesics were opioids and 45.5% of cases and 30.1% of controls received two or more 
intra-operative analgesics. 
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Table 6.6 Results of univariate analysis, drug-related variables 
Categorical Variable All No POV n (%) POV n (%) Difference (95%CI) p-valuexxxiii 
Premedication (n=723)  n=349 n=374  
0.006 Yes 115 42 (12.0%) 73 (19.5%) 
7.5% (2.2%, 12.8%) 
No 608 307 (88.0%) 301 (80.5%)  
Induction agent (n=716)  n=342 n=374  
0.007 
Inhaled 290 148 (43.3%) 142 (38.0%) 5.3% (-1.9%, 12.5%) 
Intravenous 372 179 (52.3%) 193 (51.6%) 0.7% (-6.6%, 8.1%) 
Both 54 15 (4.4%) 39 (10.4%) -6.0% (-9.8%, -2.3%) 
Maintenance agent (n=703)  n=331 n=374  
0.264 
Inhaled 650 312 (94.3%) 338 (90.4%) 4.5% (0.6%, 8.3%) 
Intravenous 29 9 (2.7%) 20 (5.3%) -2.6% (-5.5%, 0.3%) 
Both 24 8 (2.4%) 16 (1.9%) -1.8% (-4.5%, 0.8%) 
Intra-op analgesia (n=723)  n=349  n=374  
<0.001 Yes 471 183 (52.3%) 288 (77.0%)  
24.6% (17.8%, 31.3%) 
No 252 166 (47.6%) 86 (23.0%)  
Intra-op tranexamic acid (n=723)  n=349 n=374  
0.003 Yes 26 5 (1.4%) 21 (5.6%) 
4.2% (1.5%, 6.8%) 
No 697 344 (94.4%) 353 (98.6%) 
Reversal (n=723)  n=349 n=374  
0.103 Yes 81 46 (13.2%) 35 (9.4%) 
-3.8% (-8.4%, 0.8%) 
No 642 303 (86.8%) 339 (90.6%)  
Intra-op anti-emetic (n=723)  n=349 n=374  
<0.001 Yes 401 155 (44.4%) 246 (65.8%) 
21.4% (14.3%, 28.5%) 
No 322 194 (55.6%) 128 (34.2%) 
Intra-op ondansetron (n=723)  n=349 n=374  
<0.001 Yes 303 110 (31.5%) 193 (51.6%) 
20.1% (13.1%, 27.1%) 
No 420 239 (68.5%) 181 (48.4%) 
Intra-op droperidol (n=723)  n=349 n=374  
0.071 Yes 7 1 (0.3%) 6 (1.6%) 
1.3% (-0.1%, 2.7%) 
No 716 348 (98.4%) 368 (99.7%) 
Intra-op dexamethasone (n=723)  n=349 n=374   
0.003 Yes 231 93 (26.6%) 138 (36.9%) 
10.3% (3.5%, 17.0%) 
No 492 256 (73.4%) 236 (63.1%) 
Intra-op cyclizine (n=723)  n=349 n=374  
0.523 Yes 3 2 (0.6%) 1 (0.3%) 
-0.3% (-1.3%, 0.6%) 
No 720 347 (99.4%) 373 (99.7%) 
Post-op morphine infusion (n=723)  n=349 n=374  
<0.001 Yes 187 64 (18.3%) 123 (32.9%)  
14.5% (8.3%, 20.8%) 
No 536 285 (81.7%)  251 (67.1%)  
Post-op fentanyl infusion (n=723)  n=349 n=374  
<0.001 Yes 79 17 (4.9%) 62 (16.6%) 
11.7% (7.3%, 16.1%) 
No 644 332 (95.1%) 312 (83.4%) 
Post-op clonidine infusion (n=723)  n=349 n=374  
0.300 Yes 1 1 (0.3%) 0  
-0.3% (-0.8%, 0.3%) 
No 722 348 (99.7%) 374 (100%) 
Post-op ketamine infusion (n=723)  n=349 n=374  
0.005 Yes 46 13 (3.7%) 33 (8.8%) 
5.1% (1.6%, 8.6%) 
No 677 336 (96.3%) 341 (91.2%) 
Post-op enteral opioids (n=723)  n=349 n=374  
<0.001 Yes 509 202 (57.9%) 307 (82.1%) 
24.2% (17.7%, 30.7%) 
No 214 147 (42.1%) 67 (17.9%) 
Post-op fentanyl + levobupivicaine 
epidural (n=723) 
 n=349 n=374  
0.014 
Yes 70 24 (6.9%) 46 (12.3%) 
5.4% (1.2%, 9.7%) 
No 653 325 (93.1%) 328 (87.7%) 
Post-op clonidine + levobupivicaine 
epidural (n=723) 
 n=349 n=374  
0.702 
Yes 21 11 (3.2%) 10 (2.7%) 
-0.5% (-2.9%, 2.0%) 
No 702 338 (96.8%) 364 (97.3%) 
Post-op levobupivicaine epidural (n=723)  n=349 n=374  
0.041 Yes 30 9 (2.6%) 21 (5.6%) 
3.0% (0.2%, 5.9%) 
No 693 340 (97.4%) 353 (94.4%) 
Post-op NSAID (n=723)  n=349 n=374  
<0.001 Yes 495 198 (56.7%) 297 (79.4%) 
22.7% (16.1%, 29.3%) 
No 228 151 (43.3%) 77 (20.6%) 
                                                          
xxxiii
 Chi-square statistic 
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Table 6.7 Frequency of use for individual intra-operative analgesics 
  
Drug 
Frequency 
Cases (% of total) Controls (% of total) Total (% of total) 
    
Morphine 189 (43.8%) 112 (46.1%) 301 (44.6%) 
Fentanyl 75 (17.4%) 49 (20.2%) 124 (18.4%) 
Ketamine 35 (8.1%) 29 (11.9%) 64 (9.5%) 
Remifentanil 132 (30.6%) 52 (21.4%) 184 (27.3%) 
Clonidine 1 (0.2%) 1(0.4%) 2 (0.3%) 
    
Total 432 243 675 
    
 
6.3.3 Selection of variables for multivariate analysis 
The results of the univariate analysis were reviewed in order to select variables for inclusion 
in the multivariate modelling. This was undertaken with expert clinical and statistical 
advice. In general, we aimed to include all significant predictors. The decision about each 
individual variable and a rationale are provided in Table 6.8. This process resulted in the 
inclusion of 11 predictors in the multivariate modelling process. 
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Table 6.8 Selection of variables for multivariate analysis 
Variable 
Significant impact 
demonstrated in 
univariate 
analysis? 
Decision about inclusion in 
multivariate analysis 
Rationale 
Specialty Group  Yes 
Include but combine some outcomes to 
reduce number from 8 to 6: 
1. OTHER (ANAES CAD  
    CARD CSUR HAEM    
    HO ONC) 
2. BURN PLAS 
3. CRANIO NEUS OSUR 
4. ENT EYE 
5. PAES NEO PAED  
    GASTRO RENAL RESP  
    UROP NEPH 
6. ORTH SPIN 
Very few patients in some 
categories 
Gender  No Include 
Would expect to see gender 
in a risk prediction model 
History of POV  Yes Exclude 
Not recorded for all patients, 
dependent on previous 
exposure to anaesthetic 
Premedication  Yes Include - 
Induction agent  Yes Exclude 
Use of a combination of 
inhaled and intravenous is 
the significant predictor but 
it was used in relatively few 
patients 
Maintenance agent  No Exclude - 
Intra-operative analgesia  Yes Include - 
Intra-operative tranexamic 
acid  
Yes Exclude 
Used in relatively few 
patients 
Reversal  No Exclude - 
Intra-operative anti-emetic  Yes Include - 
    
    
    
Intra-operative ondansetron  Yes 
Exclude -  use variable ‘intra-operative 
antiemetic’ only 
Droperidol and cyclizine 
used in very few patients, 
some patients received two 
or more anti-emetics 
Intra-operative droperidol  No 
Intra-operative 
dexamethasone  
Yes 
Intra-operative cyclizine  No 
Post-operative morphine 
infusion  
Yes 
Combine with post-operative enteral 
opioid -  name variable ‘post-operative 
opioid’ 
 
Reduce number of variables 
Post-operative fentanyl 
infusion) 
Yes 
Post-operative clonidine 
infusion  
No Exclude - 
Post-operative ketamine 
infusion  
No Exclude - 
Post-operative enteral 
opioids  
Yes 
Combine with post-operative morphine 
and fentanyl infusion -  name variable 
‘post-operative opioid’ 
 
Reduce number of variables 
Fentanyl + levobupivicaine 
epidural  
Yes 
Combine -  name variable ‘post-
operative epidural’ 
 
Reduce number of variables Clonidine + levobupivicaine 
epidural  
No 
Levobupivicaine epidural  Yes 
Post-operative NSAID  Yes Include - 
Intra-operative hypotension  Yes Include - 
Post-operative hypotension No Exclude - 
Age (years) Yes Include - 
Duration of anaesthesia 
(minutes) 
Yes Include - 
Intraoperative fluid rate 
(mL/kg/hour) 
No Exclude - 
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6.3.4 Multivariate analysis 
Forward and backward stepwise selection took six steps and the following six predictors 
appeared in the model at the final step: age, duration of anaesthetic, premedication, intra-
operative analgesia, post-operative NSAID and intra-operative hypotension (Table 6.9).  
Table 6.9 Results of forward and backward stepwise selection 
    
Variablexxxiv 
Estimated 
odds ratio 
95% CI p-value 
    
Age 
 
1.045 1.013, 1.079 0.006 
Duration of anaesthesia 
 
1.003 1.001, 1.005 <0.001 
Pre-medication(1) 
 
1.627 1.043, 2.538 0.032 
Intra-operative analgesia(1) 
 
2.006 1.413, 2.847 <0.001 
Post-operative NSAID(1) 
 
1.930 1.342, 2.776 <0.001 
Intra-operative hypotension(0,1) 9.454 1.192, 74.993 0.034 
 
                                                          
xxxiv Coding for categorical variables:  
Variable Outcomes 
Parameter 
coding 1 
Parameter 
coding 2 
    
Pre-medication 
Yes 
No 
1 
0 
- 
    
Intra-operative analgesia 
Yes 
No 
1 
0 
- 
    
Post-operative opioid 
Yes 
No 
1 
0 
- 
    
Post-operative NSAID 
Yes 
No 
1 
0 
- 
    
Intra-operative 
hypotension 
Yes 
No 
Unrecorded 
0 
1 
0 
1 
0 
0 
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The variables selected for the model were those which were selected by both stepwise 
methods: age, duration of anaesthesia, pre-medication, intra-operative analgesia and post-
operative NSAID. The duration of anaesthesia was a significant predictor of POV risk, 
however the magnitude of the estimated odds ratio for this variable was small. The 
interpretation of the odds ratio is that for every additional minute of anaesthesia, the risk 
of POV increases by 0.3%. Intra-operative hypotension was excluded because of the 
imprecision in the estimate. 
The Nagelkerke R Square value for the model was 0.196. The p-value for the Hosmer-
Lemeshow statistic was 0.040. Therefore the model was not a good fit to the data.  In order 
to achieve a better fit, ‘premedication’ was removed because it was the least significant 
predictor in the model (p=0.030) and was only administered to 115/723 (15.9%) of 
participants (Table 6.6). For the revised model, the Nagelkerke R Square value was 0.188 
and the goodness-of-fit of the model improved (p=0.523).  
Finally, the variable post-operative NSAID was removed from the model. We assume that 
POV risk would be assessed pre-operatively or in the immediate post-operative period, and 
thus the administration of NSAIDs may not be predictable at this time. A NSAID may be 
prescribed by the anaesthetist but never administered or, it may be written up in the days 
that follow the operation.  
The variables entered into the final model (Table 6.10) were:  
1. age  
2. duration of anaesthesia 
3. intra-operative analgesia 
The Nagelkerke R Square value for the final model was 0.164 and the model was a good fit 
to the data (p = 0.489). No outliers were identified. Four influential observations were 
identified and the participants were removed temporarily from the dataset. The remaining 
data (719 participants) were used to produce a new model but this had little impact on the 
parameter estimates, and therefore these four participants were returned to the dataset.  
The risk score is the equation of the final model: 
Score = 0.061 (age in years) + 0.004 (duration of anaesthetic) + 0.798 (intraoperative analgesia) 
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Table 6.10 Final model – predictors of post-operative vomiting in children 
Variable Estimated odds 
ratio exp(B) 
Standard error p-value 95% CI for 
estimated odds 
ratio 
     
Age 1.063 0.015 <0.001 1.032, 1.095 
     
Duration of 
anaesthesia 
1.004 0.001 <0.001 1.002, 1.006 
     
Intraoperative 
analgesia (1)xxxv  
2.222 0.173 <0.001 1.584, 3.117 
     
Constant 0.227 0.192 <0.001 - 
 
                                                          
xxxv Coding for categorical variable:  
Variable Outcomes 
Parameter 
coding 1 
Parameter 
coding 2 
Intra-operative analgesia 
Yes 
No 
1 
0 
- 
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6.3.5 Evaluation of risk score 
The risk score was evaluated by determining how well it predicted a) the occurrence of POV 
(sensitivity) and b) the non-occurrence of POV (specificity). With a cut value of 0.5, 
sensitivity was 67.4% and specificity was 60.2%. The area under the ROC curve for the score 
was 0.706 which demonstrated acceptable discrimination between outcomes (Figure 6.2).  
Figure 6.2 ROC Curve for the risk score 
 
Area under the 
curve 
Standard 
error 
Asymptotic significancexxxvi Asymptotic 95% CI 
0.706 0.019 <0.001 0.668, 0.743 
 
 
                                                          
xxxvi
 null hypothesis = area is 0.5 
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The frequency of each score was plotted as two histograms, one for cases and one for 
controls (Figure 6.3). It was difficult to identify a score above which patients were at ‘high 
risk’.  
Figure 6.3 Comparison of risk score frequency for cases and controls 
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6.3.6 Comparison of risk scores in participants who received anti-emetic and  those who 
did not 
Evaluation of the model was complicated by the fact that anti-emetic was administered to 
some of the participants, in accordance with local and/or national guidelines and the 
clinical judgement of the anaesthetist. Therefore those who received intra-operative anti-
emetic were already predicted to be at high risk of POV. In order to explore this in more 
detail, we compared the median risk score for patients in each of four groups:  
1. Administered antiemetic and experienced POV (antiemetic + POV)  
2. Administered antiemetic and did not experience POV (antiemetic + no POV) 
3. Not administered antiemetic and experienced POV (no antiemetic + POV)  
4. Not administered antiemetic and did not experience POV (no antiemetic + no POV)  
A Kruskal-Wallis test demonstrated a significant difference between the median scores for 
the four groups (p<0.001), (Table 6.11). A pair-wise comparison of the groups (Mann-
Whitney U test) demonstrated that the difference in score was significant for all pairs 
(Table 6.12). Patients who received antiemetic and experienced POV had the highest 
median score.  
Table 6.11 Comparison of median scoresxxxvii  
     
 POV Median score 
(IQR) 
No POV Median score 
(IQR) 
     
Anti-emetic 246 2.01 
(1.69, 2.44) 
155 1.65 
(1.29, 2.01) 
     
No anti-emetic 128 1.38 
(1.00, 1.79) 
194 0.94 
(0.36, 1.39) 
     
 
 
                                                          
xxxvii
 Score =  0.061 (age in years) + 0.004 (duration of anaesthetic) + 0.798 (intraoperative analgesia) 
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Table 6.12 Pairwise comparison of median scoresxxxviii 
 
Antiemetic + 
POV 
Antiemetic +   
no POV 
No antiemetic + 
POV 
No antiemetic + 
no POV 
     
Antiemetic + 
POV     
 
    
Antiemetic + no 
POV 
<0.001xxxix    
 
    
No antiemetic + 
POV 
<0.001xxxix 0.002xxxix   
 
    
No antiemetic + 
no POV 
<0.001xxxix <0.001xxxix <0.001xxxix  
     
 
                                                          
xxxviii Score =  0.061 (age in years) + 0.004 (duration of anaesthetic) + 0.798 (intraoperative analgesia) 
xxxix
 Mann-Whitney U test 
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6.3.7 Comparison of anti-emetic dose between cases and controls 
Since prophylactic anti-emetic use was effective in 155 participants (antiemetic + no POV) 
but ineffective in 246 patients (antiemetic + POV), we compared the doses of ondansetron 
and dexamethasone used in these two groups. The aim was to identify whether differences 
in dosing could account for differences in efficacy. Droperidol was administered to 6 cases 
and 1 control and cyclizine was administered to 1 case and 2 controls, these participants 
were not included in this analysis. There was no significant difference in the median 
ondansetron and dexamethasone doses between the case and control groups (Table 6.13). 
The exception was the dose of dexamethasone when used in combination with 
ondansetron (p = 0.028) where the median dose received by cases was greater than that 
received by controls.  
Table 6.13 Comparison of anti-emetic doses between cases (n=239) and controls (n=152) 
Antiemetic(s) 
POV or 
no POV 
Number 
of 
patients 
Number of 
patients with 
dose 
recorded 
Median dose (IQR) mg/kg 
     
Ondansetron 
alone 
POV 106 101 0.94 (0.08  - 0.11) 
0.96 (0.08 – 0.10) 
p-valuexl 0.824 
No POV 59 58 
   
      
Ondansetron 
with 
dexamethasone 
   Ondansetron Dexamethasone 
POV 83 83 
0.10 
(0.09 – 0.13) 
0.13 
(0.10 – 0.18) 
No POV 50 48 
0.1021 
(0.09 – 0.12) 
0.1021 
(0.87 – 0.14) 
   p-valuexl0.990 p-valuexl0.028 
     
Dexamethasone 
alone 
POV 50 50 0.12 (0.10 – 0.18) 
0.13 (0.10 – 0.17) 
p-valuexl 0.844 
No POV 43 43 
   
                                                          
xl
 Mann-Whitney U test 
 207 
 
6.4 Discussion 
A risk score for POV in children was developed using a dataset derived from a large 
observational cohort study of paediatric admissions (Thiesen et al., 2013). During the 
development of the risk score, 21 additional cases of POV (5.5% of all cases) were 
identified, these had been overlooked in the cohort study. This highlights that ADRs were 
overlooked in the studies described in Chapters 2 and 3, however checks were undertaken 
to minimise this. For example, in the admissions study, three senior investigators 
independently assessed 4.8% reports of admissions deemed not to have had an ADR, they 
concluded that none had been wrongly classified (Gallagher R.M. et al., 2012). 
The following variables were included in our risk score:  
1. age  
2. duration of anaesthesia  
3. administration of an intra-operative analgesia  
The use of intra-operative anti-emetics was a positive predictor of POV risk (albeit non-
significant). Patients were administered anti-emetics at the discretion of the anaesthetist 
and therefore we would expect patients at high risk to have received an anti-emetic. 
However, this observation indicates that anti-emetics were not always effective (see 6.4.3). 
The ability of the model to discriminate between outcomes was acceptable but it was not 
possible to say at which point on the scoring scale patients became ‘high risk’. This is 
unsurprising in a population which was heterogeneous in terms of both the characteristics 
of individuals and in terms of how they were surgically and medically managed. 
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6.4.1 Comparison with previous studies 
Any comparison of this work with previous studies must take into account differences in 
the patients included, the setting and the variables selected for evaluation. Here the results 
of one previous paediatric risk score development study are compared to the present 
study. 
The design of the study by Eberhart et al. (2004) differed from this study in several ways. 
Notably, in Eberhart’s study, children who receive intra-operative anti-emetic were 
excluded from the analysis. Furthermore, the cardiac, craniofacial, neuro- and oral surgery 
patients included in this study were absent from Eberhart’s study, whereas the large 
proportion of ENT and ophthalmology patients in their study was not observed here. The 
differences between the two studies are summarised in Table 6.14.  
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Table 6.14 Comparison of the designs of the present study and the study by Eberhart et 
al. (2004) 
Item Present study Eberhart et al. (2004) 
   
Data collection Prospective + retrospective Prospective 
   
Duration 12 months 22 months 
   
Number of sites 1 4 
   
Age of participants 0-16 years 0-14 years 
   
Number of 
participants 
769 1401 
   
Number of 
participants 
included in 
analysis 
723 1257 
   
Reasons for 
exclusion from 
analysis 
Retrospective data could not be retrieved Lost to follow up 
Incomplete dataset 
Received intra-operative anti-
emetic 
   
Surgery types Specialty Group 
xxviii
(n = 723) 
Anaesthetics (0.6%) 
Burns, plastic surgery  (6.6%) 
Cardiology, cardiac surgery  (3.0%) 
Craniofacial, neuro- and oral surgery 22.0%) 
Ear, nose and throat, opthalmology (5.8%) 
Haematology/oncology (1.7%) 
Paediatric and neonatal surgery,  paediatrics, 
gastroenterology, nephrology, respiratory 
medicine, urology, nephrology (35.8%) 
Orthopaedics and spinal surgery (24.5%) 
Surgery type (n = 1375) 
ENT (33.6%) 
Ophthalmological (12.9%) 
Urological (21.5%) 
Abdominal (11.6%) 
Orthopaedic (4.9%) 
Dental (5.2%) 
Diagnostic (3.1%) 
Plastic (4.8%) 
Miscellaneous (2.4%) 
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In the development of the POVOC score, Eberhart et al. (2004) selected variables for their 
exploratory analysis and subsequent logistic regression modelling which differed from this 
study. The additional variables included in their score development were: height, history of 
POV in the child, history of PONV in the father, mother or siblings, duration of surgery and 
type of airway device. Rather than grouping children into categories by specialty, they 
grouped them by type of surgery.  
Eberhart et al. (2004) used stepwise forward and backward logistic regression analysis for 
variable selection in accordance with the approach in this study. They also calculated 
Nagelkerke’s R Square value for their model. This value demonstrated that their model 
explained 27.1% of the variation in the outcome variable compared to 19.6% in this study. 
The R Square value is most useful for the assessment of linear regression models therefore 
a high R Square value would not be expected for a logistic regression model. The R Square 
value is not a measure of goodness-of-fit for the model although this is implied by Eberhart 
et al. (2004). A more useful measure of goodness-of-fit is the Hosmer-Lemeshow statistic 
which was calculated for the present model and demonstrated that it was a good fit to the 
data. The area under the ROC curve for Eberhart’s model was 0.72 (95% CI 0.68, 0.77) 
which demonstrated only similar discrimination between outcomes to the model 
developed here (AUC 0.71, 95% CI 0.67, 0.74). 
Variables excluded by Eberhart et al. (2004) following an explorative backward logistic 
regression analysis were:  
 Administration of local or regional anaesthesia 
 Intra-operative opioid administration 
 Post-operative opioid administration 
 Female gender 
 Surface surgery 
Not all of these variables were analysed in our study but intraoperative analgesia (mainly 
opioids), post-operative opioid and gender were included. Our analysis resulted in the 
exclusion of the variables post-operative opioid administration and gender but the inclusion 
of intra-operative analgesia. 
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In concordance with the present score, the final POVOC score included age as a predictor of 
POV, using a categorical variable (age ≥3 years). It also included duration of surgery as a 
categorical variable (duration >30 minutes) which is analogous to duration of anaesthesia. 
In contrast with the present score, Eberhart did not include administration of intra-
operative analgesia but did include the following additional predictors:  
 strabismus surgery  
 a history of POV in the child or PONV in the father, mother or siblings  
Strabismus surgery was not identified as a predictor in this study because a) specialty group 
was included rather than procedure type, and b) there were only three patients who 
underwent ophthalmological surgery in this study. A history of POV was not included as a 
predictor because it could only be ascertained for 38.5% of participants. A history of PONV 
in family members was not included because it is not routinely recorded at this centre. 
The POVOC score has been externally validated by its developers in a study of 524 patients 
(Kranke et al., 2007). The risk factor strabismus surgery was not included because it is not 
relevant to all paediatric surgery settings. The area under the curve for the ROC curve in the 
validation study was 0.72 (95% CI 0.68, 0.77), sensitivity was 76% and specificity was 60%. 
6.4.2 Study limitations 
A limitation of this study was its retrospective design, the selection of variables was 
dictated by the routine availability of outcome data in the patient records and the 
collection of data relied on the accuracy and completeness of those records. For example, 
the use of reversal was recorded in relatively few patients (n=81) but this apparent low 
frequency of use is thought to be due to the absence of a written record. 
In terms of risk score development, this work has limitations common to all risk score 
development studies. There is no definitive approach to score development but some 
general principles should be adhered to: these include the use of high quality data and an 
adequate sample size (Royston et al., 2009). The limitations on data quality have been 
described above. The sample size was adequate for logistic regression analysis, and the 
number of controls was less than ten times the number of variables entered into the model 
(Peduzzi et al., 1996). The selection of predictors is of utmost importance and must be 
guided by both statistical and clinical considerations. In this study, this process was 
conducted with attention to these details but inevitably opinions will differ about the 
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clinical relevance of individual predictors and the appropriateness of combining variables. 
There are limitations of the Hosmer-Lemeshow test for goodness-of-fit and of the 
Nagelkerke R Square value to explain the variability of the data. However, both are 
reported here for comparison with previous studies and because these are both widely 
used measures in risk score evaluation.  
A further limitation was that the same dataset was used to both develop and test the 
predictive validity of the score. A better test of the predictive validity of the score, and thus 
its clinical value, would be to conduct external validation on a different dataset. External 
validation may highlight deficiencies in the risk score which may have arisen as a result of 
the modelling methods used or the population chosen for score development. The original 
development may have omitted an important predictor or the population chosen for 
validation may have different characteristics than that used for development (Altman et al., 
2009). Resources were not available to carry out an external validation of the risk score 
developed here.  
The generalizability of the score may be limited by the study design. Only patients who 
stayed for longer than 48 hours were included and certain surgery types (e.g. day cases, 
ENT procedures) were almost entirely excluded. Cases of POV in patients who went to PICU 
in the immediate post-operative period were not detected. Complex cardiac surgery 
patients who routinely go to PICU in the immediate post-operative period were thus 
indirectly excluded from the study. The score was developed with the inclusion of patients 
who had received intra- and/or post-operative anti-emetics which complicated the 
interpretation of the findings. 
6.4.3 Post-operative vomiting in patients who received anti-emetic 
Since local and national guidelines recommend the use of anti-emetics in particular 
patients, it was inevitable that the dataset would contain patients who had received them. 
Ideally, the variable ‘intra-operative anti-emetic’ would have been included in the risk 
score. This would have allowed the prediction of the reduction in POV risk achieved by 
adding an anti-emetic for individual patients.  
The administration of intra-operative anti-emetic to prevent POV was not effective in 61.3% 
of patients. Amongst patients who received anti-emetic, the median risk score for those 
who experienced POV was higher than that for those who did not; this suggests that 
baseline risk impacts the efficacy of the anti-emetic. 
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The doses of the most frequently used intra-operative anti-emetics were compared 
between the case and control groups. Patients receiving ondansetron alone and in 
combination with dexamethasone were evaluated.  There was no difference in the median 
ondansetron dose between the case and control groups and the dose reflected local 
guideline recommendations – 0.1mg/kg ondansetron. Although the local guideline 
recommends the addition of 0.1-0.15mg/kg dexamethasone in children undergoing 
adenotonsillectomy or strabismus surgery, the use of this combination was common 
despite that fact that this study included only 17 (adeno) tonsillectomy patients and no 
strabismus surgery patients. The median dose of dexamethasone administered to cases, 
when used in combination with ondansetron, was greater than that received by controls. 
This counter-intuitive finding may reflect the administration of higher doses of 
dexamethasone to patients undergoing neurosurgery. 
Interestingly, in the UK national guideline, ondansetron at a dose of 0.15mg/kg is 
recommended for children at an increased risk of POV which is different from that 
recommended in the local guideline (The Association of Paediatric Anaesthetists of Great 
Britain & Ireland, 2009). Dexamethasone 0.15mg/kg is also recommended in combination 
with ondansetron 0.05mg/kg for adenotonsillectomy and strabismus surgery. By contrast, 
the US guideline recommends ondansetron 0.05-0.1mg/kg (Gan et al., 2007).  
In this study, a significant proportion of patients who received an anti-emetic in theatre 
subsequently experienced POV. It is clear from the variation seen in the three guidelines for 
that the optimum regime for the prevention of POV in children, including the doses to be 
used, has not been agreed. A consistent approach to deciding which patients are at high 
risk may reduce the incidence of POV but only if effective anti-emetic regimes at 
appropriate doses can be administered to those at high risk. The development of a generic 
tool is difficult because the heterogeneity in the surgical and medical management of 
patients results in a large number of variables, some of which become redundant for some 
patients. However, differences will be less within specialties and the possibility of specialty-
specific tools could be explored.  
One of the study limitations was the administration of post-operative anti-emetics. Neither 
local, UK nor US guidelines are prescriptive about when post-operative anti-emetics should 
be administered. Anti-emetics may be administered when a child complains of being 
nauseated or experiences retching or not until they vomit.  A consistent approach to the 
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prevention of POV after the patient has returned to the ward may have the potential to 
reduce the number of children experiencing POV.  
6.5 Conclusion 
It was not possible to develop a robust risk score for POV in children using data derived 
from a large prospective cohort study, supplemented by retrospective chart review. One 
approach to developing a robust risk score may be to focus on individual specialties. There 
is evidence that the risk of POV is greater with some surgery types (Kovac, 2007) but 
whether this is attributable to the surgery itself or independent risk factors associated with 
that surgery is unknown. Evidence exists to support both hypotheses (Gan et al., 2007). A 
specialty-specific score may discriminate better between cases and controls, as less clinical 
heterogeneity within the population would be expected to result in fewer predictor 
variables.  
The optimum prophylactic anti-emetic regime for children undergoing surgery has not been 
determined and this is reflected by discrepancies between the recommendations of various 
guidelines. The NNT for both ondansetron and dexamethasone indicate that none of 
recommended regimes will be effective for every child (Steward, Grisel and Meinzen-Derr, 
2011, Tramer et al., 1997, Bolton et al., 2006). It is also important to highlight that even 
where efficacy has been well studied, adequate safety data may be lacking (see Chapter 5 
of this thesis). A robust tool for the prediction of POV has limited value if safe and effective 
measures for its prevention are not available. Further clinical studies of established and 
novel anti-emetics are warranted. 
Since not all children will benefit from prophylactic anti-emetics, it is important to consider 
how we can optimise the management of POV when it occurs. This may be in recovery, on a 
hospital ward or in the child’s home. The evidence to support recommendations for the 
management of established POV is less than that for prevention. There is some evidence 
that the administration of anti-emetics in practice is inconsistent (Jolley, 2000) and nursing 
staff do not always feel confident about which anti-emetic to administer or when (Sussanne 
et al., 2010). It may be possible to reduce the incidence of POV by developing a tool for 
clinicians, patients and parents which informs their decision about whether or not to 
administer anti-emetic treatment. Such a tool could incorporate an assessment of the 
likelihood of vomiting in an individual patient based on risk factors and reported symptoms. 
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A guideline for the selection of a safe and effective treatment would need to be 
incorporated. 
In summary, the findings of this study do not provide any additional information to assist 
the clinician to identify patients who are high risk of developing POV. Furthermore, even if 
one is able to identify patients who are at high risk, there are limits to how far anaesthetic 
practice can be modified whilst still retaining the benefits of treatment. Nevertheless, 
additional evidence to inform the optimum approach to the prediction, prevention and 
management of POV is required.  
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7 Discussion 
7.1 Summary of findings 
This thesis focuses on adverse drug reactions occurring in children either as a result of 
prescribing in the community or hospital.  A major aspect covered, because of the concerns 
expressed over the years by paediatricians, is the role of unlicensed and off-label 
medicines.  In the largest studies undertaken so far, the contribution of off-label and 
unlicensed medicines to ADR risk in children has been assessed, in both children admitted 
to hospital and inpatients. In both studies, off-label and unlicensed medicines were more 
likely to be implicated in an ADR. Medicines licensed in children but given to a child below 
the minimum age or weight were over three times more likely to be implicated in an ADR 
than authorised medicines. A significant number of ADRs could be attributed to more than 
one medicine and in many cases a combination of two or more authorised, off-label or 
unlicensed medicines was the cause of the ADR. The number of off-label or unlicensed 
medicines administered to an individual was a positive predictor of ADR risk in both studies. 
However, the number of authorised medicines also predicted the likelihood of an ADR 
occurring. 
The thesis also looked at three other aspects relating to the occurrence and detection of 
ADRs in children. First, the validity of clinical codes as a tool for pharmacovigilance in 
paediatric admissions was evaluated. The data show that the usefulness of clinical coding is 
limited and sole reliance on this to detect ADRs would lead to a gross under-estimate.  
Secondly, post-tonsillectomy haemorrhage was detected in the admissions study described 
in Chapter 2 of this thesis. We contend that although many factors contribute to the 
likelihood of haemorrhage, the combination of dexamethasone (off-label) and NSAID may 
increase the likelihood. A systematic review was undertaken to test this hypothesis. The 
results demonstrate that, although a considerable number of studies of dexamethasone 
with or without NSAID in tonsillectomy have been conducted, methodologies for the 
detection and recording of haemorrhage rates could not be considered reliable enough to 
test the hypothesis. Finally, post-operative vomiting (POV) was evaluated in further detail 
as it was the most common ADR in the inpatient study described in Chapter 3 of this thesis. 
Many factors contribute to the likelihood of POV, including the use of anaesthetic agents 
and post-operative analgesics. The study aimed to develop a prognostic score to predict the 
likelihood of POV in children. However, due to the observational design of the study, the 
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analysis was confounded by the administration of intra- and post-operative anti-emetics to 
our participants. The analysis also showed that intra-operative anti-emetics have limited 
efficacy, and when POV does occur, the use of post-operative interventions needs to be 
improved. 
7.2 Interpretation of Findings & Limitations 
7.2.1 Off-label and unlicensed prescribing and ADR risk 
The study findings about the positive association between off-label and unlicensed 
medicine use and ADR risk concur with those of previous studies (Neubert et al., 2004, 
Santos et al., 2008). A positive association between ADR risk and an increase in the number 
of medicines, regardless of category, was also identified. In terms of study design, an 
observational approach to both ADR identification and prescription data collection has 
limitations. ADR identification relied on the recording of signs and symptoms by the clinical 
team and the identification of the causal link by the research team. Prescription data 
collection relied on accurate prescription records being available. Furthermore, these did 
not always contain the information required to assign off-label or unlicensed status to a 
medicine course, such that 6.8% of medicine courses in the admissions study and 5.2% of 
medicine courses in the inpatient study could not be classified. There were also areas of 
paediatric care not included in this study in which off-label and unlicensed medicine use is 
common, including paediatric- and neonatal intensive care and paediatric psychiatry. 
Finally, the definitions used for the classification of off-label and unlicensed medicines were 
selected because they had been used in the majority of previous studies but their 
application may still be open to interpretation. For example, at the time of the study 
described in Chapter 3, only one parenteral morphine product was licensed for use in 
children. The product in use at our centre was only licensed in children 12 years or older 
and, because the study methodology considered the brand in use rather than the active 
pharmaceutical ingredient, this impacted on the number of off-label morphine courses.  
A simplistic interpretation of why off-label and unlicensed medicines increase ADR risk is 
because there is a lack of evidence for their use and this poses a risk. Indeed, this is 
supported by our finding that medicines given to children below the minimum age or 
weight specified in the drug literature were the category most likely to be implicated in an 
ADR. Systemic exposure to these medicines may have been greater than required for 
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therapeutic effect because of a lack of pharmacokinetic data in children. Studies which 
address this knowledge deficit will inform a more tailor-made approach to dosing in 
children than historical approaches such as scaling down adult doses and with this will 
come improved safety and efficacy (Hawcutt and Smyth, 2008). Such studies now form part 
of the paediatric investigation plan (PIP) required for all new medicines under development 
in Europe (The European Parliament and the Council of the European Union, 2006). 
However, the data in the thesis show that off-label and unlicensed medicines were diverse 
in terms of the quality of evidence to support their use and the frequency with which they 
caused ADRs. This prompts the question ‘would this off-label or unlicensed medicine have 
caused the ADR if it was authorised?’. If there is sparse evidence to support the use of an 
off-label or unlicensed medicine, the answer is ‘possibly’. The authorisation process 
demands a minimum amount of data to be generated and these will guide the safe and 
appropriate use of the medicine but, the ADR may still occur. However, if there is already 
evidence to support the safe and appropriate prescribing of an off-label or unlicensed 
medicine, it is difficult to see how the authorisation of that use would make a difference to 
ADR risk. This is evidenced by the finding that the number of medicines prescribed per se 
was an important predictor of risk, irrespective of whether they were off-label or not. This 
finding also points towards another predictor of ADR risk which was not explored in this 
thesis: disease state. Since the children included in the two cohort studies were admitted to 
hospital or had been in hospital for longer than 48 hours, we can assume that they were 
acutely unwell and/or had recently undergone significant surgery. In these complex cases 
there was potential for the development of ADRs in children who were already 
physiologically compromised with the additional risk of drug-drug interactions when 
multiple medicines were being administered. 
 In this thesis, the evidence base for an example of off-label medicine use in children was 
examined: intraoperative dexamethasone as an anti-emetic in tonsillectomy. There is good 
evidence for the efficacy of dexamethasone in this setting, but the systematic review 
determined that the evidence base for safety was more difficult to demonstrate. The 
systematic collection, recording and reporting of adverse outcomes is a vital component in 
the development of a robust evidence base so that advice on the use of medicines can 
facilitate benefit-risk assessments. In conclusion, although off-label and unlicensed 
medicine use does not, by definition, fall within the terms of a marketing authorisation, this 
does not always equate to a lack of evidence.  
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Although for some medicines the existence of a marketing authorisation may not have a 
direct impact on whether the prescriber has evidence to support their decision, it has other 
important benefits. Evidence-based off-label medicine prescribing often necessitates the 
use of formulations which are not age-appropriate, and thus risk is introduced at the point 
of administration. There is some evidence that off-label and unlicensed medicines are more 
likely to be implicated in medication errors (Conroy, 2011) and that the use of non-age 
appropriate formulations leads to dose inaccuracy (Aguado-Lorenzo et al., 2013).  There 
may be an evidence-base for the use of the active pharmaceutical ingredient (API) in an 
unlicensed special, but data on bioavailability and stability of the product itself may be 
sparse or vary depending on the manufacturer (Mulla et al., 2011). Several regulatory 
measures in Europe have been implemented with the intention of increasing the availability 
of evidence based, age-appropriate medicines on which robust formulation studies have 
been performed. New medicines in development must have a paediatric investigation plan 
(PIP), older medicines still under patent protection can be granted a ‘paediatric extension’ 
for the completion of studies in children and for off-patent products,  and a paediatric use 
marketing authorisation (PUMA) can be granted which is associated with a ten-year period 
of data and market protection.  In the UK, since the introduction of the regulation, 74% of 
PIP submissions have been for new medicinal products and 24% have been for existing 
products, whereas only 2% of submissions have been for PUMAs. Six new paediatric 
formulations have been authorised and 13 paediatric extensions have been granted (data 
correct as of May 2012) (Branch, 2012). Finally, the new pharmacovigilance regulation 
introduced in Europe in 2012 is intended to enhance the timely identification of safety 
issues for authorised medicines, another advantage of the authorisation process for 
medicines (The European Parliament and the Council of the European Union, 2010).  
7.2.2 ICD-10 coding of ADRs 
ADRs detected in the admissions study (Chapter 2) were not reliably recorded in the clinical 
coding process. Therefore it is concluded that the screening of ICD-10 codes is not a reliable 
method for detecting ADRs. Compared to all other ADR types, a significantly greater 
number of neutropenia cases were assigned an ICD-10 code. This was a result of the use of 
a structured admission proforma to document neutropenia on the oncology unit and the 
assignment of specifically trained coding staff to that unit. The adoption of this approach in 
other clinical specialties may increase the rate of ADRs being coded, and improve our ability 
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to determine the burden of ADRs in the whole NHS used hospital episode statistics, but this 
will of course still also rely on the accurate identification of ADRs by healthcare staff in their 
assessment of patients. 
7.2.3 Dexamethasone and post-tonsillectomy haemorrhage risk in children  
The systematic review demonstrated that an increased risk of post-tonsillectomy 
haemorrhage with dexamethasone use cannot be ruled out and that there are currently 
inadequate data available to assess the risk associated with use of dexamethasone in 
combination with NSAIDs. In terms of study selection for our systematic review, the 
systematic search strategy applied, the range of primary and secondary sources searched 
and the rigorous screening process have been described. Limitations arose from the 
exclusion of non-English language publications and the potential for errors in the study 
selection methodology. However the latter of course applies to any systematic review. The 
major limitation of the systematic review arises from the characteristics of the included 
studies. There was significant clinical heterogeneity between studies and differences 
between the quality of haemorrhage rate data collection and reporting. Despite these 
limitations, the meta-analysis findings are supported by those of other similar reviews. The 
finding emphasised here is that the data available are inadequate and further well designed 
studies are needed.  
7.2.4 Development of a risk score for post-operative vomiting 
A robust risk score for POV in children was not developed. The use of data from a 
prospective cohort in which participants were evaluated for POV risk and managed 
accordingly as part of routine clinical practice meant that the interpretation of the findings 
was complex. However, the risk factors for POV were investigated via a univariate analysis 
and an exploration of the evidence and guidelines was undertaken. The interpretation of 
the findings must be in the context of the limitations of the study design; it was a 
retrospective analysis which included patients who stayed for longer than 48 hours but not 
those who were in intensive care. The risk factors identified by the authors of a previous 
risk score development study were similar to those identified here and the predictive 
properties of their model were no better (Eberhart et al., 2004). In concordance with the 
study described here, they identified that clinical heterogeneity in terms of both 
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anaesthetic and surgical techniques even for the same procedure will limit the predictive 
ability of any tool. Even when POV can be predicted, the available preventative measures 
may not always be effective. Therefore some attention should be given to establishing 
evidence-based guideline for the effective management of established POV.  
7.3 Implications for Research 
Despite the implementation of the Paediatric Regulation in Europe, the use of off-label and 
unlicensed medicines in paediatric practice will continue to be necessary. Irrespective of 
this, ADRs remain a function of the number of medicines prescribed, and research should 
focus on optimising the use of all medicines in children.  Identifying the right dose is a good 
starting point. 
The existing evidence for the use of individual authorised, off-label and unlicensed 
medicines should be properly evaluated and consolidated. Gaps in the evidence can thus be 
identified. For some medicines a synthesis of existing data will provide adequate evidence 
to support the assessment of benefit-risk. For others more clinical studies will be required 
and key to these will be an emphasis on the collection of safety as well as efficacy data. 
Since many off-label and unlicensed medicines require manipulation before they can be 
administered, studies which generate evidence for safe practice are needed. A prospective 
study of off-label and unlicensed medicine use and medication error risk, inclusive of a root 
cause analysis of each error, would inform the development of interventions to reduce the 
risk of errors.  Data from the studies described in this thesis can inform priorities for clinical 
research. Additional studies in areas not covered, for example in paediatric and neonatal 
intensive care and paediatric psychiatry should be conducted to provide data pertaining to 
ADR incidence and risk factors.   
It may be possible to enhance the value of ICD-10 codes as one facet of a 
pharmacovigilance strategy. This could be achieved through specific training alongside 
specific tools (e.g. structured proformas) for both those who record ADRs in the clinical 
notes and those who carry out the coding. However, the more fundamental problem is a 
lack of awareness and understanding about ADRs amongst health care professionals (Hazell 
and Shakir, 2006). Research should focus on the development of strategies to improve the 
detection, assessment and reporting of ADRs by healthcare professionals. 
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There is a lack of conclusive evidence for the safety of dexamethasone and NSAIDs in 
tonsillectomy. Evidence could be provided via a large prospective study of haemorrhage 
rates in children who receive dexamethasone, dexamethasone plus NSAID or neither. Some 
ongoing randomised studies promise to provide some additional data on both 
dexamethasone and ibuprofen use (Centre Hospitalier Universitaire Vaudois, University of 
Turku, Massachusetts Eye and Ear Infirmary, Cumberland Pharmaceuticals). 
Although there are evidence-based interventions for the prevention of POV in children, 
they are not effective in every patient and the incidence of POV remains high. The focus of 
future research should be to reduce the incidence of POV and to improve its management. 
The incidence of POV could be reduced by improving the accuracy with which high risk 
patients are identified and by designing tailored interventions for its prevention. The 
management of POV could be improved by the design of evidence-based interventions 
appropriate to the post-operative setting, be that in hospital or at home. 
7.4 Conclusion 
The use of off-label and unlicensed medicines in children is common and these medicines 
are frequently associated with ADRs. The number of medicines administered whether 
authorised, off-label or unlicensed is a significant predictor of ADR risk.  
A requirement to authorise all medicines used in children would lead to changes in the way 
we use some medicines and reduce the potential for adverse effects. For other medicines, 
authorisation would not change the way we use them and adverse effects would be no less 
likely, however it would bring with it other advantages. A requirement to authorise all 
medicines before use in children is obviously not immediately practicable. The rational 
prescribing of medicines is an important measure in the reduction of ADR risk which can be 
applied to all medicine use. This should be supported by on-going medication review, with 
the active participation of patients and their families. The aim is to ensure that the 
minimum number of medicines is used safely and effectively for the minimum duration 
necessary. 
 223 
 
There continues to be enormous scope to optimise the use of medicines, authorised or 
otherwise, in children and further well-designed research will contribute to improvements 
in how we use medicines. 
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Appendix 1 Search strategy for narrative review 
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Appendix 2 Non-oncology ADRs which involved at least one off-label or unlicensed medicine course (n=48) greatest total number of medicines 
implicated first 
 
        
Description Of ADR Severityxli Avoidability Causality Total 
Number Of 
Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-Label Unlicensed 
        
Constipation 3 Possibly 
Avoidable 
Probable 3 Codeine Tablets 
Diclofenac Tablets 
Ondansetron Oral 
Syrup 
- 
                                                          
xli Modified Hartwig scale (Hartwig, Siegel and Schneider, 1992) 
Severity level Description 
1 Required no change in treatment 
2 Drug dosing or frequency changed 
3 Required treatment, or drug administration discontinued 
4 Result in patient transfer to higher level of care 
5 Caused permanent harm to patient or significant haemodynamic instability 
6 Directly or indirectly resulted in patient death 
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Description Of ADR Severityxli Avoidability Causality Total 
Number Of 
Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-Label Unlicensed 
Immunosuppression 4 Possibly 
Avoidable 
Definite 3 Prednisolone Tablets Infliximab Infusion Tacrolimus Oral Liquid 
        
Immunosuppression 3 Unavoidable Definite 3 Prednisolone Tablets Mycophenolate Mofetil 
Capsules 
Tacrolimus Oral Liquid 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 3 Ibuprofen Oral Syrup Dexamethasone 
Injection 
Diclofenac Dispersible 
Tablets 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 3 Ibuprofen Oral Syrup Dexamethasone 
Injection 
Diclofenac Dispersible 
Tablets 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 3 Diclofenac Injection Dexamethasone 
Injection 
Ibuprofen Oral Syrup 
- 
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Description Of ADR Severityxli Avoidability Causality Total 
Number Of 
Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-Label Unlicensed 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 3 Ibuprofen Oral Syrup Dexamethasone 
Injection 
Diclofenac Dispersible 
Tablets 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 3 Ibuprofen Oral Syrup 
Diclofenac 
Suppositories 
Dexamethasone 
Injection 
- 
Immunosuppression 3 Unavoidable Possible 2 Prednisolone Tablets 
 
- Tacrolimus Oral Liquid 
Constipation 3 Possibly 
Avoidable 
Probable 2 - - Calcium Carbonate 
Oral Liquid 
Amlodipine Oral Liquid 
Ileus 3 Possibly 
Avoidable 
Probable 2 Codeine Tablets Fentanyl Citrate 
Injection 
- 
Immunosuppression 3 Unavoidable Possible 2 Methylprednisolone 
Injection 
Methotrexate Tablets - 
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Description Of ADR Severityxli Avoidability Causality Total 
Number Of 
Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-Label Unlicensed 
Immunosuppression 3 Unavoidable Possible 2 Prednisolone Tablets Tacrolimus Capsules 1 
Immunosuppression 3 Unavoidable Possible 2 Prednisolone Tablets Mycophenolate Mofetil 
Capsules 
- 
Immunosuppression 4 Unavoidable Probable 2 Prednisolone Tablets Mycophenolate Mofetil 
Capsules 
- 
Immunosuppression 3 Unavoidable Possible 2 Prednisolone Tablets - Tacrolimus Oral Liquid 
Immunosuppression 4 Unavoidable Probable 2 Prednisolone Tablets - Tacrolimus Oral Liquid 
Immunosuppression 3 Unavoidable Possible 2 Prednisolone Tablets - Tacrolimus Oral Liquid 
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Description Of ADR Severityxli Avoidability Causality Total 
Number Of 
Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-Label Unlicensed 
Immunosuppression 3 Unavoidable Possible 2 Prednisolone Tablets - Tacrolimus Oral Liquid 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 2 Ibuprofen Oral Syrup Dexamethasone 
Injection 
- 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 2 - Dexamethasone 
Injection 
Diclofenac Dispersible 
Tablets 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 2 Ibuprofen Oral Syrup Dexamethasone 
Injection 
- 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 2 - Dexamethasone 
Injection 
Ibuprofen Oral Syrup 
 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 2 - Dexamethasone 
Injection 
Ibuprofen Oral Syrup 
- 
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Description Of ADR Severityxli Avoidability Causality Total 
Number Of 
Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-Label Unlicensed 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 2 - Diclofenac Dispersible 
Tablets 
Ibuprofen Oral Syrup 
- 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 2 Ibuprofen Tablets Dexamethasone 
Injection 
- 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 2 Ibuprofen Oral Syrup Dexamethasone 
Injection 
- 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 2 Ibuprofen Oral Syrup Dexamethasone 
Injection 
- 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 2 Ibuprofen Oral Syrup Dexamethasone 
Injection 
- 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 2 Ibuprofen Oral Syrup Dexamethasone 
Injection 
- 
 249 
 
        
Description Of ADR Severityxli Avoidability Causality Total 
Number Of 
Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-Label Unlicensed 
Post-Operative 
Bleeding 
3 Unavoidable Possible 2 Ibuprofen Oral Syrup Dexamethasone 
Injection 
- 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 2 Ibuprofen Oral Syrup Dexamethasone 
Injection 
- 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 2 Prednisolone Tablets Dexamethasone 
Injection 
- 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 2 - Dexamethasone 
Injection 
Diclofenac Dispersible 
Tablets 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 2 Ibuprofen Oral Syrup Dexamethasone 
Injection 
- 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 2 Diclofenac Injection Ibuprofen Oral Syrup - 
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Description Of ADR Severityxli Avoidability Causality Total 
Number Of 
Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-Label Unlicensed 
Respiratory 
Depression 
4 Possibly 
Avoidable 
Probable 2 Diazepam Rectal - Midazolam Buccal 
Constipation 3 Unavoidable Possible 1 - Oxybutynin Oral Elixir - 
Constipation 3 Possibly 
Avoidable 
Definite 1 - Dihydrocodeine 
Tartrate Oral Solution 
- 
Candida 1 Unavoidable Probable 1 - Anakinra Injection - 
Deranged Renal 
Function 
3 Definitely 
Avoidable 
Probable 1 - - Captopril Oral Liquid 
Headache 3 Unavoidable Possible 1 - Acetazolamide  Tablet - 
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Description Of ADR Severityxli Avoidability Causality Total 
Number Of 
Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-Label Unlicensed 
Hyperkalemia 2 Unavoidable Probable 1 - - Spironolactone Oral 
Liquid 
Immunosuppression 3 Unavoidable Possible 1 - Methotrexate Injection - 
Inter-Menstrual 
Bleed 
3 Unavoidable Probable 1 - Desogestrel, 
Ethinylestradiol Tablet 
- 
Post-Tonsillectomy 
Bleed 
3 Unavoidable Possible 1 - Ibuprofen Oral Syrup - 
Respiratory 
Depression 
4 Possibly 
Avoidable 
Probable 1 - - Midazolam Buccal 
Wheeze And 
Increased Work Of 
Breathing 
3 Unavoidable Probable 1 - Propanolol Oral 
Solution 
- 
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Appendix 3  Oncology ADRs which involved at least one off-label or unlicensed medicine course (n=93) greatest total number of medicines implicated 
first 
 
      
Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
        
                                                          
xlii Modified Hartwig scale (Hartwig, Siegel and Schneider, 1992) 
Severity level Description 
1 Required no change in treatment 
2 Drug dosing or frequency changed 
3 Required treatment, or drug administration discontinued 
4 Result in patient transfer to higher level of care 
5 Caused permanent harm to patient or significant haemodynamic instability 
6 Directly or indirectly resulted in patient death 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Immunosuppression 
Neutropenia 
3 Unavoidable Definite 6 Vincristine 
Dexamethasone 
Tablets 
Teicoplanin 
Doxorubicin Methotrexate oral 
liquid 
Mercaptopurine oral 
liquid 
        
Anaemia 
Immunosuppression 
Neutropenia  
Thrombocytopenia 
3 Unavoidable Definite 5 Methotrexate 
injection 
Vincristine 
Cyclophosphamide 
Cytarabine 
Doxorubicin 
- 
        
Immunosuppression 
Mucositis  
Neutropenia 
3 Unavoidable Probable 5 Vincristine Cyclophosphamide 
Cytarabine 
Doxorubicin 
Methotrexate 
- 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Anaemia 
Immunosuppression 
Neutropenia   
Thrombocytopenia 
3 Unavoidable Definite 4 Dexamethasone 
liquid 
Vincristine 
- Mercaptopurine oral 
liquid 
Methotrexate oral 
liquid 
        
Anaemia  
Immunosuppression 
Neutropenia 
Thrombocytopenia 
3 Unavoidable Probable 4 Vincristine 
Ifosfamide 
Doxorubicin 
Etoposide 
- 
        
Anaemia 
Immunosuppression 
Nausea Neutropenia 
Thrombocytopenia 
Vomiting 
3 Unavoidable Definite 4 Prednisolone Tablets 
Vincristine 
Cyclophosphamide 
Doxorubicin 
- 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Anaemia  
Neutropenia  
Thrombocytopenia 
3 Unavoidable Definite 4 Ifosfamide  
Vincristine 
Doxorubicin 
Etoposide 
- 
        
        
Anaemia  
Mucositis  
Neutropenia 
Thrombocytopenia 
3 Unavoidable Probable 4 Doxorubicin 
Vincristine 
Cyclophosphamide 
Cisplatin 
- 
        
Anaemia 
Immunosuppression 
Neutropenia  
Thrombocytopenia 
3 Unavoidable Definite 4 Doxorubicin 
Vincristine 
Ifosfamide 
Dactinomycin - 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Anaemia 
Immunosuppression 
Neutropenia 
Thrombocytopenia 
3 Unavoidable Probable 4 Vincristine Cyclophosphamide 
Doxorubicin 
Dexamethasone 
injection 
- 
        
Anaemia 
Immunosuppression 
Neutropenia  
Thrombocytopenia 
3 Unavoidable Definite 4 Vincristine Doxorubicin 
Etoposide 
Ifosfamide 
- 
        
Anaemia  
Neutropenia   
Thrombocytopenia 
3 Unavoidable Definite 4 Vincristine 
Ifosfamide 
Doxorubicin 
Etoposide 
- 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Deranged LFTs 1 Unavoidable Definite 4 Teicoplanin Doxorubicin Methotrexate oral 
liquid 
Mercaptopurine oral 
liquid 
        
Gastritis 3 Possibly 
Avoidable 
Possible 4 Daunorubicin 
Dexamethasone 
liquid 
Vincristine 
Cyclophosphamide - 
        
Immunosuppression 3 Unavoidable Definite 4 Dexamethasone oral 
liquid 
Vincristine 
- Mercaptopurine oral 
liquid 
Methotrexate oral 
liquid 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Immunosuppression 
Neutropenia  
Thrombocytopenia 
3 Unavoidable Probable 4 Vincristine 
Ifosfamide 
Dactinomycin 
Doxorubicin 
- 
        
Immunosuppression 
Neutropenia 
Thrombocytopenia 
3 Unavoidable Definite 4 Cytarabine 
Vincristine 
 
Cyclophosphamide Mercaptopurine oral 
liquid 
        
Mucositis  
Neutropenia   
Thrombocytopenia 
3 Unavoidable Definite 4 Vincristine 
Ifosfamide 
Dactinomycin 
Doxorubicin 
- 
        
Neutropenia 1 Unavoidable Probable 4 Daunorubicin 
Dexamethasone 
liquid 
Vincristine 
Cyclophosphamide - 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
        
Anaemia 
Immunosuppression 
Neutropenia   
Thrombocytopenia 
3 Unavoidable Definite 3 Vincristine Cyclophosphamide 
Doxorubicin 
- 
        
Anaemia  
Mucositis 
Neutropenia   
Thrombocytopenia 
3 Unavoidable Definite 3 - Cyclophosphamide 
Etoposide 
Methotrexate 
injection 
- 
        
Anaemia 
Immunosuppression 
Neutropenia   
Thrombocytopenia 
3 Unavoidable Definite 3 Cytarabine 
Methotrexate 
injection 
Etoposide - 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Anaemia  
Neutropenia 
3 Unavoidable Probable 3 Vincristine Carboplatin 
Etoposide 
- 
        
Anaemia   
Neutropenia   
Thrombocytopenia 
3 Unavoidable Probable 3 Cytarabine 
Daunorubicin 
Etoposide - 
        
Anaemia 
Immunosuppression 
Neutropenia  
Thrombocytopenia 
3 Unavoidable Definite 3 Vincristine Etoposide 
Doxorubicin 
- 
        
Anaemia  
Mucositis  
Neutropenia   
Thrombocytopenia 
3 Unavoidable Definite 3 Cytarabine Amsacrine 
Etoposide 
- 
 261 
 
      
Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
        
Anaemia Nausea 
Neutropenia  
Thrombocytopenia 
Vomiting 
3 Unavoidable Definite 3 Cytarabine 
Methotrexate 
injection 
Etoposide - 
        
Anaemia  
Haematuria 
Thrombocytopenia 
3 Unavoidable Probable 3 Methotrexate 
injection 
Cytarabine 
Cyclophosphamide - 
        
Back Pain 3 Unavoidable Definite 3 Dexamethasone oral 
solution 
Vincristine 
Doxorubicin - 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Constipation 3 Unavoidable Possible 3 Dihydrocodeine 
tablets 
Ifosfamide 
Doxorubicin - 
        
Immunosuppression 
Neutropenia 
3 Unavoidable Probable 3 Vincristine Etoposide 
Doxorubicin 
- 
        
Immunosuppression 3 Possibly 
Avoidable 
Probable 3 Prednisolone tablets 
Tacrolimus capsules 
Mycophenolate 
Mofetil Capsules 
- 
        
Immunosuppression 
Neutropenia 
5 Unavoidable Definite 3 Dexamethasone oral 
solution 
Vincristine 
Doxorubicin - 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Immunosuppression 
Nausea  
Neutropenia  
Vomiting 
3 Unavoidable Definite 3 Ifosfamide Dactinomycin  
Doxorubicin 
- 
        
Immunosuppression 
Neutropenia 
3 Unavoidable Definite 3 Dexamethasone oral 
solution 
Vincristine 
Doxorubicin - 
        
Immunosuppression 
Neutropenia 
3 Unavoidable Definite 3 Dexamethasone oral 
liquid 
Vincristine 
Doxorubicin - 
        
Immunosuppression 3 Unavoidable Possible 3 Prednisolone Tablets 
Tacrolimus Capsules 
Mycophenolate 
Mofetil Capsules 
- 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Immunosuppression 
Neutropenia 
3 Unavoidable Definite 3 Vincristine - Mercaptopurine oral 
liquid 
Methotrexate oral 
liquid 
        
Immunosuppression 
Neutropenia 
3 Unavoidable Definite 3 Vincristine - Mercaptopurine oral 
liquid 
Methotrexate oral 
liquid 
        
Immunosuppression 
Neutropenia 
3 Unavoidable Definite 3 Vincristine - Mercaptopurine oral 
liquid 
Methotrexate oral 
liquid 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Immunosuppression 3 Unavoidable Definite 3 Dexamethasone oral 
liquid 
- Mercaptopurine oral 
liquid 
Methotrexate oral 
liquid 
        
Immunosuppression 
Neutropenia 
3 Unavoidable Definite 3 Vincristine Doxorubicin 
Etoposide 
- 
        
Neutropenia  
Thrombocytopenia 
3 Unavoidable Definite 3 Vincristine Carboplatin 
Etoposide 
- 
        
Neutropenia  
Thrombocytopenia 
3 Unavoidable Definite 3 Vincristine Carboplatin 
Etoposide 
- 
        
Vomiting 3 Unavoidable Definite 3 Vincristine Carboplatin 
Etoposide 
- 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
        
Anaemia  
Deranged LFTs 
Diarrhoea  
Nausea 
Thrombocytopenia 
Vomiting 
3 Unavoidable Definite 2 - Irinotecan  
Temozolomide 
capsules 
- 
        
Anaemia Neutropenia 
Thrombocytopenia 
3 Unavoidable Probable 2 - Carboplatin 
Etoposide 
- 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Anaemia  
Diarrhoea   
Headache  
Neutropenia 
Thrombocytopenia 
Vomiting 
3 Unavoidable Definite 2 Cytarabine Etoposide 
 
- 
        
Anaemia 
Immunosuppression 
Neutropenia   
Thrombocytopenia 
3 Unavoidable Definite 2 Cytarabine Doxorubicin - 
        
Anaemia  
Neutropenia  
Thrombocytopenia 
3 Unavoidable Probable 2 - Carboplatin 
Etoposide 
- 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Anaemia Deranged 
Renal Function 
3 Unavoidable Probable 2 - Doxorubicin 
Cisplatin 
- 
        
Anaemia Neutropenia 3 Unavoidable Definite 2 Ifosfamide Etoposide - 
        
Anaemia  
Mucositis  
Neutropenia   
Thrombocytopenia 
3 Unavoidable Definite 2 - Cytarabine 
Etoposide 
- 
        
Anaemia  
Neutropenia  
Thrombocytopenia 
3 Possibly 
Avoidable 
Definite 2 Vincristine - Pegasparaginase 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Anaemia  
Neutropenia  
Immunosuppression 
3 Unavoidable Definite 2 - - Mercaptopurine oral 
liquid 
Methotrexate oral 
liquid 
        
Constipation 3 Possibly 
Avoidable 
Definite 2 Vincristine Ondansetron tablets - 
        
Deranged LFTs 1 Unavoidable Probable 2 - - Mercaptopurine oral 
liquid 
Methotrexate oral 
liquid 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Deranged LFTs 
Diarrhoea 
Immunosuppression 
Neutropenia  
Thrombocytopenia 
Vomiting 
3 Unavoidable Definite 2 - Ifosfamide 
Doxorubicin 
- 
        
Deranged LFTs 
Immunosuppression 
Neutropenia  
Thrombocytopenia 
3 Unavoidable Definite 2 Vincristine Doxorubicin - 
        
Diarrhoea 1 Unavoidable Possible 2 Vincristine Prednisolone tablets - 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Diarrhoea 
Immunosuppression 
Neutropenia 
3 Unavoidable Definite 2 Vincristine Doxorubicin - 
        
Immunosuppression 
Neutropenia 
3 Unavoidable Definite 2 Ifosfamide Etoposide - 
        
Immunosuppression 
Neutropenia 
3 Unavoidable Probable 2 Ifosfamide Doxorubicin - 
        
Immunosuppression 
Neutropenia 
3 Unavoidable Definite 2 Ifosfamide Doxorubicin - 
        
Immunosuppression 3 Unavoidable Possible 2 Vincristine Prednisolone tablets - 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Immunosuppression 
Neutropenia 
3 Unavoidable Definite 2 Ifosfamide Doxorubicin - 
        
Immunosuppression 
Mucositis  
Neutropenia  
Thrombocytopenia 
3 Unavoidable Definite 2 Vincristine Doxorubicin - 
        
Immunosuppression 
Neutropenia 
3 Unavoidable Definite 2 Prednisolone tablets Vinblastine - 
        
Immunosuppression 
Neutropenia 
3 Unavoidable Definite 2 Vincristine Doxorubicin - 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Immunosuppression 
Neutropenia   
Thrombocytopenia 
3 Unavoidable Definite 2 Ifosfamide Doxorubicin - 
        
Immunosuppression 
Neutropenia 
3 Unavoidable Definite 2 Vinblastine - Mercaptopurine oral 
liquid 
        
Immunosuppression 
Neutropenia 
3 Unavoidable Definite 2 - - Mercaptopurine oral 
liquid 
Methotrexate oral 
liquid 
        
Immunosuppression 
Neutropenia 
3 Unavoidable Definite 2 - - Mercaptopurine oral 
liquid 
Methotrexate oral 
liquid 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
        
Anaemia  
Neutropenia  
Thrombocytopenia 
3 Unavoidable Definite 2 - Carboplatin 
Etoposide 
- 
        
Neutropenia   
Thrombocytopenia 
3 Unavoidable Definite 2 - Cyclophosphamide 
Doxorubicin 
- 
        
Neutropenia  
Thrombocytopenia 
3 Unavoidable Definite 2 Cytarabine Etoposide - 
        
Neutropenia   
Thrombocytopenia 
3 Unavoidable Definite 2 - Doxorubicin 
Cisplatin 
- 
        
Neutropenia  
Thrombocytopenia 
3 Unavoidable Definite 2 - Cyclophosphamide 
Doxorubicin 
- 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
        
Neutropenia  
Thrombocytopenia 
3 Unavoidable Definite 2 - Cyclophosphamide 
Etoposide 
- 
        
Neutropenia  
Thrombocytopenia 
3 Unavoidable Definite 2 - Cyclophosphamide 
Etoposide 
- 
        
Neutropenia  
Thrombocytopenia 
3 Unavoidable Definite 2 - Irinotecan  
Temozolomide 
capsules 
- 
        
Neutropenia  
Thrombocytopenia 
3 Unavoidable Definite 2 Cytarabine Fludarabine 
Phosphate 
- 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Neutropenia 3 Unavoidable Definite 2 - - Mercaptopurine oral 
liquid 
Methotrexate oral 
liquid 
        
Neutropenia 3 Unavoidable Probable 2 - - Mercaptopurine oral 
liquid 
Methotrexate oral 
liquid 
        
Neutropenia 3 Unavoidable Definite 2 - - Mercaptopurine oral 
liquid 
Methotrexate oral 
liquid 
        
Thrombocytopenia 3 Unavoidable Probable 2 Cytarabine Etoposide - 
 277 
 
      
Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
        
Anaemia  
Neutropenia 
Thrombocytopenia 
3 Unavoidable Definite 1 - - Mercaptopurine oral 
liquid 
        
Immunosuppression 3 Unavoidable Possible 1 - - Methotrexate oral 
liquid 
        
Immunosuppression 
Neutropenia 
3 Unavoidable Probable 1 - - Mercaptopurine oral 
liquid 
        
Immunosuppression 3 Unavoidable Definite 1 - Cyclophosphamide - 
        
Neutropenia 3 Unavoidable Definite 1 - Vinblastine - 
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Description Of ADR(S) Severityxlii Avoidability Causality Total Number 
Of Medicines 
Implicated 
Categories of medicines implicated 
Authorised Off-label Unlicensed 
Neutropenia  
Thrombocytopenia 
3 Unavoidable Definite 1 - Methotrexate 
injection 
- 
        
Vomiting 3 Possibly 
Avoidable 
Probable 1 - Imatinib tablets - 
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Appendix 4 Identification and selection of controls 
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Appendix 5 Decision trees for off-label medicine use 
 
For each use of a medicine licensed for use in children, follow Tree 1 + either Trees 2 or 
Tree 3.  This two stage layout for medicines licensed for use in children is to accommodate 
all the necessary steps on a single page. For each use of a medicine NOT licensed for use in 
children, follow Tree 4. 
Guidance notes for use of the decision trees  
For the contents of each box answer the question ‘does this aspect of use correspond to 
the terms of the MA outlined in the SmPC?’ 
The answer will either be: 
Y = this aspect of use is authorised  
N= this aspect of use is not authorised  
 Authorised use of licensed medicines will fall into category 1 because we can select 
Y for every aspect of use. 
 When considering contraindications (CI), select Y if there are no contraindications 
and N if a contraindication exists. 
 When considering dose, select N if dose > than recommended but Y if dose < 
recommended. 
When all questions have been answered, a category (1-28) can be assigned.  
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Tree 1– Medicines licensed for use in children  
 
 
 
 
Indication 
 
  
Go to Tree 2 Go to Tree 3 
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Tree 2 – Medicines licensed for use in children and indication authorised 
 
Route 
 
 
Age 
 
Age 
Dose CI CI 
CI 5 6 CI 
CI 
9 10 
1 2 3 4 
7 8 
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Tree 3 - Medicines licensed for use in children but indication not authorised 
 
 
Route 
    
 
Age Age 
Dose CI CI 
CI 15 16 CI 
CI 
19 20 
11 12 13 14 
17 18 
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Tree 4 – Medicines not licensed for use in children 
Indication 
 
Route Route 
CI CI CI CI 
21 23 24 22 25 26 27 28 
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Appendix 6 Unlicensed medicines recorded in the study by category 
   
Drug Name Preparation Category 
   
Acetazolamide Acetazolamide 250mg In 5ml 31 
Acetazolamide Acetazolamide 250mg In 5ml 
Suspension 
31 
Acetylcysteine Acetylcysteine 10% Oral Solution 31 
Acetylcysteine Acetylcysteine 20% Oral Solution 31 
Acetylcysteine & 
Sodium Chloride 
Acetylcysteine 10% In Sodium 
Chloride 0.9% For Nebulisation 
(2ml) 
31 
Allopurinol Allopurinol (Sugar Free) 100mg In 
5ml Suspension 
32 
Amikacin Amikacin 2mg In 1ml Line Lock 31 
Amikacin Amikacin 5mg In 5ml Line Lock 31 
Amiodarone Amiodarone 10mg In 1ml 
Suspension 
31 
Amlodipine Amlodipine 1mg In 1ml Suspension 31 
Amphotericin Amphotericin 100mg In 1ml 
Suspension 
31 
Amphotericin B Amphotericin B 1mg In 1ml Line 
Lock 
31 
Amphotericin B Amphotericin B For Addition To PD 
Fluid 
31 
Arginine Hydrochloride Arginine 10% Infusion 31 
Arginine 
Monohydrochloride 
Arginine Monohydrochloride 
400mg In 1ml Oral Solution 
31 
Azathioprine Azathioprine 10mg Capsules 32 
Azathioprine Azathioprine 10mg In 1ml 
Suspension 
32 
Bio-Kult Capsules Bio-Kult Capsules none - food supplement 
Caffeine Citrate Caffeine Citrate 50mg In 5ml 
Injection 
32 
Caffeine Citrate Caffeine Citrate 50mg In 5ml Oral 
Solution 
32 
Calcium Carbonate Calcium Carbonate 500mg 
Capsules 
32 
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Drug Name Preparation Category 
Calcium Carbonate Calcium Carbonate Liquid 100 000 
Units / Ml (250mg/5ml) 
32 
Captopril Captopril 1mg In 1ml Suspension 32 
Captopril Captopril 5mg In 1ml Oral Solution 32 
Ceftazidime Ceftazidime 125mg In 0.63ml 
Subconjunctival Injection 
31 
Ceftazidime Ceftazidime Intravenous Injection 31 
Cefuroxime Cefuroxime Eye Drops 31 
Chloral Hydrate Chloral Hydrate 50mg 
Suppositories 
32 
Chloral Hydrate Chloral Hydrate 500MG In 5ML 32 
Chlorothiazide Chlorothiazide 250mg In 5ml 
Suspension 
32 or 33 
Chlorothiazide Chlorthiazide Oral Solution 34 
Cholesterol Cholesterol (C-8503) Oral Powder 32 
Cholic Acid Cholic Acid 75mg & 150mg 
Capsules 
32 
Ciprofloxacin Ciprofloxacin 0.2% Eye Drops 31 
Ciprofloxacin Ciprofloxacin 0.2mg In 0.1ml 
Intravitreal Injection 
31 
Ciprofloxacin Ciprofloxacin 2mg In 1ml Line Lock 31 
Clindamycin Clindamycin  Liquid, 75 Mg/5 Ml 32 
Clobazam Clobazam 5mg In 5ml Suspension 31 
Clonazepam Clonazepam 2.5mg In 1ml Drops 34 
Clonazepam Clonazepam 2mg In 5ml Sugar Free 
Oral Solution 
32 
Clonidine Clonidine 50micrograms In 1ml 
Suspension 
31 
Clonidine + 
Levobupivicaine 
Clonidine + Levobupivicaine 
Epidural 
31 
Co-Careldopa Co-Careldopa(Sinemet) 62.5mg In 
10ml Suspension 
31 
Codeine Phosphate Codeine Phosphate 10mg 
Suppositories 
32 
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Drug Name Preparation Category 
Codeine Phosphate Codeine Phosphate 2mg, 3mg 32 
Colecalciferol Colecalciferol 3000units In 1ml 32 
Colistin Colistin 100mg Base(3 Mega Units) 
In 1ml Oral Solution 
31 
Colistin, Tobramycin, 
Amphotericin 
SDD Paste 31 
Colomicin & Tobramycin 
& Amphotericin 
SDD(Col/Tob/Amph 2%) Gel 31 
Corticotrophin Corticotropin Releasing Hormone 
(HCRF) 100microgram Ampoule 
34 
Creatine Creatine Monohydrate Oral 
Powder 
34 
Cyclizine Cyclizine 5mg In 5ml Suspension 31 
Dantrolene Dantrolene 25mg In 5ml 
Suspension 
31 
Defibrotide Defibrotide 200MG (2.5ml 
Ampoule) 
34 
Deflazacort Deflazacort 22.75mg In 1ml Oral 
Drops 
34 
Diazoxide Diazoxide 250mg In 5ml 
Suspension 
31 
Diazoxide Diazoxide 50mg In 5ml Suspension 31 
Diclofenac Diclofenac 10mg Dispersible 
Tablets 
32 
Dinoprostone Dinoprostone Oral Solution 31 
Docosahexaenoic Acid / 
Arachidonic Acid 
Powder 
DHA Powder 34 
Asparaginase E-Coli L-Asparaginase 500units 
Injection (Medac) 
34 
Enalapril Enalapril Liquid Unknown - not used at 
Alder Hey 
Enoxaparin Enoxaparin Subcutaneous Injection 31 
Fentanyl + 
Levobupivicaine 
Fentanyl + Levobupivicaine 
Epidural 
32 
Filgrastim G-CSF(Filgrastim) Subcutaneous 
Injection 
31 
Flecainide Flecainide 5mg In 1ml Oral 
Solution 
32 
Fludrocortisone Fludrocortisone 10micrograms In 
1ml Suspension 
31 
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Drug Name Preparation Category 
Gabapentin Gabapentin 250mg In 5ml 31 
Gentamicin Gentamicin 10mg In 0.25ml 
Subconjunctival Injection 
31 
Gentamicin Gentamicin 1mg In 1ml Line Lock 31 
Gentamicin Gentamicin 2mg In 1ml Line Lock 31 
Glibenclamide Glibenclamide 5mg/5ml 31 
Glycopyrolate Glycopyrolate 1mg/5ml Oral 
Solution 
31 
Glycopyrronium + 
Neostigmine 
Glycopyrronium + Neostigmine 
0.5/2.5 Injection 
31 
Glycopyrronium Glycopyrronium Bromide 1mg 
Tablets 
34 
Gonadorelin Gonadorelin 100micrograms 
Ampoule (Relefact Lh-Rh) 
34 
Heparin Heparin 1unit In 1ml Infusion 
(50ml) 
31 
Hydralazine Hydralazine 10mg In 5ml 
Suspension 
31 
Hydralazine Hydralazine 10mg In 5ml Mixture 31 
Hydrocortisone Hydrocortisone Oral Liquid 32 
Hydrocortisone Hydrocortisone 10mg In 5ml 
Suspension 
32 
Hydroxychloroquine Hydroxychloroquine 35mg In 5ml 
Suspension 
31 
Hyoscone 
Hydrobromide 
Hyoscine Hydrobromide 100 
Micrograms In 1ml Mixture 
32 
Iloprost Iloprost 50micrograms In 250ml 
Sodium Chloride 0.9% Intravenous 
Infusion 
31 
Iloprost Iloprost 100micrograms In 1ml 
Injection 
34 
Indometacin Indometacin 25mg In 5ml 
Suspension 
34 
Isoniazid Isoniazid 50mg In 5ml Elixir 32 
Isoprenaline Isoprenaline Sulphate 2.25mg In 
2ml Injection 
32 
Ketamine Ketamine 100mg In 1ml Oral 
Solution 
31 
LAT Gel Lat (Lidocaine 4% & Adrenaline 
0.1% & Tetracaine 0.5%) Gel 
32 
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Drug Name Preparation Category 
Levomepromazine Levomepromazine 1mg In 1ml 
Suspension 
31 
Levothroxine Levothyroxine Sodium 
25micrograms In 5ml Suspension 
31 
Lisinopril Lisinopril Liquid 32 
Lomustine Lomustine 20mg In 5ml 
Suspension 
31 
Loperamide Loperamide 1mg Oral Powder 32 
Magnesium 
Glycerophosphate 
Magnesium Glycerophosphate 
1mmol In 1ml Mixture 
32 
Magnesium 
Glycerophosphate 
Magnesium Glycerophosphate 
2mmol (500mg) Capsules 
32 
Melatonin Melatonin 1mg/1ml Liquid Unknown - not used at 
Alder Hey 
Melatonin Melatonin 2mg Capsules 32 
Melatonin Melatonin 3mg (6 Hour Timed 
Release) Capsule 
34 
Mercaptopurine Mercaptopurine 100mg In 5ml 
Suspension 
32 
Methotrexate Methotrexate 10mg Syringe 31 
Methotrexate Methotrexate 12.5mg Syringe 31 
Methotrexate Methotrexate 7.5mg Syringe 31 
Methotrexate Methotrexate 10mg In 5ml Oral 
Solution 
32 
Metoprolol Metoprolol 10mg In 1ml Mixture 31 
Midazolam Midazolam Hydrochloride 2.5mg In 
1ml Oral Solution 
31 
Midazolam Midazolam 10mg In 1ml Buccal 
Liquid 
32 
Morphine Sulphate Morphine Sulphate 
500micrograms In 1ml Oral 
Solution 
32 
Nadolol Nadol l 10mg In 5ml Suspension 31 
Nifedipine Nifedipine 2% Drops (20mg/Ml) 34 
Olive Oil Olive Oil Ear Drops 33 
Omeprazole Omeprazole 10mg In 5ml 31 
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Drug Name Preparation Category 
Oxybutinin Oxybutynin 5mg In 15ml Bladder 
Instillation 
31 
Paracetamol Paracetamol Intravenous Infusion 31 
Paracetamol Paracetamol 30mg Paediatric 
Suppositories 
32 
Paraldehyde Paraldehyde Enema 32 
Phenytoin Phenytoin 90mg in 5ml Suspension 32 
Potassium Acetate Potassium Acetate 4.9g In 10ml 
Injection 
32 
Potassium Acid 
Phosphate 
Potassium Acid Phosphate 1mmol 
In 1ml Oral Solution 
32 
Potassium Bicarbonate Potassium Bicarbonate 500mg 
Capsule 
32 
Potassium Canrenoate Potassium Canrenoate 200mg 
Injection 
32 
Potassium Chloride Potassium Chloride 2mmol/Ml 31 
Potassium Dihydrogen 
Phosphate 
Potassium 1mmol & Phosphate 
1mmol In 1ml Oral Solution 
31 
Potassium Dihydrogen 
Phosphate 
Potassium Dihydrogen Phosphate 
13.6% Injection (50ml) 
32 
Pyridostigmine Pyridostigmine 15mg In 5ml 
Suspension 
31 
Pyridoxal Pyridoxal  5 Phosphate 50mg 
Capsule 
34 
Pyridoxine Pyridoxine Hydrochloride 150mg 
In 5ml Mixture 
31 
Pyridoxine Pyridoxine Hydrochloride Powder 
Code 440865q 
34 
Pyrimethamine Pyrimethamine 2mg In 1ml Oral 
Suspension 
31 
Ribavirin Ribavirin Injection 34 
Sildenafil Sildenafil 2.5mg In 1ml Suspension 31 
Sildenafil Sildenafil 5mg In 5ml Suspension 31 
Sodium Acid Phosphate Sodium Acid Phosphate Powder 32 
Sodium Benzoate Sodium Benzoate 500mg In 5ml 
Oral Solution 
32 
Sodium Bicarbonate Sodium Bicarbonate 1mmol In 1ml 
Oral Solution 
32 
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Drug Name Preparation Category 
Sodium Bicarbonate Sodium Bicarbonate 500mg 
Capsules 
32 
Sodium Chloride Sodium Chloride 0.9% Nasal Drops 31 
Sodium Chloride Sodium Chloride 30% Syrup 31 
Sodium Chloride Sodium Chloride 5mmol In 1ml 
Sterile Oral Solution (100ml) 
31 
Sodium Chloride Sodium Chloride 5% Drops 32 
Sodium Chloride Sodium Chloride 500mg Capsules 32 
Sodium Chloride Sodium Chloride 7% Nebules Classed as a medical 
device not pharmaceutical 
product Sodium Phenylbutyrate Sodium Phenylbutyrate 1g In 5ml 
Injection 
32 
Spironolactone Spironolactone 25mg/5ml 
Suspension 
32 
Stiripentol Stiripentol 250mg Capsules 34 
Stiripentol Stiripentol 250mg Sachet 34 
Sucrose Sucraid 34 
Sucralfate Sucralfate Paste 31 
Sucrose Sucrose 12% Solution 34 
Sultiame Sultiame 200mg Tablets 34 
Sultiame Sultiame 50mg & 200mg Tablets 34 
Tacrolimus Tacrolimus 2.5mg In 5ml 
Suspension 
32 
Taurolin Taurolin 2% 34 
Teicoplanin Teicoplanin 1mg In 0.1ml 
Intravitreal Injection 
31 
Thiamine Thiamine Hydrochloride 100mg In 
1ml Oral Solution 
31 
Tobramycin Tobramycin Base 31 
Tranexamic Acid Tranexamic Acid 500mg In 5ml 
Oral Solution 
32 
Urokinase Urokinase 40 000units In 40ml 
Sodium Chloride 0.9% Intra-Pleural 
Infusion 
31 
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Drug Name Preparation Category 
Urokinase Urokinase Line Lock 31 
Vancomycin Intraocular Injection  Vancomycin 
1mg In 0.1ml Sodium Chloride 
0.9% 
31 
Vancomycin Intravitreal Injection  Vancomycin 
1mg In 0.1ml Sodium Chloride 
0.9% 
31 
Vancomycin Vancomycin 10mg In 2ml 
Intraventricular/Intrathecal 
Injection 
31 
Vancomycin Van omycin 2mg In 1ml Line Lock 31 
Vancomycin Vancomycin 500mg In 30ml Oral 
Solution 
31 
Vancomycin Vancomycin Solution For 
Nebulisation 
31 
Vitamin A Vitamin A (Retinol) Aqueous 
150,000u/Ml Oral Solution 
34 
Vitamin E Vitamin E 100mg Chewable Tablets 34 
Vitamin E Vitamin E 100mg In 2ml Injection 34 
Vitamin K Vitamin K 1mg Capsules Unknown – not used at 
Alder Hey 
Warfarin Warfarin 1mg In 1ml Oral 
Suspension  (Sugar Free) 
32 
Zonisamide Zonisamide 10mg In 1ml Oral 
Suspension 
31 
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Appendix 7 Database Search Strategies 
BioSciences Information Service of Biological Abstracts (BIOSIS) Citation Index via 
webofknowledge.com 
1. TS=(nsaid* or non-steroidal anti-inflammatory agent* or nonsteroidal anti-inflammatory 
agent* or non-steroidal antiinflammatory agent* or nonsteroidal antiinflammatory agent* 
or non steroidal anti inflammatory drug* or non steroidal antiinflammatory drug* or 
nonsteroidal antiinflammatory drug* or nonsteroidal anti inflammatory drug* or non-
steroidal anti-rheumatic agent* or non-steroidal antirheumatic agent* or nonsteroidal anti-
rheumatic agent* or nonsteroidal antirheumatic agent* or anti-inflammatory analgesic* or 
antiinflammatory analgesic* or aspirin-like agent*) OR TI=(nsaid* or non-steroidal anti-
inflammatory agent* or nonsteroidal anti-inflammatory agent* or non-steroidal 
antiinflammatory agent* or nonsteroidal antiinflammatory agent* or non steroidal anti 
inflammatory drug* or non steroidal antiinflammatory drug* or nonsteroidal 
antiinflammatory drug* or nonsteroidal anti inflammatory drug* or non-steroidal anti-
rheumatic agent* or non-steroidal antirheumatic agent* or nonsteroidal anti-rheumatic 
agent* or nonsteroidal antirheumatic agent* or anti-inflammatory analgesic* or 
antiinflammatory analgesic* or aspirin-like agent*) 
2. TS=(non-steroid anti-inflammatory agent* or nonsteroid anti-inflammatory agent* or 
non-steroid antiinflammatory agent* or nonsteroid antiinflammatory agent* or non steroid 
anti inflammatory drug* or non steroid antiinflammatory drug* or nonsteroid 
antiinflammatory drug* or nonsteroid anti inflammatory drug* or non-steroid anti-
rheumatic agent* or non-steroid antirheumatic agent* or nonsteroid anti-rheumatic agent* 
or nonsteroid antirheumatic agent*) OR TI=(non-steroid anti-inflammatory agent* or 
nonsteroid anti-inflammatory agent* or non-steroid antiinflammatory agent* or nonsteroid 
antiinflammatory agent* or non steroid anti inflammatory drug* or non steroid 
antiinflammatory drug* or nonsteroid antiinflammatory drug* or nonsteroid anti 
inflammatory drug* or non-steroid anti-rheumatic agent* or non-steroid antirheumatic 
agent* or nonsteroid anti-rheumatic agent* or nonsteroid antirheumatic agent*) 
3. TS=(aceclofenac or acemetacin or acetylsalicyl* or actaritajulemic acid or alclofenac or 
alminoprofen or aloxiprin or amfenac or aminosalicylic acid or ampiroxicam or amtolmetin 
guacil or anacin or anirolac or antiflammin or apadenoson or arthrotec or ascriptin or 
balsalazide or bardoxolone or bendazac or benorilate or benoxaprofen or bermoprofen or 
bimosiamose or bromfenac or broperamole or bucloxic acid or bucolome or bufexamac or 
butibufen or camobucol or carbasalate calcium or carprofen or celecoxib or centchroman 
or cicloprofen or cimicoxib or cinmetacin or cinnoxicam or clidanac or clofenamic acid or 
clofezone or clonixin or cloximate or dehydrozingerone or demethoxycurcumin or 
deracoxib or dexibuprofen or dexketoprofen or diclofenac or didemethoxycurcumin or 
diflunisal or diftalone or dimethyl sulfoxide or diphenpyramide or ditazole or droxicam 
ebselen or emorfazone or endolac or enfenamic acid or epirizole or etodolac or 
etofenamate or etoricoxib or excedrin or felbinac or fenamic acid derivative or fenbufen or 
fenclofenac or fenclozic acid or fendosal or fenflumizole or fenoprofen or fentiazac or 
fepradinol or feprazone or firategrast or firocoxib or flobufen or flosulide or flufenamate 
aluminum or flufenamic acid or flunixin or flunoxaprofen or fluproquazone or flurbiprofen 
or fosfosal or furaprofen or furobufen or furofenac or glucametacin or gluconate zinc or 
guacetisal or guaimesal or gw 406381 or ibufenacOR ibuprofen or ibuproxam or icoduline 
or iguratimod or imidazole salicylate or incb 3284 or incyclinide or indameth or indometacin 
or indoprofen or ipsalazide or isofezolac or isonixin or isoxepac or isoxicam or kebuzone or 
ketoprofen or ketorolac or leflunomide or licofelone or lonazolac or lornoxicam or 
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loxoprofen or lumiracoxib or lyprinol or lysine acetylsalicylate or magnesium salicylate or 
manoalide or mavacoxib or meclofenamate sodium or meclofenamic acid or mefenamic 
acid or meloxicam or mesalazine or metamizol or metiazinic acid or metoxibutropate or 
mirococept or miroprofen or mofebutazone or mofezolac or morazone or morniflumate or 
nabumetone or naproxcinod or naproxen or nepafenac or neurofenac or neurotropin or 
nictindole or niflumic acid or nimesulide or olsalazine or orpanoxin or oxaceprol or 
oxametacin or oxaprazine or oxaprozin or oxicam derivative or oxindanac or 
oxyphenbutazone or palifermin or parecoxib or pelubiprofen or pemedolac or perisoxal or 
phenazone or phenylbutazone or picolamine salicylate or piketoprofen or pimeprofen or 
pipebuzone or piproxen or pirazolac or piroxicam or pirprofen or pralnacasan or 
pranoprofen or prinomide or proglumetacin or proglumetacin maleate or propyphenazone 
or proquazone or pyrazinobutazone or resatorvid or rimazolium or robenacoxib or 
rofecoxib or romazarit or rosmarinic acid or salicylic acid or salsalate or scalaradial or 
semapimod or sudoxicam or sulindac or suprofen or suxibuzone or talniflumate or tenidap 
or tenoxicam or tepoxalin or teriflunomide or tiaprofenic acid or tiaramide or tilmacoxib or 
tilnoprofen arbamel or tilomisole or timegadine or tioxamast or tioxaprofen or tolfenamic 
acid or tolmetin or tribuzone or triethanolamine salicylate or tropesin or ufenamate or 
valategrast or valdecoxib or ximoprofen or zaltoprofen or zidometacin or zinc salicylate or 
zoliprofen or zomepirac) OR TI=(aceclofenac or acemetacin or acetylsalicyl* or 
actaritajulemic acid or alclofenac or alminoprofen or aloxiprin or amfenac or aminosalicylic 
acid or ampiroxicam or amtolmetin guacil or anacin or anirolac or antiflammin or 
apadenoson or arthrotec or ascriptin or balsalazide or bardoxolone or bendazac or 
benorilate or benoxaprofen or bermoprofen or bimosiamose or bromfenac or broperamole 
or bucloxic acid or bucolome or bufexamac or butibufen or camobucol or carbasalate 
calcium or carprofen or celecoxib or centchroman or cicloprofen or cimicoxib or cinmetacin 
or cinnoxicam or clidanac or clofenamic acid or clofezone or clonixin or cloximate or 
dehydrozingerone or demethoxycurcumin or deracoxib or dexibuprofen or dexketoprofen 
or diclofenac or didemethoxycurcumin or diflunisal or diftalone or dimethyl sulfoxide or 
diphenpyramide or ditazole or droxicam ebselen or emorfazone or endolac or enfenamic 
acid or epirizole or etodolac or etofenamate or etoricoxib or excedrin or felbinac or fenamic 
acid derivative or fenbufen or fenclofenac or fenclozic acid or fendosal or fenflumizole or 
fenoprofen or fentiazac or fepradinol or feprazone or firategrast or firocoxib or flobufen or 
flosulide or flufenamate aluminum or flufenamic acid or flunixin or flunoxaprofen or 
fluproquazone or flurbiprofen or fosfosal or furaprofen or furobufen or furofenac or 
glucametacin or gluconate zinc or guacetisal or guaimesal or gw 406381 or ibufenacOR 
ibuprofen or ibuproxam or icoduline or iguratimod or imidazole salicylate or incb 3284 or 
incyclinide or indameth or indometacin or indoprofen or ipsalazide or isofezolac or isonixin 
or isoxepac or isoxicam or kebuzone or ketoprofen or ketorolac or leflunomide or licofelone 
or lonazolac or lornoxicam or loxoprofen or lumiracoxib or lyprinol or lysine acetylsalicylate 
or magnesium salicylate or manoalide or mavacoxib or meclofenamate sodium or 
meclofenamic acid or mefenamic acid or meloxicam or mesalazine or metamizol or 
metiazinic acid or metoxibutropate or mirococept or miroprofen or mofebutazone or 
mofezolac or morazone or morniflumate or nabumetone or naproxcinod or naproxen or 
nepafenac or neurofenac or neurotropin or nictindole or niflumic acid or nimesulide or 
olsalazine or orpanoxin or oxaceprol or oxametacin or oxaprazine or oxaprozin or oxicam 
derivative or oxindanac or oxyphenbutazone or palifermin or parecoxib or pelubiprofen or 
pemedolac or perisoxal or phenazone or phenylbutazone or picolamine salicylate or 
piketoprofen or pimeprofen or pipebuzone or piproxen or pirazolac or piroxicam or 
pirprofen or pralnacasan or pranoprofen or prinomide or proglumetacin or proglumetacin 
maleate or propyphenazone or proquazone or pyrazinobutazone or resatorvid or 
rimazolium or robenacoxib or rofecoxib or romazarit or rosmarinic acid or salicylic acid or 
salsalate or scalaradial or semapimod or sudoxicam or sulindac or suprofen or suxibuzone 
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or talniflumate or tenidap or tenoxicam or tepoxalin or teriflunomide or tiaprofenic acid or 
tiaramide or tilmacoxib or tilnoprofen arbamel or tilomisole or timegadine or tioxamast or 
tioxaprofen or tolfenamic acid or tolmetin or tribuzone or triethanolamine salicylate or 
tropesin or ufenamate or valategrast or valdecoxib or ximoprofen or zaltoprofen or 
zidometacin or zinc salicylate or zoliprofen or zomepirac) 
4. TS=(azium or colofoam or decadron or decadrone or decaesadril or decamethasone or 
dectancyl or deltafluorene or deronil or dexa-p or dexacort or dexagel or dexame or 
dexameson or dexametason or dexametasone or dexameth or dexamethason or 
dexamethasone or dexamethazon or dexamethazone or dexamonozon or dexan or 
dexascheroson or dexason or dexasone or dexmethsone or dexone or diodex or fluorocort 
or fortecortin or gammacorten or hexadecadrol or hexadrol or isopto-dex or isopto-
maxidex or maxidex or methylfluorprednisolone or millicorten or opticortinol or oradexon 
or oradexone or orgadrone or ozurdex or policort or posurdex or prednisolone or 
thilodexine) OR TI=(azium or colofoam or decadron or decadrone or decaesadril or 
decamethasone or dectancyl or deltafluorene or deronil or dexa-p or dexacort or dexagel or 
dexame or dexameson or dexametason or dexametasone or dexameth or dexamethason or 
dexamethasone or dexamethazon or dexamethazone or dexamonozon or dexan or 
dexascheroson or dexason or dexasone or dexmethsone or dexone or diodex or fluorocort 
or fortecortin or gammacorten or hexadecadrol or hexadrol or isopto-dex or isopto-
maxidex or maxidex or methylfluorprednisolone or millicorten or opticortinol or oradexon 
or oradexone or orgadrone or ozurdex or policort or posurdex or prednisolone or 
thilodexine) 
5. (#1 OR #2 OR #3) AND #4 
6. TS=((tonsil* adj3 surgery) or (remov* adj3 tonsil*) or (tonsillectom* or tonsilectom* or 
adenotonsil* or adeno-tonsill*)) OR TI=((tonsil* adj3 surgery) or (remov* adj3 tonsil*) or 
(tonsillectom* or tonsilectom* or adenotonsil* or adeno-tonsill*)) 
7. TS=(child* or adolescen* or kid or kids or youth* or youngster* or minor or minors or 
teen* or juvenile* or student* or pupil or pupils or boy or boys or girl or girls or under 
eighteen* or under age* or pediatric* or paediatric*) OR TI=(child* or adolescen* or kid or 
kids or youth* or youngster* or minor or minors or teen* or juvenile* or student* or pupil 
or pupils or boy or boys or girl or girls or under 18* or underage 18* or under eighteen* or 
under age* or pediatric* or paediatric*) 
8. TS=(young adj (person* or people or adult* or individual* or women or woman or men 
or man)) OR TI=(young adj (person* or people or adult* or individual* or women or woman 
or men or man)) 
9. #7 OR #8 
10. (#5 AND #6 AND #9) OR (#4 AND #6 AND #9)  
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Cumulative Index to Nursing and Allied Health Literature (CINAHL®) via ebscohost.com 
1. exp ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL 
2. nsaid* or non-steroidal anti-inflammatory agent* or nonsteroidal anti-inflammatory 
agent* or non-steroidal antiinflammatory agent* or nonsteroidal antiinflammatory agent* 
or non steroidal anti inflammatory drug* or non steroidal antiinflammatory drug* or 
nonsteroidal antiinflammatory drug* or nonsteroidal anti inflammatory drug* or non-
steroidal anti-rheumatic agent* or non-steroidal antirheumatic agent* or nonsteroidal anti-
rheumatic agent* or nonsteroidal antirheumatic agent* or anti-inflammatory analgesic* or 
antiinflammatory analgesic* or aspirin-like agent*.ti,ab. 
3. non-steroid anti-inflammatory agent* or nonsteroid anti-inflammatory agent* or non-
steroid antiinflammatory agent* or nonsteroid antiinflammatory agent* or non steroid anti 
inflammatory drug* or non steroid antiinflammatory drug* or nonsteroid antiinflammatory 
drug* or nonsteroid anti inflammatory drug* or non-steroid anti-rheumatic agent* or non-
steroid antirheumatic agent* or nonsteroid anti-rheumatic agent* or nonsteroid 
antirheumatic agent*.ti,ab 
4. aceclofenac or acemetacin or acetylsalicyl* or actaritajulemic acid or alclofenac or 
alminoprofen or aloxiprin or amfenac or aminosalicylic acid or ampiroxicam or amtolmetin 
guacil or anacin or anirolac or antiflammin or apadenoson or arthrotec or ascriptin or 
balsalazide or bardoxolone or bendazac or benorilate or benoxaprofen or bermoprofen or 
bimosiamose or bromfenac or broperamole or bucloxic acid or bucolome or bufexamac or 
butibufen or camobucol or carbasalate calcium or carprofen or celecoxib or centchroman 
or cicloprofen or cimicoxib or cinmetacin or cinnoxicam or clidanac or clofenamic acid or 
clofezone or clonixin or cloximate or dehydrozingerone or demethoxycurcumin or 
deracoxib or dexibuprofen or dexketoprofen or diclofenac or didemethoxycurcumin or 
diflunisal or diftalone or dimethyl sulfoxide or diphenpyramide or ditazole or droxicam 
ebselen or emorfazone or endolac or enfenamic acid or epirizole or etodolac or 
etofenamate or etoricoxib or excedrin or felbinac or fenamic acid derivative or fenbufen or 
fenclofenac or fenclozic acid or fendosal or fenflumizole or fenoprofen or fentiazac or 
fepradinol or feprazone or firategrast or firocoxib or flobufen or flosulide or flufenamate 
aluminum or flufenamic acid or flunixin or flunoxaprofen or fluproquazone or flurbiprofen 
or fosfosal or furaprofen or furobufen or furofenac or glucametacin or gluconate zinc or 
guacetisal or guaimesal or gw 406381 or ibufenacOR ibuprofen or ibuproxam or icoduline 
or iguratimod or imidazole salicylate or incb 3284 or incyclinide or indameth or indometacin 
or indoprofen or ipsalazide or isofezolac or isonixin or isoxepac or isoxicam or kebuzone or 
ketoprofen or ketorolac or leflunomide or licofelone or lonazolac or lornoxicam or 
loxoprofen or lumiracoxib or lyprinol or lysine acetylsalicylate or magnesium salicylate or 
manoalide or mavacoxib or meclofenamate sodium or meclofenamic acid or mefenamic 
acid or meloxicam or mesalazine or metamizol or metiazinic acid or metoxibutropate or 
mirococept or miroprofen or mofebutazone or mofezolac or morazone or morniflumate or 
nabumetone or naproxcinod or naproxen or nepafenac or neurofenac or neurotropin or 
nictindole or niflumic acid or nimesulide or olsalazine or orpanoxin or oxaceprol or 
oxametacin or oxaprazine or oxaprozin or oxicam derivative or oxindanac or 
oxyphenbutazone or palifermin or parecoxib or pelubiprofen or pemedolac or perisoxal or 
phenazone or phenylbutazone or picolamine salicylate or piketoprofen or pimeprofen or 
pipebuzone or piproxen or pirazolac or piroxicam.ti,ab  
5. pirprofen or pralnacasan or pranoprofen or prinomide or proglumetacin or 
proglumetacin maleate or propyphenazone or proquazone or pyrazinobutazone or 
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resatorvid or rimazolium or robenacoxib or rofecoxib or romazarit or rosmarinic acid or 
salicylic acid or salsalate or scalaradial or semapimod or sudoxicam or sulindac or suprofen 
or suxibuzone or talniflumate or tenidap or tenoxicam or tepoxalin or teriflunomide or 
tiaprofenic acid or tiaramide or tilmacoxib or tilnoprofen arbamel or tilomisole or 
timegadine or tioxamast or tioxaprofen or tolfenamic acid or tolmetin or tribuzone or 
triethanolamine salicylate or tropesin or ufenamate or valategrast or valdecoxib or 
ximoprofen or zaltoprofen or zidometacin or zinc salicylate or zoliprofen or zomepirac.ti,ab. 
6. DEXAMETHASONE/  
7. azium or colofoam or decadron or decadrone or decaesadril or decamethasone or 
dectancyl or deltafluorene or deronil or dexa-p or dexacort or dexagel or dexame or 
dexameson or dexametason or dexametasone or dexameth or dexamethason or 
dexamethasone or dexamethazon or dexamethazone or dexamonozon or dexan or 
dexascheroson or dexason or dexasone or dexmethsone or dexone or diodex or fluorocort 
or fortecortin or gammacorten or hexadecadrol or hexadrol or isopto-dex or isopto-
maxidex or maxidex or methylfluorprednisolone or millicorten or opticortinol or oradexon 
or oradexone or orgadrone or ozurdex or policort or posurdex or prednisolone or 
thilodexine.ti,ab 
8. (OR/1-5) AND (OR/6-7)  
9. TONSILLECTOMY/ 
10. (tonsil* adj3 surgery). ti,ab. 
11. (remov* adj3 tonsil*).ti,ab. 
12. tonsillectom* or tonsilectom* or adenotonsil* or adeno-tonsill*.ti,ab. 
13. OR/9-12 
14. exp CHILD/ 
15. exp INFANT/ 
16. ADOLESCENT HEALTH SERVICES/OR exp ADOLESCENCE/OR ADOLESCENT, 
HOSPITALIZED/ 
17. exp STUDENTS/ 
18. exp PEDIATRICS/ 
19. child* or adolescen* or kid or kids or youth* or youngster* or minor or minors or teen* 
or juvenile* or student* or pupil or pupils or boy or boys or girl or girls or under 18* or 
underage 18* or under eighteen* or under age* or pediatric* or paediatric*.ti,ab 
20. (young adj person*).ti,ab 
21. (young adj people) .ti,ab 
22. (young adj adult*).ti,ab 
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23. (young adj individual*).ti,ab  
24. (young adj women) .ti,ab 
25. (young adj woman) .ti,ab 
26. (young adj men) .ti,ab 
27. (young adj man) .ti,ab 
28. OR/14-27 
29. (8 AND 13 AND 28) OR (OR/6-7 AND 13 AND 28) 
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Cochrane Library, The http://www.thecochranelibrary.com/view/0/index.html 
1. MeSH descriptor Anti-inflammatory Agents, Non-steroidal explode all trees 
2. (nsaid* or non-steroidal anti-inflammatory agent* or nonsteroidal anti-inflammatory 
agent* or non-steroidal antiinflammatory agent* or nonsteroidal antiinflammatory agent* 
or non steroidal anti inflammatory drug* or non steroidal antiinflammatory drug* or 
nonsteroidal antiinflammatory drug* or nonsteroidal anti inflammatory drug* or non-
steroidal anti-rheumatic agent* or non-steroidal antirheumatic agent* or nonsteroidal anti-
rheumatic agent* or nonsteroidal antirheumatic agent* or anti-inflammatory analgesic* or 
antiinflammatory analgesic* or aspirin-like agent*):ti 
3. (nsaid* or non-steroidal anti-inflammatory agent* or nonsteroidal anti-inflammatory 
agent* or non-steroidal antiinflammatory agent* or nonsteroidal antiinflammatory agent* 
or non steroidal anti inflammatory drug* or non steroidal antiinflammatory drug* or 
nonsteroidal antiinflammatory drug* or nonsteroidal anti inflammatory drug* or non-
steroidal anti-rheumatic agent* or non-steroidal antirheumatic agent* or nonsteroidal anti-
rheumatic agent* or nonsteroidal antirheumatic agent* or anti-inflammatory analgesic* or 
antiinflammatory analgesic* or aspirin-like agent*):ab 
4. (non-steroid anti-inflammatory agent* or nonsteroid anti-inflammatory agent* or non-
steroid antiinflammatory agent* or nonsteroid antiinflammatory agent* or non steroid anti 
inflammatory drug* or non steroid antiinflammatory drug* or nonsteroid antiinflammatory 
drug* or nonsteroid anti inflammatory drug* or non-steroid anti-rheumatic agent* or non-
steroid antirheumatic agent* or nonsteroid anti-rheumatic agent* or nonsteroid 
antirheumatic agent*):ti 
5. (non-steroid anti-inflammatory agent* or nonsteroid anti-inflammatory agent* or non-
steroid antiinflammatory agent* or nonsteroid antiinflammatory agent* or non steroid anti 
inflammatory drug* or non steroid antiinflammatory drug* or nonsteroid antiinflammatory 
drug* or nonsteroid anti inflammatory drug* or non-steroid anti-rheumatic agent* or non-
steroid antirheumatic agent* or nonsteroid anti-rheumatic agent* or nonsteroid 
antirheumatic agent*):ab 
6. (aceclofenac or acemetacin or acetylsalicyl* or actaritajulemic acid or alclofenac or 
alminoprofen or aloxiprin or amfenac or aminosalicylic acid or ampiroxicam or amtolmetin 
guacil or anacin or anirolac or antiflammin or apadenoson or arthrotec or ascriptin or 
balsalazide or bardoxolone or bendazac or benorilate or benoxaprofen or bermoprofen or 
bimosiamose or bromfenac or broperamole or bucloxic acid or bucolome or bufexamac or 
butibufen or camobucol or carbasalate calcium or carprofen or celecoxib or centchroman 
or cicloprofen or cimicoxib or cinmetacin or cinnoxicam or clidanac or clofenamic acid or 
clofezone or clonixin or cloximate or dehydrozingerone or demethoxycurcumin or 
deracoxib or dexibuprofen or dexketoprofen or diclofenac or didemethoxycurcumin or 
diflunisal or diftalone or dimethyl sulfoxide or diphenpyramide or ditazole or droxicam 
ebselen or emorfazone or endolac or enfenamic acid or epirizole or etodolac or 
etofenamate or etoricoxib or excedrin or felbinac or fenamic acid derivative or fenbufen or 
fenclofenac or fenclozic acid or fendosal or fenflumizole or fenoprofen):ti 
7. (aceclofenac or acemetacin or acetylsalicyl* or actaritajulemic acid or alclofenac or 
alminoprofen or aloxiprin or amfenac or aminosalicylic acid or ampiroxicam or amtolmetin 
guacil or anacin or anirolac or antiflammin or apadenoson or arthrotec or ascriptin or 
balsalazide or bardoxolone or bendazac or benorilate or benoxaprofen or bermoprofen or 
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bimosiamose or bromfenac or broperamole or bucloxic acid or bucolome or bufexamac or 
butibufen or camobucol or carbasalate calcium or carprofen or celecoxib or centchroman 
or cicloprofen or cimicoxib or cinmetacin or cinnoxicam or clidanac or clofenamic acid or 
clofezone or clonixin or cloximate or dehydrozingerone or demethoxycurcumin or 
deracoxib or dexibuprofen or dexketoprofen or diclofenac or didemethoxycurcumin or 
diflunisal or diftalone or dimethyl sulfoxide or diphenpyramide or ditazole or droxicam 
ebselen or emorfazone or endolac or enfenamic acid or epirizole or etodolac or 
etofenamate or etoricoxib or excedrin or felbinac or fenamic acid derivative or fenbufen or 
fenclofenac or fenclozic acid or fendosal or fenflumizole or fenoprofen):ab 
8. (fentiazac or fepradinol or feprazone or firategrast or firocoxib or flobufen or flosulide or 
flufenamate aluminum or flufenamic acid or flunixin or flunoxaprofen or fluproquazone or 
flurbiprofen or fosfosal or furaprofen or furobufen or furofenac or glucametacin or 
gluconate zinc or guacetisal or guaimesal or gw 406381 or ibufenacOR ibuprofen or 
ibuproxam or icoduline or iguratimod or imidazole salicylate or incb 3284 or incyclinide or 
indameth or indometacin or indoprofen or ipsalazide or isofezolac or isonixin or isoxepac or 
isoxicam or kebuzone or ketoprofen or ketorolac or leflunomide or licofelone or lonazolac 
or lornoxicam or loxoprofen or lumiracoxib or lyprinol or lysine acetylsalicylate or 
magnesium salicylate or manoalide or mavacoxib or meclofenamate sodium or 
meclofenamic acid or mefenamic acid or meloxicam):ti 
9. (fentiazac or fepradinol or feprazone or firategrast or firocoxib or flobufen or flosulide or 
flufenamate aluminum or flufenamic acid or flunixin or flunoxaprofen or fluproquazone or 
flurbiprofen or fosfosal or furaprofen or furobufen or furofenac or glucametacin or 
gluconate zinc or guacetisal or guaimesal or gw 406381 or ibufenacOR ibuprofen or 
ibuproxam or icoduline or iguratimod or imidazole salicylate or incb 3284 or incyclinide or 
indameth or indometacin or indoprofen or ipsalazide or isofezolac or isonixin or isoxepac or 
isoxicam or kebuzone or ketoprofen or ketorolac or leflunomide or licofelone or lonazolac 
or lornoxicam or loxoprofen or lumiracoxib or lyprinol or lysine acetylsalicylate or 
magnesium salicylate or manoalide or mavacoxib or meclofenamate sodium or 
meclofenamic acid or mefenamic acid or meloxicam):ab 
10. (mesalazine or metamizol or metiazinic acid or metoxibutropate or mirococept or 
miroprofen or mofebutazone or mofezolac or morazone or morniflumate or nabumetone 
or naproxcinod or naproxen or nepafenac or neurofenac or neurotropin or nictindole or 
niflumic acid or nimesulide or olsalazine or orpanoxin or oxaceprol or oxametacin or 
oxaprazine or oxaprozin or oxicam derivative or oxindanac or oxyphenbutazone or 
palifermin or parecoxib or pelubiprofen or pemedolac or perisoxal or phenazone or 
phenylbutazone or picolamine salicylate or piketoprofen or pimeprofen or pipebuzone or 
piproxen or pirazolac or piroxicam):ti 
11. (mesalazine or metamizol or metiazinic acid or metoxibutropate or mirococept or 
miroprofen or mofebutazone or mofezolac or morazone or morniflumate or nabumetone 
or naproxcinod or naproxen or nepafenac or neurofenac or neurotropin or nictindole or 
niflumic acid or nimesulide or olsalazine or orpanoxin or oxaceprol or oxametacin or 
oxaprazine or oxaprozin or oxicam derivative or oxindanac or oxyphenbutazone or 
palifermin or parecoxib or pelubiprofen or pemedolac or perisoxal or phenazone or 
phenylbutazone or picolamine salicylate or piketoprofen or pimeprofen or pipebuzone or 
piproxen or pirazolac or piroxicam):ab 
12. (pirprofen or pralnacasan or pranoprofen or prinomide or proglumetacin or 
proglumetacin maleate or propyphenazone or proquazone or pyrazinobutazone or 
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resatorvid or rimazolium or robenacoxib or rofecoxib or romazarit or rosmarinic acid or 
salicylic acid or salsalate or scalaradial or semapimod or sudoxicam or sulindac or suprofen 
or suxibuzone or talniflumate or tenidap or tenoxicam or tepoxalin or teriflunomide or 
tiaprofenic acid or tiaramide or tilmacoxib or tilnoprofen arbamel or tilomisole or 
timegadine or tioxamast or tioxaprofen or tolfenamic acid or tolmetin or tribuzone or 
triethanolamine salicylate or tropesin or ufenamate or valategrast or valdecoxib or 
ximoprofen or zaltoprofen or zidometacin or zinc salicylate or zoliprofen or zomepirac):ti 
13. (pirprofen or pralnacasan or pranoprofen or prinomide or proglumetacin or 
proglumetacin maleate or propyphenazone or proquazone or pyrazinobutazone or 
resatorvid or rimazolium or robenacoxib or rofecoxib or romazarit or rosmarinic acid or 
salicylic acid or salsalate or scalaradial or semapimod or sudoxicam or sulindac or suprofen 
or suxibuzone or talniflumate or tenidap or tenoxicam or tepoxalin or teriflunomide or 
tiaprofenic acid or tiaramide or tilmacoxib or tilnoprofen arbamel or tilomisole or 
timegadine or tioxamast or tioxaprofen or tolfenamic acid or tolmetin or tribuzone or 
triethanolamine salicylate or tropesin or ufenamate or valategrast or valdecoxib or 
ximoprofen or zaltoprofen or zidometacin or zinc salicylate or zoliprofen or zomepirac):ab 
14. MesH descriptor Dexamethasone explode all trees 
15. (azium or colofoam or decadron or decadrone or decaesadril or decamethasone or 
dectancyl or deltafluorene or deronil or dexa-p or dexacort or dexagel or dexame or 
dexameson or dexametason or dexametasone or dexameth or dexamethason or 
dexamethasone or dexamethazon or dexamethazone or dexamonozon or dexan or 
dexascheroson or dexason or dexasone or dexmethsone or dexone or diodex or fluorocort 
or fortecortin or gammacorten or hexadecadrol or hexadrol or isopto-dex or isopto-
maxidex or maxidex or methylfluorprednisolone or millicorten or opticortinol or oradexon 
or oradexone or orgadrone or ozurdex or policort or posurdex or prednisolone or 
thilodexine):ti 
16. (azium or colofoam or decadron or decadrone or decaesadril or decamethasone or 
dectancyl or deltafluorene or deronil or dexa-p or dexacort or dexagel or dexame or 
dexameson or dexametason or dexametasone or dexameth or dexamethason or 
dexamethasone or dexamethazon or dexamethazone or dexamonozon or dexan or 
dexascheroson or dexason or dexasone or dexmethsone or dexone or diodex or fluorocort 
or fortecortin or gammacorten or hexadecadrol or hexadrol or isopto-dex or isopto-
maxidex or maxidex or methylfluorprednisolone or millicorten or opticortinol or oradexon 
or oradexone or orgadrone or ozurdex or policort or posurdex or prednisolone or 
thilodexine):ab 
17. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 
OR #14 OR #16  
18. MeSH descriptor Tonsillectomy explode all trees 
19. (tonsil* adj3 surgery):ti 
20.  (tonsil* adj3 surgery):ab 
21. (remov* adj3 tonsil*):ti 
22.  (remov* adj3 tonsil*):ab 
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23. (tonsillectom* or tonsilectom* or adenotonsil* or adeno-tonsill*):ti 
24. (tonsillectom* or tonsilectom* or adenotonsil* or adeno-tonsill*):ab 
25. #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 
26. MeSH descriptor Child explode all trees 
27. MeSH descriptor Infant explode all trees 
28. MeSH descriptor Adolescent explode all trees 
29. MeSH descriptor Students explode all trees 
30. MeSH descriptor Pediatrics explode all trees 
31. (child* or adolescen* or kid or kids or youth* or youngster* or minor or minors or teen* 
or juvenile* or student* or pupil or pupils or boy or boys or girl or girls or under 18* or 
underage 18* or under eighteen* or under age* or pediatric* or paediatric*):ti 
32. (child* or adolescen* or kid or kids or youth* or youngster* or minor or minors or teen* 
or juvenile* or student* or pupil or pupils or boy or boys or girl or girls or under 18* or 
underage 18* or under eighteen* or under age* or pediatric* or paediatric*):ab 
33. (young adj person*):ti 
34. (young adj person*):ab 
35. (young adj people):ti 
36. (young adj people*):ab 
37. (young adj adult*):ti 
38. (young adj adult*):ab 
39. (young adj individual*):ti 
40. (young adj individual*):ab 
41. (young adj women):ti 
42. (young adj women*):ab 
43. (young adj woman):ti 
44. (young adj woman*):ab 
45. (young adj men):ti 
46. (young adj men*):ab 
47. (young adj man):ti 
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48. (young adj man):ab 
49. #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR 
#37 OR #38 OR   #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 
50. #17 AND #25 AND #49 
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Database of Abstracts of Reviews of Effectiveness (DARE) 
http://www.crd.york.ac.uk/CMS2Web 
1. MeSH DESCRIPTOR Anti-Inflammatory Agents, Non-Steroidal EXPLODE ALL TREES: 
2. (nsaid*) OR (non-steroidal anti-inflammatory agent*) OR (nonsteroidal anti-inflammatory 
agent*) OR  (non-steroidal antiinflammatory agent*) OR (nonsteroidal antiinflammatory 
agent):IN DARE, NHSEED, HTA 
3. (non steroidal anti inflammatory drug*) OR (non steroidal antiinflammatory drug*) OR 
(nonsteroidal antiinflammatory drug*) OR (nonsteroidal anti inflammatory drug*) OR (non-
steroidal anti-rheumatic agent*):IN DARE, NHSEED, HTA 
4. (non-steroidal antirheumatic agent*) OR (nonsteroidal anti-rheumatic agent*) OR 
(nonsteroidal antirheumatic agent*) OR (anti-inflammatory analgesic*) OR 
(antiinflammatory analgesic*):IN DARE, NHSEED, HTA 
5. (aspirin-like agent*) OR (non-steroid anti-inflammatory agent*) OR (nonsteroid anti-
inflammatory agent*) OR (non-steroid antiinflammatory agent*) OR (nonsteroid anti-
inflammatory):IN DARE, NHSEED, HTA 
6. (non steroid anti inflammatory drug*) OR (non steroid anti-inflammatory drug*) OR 
(nonsteroid antiinflammatory drug*) OR (nonsteroid anti inflammatory drug*) OR (non-
steroid anti-rheumatic agent*) :IN DARE, NHSEED, HTA 
7. (non-steroid antirheumatic agent*) OR (nonsteroid anti-rheumatic agent*) OR 
(nonsteroid antirheumatic agent*) :IN DARE, NHSEED, HTA 
8. (aceclofenac or acemetacin or acetylsalicyl* or actaritajulemic acid or alclofenac or 
alminoprofen or aloxiprin or amfenac or aminosalicylic acid or ampiroxicam or amtolmetin 
guacil or anacin or anirolac or antiflammin or apadenoson or arthrotec or ascriptin or 
balsalazide or bardoxolone or bendazac or benorilate or benoxaprofen or bermoprofen or 
bimosiamose or bromfenac or broperamole or bucloxic acid or bucolome or bufexamac or 
butibufen or camobucol or carbasalate calcium or carprofen or celecoxib or centchroman 
or cicloprofen or cimicoxib or cinmetacin or cinnoxicam or clidanac or clofenamic acid or 
clofezone or clonixin or cloximate or dehydrozingerone or demethoxycurcumin or 
deracoxib or dexibuprofen or dexketoprofen or diclofenac or didemethoxycurcumin or 
diflunisal or diftalone or dimethyl sulfoxide or diphenpyramide or ditazole or droxicam 
ebselen or emorfazone or endolac or enfenamic acid or epirizole or etodolac or 
etofenamate or etoricoxib or excedrin or felbinac or fenamic acid derivative or fenbufen or 
fenclofenac or fenclozic acid or fendosal or fenflumizole or fenoprofen or fentiazac or 
fepradinol or feprazone or firategrast or firocoxib or flobufen or flosulide or flufenamate 
aluminum or flufenamic acid or flunixin or flunoxaprofen or fluproquazone or flurbiprofen 
or fosfosal or furaprofen or furobufen or furofenac or glucametacin or gluconate zinc or 
guacetisal or guaimesal or gw 406381 or ibufenacOR ibuprofen or ibuproxam or icoduline 
or iguratimod or imidazole salicylate or incb 3284 or incyclinide or indameth or indometacin 
or indoprofen or ipsalazide or isofezolac or isonixin or isoxepac or isoxicam or kebuzone or 
ketoprofen or ketorolac or leflunomide or licofelone or lonazolac or lornoxicam or 
loxoprofen or lumiracoxib or lyprinol or lysine acetylsalicylate or magnesium salicylate or 
manoalide or mavacoxib or meclofenamate sodium or meclofenamic acid or mefenamic 
acid or meloxicam or mesalazine or metamizol or metiazinic acid or metoxibutropate or 
mirococept or miroprofen or mofebutazone or mofezolac or morazone or morniflumate or 
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nabumetone or naproxcinod or naproxen or nepafenac or neurofenac or neurotropin or 
nictindole or niflumic acid or nimesulide or olsalazine or orpanoxin or oxaceprol or 
oxametacin or oxaprazine or oxaprozin or oxicam derivative or oxindanac or 
oxyphenbutazone or palifermin or parecoxib or pelubiprofen or pemedolac or perisoxal or 
phenazone or phenylbutazone or picolamine salicylate or piketoprofen or pimeprofen or 
pipebuzone or piproxen or pirazolac or piroxicam or pirprofen or pralnacasan or 
pranoprofen or prinomide or proglumetacin or proglumetacin maleate or propyphenazone 
or proquazone or pyrazinobutazone or resatorvid or rimazolium or robenacoxib or 
rofecoxib or romazarit or rosmarinic acid or salicylic acid or salsalate or scalaradial or 
semapimod or sudoxicam or sulindac or suprofen or suxibuzone or talniflumate or tenidap 
or tenoxicam or tepoxalin or teriflunomide or tiaprofenic acid or tiaramide or tilmacoxib or 
tilnoprofen arbamel or tilomisole or timegadine or tioxamast or tioxaprofen or tolfenamic 
acid or tolmetin or tribuzone or triethanolamine salicylate or tropesin or ufenamate or 
valategrast or valdecoxib or ximoprofen or zaltoprofen or zidometacin or zinc salicylate or 
zoliprofen or zomepirac): IN DARE, NHSEED, HTA 
9. or/1-8 
10. MeSH DESCRIPTOR Dexamethasone EXPLODE ALL TREES: 
11. (azium or colofoam or decadron or decadrone or decaesadril or decamethasone or 
dectancyl or deltafluorene or deronil or dexa-p or dexacort or dexagel or dexame or 
dexameson or dexametason or dexametasone or dexameth or dexamethason or 
dexamethasone or dexamethazon or dexamethazone or dexamonozon or dexan or 
dexascheroson or dexason or dexasone or dexmethsone or dexone or diodex or fluorocort 
or fortecortin or gammacorten or hexadecadrol or hexadrol or isopto-dex or isopto-
maxidex or maxidex or methylfluorprednisolone or millicorten or opticortinol or oradexon 
or oradexone or orgadrone or ozurdex or policort or posurdex or prednisolone or 
thilodexine): IN DARE, NHSEED, HTA 
12. or/10-11 
13. MeSH DESCRIPTOR Tonsillectomy EXPLODE ALL TREES: 
14. MeSH DESCRIPTOR Adenoidectomy EXPLODE ALL TREES: 
15. ((tonsil* adj3 surgery) OR (remov* adj3 tonsil*) OR (tonsillectom* OR tonsilectom* OR 
adenotonsil* OR adeno-tonsill*)): IN DARE, NHSEED, HTA 
16. or/13-15 
17. MeSH DESCRIPTOR Child EXPLODE ALL TREES: 
18. MeSH DESCRIPTOR Infant EXPLODE ALL TREES: 
19. MeSH DESCRIPTOR Adolescent EXPLODE ALL TREES: 
20. MeSH DESCRIPTOR Students EXPLODE ALL TREES: 
21. MeSH DESCRIPTOR Pediatrics EXPLODE ALL TREES: 
22. (child* or adolescen* or kid or kids or youth* or youngster* or minor or minors or teen* 
or juvenile* or student* or pupil or pupils or boy or boys or girl or girls or under 18* or 
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underage 18* or under eighteen* or under age* or pediatric* or paediatric*): IN DARE, 
NHSEED, HTA 
23. (young adj (person* or people or adult* or individual* or women or woman or men or 
man)): IN DARE, NHSEED, HTA 
24. or/17-23 
25. (9 and 12) and 16 and 24 
26. 12 and 16 and 24 
27. 25 or 26 
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Excerpta Medica database (EMBASE™)  via www.library.nhs.uk 
1. NONSTEROID ANTIINFLAMMATORY AGENT/ 
2. (nsaid* or non-steroidal anti-inflammatory agent* or nonsteroidal 
anti-inflammatory agent* or non-steroidal antiinflammatory agent* or 
nonsteroidal antiinflammatory agent* or non steroidal anti inflammatory 
drug* or non steroidal antiinflammatory drug* or nonsteroidal 
antiinflammatory drug* or nonsteroidal anti inflammatory drug* or 
non-steroidal anti-rheumatic agent* or non-steroidal antirheumatic agent* or 
nonsteroidal anti-rheumatic agent* or nonsteroidal antirheumatic agent* or 
anti-inflammatory analgesic* or antiinflammatory analgesic* or aspirin-like 
agent*).ti,ab. 
3. (non-steroid anti-inflammatory agent* or nonsteroid anti-inflammatory 
agent* or non-steroid antiinflammatory agent* or nonsteroid antiinflammatory 
agent* or non steroid anti inflammatory drug* or non steroid 
antiinflammatory drug* or nonsteroid antiinflammatory drug* or nonsteroid 
anti inflammatory drug* or non-steroid anti-rheumatic agent* or non-steroid 
antirheumatic agent* or nonsteroid anti-rheumatic agent* or nonsteroid 
antirheumatic agent*).ti,ab. 
4. (aceclofenac or acemetacin or acetylsalicyl* or actaritajulemic acid or 
alclofenac or alminoprofen or aloxiprin or amfenac or aminosalicylic acid or 
ampiroxicam or amtolmetin guacil or anacin or anirolac or antiflammin or 
apadenoson or arthrotec or ascriptin or balsalazide or bardoxolone or 
bendazac or benorilate or benoxaprofen or bermoprofen or bimosiamose or 
bromfenac or broperamole or bucloxic acid or bucolome or bufexamac or 
butibufen or camobucol or carbasalate calcium or carprofen or celecoxib or 
centchroman or cicloprofen or cimicoxib or cinmetacin or cinnoxicam or 
clidanac or clofenamic acid or clofezone or clonixin or cloximate or 
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dehydrozingerone or demethoxycurcumin or deracoxib or dexibuprofen or 
dexketoprofen or diclofenac or didemethoxycurcumin or diflunisal or 
diftalone or dimethyl sulfoxide or diphenpyramide or ditazole or droxicam 
ebselen or emorfazone or endolac or enfenamic acid or epirizole or etodolac 
or etofenamate or etoricoxib or excedrin or felbinac or fenamic acid 
derivative or fenbufen or fenclofenac or fenclozic acid or fendosal or 
fenflumizole or fenoprofen or fentiazac or fepradinol or feprazone or 
firategrast or firocoxib or flobufen or flosulide or flufenamate aluminum or 
flufenamic acid or flunixin or flunoxaprofen or fluproquazone or 
flurbiprofen or fosfosal or furaprofen or furobufen or furofenac or 
glucametacin or gluconate zinc or guacetisal or guaimesal or gw 406381 or 
ibufenac OR ibuprofen or ibuproxam or icoduline or iguratimod or imidazole 
salicylate or incb 3284 or incyclinide or indameth or indomethacin) .ti,ab 
5. indoprofen or ipsalazide or isofezolac or isonixin or isoxepac or isoxicam 
or kebuzone or ketoprofen or ketorolac or leflunomide or licofelone or 
lonazolac or lornoxicam or loxoprofen or lumiracoxib or lyprinol or lysine 
acetylsalicylate or magnesium salicylate or manoalide or mavacoxib or 
meclofenamate sodium or meclofenamic acid or mefenamic acid or meloxicam or 
mesalazine or metamizol or metiazinic acid or metoxibutropate or mirococept 
or miroprofen or mofebutazone or mofezolac or morazone or morniflumate or 
nabumetone or naproxcinod or naproxen or nepafenac or neurofenac or 
neurotropin or nictindole or niflumic acid or nimesulide or olsalazine or 
orpanoxin or oxaceprol or oxametacin or oxaprazine or oxaprozin or oxicam 
derivative or oxindanac or oxyphenbutazone or palifermin or parecoxib or 
pelubiprofen or pemedolac or perisoxal or phenazone or phenylbutazone or 
picolamine salicylate or piketoprofen or pimeprofen or pipebuzone or 
piproxen or pirazolac or piroxicam or pirprofen or pralnacasan or 
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pranoprofen or prinomide or proglumetacin or proglumetacin maleate or 
propyphenazone or proquazone or pyrazinobutazone or resatorvid or rimazolium 
or robenacoxib or rofecoxib or romazarit or rosmarinic acid or salicylic 
acid or salsalate or scalaradial or semapimod or sudoxicam or sulindac or 
suprofen or suxibuzone or talniflumate or tenidap or tenoxicam or tepoxalin 
or teriflunomide or tiaprofenic acid or tiaramide or tilmacoxib or 
tilnoprofen arbamel or tilomisole or timegadine or tioxamast or tioxaprofen 
or tolfenamic acid or tolmetin or tribuzone or triethanolamine salicylate or 
tropesin or ufenamate or valategrast or valdecoxib or ximoprofen or 
zaltoprofen or zidometacin or zinc salicylate or zoliprofen or 
zomepirac).ti,ab 
6. or/1-5 
7. exp DEXAMETHASONE/ OR exp DEXAMETHASONE 17 VALERATE/ OR exp 
DEXAMETHASONE ACETATE/ OR exp DEXAMETHASONE CIPECILATE/ OR exp 
DEXAMETHASONE DERIVATIVE/ OR exp DEXAMETHASONE SODIUM PHOSPHATE/ OR exp 
DEXAMETHASONE 17,21 DIPROPIONATE/ OR exp DEXAMETHASONE 21 MESILATE/ OR exp 
DEXAMETHASONE ISONICOTINATE/ 8. (azium or colofoam or decadron or decadrone or 
decaesadril or 
decamethasone or dectancyl or deltafluorene or deronil or dexa-p or dexacort 
or dexagel or dexame or dexameson or dexametason or dexametasone or dexameth 
or dexamethason or dexamethasone or dexamethazon or dexamethazone or 
dexamonozon or dexan or dexascheroson or dexason or dexasone or dexmethsone 
or dexone or diodex or fluorocort or fortecortin or gammacorten or 
hexadecadrol or hexadrol or isopto-dex or isopto-maxidex or maxidex or 
methylfluorprednisolone or millicorten or opticortinol or oradexon or 
oradexone or orgadrone or ozurdex or policort or posurdex or prednisolone or 
thilodexine).ti,ab 
9. or/7-8 
10. TONSILLECTOMY/ 
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11. ((tonsil* adj3 surgery) or (remov* adj3 tonsil*) or (tonsillectom* or 
tonsilectom* or adenotonsil* or adeno-tonsill*)).ti,ab. 
12. or/10-11 
13. exp CHILD/ 
14. exp INFANT/ 
15. exp ADOLESCENT/ 
16. exp STUDENT/   
17. exp PEDIATRICS/ 
18. (child* or adolescen* or kid or kids or youth* or youngster* or minor or 
minors or teen* or juvenile* or student* or pupil or pupils or boy or boys 
or girl or girls or under 18* or underage 18* or under eighteen* or under  
age* or pediatric* or paediatric*).ti,ab 
19. (young ADJ person* OR young ADJ people OR young ADJ adult* OR young ADJ 
individual* OR young ADJ women OR young ADJ woman OR young ADJ men OR young ADJ 
man).ti,ab  
20. or/13-19 
21. (6 and 9 and 12 and 20) or (9 and 12 and 20) 
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Medical Literature Analysis and Retrieval System Online (MEDLINE®) via ovid.com 
1. anti-inflammatory agents, non-steroidal/ 
2. (nsaid* or non-steroidal anti-inflammatory agent* or nonsteroidal 
anti-inflammatory agent* or non-steroidal antiinflammatory agent* or 
nonsteroidal antiinflammatory agent* or non steroidal anti inflammatory 
drug* or non steroidal antiinflammatory drug* or nonsteroidal 
antiinflammatory drug* or nonsteroidal anti inflammatory drug* or 
non-steroidal anti-rheumatic agent* or non-steroidal antirheumatic agent* or 
nonsteroidal anti-rheumatic agent* or nonsteroidal antirheumatic agent* or 
anti-inflammatory analgesic* or antiinflammatory analgesic* or aspirin-like 
agent*).ti,ab. 
3. (non-steroid anti-inflammatory agent* or nonsteroid anti-inflammatory 
agent* or non-steroid antiinflammatory agent* or nonsteroid antiinflammatory 
agent* or non steroid anti inflammatory drug* or non steroid 
antiinflammatory drug* or nonsteroid antiinflammatory drug* or nonsteroid 
anti inflammatory drug* or non-steroid anti-rheumatic agent* or non-steroid 
antirheumatic agent* or nonsteroid anti-rheumatic agent* or nonsteroid 
antirheumatic agent*).ti,ab. 
4. (aceclofenac or acemetacin or acetylsalicyl* or actaritajulemic acid or 
alclofenac or alminoprofen or aloxiprin or amfenac or aminosalicylic acid or 
ampiroxicam or amtolmetin guacil or anacin or anirolac or antiflammin or 
apadenoson or arthrotec or ascriptin or balsalazide or bardoxolone or 
bendazac or benorilate or benoxaprofen or bermoprofen or bimosiamose or 
bromfenac or broperamole or bucloxic acid or bucolome or bufexamac or 
butibufen or camobucol or carbasalate calcium or carprofen or celecoxib or 
centchroman or cicloprofen or cimicoxib or cinmetacin or cinnoxicam or 
clidanac or clofenamic acid or clofezone or clonixin or cloximate or 
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dehydrozingerone or demethoxycurcumin or deracoxib or dexibuprofen or 
dexketoprofen or diclofenac or didemethoxycurcumin or diflunisal or 
diftalone or dimethyl sulfoxide or diphenpyramide or ditazole or droxicam 
ebselen or emorfazone or endolac or enfenamic acid or epirizole or etodolac 
or etofenamate or etoricoxib or excedrin or felbinac or fenamic acid 
derivative or fenbufen or fenclofenac or fenclozic acid or fendosal or 
fenflumizole or fenoprofen or fentiazac or fepradinol or feprazone or 
firategrast or firocoxib or flobufen or flosulide or flufenamate aluminum or 
flufenamic acid or flunixin or flunoxaprofen or fluproquazone or 
flurbiprofen or fosfosal or furaprofen or furobufen or furofenac or 
glucametacin or gluconate zinc or guacetisal or guaimesal or gw 406381 or 
ibufenac OR ibuprofen or ibuproxam or icoduline or iguratimod or imidazole 
salicylate or incb 3284 or incyclinide or indameth or indomethacin)ti,ab 
5. (indoprofen or ipsalazide or isofezolac or isonixin or isoxepac or isoxicam 
or kebuzone or ketoprofen or ketorolac or leflunomide or licofelone or 
lonazolac or lornoxicam or loxoprofen or lumiracoxib or lyprinol or lysine 
acetylsalicylate or magnesium salicylate or manoalide or mavacoxib or 
meclofenamate sodium or meclofenamic acid or mefenamic acid or meloxicam or 
mesalazine or metamizol or metiazinic acid or metoxibutropate or mirococept 
or miroprofen or mofebutazone or mofezolac or morazone or morniflumate or 
nabumetone or naproxcinod or naproxen or nepafenac or neurofenac or 
neurotropin or nictindole or niflumic acid or nimesulide or olsalazine or 
orpanoxin or oxaceprol or oxametacin or oxaprazine or oxaprozin or oxicam 
derivative or oxindanac or oxyphenbutazone or palifermin or parecoxib or 
pelubiprofen or pemedolac or perisoxal or phenazone or phenylbutazone or 
picolamine salicylate or piketoprofen or pimeprofen or pipebuzone or 
piproxen or pirazolac or piroxicam or pirprofen or pralnacasan or 
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pranoprofen or prinomide or proglumetacin or proglumetacin maleate or 
propyphenazone or proquazone or pyrazinobutazone or resatorvid or rimazolium 
or robenacoxib or rofecoxib or romazarit or rosmarinic acid or salicylic 
acid or salsalate or scalaradial or semapimod or sudoxicam or sulindac or 
suprofen or suxibuzone or talniflumate or tenidap or tenoxicam or tepoxalin 
or teriflunomide or tiaprofenic acid or tiaramide or tilmacoxib or 
tilnoprofen arbamel or tilomisole or timegadine or tioxamast or tioxaprofen 
or tolfenamic acid or tolmetin or tribuzone or triethanolamine salicylate or 
tropesin or ufenamate or valategrast or valdecoxib or ximoprofen or 
zaltoprofen or zidometacin or zinc salicylate or zoliprofen or 
zomepirac).ti,ab. 
6. or/1-5 
7. exp Dexamethasone/ 
8. (azium or colofoam or decadron or decadrone or decaesadril or 
decamethasone or dectancyl or deltafluorene or deronil or dexa-p or dexacort 
or dexagel or dexame or dexameson or dexametason or dexametasone or dexameth 
or dexamethason or dexamethasone or dexamethazon or dexamethazone or 
dexamonozon or dexan or dexascheroson or dexason or dexasone or dexmethsone 
or dexone or diodex or fluorocort or fortecortin or gammacorten or 
hexadecadrol or hexadrol or isopto-dex or isopto-maxidex or maxidex or 
methylfluorprednisolone or millicorten or opticortinol or oradexon or 
oradexone or orgadrone or ozurdex or policort or posurdex or prednisolone or 
thilodexine).ti,ab. 
9. or/7-8 
10. Tonsillectomy/ 
11. ((tonsil* adj3 surgery) or (remov* adj3 tonsil*) or (tonsillectom* or 
tonsilectom* or adenotonsil* or adeno-tonsill*)).ti,ab. 
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12. or/10-11 
13. exp child/ 
14. exp Infant/ 
15. exp adolescent/ 
16. exp Students/ 
17. exp Pediatrics/ 
18. (child* or adolescen* or kid or kids or youth* or youngster* or minor or 
minors or teen* or juvenile* or student* or pupil or pupils or boy or boys 
or girl or girls or under 18* or underage 18* or under eighteen* or under  
age* or pediatric* or paediatric*).ti,ab. 
19. (young ADJ person* OR young ADJ people OR young ADJ adult* OR young ADJ 
individual* OR young ADJ women OR young ADJ woman OR young ADJ men OR young ADJ 
man).ti,ab  
20. or/13-19 
21. ((6 and 9) and 12 and 20) or (9 and 12 and 20)  
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Science Citation Index via ebscohost.com 
1. TS=(nsaid* or non-steroidal anti-inflammatory agent* or nonsteroidal anti-inflammatory 
agent* or non-steroidal antiinflammatory agent* or nonsteroidal antiinflammatory agent* 
or non steroidal anti inflammatory drug* or non steroidal antiinflammatory drug* or 
nonsteroidal antiinflammatory drug* or nonsteroidal anti inflammatory drug* or non-
steroidal anti-rheumatic agent* or non-steroidal antirheumatic agent* or nonsteroidal anti-
rheumatic agent* or nonsteroidal antirheumatic agent* or anti-inflammatory analgesic* or 
antiinflammatory analgesic* or aspirin-like agent*) OR TI=(nsaid* or non-steroidal anti-
inflammatory agent* or nonsteroidal anti-inflammatory agent* or non-steroidal 
antiinflammatory agent* or nonsteroidal antiinflammatory agent* or non steroidal anti 
inflammatory drug* or non steroidal antiinflammatory drug* or nonsteroidal 
antiinflammatory drug* or nonsteroidal anti inflammatory drug* or non-steroidal anti-
rheumatic agent* or non-steroidal antirheumatic agent* or nonsteroidal anti-rheumatic 
agent* or nonsteroidal antirheumatic agent* or anti-inflammatory analgesic* or 
antiinflammatory analgesic* or aspirin-like agent*) 
2. TS=(non-steroid anti-inflammatory agent* or nonsteroid anti-inflammatory agent* or 
non-steroid antiinflammatory agent* or nonsteroid antiinflammatory agent* or non steroid 
anti inflammatory drug* or non steroid antiinflammatory drug* or nonsteroid 
antiinflammatory drug* or nonsteroid anti inflammatory drug* or non-steroid anti-
rheumatic agent* or non-steroid antirheumatic agent* or nonsteroid anti-rheumatic agent* 
or nonsteroid antirheumatic agent*) OR TI=(non-steroid anti-inflammatory agent* or 
nonsteroid anti-inflammatory agent* or non-steroid antiinflammatory agent* or nonsteroid 
antiinflammatory agent* or non steroid anti inflammatory drug* or non steroid 
antiinflammatory drug* or nonsteroid antiinflammatory drug* or nonsteroid anti 
inflammatory drug* or non-steroid anti-rheumatic agent* or non-steroid antirheumatic 
agent* or nonsteroid anti-rheumatic agent* or nonsteroid antirheumatic agent*) 
3. TS=(aceclofenac or acemetacin or acetylsalicyl* or actaritajulemic acid or alclofenac or 
alminoprofen or aloxiprin or amfenac or aminosalicylic acid or ampiroxicam or amtolmetin 
guacil or anacin or anirolac or antiflammin or apadenoson or arthrotec or ascriptin or 
balsalazide or bardoxolone or bendazac or benorilate or benoxaprofen or bermoprofen or 
bimosiamose or bromfenac or broperamole or bucloxic acid or bucolome or bufexamac or 
butibufen or camobucol or carbasalate calcium or carprofen or celecoxib or centchroman 
or cicloprofen or cimicoxib or cinmetacin or cinnoxicam or clidanac or clofenamic acid or 
clofezone or clonixin or cloximate or dehydrozingerone or demethoxycurcumin or 
deracoxib or dexibuprofen or dexketoprofen or diclofenac or didemethoxycurcumin or 
diflunisal or diftalone or dimethyl sulfoxide or diphenpyramide or ditazole or droxicam 
ebselen or emorfazone or endolac or enfenamic acid or epirizole or etodolac or 
etofenamate or etoricoxib or excedrin or felbinac or fenamic acid derivative or fenbufen or 
fenclofenac or fenclozic acid or fendosal or fenflumizole or fenoprofen or fentiazac or 
fepradinol or feprazone or firategrast or firocoxib or flobufen or flosulide or flufenamate 
aluminum or flufenamic acid or flunixin or flunoxaprofen or fluproquazone or flurbiprofen 
or fosfosal or furaprofen or furobufen or furofenac or glucametacin or gluconate zinc or 
guacetisal or guaimesal or gw 406381 or ibufenacOR ibuprofen or ibuproxam or icoduline 
or iguratimod or imidazole salicylate or incb 3284 or incyclinide or indameth or indometacin 
or indoprofen or ipsalazide or isofezolac or isonixin or isoxepac or isoxicam or kebuzone or 
ketoprofen or ketorolac or leflunomide or licofelone or lonazolac or lornoxicam or 
loxoprofen or lumiracoxib or lyprinol or lysine acetylsalicylate or magnesium salicylate or 
manoalide or mavacoxib or meclofenamate sodium or meclofenamic acid or mefenamic 
acid or meloxicam or mesalazine or metamizol or metiazinic acid or metoxibutropate or 
 316 
 
mirococept or miroprofen or mofebutazone or mofezolac or morazone or morniflumate or 
nabumetone or naproxcinod or naproxen or nepafenac or neurofenac or neurotropin or 
nictindole or niflumic acid or nimesulide or olsalazine or orpanoxin or oxaceprol or 
oxametacin or oxaprazine or oxaprozin or oxicam derivative or oxindanac or 
oxyphenbutazone or palifermin or parecoxib or pelubiprofen or pemedolac or perisoxal or 
phenazone or phenylbutazone or picolamine salicylate or piketoprofen or pimeprofen or 
pipebuzone or piproxen or pirazolac or piroxicam or pirprofen or pralnacasan or 
pranoprofen or prinomide or proglumetacin or proglumetacin maleate or propyphenazone 
or proquazone or pyrazinobutazone or resatorvid or rimazolium or robenacoxib or 
rofecoxib or romazarit or rosmarinic acid or salicylic acid or salsalate or scalaradial or 
semapimod or sudoxicam or sulindac or suprofen or suxibuzone or talniflumate or tenidap 
or tenoxicam or tepoxalin or teriflunomide or tiaprofenic acid or tiaramide or tilmacoxib or 
tilnoprofen arbamel or tilomisole or timegadine or tioxamast or tioxaprofen or tolfenamic 
acid or tolmetin or tribuzone or triethanolamine salicylate or tropesin or ufenamate or 
valategrast or valdecoxib or ximoprofen or zaltoprofen or zidometacin or zinc salicylate or 
zoliprofen or zomepirac) OR TI=(aceclofenac or acemetacin or acetylsalicyl* or 
actaritajulemic acid or alclofenac or alminoprofen or aloxiprin or amfenac or aminosalicylic 
acid or ampiroxicam or amtolmetin guacil or anacin or anirolac or antiflammin or 
apadenoson or arthrotec or ascriptin or balsalazide or bardoxolone or bendazac or 
benorilate or benoxaprofen or bermoprofen or bimosiamose or bromfenac or broperamole 
or bucloxic acid or bucolome or bufexamac or butibufen or camobucol or carbasalate 
calcium or carprofen or celecoxib or centchroman or cicloprofen or cimicoxib or cinmetacin 
or cinnoxicam or clidanac or clofenamic acid or clofezone or clonixin or cloximate or 
dehydrozingerone or demethoxycurcumin or deracoxib or dexibuprofen or dexketoprofen 
or diclofenac or didemethoxycurcumin or diflunisal or diftalone or dimethyl sulfoxide or 
diphenpyramide or ditazole or droxicam ebselen or emorfazone or endolac or enfenamic 
acid or epirizole or etodolac or etofenamate or etoricoxib or excedrin or felbinac or fenamic 
acid derivative or fenbufen or fenclofenac or fenclozic acid or fendosal or fenflumizole or 
fenoprofen or fentiazac or fepradinol or feprazone or firategrast or firocoxib or flobufen or 
flosulide or flufenamate aluminum or flufenamic acid or flunixin or flunoxaprofen or 
fluproquazone or flurbiprofen or fosfosal or furaprofen or furobufen or furofenac or 
glucametacin or gluconate zinc or guacetisal or guaimesal or gw 406381 or ibufenacOR 
ibuprofen or ibuproxam or icoduline or iguratimod or imidazole salicylate or incb 3284 or 
incyclinide or indameth or indometacin or indoprofen or ipsalazide or isofezolac or isonixin 
or isoxepac or isoxicam or kebuzone or ketoprofen or ketorolac or leflunomide or licofelone 
or lonazolac or lornoxicam or loxoprofen or lumiracoxib or lyprinol or lysine acetylsalicylate 
or magnesium salicylate or manoalide or mavacoxib or meclofenamate sodium or 
meclofenamic acid or mefenamic acid or meloxicam or mesalazine or metamizol or 
metiazinic acid or metoxibutropate or mirococept or miroprofen or mofebutazone or 
mofezolac or morazone or morniflumate or nabumetone or naproxcinod or naproxen or 
nepafenac or neurofenac or neurotropin or nictindole or niflumic acid or nimesulide or 
olsalazine or orpanoxin or oxaceprol or oxametacin or oxaprazine or oxaprozin or oxicam 
derivative or oxindanac or oxyphenbutazone or palifermin or parecoxib or pelubiprofen or 
pemedolac or perisoxal or phenazone or phenylbutazone or picolamine salicylate or 
piketoprofen or pimeprofen or pipebuzone or piproxen or pirazolac or piroxicam or 
pirprofen or pralnacasan or pranoprofen or prinomide or proglumetacin or proglumetacin 
maleate or propyphenazone or proquazone or pyrazinobutazone or resatorvid or 
rimazolium or robenacoxib or rofecoxib or romazarit or rosmarinic acid or salicylic acid or 
salsalate or scalaradial or semapimod or sudoxicam or sulindac or suprofen or suxibuzone 
or talniflumate or tenidap or tenoxicam or tepoxalin or teriflunomide or tiaprofenic acid or 
tiaramide or tilmacoxib or tilnoprofen arbamel or tilomisole or timegadine or tioxamast or 
tioxaprofen or tolfenamic acid or tolmetin or tribuzone or triethanolamine salicylate or 
 317 
 
tropesin or ufenamate or valategrast or valdecoxib or ximoprofen or zaltoprofen or 
zidometacin or zinc salicylate or zoliprofen or zomepirac) 
4. TS=(azium or colofoam or decadron or decadrone or decaesadril or decamethasone or 
dectancyl or deltafluorene or deronil or dexa-p or dexacort or dexagel or dexame or 
dexameson or dexametason or dexametasone or dexameth or dexamethason or 
dexamethasone or dexamethazon or dexamethazone or dexamonozon or dexan or 
dexascheroson or dexason or dexasone or dexmethsone or dexone or diodex or fluorocort 
or fortecortin or gammacorten or hexadecadrol or hexadrol or isopto-dex or isopto-
maxidex or maxidex or methylfluorprednisolone or millicorten or opticortinol or oradexon 
or oradexone or orgadrone or ozurdex or policort or posurdex or prednisolone or 
thilodexine) OR TI=(azium or colofoam or decadron or decadrone or decaesadril or 
decamethasone or dectancyl or deltafluorene or deronil or dexa-p or dexacort or dexagel or 
dexame or dexameson or dexametason or dexametasone or dexameth or dexamethason or 
dexamethasone or dexamethazon or dexamethazone or dexamonozon or dexan or 
dexascheroson or dexason or dexasone or dexmethsone or dexone or diodex or fluorocort 
or fortecortin or gammacorten or hexadecadrol or hexadrol or isopto-dex or isopto-
maxidex or maxidex or methylfluorprednisolone or millicorten or opticortinol or oradexon 
or oradexone or orgadrone or ozurdex or policort or posurdex or prednisolone or 
thilodexine) 
5. (#1 OR #2 OR #3) AND #4 
6. TS=((tonsil* adj3 surgery) or (remov* adj3 tonsil*) or (tonsillectom* or tonsilectom* or 
adenotonsil* or adeno-tonsill*)) OR TI=((tonsil* adj3 surgery) or (remov* adj3 tonsil*) or 
(tonsillectom* or tonsilectom* or adenotonsil* or adeno-tonsill*)) 
7. TS=(child* or adolescen* or kid or kids or youth* or youngster* or minor or minors or 
teen* or juvenile* or student* or pupil or pupils or boy or boys or girl or girls or under 
eighteen* or under age* or pediatric* or paediatric*) OR TI=(child* or adolescen* or kid or 
kids or youth* or youngster* or minor or minors or teen* or juvenile* or student* or pupil 
or pupils or boy or boys or girl or girls or under 18* or underage 18* or under eighteen* or 
under age* or pediatric* or paediatric*) 
8. TS=(young adj (person* or people or adult* or individual* or women or woman or men 
or man)) OR TI=(young adj (person* or people or adult* or individual* or women or woman 
or men or man)) 
9. #7 OR #8 
10. #5 AND #6 AND #9 
11. #4 AND #6 AND #9 
12. #10 OR #11 
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Scopus via ebscohost.com 
1. TITLE-ABS-KEY(nsaid*) OR TITLE-ABS-KEY(non-steroidal anti-inflammatory agent*) OR 
TITLE-ABS-KEY (nonsteroidal anti-inflammatory agent*) OR TITLE-ABS-KEY (non-steroidal 
antiinflammatory agent*) OR TITLE-ABS-KEY(nonsteroidal antiinflammatory agent*) OR 
TITLE-ABS-KEY(non steroidal anti inflammatory drug*) OR TITLE-ABS-KEY(non steroidal 
antiinflammatory drug*) OR TITLE-ABS-KEY(nonsteroidal antiinflammatory drug*) OR TITLE-
ABS-KEY(nonsteroidal anti inflammatory drug*) OR TITLE-ABS-KEY(non-steroidal anti-
rheumatic agent*) OR TITLE-ABS-KEY(non-steroidal antirheumatic agent*) OR TITLE-ABS-
KEY(nonsteroidal anti-rheumatic agent*) OR TITLE-ABS-KEY(nonsteroidal antirheumatic 
agent*) OR TITLE-ABS-KEY(anti-inflammatory analgesic*) OR TITLE-ABS-
KEY(antiinflammatory analgesic*) OR TITLE-ABS-KEY(aspirin-like agent*)  
2. TITLE-ABS-KEY (non-steroid anti-inflammatory agent*) OR TITLE-ABS-KEY(nonsteroid anti-
inflammatory agent*) OR TITLE-ABS-KEY(non-steroid antiinflammatory agent*) OR TITLE-
ABS-KEY(nonsteroid antiinflammatory agent*) OR TITLE-ABS-KEY(non steroid anti 
inflammatory drug*) OR TITLE-ABS-KEY(non steroid antiinflammatory drug*) OR TITLE-ABS-
KEY(nonsteroid antiinflammatory drug*) OR TITLE-ABS-KEY(nonsteroid anti inflammatory 
drug*) OR TITLE-ABS-KEY(non-steroid anti-rheumatic agent*) OR TITLE-ABS-KEY(non-steroid 
antirheumatic agent*) OR TITLE-ABS-KEY(nonsteroid anti-rheumatic agent*) OR TITLE-ABS-
KEY(nonsteroid antirheumatic agent*)  
3. TITLE-ABS-KEY(taceclofenac) OR TITLE-ABS-KEY(acemetacin) OR TITLE-ABS-
KEY(acetylsalicyl*) OR TITLE-ABS-KEY(actaritajulemic acid) OR TITLE-ABS-KEY(alclofenac) OR 
TITLE-ABS-KEY(alminoprofen) OR TITLE-ABS-KEY(aloxiprin) OR TITLE-ABS-KEY(amfenac) OR 
TITLE-ABS-KEY(aminosalicylic acid) OR TITLE-ABS-KEY(ampiroxicam) OR TITLE-ABS-
KEY(amtolmetin guacil) OR TITLE-ABS-KEY(anacin) OR TITLE-ABS-KEY(anirolac) OR TITLE-
ABS-KEY(antiflammin) OR TITLE-ABS-KEY(apadenoson) OR TITLE-ABS-KEY(arthrotec) OR 
TITLE-ABS-KEY(ascription) OR TITLE-ABS-KEY(balsalazide) OR TITLE-ABS-KEY(bardoxolone) 
OR TITLE-ABS-KEY(bendazac) OR TITLE-ABS-KEY(benorilate) OR TITLE-ABS-
KEY(benoxaprofen) OR TITLE-ABS-KEY(bermoprofen)  OR TITLE-ABS-KEY (bimosiamose) OR 
TITLE-ABS-KEY(bromfenac) OR TITLE-ABS-KEY(broperamole) OR TITLE-ABS-KEY(bucloxic 
acid) OR TITLE-ABS-KEY(bucolome) OR TITLE-ABS-KEY(bufexamac) OR TITLE-ABS-
KEY(butibufen) OR TITLE-ABS-KEY(camobucol) OR TITLE-ABS-KEY(carbasalate calcium) OR 
TITLE-ABS-KEY(carprofen) OR TITLE-ABS-KEY (celecoxib) OR TITLE-ABS-KEY(centchroman) 
OR TITLE-ABS-KEY(cicloprofen) OR TITLE-ABS-KEY(cimicoxib) OR TITLE-ABS-KEY(cinmetacin) 
OR TITLE-ABS-KEY(cinnoxicam) OR TITLE-ABS-KEY(clidanac) OR TITLE-ABS-KEY(clofenamic 
acid) OR TITLE-ABS-KEY(clofezone) OR TITLE-ABS-KEY(clonixin) OR TITLE-ABS-KEY(cloximate) 
OR TITLE-ABS-KEY (dehydrozingerone) OR TITLE-ABS-KEY(demethoxycurcumin) OR TITLE-
ABS-KEY(deracoxib) OR TITLE-ABS-KEY (dexibuprofen) OR TITLE-ABS-KEY(dexketoprofen) OR 
TITLE-ABS-KEY(diclofenac) OR TITLE-ABS-KEY(didemethoxycurcumin) OR TITLE-ABS-
KEY(diflunisal) OR TITLE-ABS-KEY(diftalone) OR TITLE-ABS-KEY(dimethyl sulfoxide) OR TITLE-
ABS-KEY(diphenpyramide) OR TITLE-ABS-KEY(ditazole) OR TITLE-ABS-KEY (droxicam 
ebselen) OR TITLE-ABS-KEY(emorfazone) OR TITLE-ABS-KEY(endolac) OR TITLE-ABS-
KEY(enfenamic acid) OR TITLE-ABS-KEY(epirizole) OR TITLE-ABS-KEY(etodolac) OR TITLE-
ABS-KEY(etofenamate) OR TITLE-ABS-KEY (etoricoxib) OR TITLE-ABS-KEY(excedrin) OR TITLE-
ABS-KEY(felbinac) OR TITLE-ABS-KEY(fenamic acid derivative) OR TITLE-ABS-KEY(fenbufen) 
OR TITLE-ABS-KEY(fenclofenac) OR TITLE-ABS-KEY(fenclozic acid) OR TITLE-ABS-KEY 
(fendosal) OR TITLE-ABS-KEY(fenflumizole) OR TITLE-ABS-KEY(fenoprofen) OR TITLE-ABS-
KEY(fentiazac) OR TITLE-ABS-KEY(fepradinol) OR TITLE-ABS-KEY(feprazone) OR TITLE-ABS-
KEY(firategrast) OR TITLE-ABS-KEY(firocoxib) OR TITLE-ABS-KEY(flobufen) OR TITLE-ABS-
KEY(flosulide) OR TITLE-ABS-KEY(flufenamate aluminium) OR TITLE-ABS-KEY(flufenamic 
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acid) OR TITLE-ABS-KEY(flunixin) OR TITLE-ABS-KEY( flunoxaprofen ) OR TITLE-ABS-KEY( 
fluproquazone ) OR TITLE-ABS-KEY( flurbiprofen ) OR TITLE-ABS-KEY( fosfosal ) OR TITLE-
ABS-KEY( furaprofen ) OR TITLE-ABS-KEY( furobufen ) OR TITLE-ABS-KEY( furofenac ) OR 
TITLE-ABS-KEY( glucametacin ) OR TITLE-ABS-KEY( gluconate zinc ) OR TITLE-ABS-KEY( 
guacetisal ) OR TITLE-ABS-KEY( guaimesal ) OR TITLE-ABS-KEY( gw 406381 ) OR TITLE-ABS-
KEY( ibufenacOR ibuprofen ) OR TITLE-ABS-KEY( ibuproxam ) OR TITLE-ABS-KEY( icoduline ) 
OR TITLE-ABS-KEY( iguratimod ) OR TITLE-ABS-KEY( imidazole salicylate ) OR TITLE-ABS-KEY( 
incb 3284 ) OR TITLE-ABS-KEY( incyclinide ) OR TITLE-ABS-KEY( indameth ) OR TITLE-ABS-
KEY( indometacin ) OR TITLE-ABS-KEY( indoprofen ) OR TITLE-ABS-KEY( ipsalazide ) OR TITLE-
ABS-KEY( isofezolac ) OR TITLE-ABS-KEY( isonixin ) OR TITLE-ABS-KEY( isoxepac ) OR TITLE-
ABS-KEY( isoxicam ) OR TITLE-ABS-KEY( kebuzone ) OR TITLE-ABS-KEY( ketoprofen ) OR 
TITLE-ABS-KEY( ketorolac ) OR TITLE-ABS-KEY( leflunomide ) OR TITLE-ABS-KEY( licofelone ) 
OR TITLE-ABS-KEY( lonazolac ) OR TITLE-ABS-KEY( lornoxicam ) OR TITLE-ABS-KEY( 
loxoprofen ) OR TITLE-ABS-KEY( lumiracoxib ) OR TITLE-ABS-KEY( lyprinol ) OR TITLE-ABS-
KEY( lysine acetylsalicylate ) OR TITLE-ABS-KEY( magnesium salicylate ) OR TITLE-ABS-KEY( 
manoalide ) OR TITLE-ABS-KEY( mavacoxib ) OR TITLE-ABS-KEY( meclofenamate sodium ) OR 
TITLE-ABS-KEY( meclofenamic acid ) OR TITLE-ABS-KEY( mefenamic acid ) OR TITLE-ABS-KEY( 
meloxicam ) OR TITLE-ABS-KEY( mesalazine ) OR TITLE-ABS-KEY( metamizol ) OR TITLE-ABS-
KEY( metiazinic acid ) OR TITLE-ABS-KEY( metoxibutropate ) OR TITLE-ABS-KEY( mirococept ) 
OR TITLE-ABS-KEY( miroprofen ) OR TITLE-ABS-KEY( mofebutazone ) OR TITLE-ABS-KEY( 
mofezolac ) OR TITLE-ABS-KEY( morazone ) OR TITLE-ABS-KEY( morniflumate ) OR TITLE-
ABS-KEY( nabumetone ) OR TITLE-ABS-KEY( naproxcinod ) OR TITLE-ABS-KEY( naproxen ) OR 
TITLE-ABS-KEY( nepafenac ) OR TITLE-ABS-KEY( neurofenac ) OR TITLE-ABS-KEY( neurotropin 
) OR TITLE-ABS-KEY( nictindole ) OR TITLE-ABS-KEY( niflumic acid ) OR TITLE-ABS-KEY( 
nimesulide ) OR TITLE-ABS-KEY( olsalazine ) OR TITLE-ABS-KEY( orpanoxin ) OR TITLE-ABS-
KEY( oxaceprol ) OR TITLE-ABS-KEY( oxametacin ) OR TITLE-ABS-KEY( oxaprazine ) OR TITLE-
ABS-KEY( oxaprozin ) OR TITLE-ABS-KEY( oxicam derivative ) OR TITLE-ABS-KEY( oxindanac ) 
OR TITLE-ABS-KEY( oxyphenbutazone ) OR TITLE-ABS-KEY( palifermin ) OR TITLE-ABS-KEY( 
parecoxib ) OR TITLE-ABS-KEY( pelubiprofen ) OR TITLE-ABS-KEY( pemedolac ) OR TITLE-ABS-
KEY( perisoxal ) OR TITLE-ABS-KEY( phenazone ) OR TITLE-ABS-KEY( phenylbutazone ) OR 
TITLE-ABS-KEY( picolamine salicylate ) OR TITLE-ABS-KEY( piketoprofen ) OR TITLE-ABS-KEY( 
pimeprofen ) OR TITLE-ABS-KEY( pipebuzone ) OR TITLE-ABS-KEY( piproxen ) OR TITLE-ABS-
KEY( pirazolac ) OR TITLE-ABS-KEY( piroxicam ) OR TITLE-ABS-KEY( pirprofen ) OR TITLE-ABS-
KEY( pralnacasan ) OR TITLE-ABS-KEY( pranoprofen ) OR TITLE-ABS-KEY( prinomide ) OR 
TITLE-ABS-KEY( proglumetacin ) OR TITLE-ABS-KEY( proglumetacin maleate ) OR TITLE-ABS-
KEY( propyphenazone ) OR TITLE-ABS-KEY( proquazone ) OR TITLE-ABS-KEY( 
pyrazinobutazone ) OR TITLE-ABS-KEY( resatorvid ) OR TITLE-ABS-KEY( rimazolium ) OR 
TITLE-ABS-KEY( robenacoxib ) OR TITLE-ABS-KEY( rofecoxib ) OR TITLE-ABS-KEY( romazarit ) 
OR TITLE-ABS-KEY( rosmarinic acid ) OR TITLE-ABS-KEY( salicylic acid ) OR TITLE-ABS-KEY( 
salsalate ) OR TITLE-ABS-KEY( scalaradial ) OR TITLE-ABS-KEY( semapimod ) OR TITLE-ABS-
KEY( sudoxicam ) OR TITLE-ABS-KEY( sulindac ) OR TITLE-ABS-KEY( suprofen ) OR TITLE-ABS-
KEY( suxibuzone ) OR TITLE-ABS-KEY( talniflumate ) OR TITLE-ABS-KEY( tenidap ) OR TITLE-
ABS-KEY( tenoxicam ) OR TITLE-ABS-KEY( tepoxalin ) OR TITLE-ABS-KEY( teriflunomide ) OR 
TITLE-ABS-KEY( tiaprofenic acid ) OR TITLE-ABS-KEY( tiaramide ) OR TITLE-ABS-KEY( 
tilmacoxib ) OR TITLE-ABS-KEY( tilnoprofen arbamel ) OR TITLE-ABS-KEY( tilomisole ) OR 
TITLE-ABS-KEY( timegadine ) OR TITLE-ABS-KEY( tioxamast ) OR TITLE-ABS-KEY( tioxaprofen ) 
OR TITLE-ABS-KEY( tolfenamic acid ) OR TITLE-ABS-KEY( tolmetin ) OR TITLE-ABS-KEY( 
tribuzone ) OR TITLE-ABS-KEY( triethanolamine salicylate ) OR TITLE-ABS-KEY( tropesin ) OR 
TITLE-ABS-KEY( ufenamate ) OR TITLE-ABS-KEY( valategrast ) OR TITLE-ABS-KEY( valdecoxib ) 
OR TITLE-ABS-KEY( ximoprofen ) OR TITLE-ABS-KEY( zaltoprofen ) OR TITLE-ABS-KEY( 
zidometacin ) OR TITLE-ABS-KEY( zinc salicylate ) OR TITLE-ABS-KEY( zoliprofen ) OR TITLE-
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ABS-KEY( zomepirac)  
4. TITLE-ABS-KEY(azium ) OR TITLE-ABS-KEY( colofoam ) OR TITLE-ABS-KEY( decadron ) OR 
TITLE-ABS-KEY( decadrone ) OR TITLE-ABS-KEY( decaesadril ) OR TITLE-ABS-KEY( 
decamethasone ) OR TITLE-ABS-KEY( dectancyl ) OR TITLE-ABS-KEY( deltafluorene ) OR 
TITLE-ABS-KEY( deronil ) OR TITLE-ABS-KEY( dexa-p ) OR TITLE-ABS-KEY( dexacort ) OR TITLE-
ABS-KEY( dexagel ) OR TITLE-ABS-KEY( dexame ) OR TITLE-ABS-KEY( dexameson ) OR TITLE-
ABS-KEY( dexametason ) OR TITLE-ABS-KEY( dexametasone ) OR TITLE-ABS-KEY( dexameth ) 
OR TITLE-ABS-KEY( dexamethason ) OR TITLE-ABS-KEY( dexamethasone ) OR TITLE-ABS-KEY( 
dexamethazon ) OR TITLE-ABS-KEY( dexamethazone ) OR TITLE-ABS-KEY( dexamonozon ) OR 
TITLE-ABS-KEY( dexan ) OR TITLE-ABS-KEY( dexascheroson ) OR TITLE-ABS-KEY( dexason ) OR 
TITLE-ABS-KEY( dexasone ) OR TITLE-ABS-KEY( dexmethsone ) OR TITLE-ABS-KEY( dexone ) 
OR TITLE-ABS-KEY( diodex ) OR TITLE-ABS-KEY( fluorocort ) OR TITLE-ABS-KEY( fortecortin ) 
OR TITLE-ABS-KEY( gammacorten ) OR TITLE-ABS-KEY( hexadecadrol ) OR TITLE-ABS-KEY( 
hexadrol ) OR TITLE-ABS-KEY( isopto-dex ) OR TITLE-ABS-KEY( isopto-maxidex ) OR TITLE-
ABS-KEY( maxidex ) OR TITLE-ABS-KEY( methylfluorprednisolone ) OR TITLE-ABS-KEY( 
millicorten ) OR TITLE-ABS-KEY( opticortinol ) OR TITLE-ABS-KEY( oradexon ) OR TITLE-ABS-
KEY( oradexone ) OR TITLE-ABS-KEY( orgadrone ) OR TITLE-ABS-KEY( ozurdex ) OR TITLE-
ABS-KEY( policort ) OR TITLE-ABS-KEY( posurdex ) OR TITLE-ABS-KEY( prednisolone ) OR 
TITLE-ABS-KEY( thilodexine)  
5. (#1 OR #2 OR #3) AND #4 
6. TITLE-ABS-KEY(tonsil* W/3 surgery) OR TITLE-ABS-KEY(remov* W/3 tonsil*) OR TITLE-
ABS-KEY(tonsillectom*) OR TITLE-ABS-KEY(tonsilectom*) OR TITLE-ABS-KEY(adenotonsil*) 
OR TITLE-ABS-KEY(adeno-tonsill*) 
7. TITLE-ABS-KEY (child* ) OR TITLE-ABS-KEY( adolescen* ) OR TITLE-ABS-KEY( kid ) OR TITLE-
ABS-KEY( kids ) OR TITLE-ABS-KEY( youth* ) OR TITLE-ABS-KEY( youngster* ) OR TITLE-ABS-
KEY( minor ) OR TITLE-ABS-KEY( minors ) OR TITLE-ABS-KEY( teen* ) OR TITLE-ABS-KEY( 
juvenile* ) OR TITLE-ABS-KEY( student* ) OR TITLE-ABS-KEY( pupil ) OR TITLE-ABS-KEY( 
pupils ) OR TITLE-ABS-KEY( boy ) OR TITLE-ABS-KEY( boys ) OR TITLE-ABS-KEY( girl ) OR TITLE-
ABS-KEY( girls ) OR TITLE-ABS-KEY( under 18* ) OR TITLE-ABS-KEY( underage 18* ) OR TITLE-
ABS-KEY( under eighteen* ) OR TITLE-ABS-KEY( under age* ) OR TITLE-ABS-KEY( pediatric* ) 
OR TITLE-ABS-KEY( paediatric*) 
8. TITLE-ABS-KEY (young W/person* ) OR TITLE-ABS-KEY(young W/people ) OR TITLE-ABS-
KEY(young W/adult* ) OR TITLE-ABS-KEY(young W/individual* ) OR TITLE-ABS-KEY(young 
W/women ) OR TITLE-ABS-KEY(young W/woman ) OR TITLE-ABS-KEY(young W/men ) OR 
TITLE-ABS-KEY(young W/man))  
9. #7 OR #8 
10. #4 AND #6 AND #9 
11. #5 AND #6 AND #9 
12. #10 OR #11 
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Appendix 8 Restricted Interface Search Strategies  
Agency for Health & Research Quality http://www.ahrq.gov/ 
With at least one of the words (tonsillectomy adenotonsillectomy adenoidectomy  
tonsil* tonsillectom* tonsilectom* adenotonsil* adeno-tonsill*) 
Results can occur anywhere in the page 
 
British Nursing Index (BNI) via www.library.nhs.uk 
1. adenotonsillectomy.ti,ab 
2. adenoidectomy.ti,ab 
3. tonsil$.ti,ab 
4. tonsillectomy$.ti,ab 
5. tonsilectom$.ti,ab 
6. adenotonsil$.ti,ab 
7. adeno-tonsill$.ti,ab 
8. (tonsil$ adj3 surgery).ti,ab 
9. (remov$ adj3 tonsil$).ti,ab 
10. OR/1-9 
 
British Library Direct http://direct.bl.uk/bld/Home.do 
1. (tonsillectomy or adenotonsillectomy or adenoidectomy or tonsil$ or 
tonsillectomy$ or tonsilectom$ or adenotonsil$ or adeno-tonsill$).ti 
 OR 
2. (tonsil$ adj3 surgery) or (remov$ adj3 tonsil$)).ti 
 
Current Controlled trials http://www.controlled-trials.com/ 
 322 
 
Search each term and screen results of each search 
1. tonsillectomy 
2. adenotonsillectomy 
3. adenoidectomy 
4. tonsil* 
5. tonsillectom* 
6. tonsilectom* 
7. adenotonsil* 
8. adeno-tonsill 
 
Faculty of 1000 http://f1000.com/ 
Search each term and screen results of each search 
1. tonsillectomy  
2. adenotonsillectomy  
3. adenoidectomy   
4. tonsil*  
5. adenotonsil*  
 
Iowa Drug Information Service (IDIS) via http://www.uiowa.edu/idis 
1. "DEXAMETHASONE 68040003" 
 
2. Disease(s): "TONSILLECTOMY/ADENOIDECTOMY 28.2" 
 
3. 1 AND 2 
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Medscape http://www.medscape.com/ 
Search each term and screen results of each search 
Reference & Education 
1. tonsillectomy  
2. adenotonsillectomy  
3. adenoidectomy  
4. tonsil  
5. adenotonsillar  
 
Scirus http://www.scirus.com/ 
1. Any of the words (tonsillectomy or adenotonsillectomy or 
adenoidectomy).article title   
OR 
2. Any of the words (tonsil* or tonsillectom* or tonsilectom* or adenotonsil* 
or adeno-tonsill*).article title 
Search Journal Sources only 
Deselect: MEDLINE / PubMed, Pubmed Central, Wiley-Blackwell, Science Direct 
 
Toxicology Information Online (TOXLINE®) – US National Library of Medicine via 
proquest.com 
Combine the following terms with OR 
Include PubMed = No 
1. tonsillectomy  
2. adenoidectomy  
3. tonsillectom* 
4. tonsilectom* 
5. adenotonsil* 
6. adeno-tonsill* 
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TRIP database http://www.tripdatabase.com/ 
Any of these words (tonsillectomy adenotonsillectomy adenoidectomy  tonsil* 
tonsillectom* tonsilectom* adenotonsil* adeno 
tonsill*).title only 
 
UK Clinical Research Network Portfolio Database http://public.ukcrn.org.uk/search/ 
Search database by looking at the studies listed under the following categories: 
Topic: Generic Relevance & Cross-cutting themes 
 Specialty groups: Anaes Peri-Op Med & Pain 
    Other 
    Surgery 
Topic: Meds for Children 
 Specialty groups: Anaes., IC & Pain Control 
    General Paediatric 
    Not Assigned 
    Pharmacy and Pharmacology 
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US Food & Drug Administration http://www.fda.gov/ 
With at least one of the words (tonsillectomy adenotonsillectomy adenoidectomy  
tonsil* tonsillectom* tonsilectom* adenotonsil* adeno-tonsill*) 
 
Advisory Committees, Drugs, Guidance, MedWatch, Warning Letters 
 
Results can occur anywhere in the page 
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Appendix 9 Study Eligibility Screening Form 
Study ID: Assessor: Date: 
Question 1: Did some or all 
of the participants receive 
dexamethasone or 
dexamethasone + NSAID? 
(excluding dexamethasone 
by peri-tonsillar infiltration) 
 
If no: EXCLUDE 
If yes: go to Question 2 
If unsure: go to Question 2 
Question 2: Are some or all 
of the participants 
Children <18 years 
undergoing tonsillectomy 
with or without 
adenoidectomy? 
 
If no: EXCLUDE 
If yes: go to Question 3 
If unsure: go to Question 3 
Question 3: Does the paper 
report a randomised 
controlled trial or a non-
randomised study which 
included >20 patients? 
 
If no: EXCLUDE 
If yes: INCLUDE 
If unsure: INCLUDE 
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Appendix 10 Data collection form for randomised studies 
Paper ID: Reviewer: Date: 
Study Characteristics 
Number of participants  
Number of participants in each intervention 
group 
 
Year completed  
Setting  
Inclusion criteria  
Definition of post-operative haemorrhage  
Length of follow up  
Participants 
Age  
Gender  
Underlying disease  
Indication for surgery  
Interventions 
Number of intervention groups  
Pre-operative medicines (inclusive of dose, 
frequency and duration) 
 
Intra-operative medicines (inclusive of dose) Anaesthesia 
Analgesia 
Anti-emetics 
Anti-biotics 
Other (specify) 
Post-operative medicines (inclusive of dose, 
frequency and duration) 
Analgesia 
Anti-emetics 
Antibiotics 
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Other (specify) 
Surgical technique  
Outcomes 
Post-operative haemorrhage rate  
Additional Data Relating to Haemorrhage 
Additional data on haemorrhages Timing (primary/secondary) 
Severity 
Need for intervention 
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Appendix 11 Data collection form for non-randomised studies 
Paper ID: Reviewer: Date: 
Study Characteristics 
Number of participants  
If there were two intervention groups, 
number of participants in each intervention 
group  
 
Year completed  
Setting  
Inclusion criteria  
Definition of post-operative haemorrhage  
Length of follow up  
Participants 
Age  
Gender  
Underlying disease  
Indication for surgery  
Interventions 
Surgical technique  
Pre-operative medicines (inclusive of dose, 
frequency and duration) 
 
Intra-operative medicines (inclusive of dose) Anaesthesia 
Analgesia 
Anti-emetics 
Anti-biotics 
Other (specify) 
Post-operative medicines (inclusive of dose, 
frequency and duration) 
Analgesia 
Anti-emetics 
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Antibiotics 
Other (specify) 
Outcomes  
Post-operative haemorrhage   
Additional Data Relating to Haemorrhage 
Additional data on haemorrhages Timing (primary/secondary) 
Severity  
Risk factors identified 
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Appendix 12 Elements adapted from McHarm Scale 
1. Was haemorrhage pre-defined using standardised or precise definitions? 
2. Was the mode of haemorrhage rate data collection specified as active? 
3. Was the mode of haemorrhage rate data collection specified as passive? 
4. Did the study specify the timing and frequency of the haemorrhage rate data 
collection? 
5. Did the authors use standard scales (s) or checklist(s) for haemorrhage rate data 
collection? 
6. Is there a possibility of selective outcome reporting? 
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Appendix 13 Letter from Liverpool Paediatric Research Ethics Committee 
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Appendix 14 Licence agreements 
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